article_title,journal_title,journal_abbre,article_date,abstract,article_type,pub_days,citation,abstract_clean,Breast Cancer,Lung Cancer,Leukemia,Prostate Cancer,Colorectal Cancer,Lymphoma,Bone Cancer,Melanoma,Liver Cancer,Kidney Cancer,Ovarian Cancer,Pancreatic Cancer,Brain Tumor,Head and Neck Cancer,Acute Myeloid Leukemia (AML),Multiple Myeloma,Sarcoma,Bladder Cancer,Skin Cancer,Gastric Cancer,Gastrointestinal Tumor,Endometrial Cancer,Acute Lymphoblastic Leukemia (ALL),Chronic Lymphocytic Leukemia (CLL),Cardiac Tumors,Cervical Cancer,Esophageal Cancer,Thyroid Cancer,Rectal Cancer,text_clean_seq,text_length,pmid,w2v_similarity_rank_bile_duct_cancer
Impact of intraoperative radiation on postoperative and disease-specific outcome after pancreatoduodenectomy for adenocarcinoma: a propensity score analysis.,American journal of clinical oncology,Am. J. Clin. Oncol.,2003-02-01,"For periampullary cancer,intraoperative radiation therapy (IORT) administered to the site with the highest locoregional recurrence risk carries the rationale to improve tumor control. An IORT effect on survival remains unclear. IORT impact on postoperative outcomes after pancreatectomy for adenocarcinoma was analyzed, with a specific attempt to correct for the nonrandom IORT treatment assignment, and to account for treatment group imbalances in the interpretation of outcome differences. A propensity-score-adjusted analysis, based on variable selection by logistic regression, was used to rebalance treatments. Between 1989 and 1999, 61 patients underwent partial or total pancreatectomy for a primary periampullary adenocarcinoma at the City of Hope National Medical Center. Diagnoses included pancreatic (n = 36), duodenal (n = 11), ampullary (n = 10), and bile duct cancer (n = 4). Thirty patients received IORT to the resection area, with a median dose of 15 Gy (range: 10-20), followed by postoperative external beam radiation (n = 24). Mortality was 0%, the complication rate 61%. Of 33 patients with a documented recurrence, 6 had an isolated locoregional recurrence only (1 IORT versus 5 no IORT, = 0.05); the systemic recurrence pattern differed as well (IORT 94%, no IORT 67%; = 0.04). IORT had no significant impact on hospital stay (overall median: 17 days), disease-free survival (16 months), and overall survival (23 months) when adjusted for those most relevant variables reflecting IORT treatment group assignment propensity. After adjustment for relevant propensity factors, IORT was not linked to a significantly increased risk for complications, hospital stay, or survival hazard. The recurrence pattern may be affected in some patients, but systemic recurrences predominate. We continue to explore IORT in combination with systemic chemotherapy.",Journal Article,6198.0,23.0,For periampullary cancer intraoperative radiation therapy IORT administered to the site with the highest locoregional recurrence risk carries the rationale to improve tumor control An IORT effect on survival remains unclear IORT impact on postoperative outcomes after pancreatectomy for adenocarcinoma was analyzed with a specific attempt to correct for the nonrandom IORT treatment assignment and to account for treatment group imbalances in the interpretation of outcome differences A propensity-score-adjusted analysis based on variable selection by logistic regression was used to rebalance treatments Between 1989 and 1999 61 patients underwent partial or total pancreatectomy for a primary periampullary adenocarcinoma at the City of Hope National Medical Center Diagnoses included n 36 duodenal n 11 ampullary n 10 and duct cancer n 4 Thirty patients received IORT to the resection area with a median dose of 15 Gy range 10-20 followed by postoperative external beam radiation n 24 Mortality was 0 the complication rate 61 Of 33 patients with a documented recurrence 6 had an isolated locoregional recurrence only 1 IORT versus 5 no IORT 0.05 the systemic recurrence pattern differed as well IORT 94 no IORT 67 0.04 IORT had no significant impact on hospital stay overall median 17 days disease-free survival 16 months and overall survival 23 months when adjusted for those most relevant variables reflecting IORT treatment group assignment propensity After adjustment for relevant propensity factors IORT was not linked to a significantly increased risk for complications hospital stay or survival hazard The recurrence pattern may be affected in some patients but systemic recurrences predominate We continue to explore IORT in combination with systemic chemotherapy,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[9, 9180, 12, 1720, 121, 36, 4158, 468, 6, 3, 606, 5, 3, 1076, 1325, 146, 43, 4942, 3, 1728, 6, 401, 30, 182, 35, 4158, 254, 23, 25, 469, 1200, 4158, 345, 23, 573, 123, 50, 3762, 9, 449, 10, 311, 5, 8, 112, 3448, 6, 4883, 9, 3, 12480, 4158, 24, 4392, 2, 6, 1967, 9, 24, 87, 10143, 4, 3, 3037, 1, 228, 362, 8, 1925, 368, 586, 65, 90, 23, 1347, 881, 20, 812, 320, 10, 95, 6, 43166, 640, 59, 3965, 2, 2043, 713, 7, 208, 450, 15, 181, 3762, 9, 8, 86, 9180, 449, 28, 3, 7235, 1, 3045, 657, 484, 574, 2403, 159, 78, 511, 4748, 78, 175, 6762, 78, 79, 2, 2920, 12, 78, 39, 977, 7, 103, 4158, 6, 3, 170, 965, 5, 8, 52, 61, 1, 167, 381, 184, 79, 179, 370, 20, 573, 1455, 1345, 121, 78, 259, 282, 10, 13, 3, 1447, 116, 713, 1, 466, 7, 5, 8, 1405, 146, 49, 42, 35, 1355, 1325, 146, 158, 14, 4158, 185, 33, 77, 4158, 13, 474, 3, 403, 146, 1177, 2512, 22, 149, 4158, 960, 77, 4158, 598, 13, 755, 4158, 42, 77, 93, 345, 23, 702, 2020, 63, 52, 269, 162, 34, 115, 25, 245, 53, 2, 63, 25, 382, 53, 198, 586, 9, 135, 96, 867, 682, 4777, 4158, 24, 87, 4392, 1925, 50, 1852, 9, 867, 1925, 130, 4158, 10, 44, 1199, 6, 8, 97, 101, 43, 9, 521, 702, 2020, 15, 25, 360, 3, 146, 1177, 68, 40, 1424, 4, 476, 7, 84, 403, 1593, 20263, 21, 1906, 6, 1645, 4158, 4, 150, 5, 403, 56]",1775.0,12576918,5
Extrahepatic bile duct stricture and elevated CA 19-9: malignant or benign?,Southern medical journal,South. Med. J.,2003-01-01,"Biliary obstruction due to a proximal bile duct stricture is commonly a result of cholangiocarcinoma. We describe a patient who began having intermittent episodes of jaundice 3 years after cholecystectomy. Despite endoscopic placement of a biliary stent and adequate biliary decompression, the serum CA 19-9 level remained elevated at 58 U/ml (normal <37 U/ml). Segmental bile duct resection and Roux-en-Y hepaticojejunostomy were done. The stricture was caused by a traumatic bile duct neuroma. Diagnostic and therapeutic considerations of this entity are discussed, with special emphasis on the value of noninvasive biliary imaging by magnetic resonance imaging (MRI), the utility and interpretation of the CA 19-9 level, and the role for resection or surgical biliary decompression.",Case Reports,6229.0,5.0,Biliary obstruction due to a proximal duct stricture is commonly a result of cholangiocarcinoma We describe a patient who began having intermittent episodes of jaundice 3 years after cholecystectomy Despite endoscopic placement of a biliary stent and adequate biliary decompression the serum CA 19-9 level remained elevated at 58 U/ml normal 37 U/ml Segmental duct resection and Roux-en-Y hepaticojejunostomy were done The stricture was caused by a traumatic duct neuroma Diagnostic and therapeutic considerations of this entity are discussed with special emphasis on the value of noninvasive biliary imaging by magnetic resonance imaging MRI the utility and interpretation of the CA 19-9 level and the role for resection or surgical biliary decompression,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2532, 3191, 520, 6, 8, 2805, 2920, 6673, 16, 841, 8, 757, 1, 2126, 21, 897, 8, 69, 54, 4603, 1041, 4102, 3750, 1, 7655, 27, 60, 50, 8493, 550, 2056, 2613, 1, 8, 2532, 7601, 2, 1658, 2532, 7638, 3, 524, 1568, 326, 83, 301, 958, 804, 28, 717, 1767, 542, 295, 567, 1767, 542, 7982, 2920, 170, 2, 15881, 4375, 2055, 23202, 11, 1822, 3, 6673, 10, 1546, 20, 8, 11272, 2920, 33381, 752, 2, 189, 3891, 1, 26, 2983, 32, 1588, 5, 3714, 3136, 23, 3, 549, 1, 2957, 2532, 270, 20, 1484, 1535, 270, 704, 3, 1207, 2, 3037, 1, 3, 1568, 326, 83, 301, 2, 3, 200, 9, 170, 15, 221, 2532, 7638]",755.0,12602726,87
Carcinoid tumor of the biliary tract: treating a rare cause of bile duct obstruction.,The American surgeon,Am Surg,2003-02-01,"Biliary carcinoids are rare with fewer than 30 cases reported in the English literature. The objective of this report is to describe an additional patient found to have a biliary carcinoid and to define the presentation, diagnosis, and management of patients with this rare biliary tumor. In our case the patient initially presented with clinical jaundice and elevated transaminases. Endoscopic retrograde cholangiogram established a mass suspicious for cholangiocarcinoma (Klatskin tumor). The patient was initially managed with an endostent, which was later removed in favor of a percutaneous transhepatic cholangiogram tube. At the time of surgery successful removal of a firm nodular mass at the area of the ductal bifurcation was achieved and biliary continuity re-established with a Roux-en-Y hepaticojejunostomy. Pathology revealed carcinoid tumor of the bile duct with one lymph node positive for tumor. The patient did not receive any adjuvant radiation or chemotherapy. This case serves to highlight that extrahepatic biliary carcinoids constitute a rare but identifiable subset of bile duct tumors. Diagnostic workup should include US, CT, and cholangiography. Surgical exploration is universally indicated in physiologically fit patients with operative management to include resection and re-establishment of biliary continuity. Data on adjuvant therapy remain investigational; however, available information suggests that patients with biliary carcinoid have an overall favorable prognosis after aggressive surgical management.",Case Reports,6198.0,22.0,Biliary carcinoids are rare with fewer than 30 cases reported in the English literature The objective of this report is to describe an additional patient found to have a biliary and to define the presentation diagnosis and management of patients with this rare biliary tumor In our case the patient initially presented with clinical jaundice and elevated transaminases Endoscopic retrograde cholangiogram established a mass suspicious for cholangiocarcinoma Klatskin tumor The patient was initially managed with an endostent which was later removed in favor of a percutaneous transhepatic cholangiogram tube At the time of surgery successful removal of a firm nodular mass at the area of the ductal bifurcation was achieved and biliary continuity re-established with a Roux-en-Y hepaticojejunostomy Pathology revealed tumor of the duct with one lymph node positive for tumor The patient did not receive any adjuvant radiation or chemotherapy This case serves to highlight that extrahepatic biliary carcinoids constitute a rare but identifiable subset of duct tumors Diagnostic workup should include US CT and cholangiography Surgical exploration is universally indicated in physiologically fit patients with operative management to include resection and re-establishment of biliary continuity Data on adjuvant therapy remain investigational however available information suggests that patients with biliary have an overall favorable prognosis after aggressive surgical management,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2532, 9878, 32, 622, 5, 1497, 76, 201, 140, 210, 4, 3, 4201, 789, 3, 461, 1, 26, 414, 16, 6, 897, 35, 402, 69, 204, 6, 47, 8, 2532, 2, 6, 1107, 3, 1031, 147, 2, 284, 1, 7, 5, 26, 622, 2532, 30, 4, 114, 473, 3, 69, 1625, 917, 5, 38, 7655, 2, 804, 9359, 2056, 10583, 28026, 635, 8, 782, 3230, 9, 2126, 33391, 30, 3, 69, 10, 1625, 2231, 5, 35, 53433, 92, 10, 1559, 2264, 4, 4283, 1, 8, 3720, 18865, 28026, 2330, 28, 3, 98, 1, 152, 1401, 2829, 1, 8, 10851, 4481, 782, 28, 3, 965, 1, 3, 1258, 18788, 10, 513, 2, 2532, 12253, 1491, 635, 5, 8, 15881, 4375, 2055, 23202, 1117, 553, 30, 1, 3, 2920, 5, 104, 263, 289, 109, 9, 30, 3, 69, 205, 44, 560, 500, 249, 121, 15, 56, 26, 473, 4711, 6, 1817, 17, 3710, 2532, 9878, 4999, 8, 622, 84, 6237, 697, 1, 2920, 57, 752, 4755, 257, 643, 843, 425, 2, 21954, 221, 3370, 16, 6813, 1103, 4, 9634, 2975, 7, 5, 1208, 284, 6, 643, 170, 2, 1491, 5346, 1, 2532, 12253, 74, 23, 249, 36, 918, 3093, 137, 390, 487, 844, 17, 7, 5, 2532, 47, 35, 63, 913, 356, 50, 571, 221, 284]",1479.0,12641346,84
CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study.,International journal of gastrointestinal cancer,Int J Gastrointest Cancer,2002-01-01,"Bile-duct and gallbladder carcinomas are rare cancers. Once they have spread beyond the point of surgical resectability, no therapies have shown meaningful long-term benefit. These cancers are typically refractory to standard chemotherapy agents. Based on preclinical work showing activity of CPT-11, we performed a phase II trial to assess its activity in patients with bile-duct or gallbladder carcinomas. Patients with histologic or cytologic evidence of locally advanced or metastatic bile-duct or gallbladder carcinoma were potentially eligible for this study. Patients meeting study eligibility and who signed an informed consent were given CPT-11 125 mg/m2 weekly for 4 wk followed by a 2-wk break from therapy. The starting dose of CPT-11 was later reduced to 100 mg/m2 grade IV toxicity. Patients continued on treatment if they showed evidence of benefit and tolerated therapy. A total of 39 patients were enrolled, and 36 were evaluable. The overall confirmed response rate was 8%. One CR and two PRs were seen. A high frequency of toxicity was seen. However, no unusual or unexpected toxicities occurred. CPT-11 is ineffective therapy for patients with locally advanced or metastatic bile-duct or gallbladder carcinoma.",Clinical Trial,6594.0,30.0,Bile-duct and carcinomas are rare cancers Once they have spread beyond the point of surgical resectability no therapies have shown meaningful long-term benefit These cancers are typically refractory to standard chemotherapy agents Based on preclinical work showing activity of CPT-11 we performed a phase II trial to assess its activity in patients with bile-duct or carcinomas Patients with histologic or cytologic evidence of locally advanced or metastatic bile-duct or carcinoma were potentially eligible for this study Patients meeting study eligibility and who signed an informed consent were given CPT-11 125 mg/m2 weekly for 4 wk followed by a 2-wk break from therapy The starting dose of CPT-11 was later reduced to 100 mg/m2 grade IV toxicity Patients continued on treatment if they showed evidence of benefit and tolerated therapy A total of 39 patients were enrolled and 36 were evaluable The overall confirmed response rate was 8 One CR and two PRs were seen A high frequency of toxicity was seen However no unusual or unexpected toxicities occurred CPT-11 is ineffective therapy for patients with locally advanced or metastatic bile-duct or carcinoma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26176, 2920, 2, 826, 32, 622, 163, 1059, 491, 47, 2579, 1654, 3, 741, 1, 221, 5150, 77, 235, 47, 443, 2538, 319, 337, 247, 46, 163, 32, 1969, 430, 6, 260, 56, 183, 90, 23, 693, 1357, 2069, 128, 1, 3361, 175, 21, 173, 8, 124, 215, 160, 6, 423, 211, 128, 4, 7, 5, 26176, 2920, 15, 826, 7, 5, 884, 15, 4195, 241, 1, 795, 131, 15, 113, 26176, 2920, 15, 134, 11, 751, 625, 9, 26, 45, 7, 2238, 45, 2317, 2, 54, 7717, 35, 2767, 3844, 11, 447, 3361, 175, 1731, 81, 821, 709, 9, 39, 3293, 370, 20, 8, 18, 3293, 4338, 29, 36, 3, 1723, 61, 1, 3361, 175, 10, 1559, 405, 6, 394, 81, 821, 88, 478, 155, 7, 1351, 23, 24, 492, 491, 224, 241, 1, 247, 2, 421, 36, 8, 181, 1, 587, 7, 11, 346, 2, 511, 11, 859, 3, 63, 557, 51, 116, 10, 66, 104, 684, 2, 100, 4018, 11, 527, 8, 64, 675, 1, 155, 10, 527, 137, 77, 4015, 15, 3792, 385, 489, 3361, 175, 16, 3957, 36, 9, 7, 5, 795, 131, 15, 113, 26176, 2920, 15, 134]",1163.0,12794246,73
Small cell carcinoma of the cystic duct: a case report.,Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,J. Gastrointest. Surg.,,"Small cell carcinoma usually involves the lung and rarely affects the biliary tract, especially the cystic duct. In this article we report a case of small cell carcinoma of the cystic duct in a 46-year-old Japanese man. The patient presented with abdominal pain and jaundice. Imaging showed a small nodule in the cystic duct invading the common bile duct with dilatation of the proximal biliary tree. The hepatic artery and portal vein were free from invasion. Extended right hepatic lobectomy, cholecystectomy, and resection of the extrahepatic proximal bile ducts were performed together with lymph node dissection under the tentative diagnosis of carcinoma of the cystic duct. Histopathologic examination of the resected specimen revealed small cell carcinoma arising in the cystic duct and extending into the common bile duct. The postoperative clinical course was uneventful, and the patient is doing well without any signs of recurrence 1 year after the operation. To our knowledge this is the first documented case of a small cell carcinoma arising in the cystic duct.",Case Reports,,3.0,Small cell carcinoma usually involves the and rarely affects the biliary tract especially the cystic duct In this article we report a case of small cell carcinoma of the cystic duct in a 46-year-old Japanese man The patient presented with abdominal pain and jaundice Imaging showed a small nodule in the cystic duct invading the common duct with dilatation of the proximal biliary tree The hepatic artery and portal vein were free from invasion Extended right hepatic lobectomy cholecystectomy and resection of the extrahepatic proximal ducts were performed together with lymph node dissection under the tentative diagnosis of carcinoma of the cystic duct Histopathologic examination of the resected specimen revealed small cell carcinoma arising in the cystic duct and extending into the common duct The postoperative clinical course was uneventful and the patient is doing well without any signs of recurrence 1 year after the operation To our knowledge this is the first documented case of a small cell carcinoma arising in the cystic duct,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[302, 31, 134, 2082, 2921, 3, 2, 2416, 2561, 3, 2532, 1696, 1093, 3, 2965, 2920, 4, 26, 946, 21, 414, 8, 473, 1, 302, 31, 134, 1, 3, 2965, 2920, 4, 8, 641, 111, 1095, 5256, 3628, 3, 69, 917, 5, 1467, 559, 2, 7655, 270, 224, 8, 302, 5072, 4, 3, 2965, 2920, 8653, 3, 186, 2920, 5, 12799, 1, 3, 2805, 2532, 4899, 3, 939, 2872, 2, 3307, 2762, 11, 115, 29, 578, 1747, 1913, 939, 3258, 8493, 2, 170, 1, 3, 3710, 2805, 7310, 11, 173, 1162, 5, 263, 289, 1161, 669, 3, 28080, 147, 1, 134, 1, 3, 2965, 2920, 2630, 1385, 1, 3, 1133, 2360, 553, 302, 31, 134, 2635, 4, 3, 2965, 2920, 2, 4782, 237, 3, 186, 2920, 3, 573, 38, 906, 10, 16742, 2, 3, 69, 16, 9647, 149, 187, 500, 3408, 1, 146, 14, 111, 50, 3, 2589, 6, 114, 922, 26, 16, 3, 157, 1405, 473, 1, 8, 302, 31, 134, 2635, 4, 3, 2965, 2920]",1042.0,12850675,26
Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays.,Human pathology,Hum. Pathol.,2004-03-01,"Using global gene expression analyses, multiple novel tumor markers overexpressed in infiltrating ductal adenocarcinomas of the pancreas have recently been identified. However, the expression of these markers in morphologically similar adenocarcinomas of the biliary tree has not been investigated. The purpose of the present study was 3-fold. First, we used 8 markers that have been shown to be overexpressed in whole tissue sections of pancreatic adenocarcinomas to validate tissue microarrays (TMAs) created from a series of pancreatic adenocarcinomas (n=68). The labeling patterns of 6 epithelial markers (fascin, mucin 4, 14-3-3sigma, prostate stem cell antigen, topoisomerase IIalpha, and cdc2/p34) were concordant with previously published studies on whole tissue sections, yet required far fewer slides and reagents. Mesothelin, an epithelial marker, and heat shock protein 47, a marker of peritumoral desmoplasia, showed lower levels of expression in the TMAs when compared with whole tissue sections. Second, we examined the previously unknown expression of the same 8 novel tumor proteins in cancers of the biliary tree by using TMAs created from a series of intrahepatic cholangiocarcinomas, gallbladder adenocarcinomas, and adenocarcinomas of the distal common bile duct (n=38). Each of the 8 markers was overexpressed in the biliary cancers, ranging from 14% demonstrating at least focal labeling with prostate stem cell antigen to 100% labeling with cdc2/p34. Most of the markers showed lower frequencies of expression in the biliary tract carcinomas in comparison to the pancreatic adenocarcinomas. In addition, expression patterns varied with location in the biliary system (intrahepatic versus gallbladder versus distal common bile duct). These differences were statistically significant (P<0.05) for mesothelin, mucin 4, and heat shock protein 47. Finally, the expression of selected markers in neoplastic progression of gallbladder cancer was examined. Two markers, fascin and mesothelin, showed up-regulation of expression with transition from carcinoma in situ to invasive adenocarcinoma, implicating a role for these markers in neoplastic progression. The results of this study indicate that TMA technology provides valid and cost-effective means to screen large numbers of novel tumor markers, even in tumors such as pancreatic and biliary adenocarcinomas that characteristically have abundant desmoplastic stroma. In addition, novel tumor markers of pancreatic adenocarcinomas show similar, yet not identical, expression patterns in biliary carcinomas. Therefore, these markers are potentially useful in developing diagnostic tests and treatment paradigms for tumors involving the biliary system.",Journal Article,5804.0,116.0,Using global gene expression analyses multiple novel tumor markers overexpressed in infiltrating ductal adenocarcinomas of the have recently been identified However the expression of these markers in morphologically similar adenocarcinomas of the biliary tree has not been investigated The purpose of the present study was 3-fold First we used 8 markers that have been shown to be overexpressed in whole tissue sections of adenocarcinomas to validate tissue microarrays TMAs created from a series of adenocarcinomas n=68 The labeling patterns of 6 epithelial markers fascin mucin 4 14-3-3sigma stem cell antigen topoisomerase IIalpha and cdc2/p34 were concordant with previously published studies on whole tissue sections yet required far fewer slides and reagents Mesothelin an epithelial marker and heat shock protein 47 a marker of peritumoral desmoplasia showed lower levels of expression in the TMAs when compared with whole tissue sections Second we examined the previously unknown expression of the same 8 novel tumor proteins in cancers of the biliary tree by using TMAs created from a series of intrahepatic cholangiocarcinomas adenocarcinomas and adenocarcinomas of the distal common duct n=38 Each of the 8 markers was overexpressed in the biliary cancers ranging from 14 demonstrating at least focal labeling with stem cell antigen to 100 labeling with cdc2/p34 Most of the markers showed lower frequencies of expression in the biliary tract carcinomas in comparison to the adenocarcinomas In addition expression patterns varied with location in the biliary system intrahepatic versus versus distal common duct These differences were statistically significant P 0.05 for mesothelin mucin 4 and heat shock protein 47 Finally the expression of selected markers in neoplastic progression of cancer was examined Two markers fascin and mesothelin showed up-regulation of expression with transition from carcinoma in situ to invasive adenocarcinoma implicating a role for these markers in neoplastic progression The results of this study indicate that TMA technology provides valid and cost-effective means to screen large numbers of novel tumor markers even in tumors such as and biliary adenocarcinomas that characteristically have abundant desmoplastic stroma In addition novel tumor markers of adenocarcinomas show similar yet not identical expression patterns in biliary carcinomas Therefore these markers are potentially useful in developing diagnostic tests and treatment paradigms for tumors involving the biliary system,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[75, 1648, 145, 55, 318, 232, 229, 30, 525, 1711, 4, 2097, 1258, 1586, 1, 3, 47, 761, 85, 108, 137, 3, 55, 1, 46, 525, 4, 6204, 288, 1586, 1, 3, 2532, 4899, 71, 44, 85, 565, 3, 743, 1, 3, 364, 45, 10, 27, 1116, 157, 21, 95, 66, 525, 17, 47, 85, 443, 6, 40, 1711, 4, 902, 246, 3013, 1, 1586, 6, 2183, 246, 2774, 11278, 2466, 29, 8, 988, 1, 1586, 78, 806, 3, 3383, 764, 1, 49, 701, 525, 19632, 5258, 39, 213, 27, 43538, 452, 31, 448, 3999, 16352, 2, 8747, 18787, 11, 3610, 5, 373, 983, 94, 23, 902, 246, 3013, 1145, 616, 3272, 1497, 3830, 2, 9543, 5402, 35, 701, 952, 2, 3545, 3971, 178, 662, 8, 952, 1, 5432, 19633, 224, 280, 148, 1, 55, 4, 3, 11278, 198, 72, 5, 902, 246, 3013, 419, 21, 409, 3, 373, 860, 55, 1, 3, 827, 66, 229, 30, 652, 4, 163, 1, 3, 2532, 4899, 20, 75, 11278, 2466, 29, 8, 988, 1, 3022, 9386, 1586, 2, 1586, 1, 3, 2107, 186, 2920, 78, 519, 296, 1, 3, 66, 525, 10, 1711, 4, 3, 2532, 163, 2223, 29, 213, 2219, 28, 506, 2137, 3383, 5, 452, 31, 448, 6, 394, 3383, 5, 8747, 18787, 96, 1, 3, 525, 224, 280, 2722, 1, 55, 4, 3, 2532, 1696, 826, 4, 1155, 6, 3, 1586, 4, 352, 55, 764, 2051, 5, 1147, 4, 3, 2532, 398, 3022, 185, 185, 2107, 186, 2920, 46, 362, 11, 712, 93, 19, 13, 474, 9, 5402, 5258, 39, 2, 3545, 3971, 178, 662, 1368, 3, 55, 1, 715, 525, 4, 2000, 91, 1, 12, 10, 409, 100, 525, 19632, 2, 5402, 224, 126, 863, 1, 55, 5, 1970, 29, 134, 4, 957, 6, 416, 449, 7912, 8, 200, 9, 46, 525, 4, 2000, 91, 3, 99, 1, 26, 45, 1008, 17, 5501, 2033, 777, 4406, 2, 835, 323, 2263, 6, 2413, 375, 1870, 1, 229, 30, 525, 871, 4, 57, 225, 22, 2, 2532, 1586, 17, 14079, 47, 4834, 5922, 2477, 4, 352, 229, 30, 525, 1, 1586, 514, 288, 1145, 44, 3038, 55, 764, 4, 2532, 826, 673, 46, 525, 32, 751, 999, 4, 931, 752, 895, 2, 24, 4887, 9, 57, 1267, 3, 2532, 398]",2534.0,15017593,7
Advances in the surgical management of liver malignancies.,"Cancer journal (Sudbury, Mass.)",Cancer J,,"Primary malignancies of the liver include tumors arising from the hepatocytes (hepatocellular carcinoma and the fibrolamellar variant) and the intrahepatic bile ducts (intrahepatic cholangiocarcinoma). Hepatocellular carcinoma is the most common primary cancer of the liver and is a leading cause of death from cancer worldwide. Although it is uncommon in the United States, the incidence of hepatocellular carcinoma is rising. Hepatitis, ethanol use, and cirrhosis often dominate the clinical picture and may dictate prognosis. New clinical and pathological staging systems have allowed for the more accurate stratification of patients to more appropriately identify patients for resection, transplantation, and percutaneous ablation therapies. A correlation between liver volume and surgical outcome has recently been demonstrated, with small liver remnant size being associated with increased morbidity. Portal vein embolization has therefore been proposed as one way to induce hypertrophy of the anticipated liver remnant before resection. Initial reports have shown that portal vein embolization decreases the incidence of postoperative complications. More recently, systemic chemotherapy and chemoembolization have been investigated as both primary and neoadjuvant therapy. Chemoimmunotherapy with 5-fluorouracil and interferon may be associated with a superior response rate in the fibrolamellar variant of hepatocellular carcinoma. Two recent randomized studies have also indicated improved survival after hepatic artery embolization in selected patients.",Journal Article,,19.0,Primary malignancies of the include tumors arising from the hepatocytes carcinoma and the fibrolamellar variant and the intrahepatic ducts intrahepatic cholangiocarcinoma carcinoma is the most common primary cancer of the and is a leading cause of death from cancer worldwide Although it is uncommon in the United States the incidence of carcinoma is rising Hepatitis ethanol use and cirrhosis often dominate the clinical picture and may dictate prognosis New clinical and pathological staging systems have allowed for the more accurate stratification of patients to more appropriately identify patients for resection transplantation and percutaneous ablation therapies A correlation between volume and surgical outcome has recently been demonstrated with small remnant size being associated with increased morbidity Portal vein embolization has therefore been proposed as one way to induce hypertrophy of the anticipated remnant before resection Initial reports have shown that portal vein embolization decreases the incidence of postoperative complications More recently systemic chemotherapy and chemoembolization have been investigated as both primary and neoadjuvant therapy Chemoimmunotherapy with 5-fluorouracil and interferon may be associated with a superior response rate in the fibrolamellar variant of carcinoma Two recent randomized studies have also indicated improved survival after hepatic artery embolization in selected patients,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[86, 441, 1, 3, 643, 57, 2635, 29, 3, 8291, 134, 2, 3, 9686, 1142, 2, 3, 3022, 7310, 3022, 2126, 134, 16, 3, 96, 186, 86, 12, 1, 3, 2, 16, 8, 1049, 708, 1, 273, 29, 12, 2358, 242, 192, 16, 2052, 4, 3, 1088, 907, 3, 287, 1, 134, 16, 3699, 3002, 9103, 119, 2, 3563, 629, 18953, 3, 38, 8951, 2, 68, 14841, 356, 217, 38, 2, 1301, 632, 1530, 47, 2313, 9, 3, 80, 1481, 1541, 1, 7, 6, 80, 4544, 255, 7, 9, 170, 497, 2, 3720, 1650, 235, 8, 816, 59, 433, 2, 221, 228, 71, 761, 85, 264, 5, 302, 5644, 444, 486, 41, 5, 101, 787, 3307, 2762, 4232, 71, 673, 85, 1587, 22, 104, 2255, 6, 1290, 9544, 1, 3, 4078, 5644, 348, 170, 388, 1198, 47, 443, 17, 3307, 2762, 4232, 2140, 3, 287, 1, 573, 521, 80, 761, 403, 56, 2, 6056, 47, 85, 565, 22, 110, 86, 2, 536, 36, 4438, 5, 33, 1404, 2, 1688, 68, 40, 41, 5, 8, 1123, 51, 116, 4, 3, 9686, 1142, 1, 134, 100, 435, 384, 94, 47, 120, 1103, 231, 25, 50, 939, 2872, 4232, 4, 715, 7]",1446.0,15130267,44
Non-pancreatic periampullary adenocarcinomas: an explanation for favorable prognosis.,Hepato-gastroenterology,Hepatogastroenterology,,"Our previous studies demonstrate that patients with non-pancreatic periampullary adenocarcinomas have a favorable prognosis relative to those with pancreatic adenocarcinoma. This study investigates histopathologic factors that contribute to the superior outcome of these patients. A retrospective review of all patients explored for periampullary neoplasms at a single institution over a 20-year period. 291 patients with periampullary neoplasms underwent exploratory laparotomy, of which 185 had resectable tumors. Periampullary adenocarcinomas were resected in 120: pancreatic head (n=74), distal common bile duct (n=10), duodenum (n=5), and ampulla of Vater (n=31). The resection rate for non-pancreatic adenocarcinomas was 90%, while that of pancreatic cancers was 44% (p<0.01). Median survival for resected non-pancreatic adenocarcinomas was 38.8 months; that of pancreatic tumors was 15.3 months (p<0.01). Non-pancreatic adenocarcinomas were significantly smaller (p<0.001), better differentiated (p<0.001), and less likely to have involved nodes (p<0.001), margins (p<0.001), perineural invasion (p<0.001), or vascular invasion (p<0.2) than pancreatic adenocarcinomas. Histopathologic features of non-pancreatic periampullary adenocarcinomas significantly differentiate them from pancreatic adenocarcinoma and contribute to their relatively favorable long-term outcome following resection.",Journal Article,,18.0,Our previous studies demonstrate that patients with non-pancreatic periampullary adenocarcinomas have a favorable prognosis relative to those with adenocarcinoma This study investigates histopathologic factors that contribute to the superior outcome of these patients A retrospective review of all patients explored for periampullary neoplasms at a single institution over a 20-year period 291 patients with periampullary neoplasms underwent exploratory laparotomy of which 185 had resectable tumors Periampullary adenocarcinomas were resected in 120 head n=74 distal common duct n=10 duodenum n=5 and ampulla of Vater n=31 The resection rate for non-pancreatic adenocarcinomas was 90 while that of cancers was 44 p 0.01 Median survival for resected non-pancreatic adenocarcinomas was 38.8 months that of tumors was 15.3 months p 0.01 Non-pancreatic adenocarcinomas were significantly smaller p 0.001 better differentiated p 0.001 and less likely to have involved nodes p 0.001 margins p 0.001 perineural invasion p 0.001 or vascular invasion p 0.2 than adenocarcinomas Histopathologic features of non-pancreatic periampullary adenocarcinomas significantly differentiate them from adenocarcinoma and contribute to their relatively favorable long-term outcome following resection,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[114, 698, 94, 608, 17, 7, 5, 220, 14061, 9180, 1586, 47, 8, 913, 356, 580, 6, 135, 5, 449, 26, 45, 7259, 2630, 130, 17, 1248, 6, 3, 1123, 228, 1, 46, 7, 8, 459, 206, 1, 62, 7, 1443, 9, 9180, 1179, 28, 8, 226, 731, 252, 8, 179, 111, 727, 8253, 7, 5, 9180, 1179, 208, 2386, 3274, 1, 92, 5805, 42, 1899, 57, 9180, 1586, 11, 1133, 4, 2031, 718, 78, 794, 2107, 186, 2920, 78, 79, 8401, 78, 33, 2, 12837, 1, 14777, 78, 456, 3, 170, 116, 9, 220, 14061, 1586, 10, 424, 369, 17, 1, 163, 10, 584, 19, 13, 355, 52, 25, 9, 1133, 220, 14061, 1586, 10, 519, 66, 53, 17, 1, 57, 10, 167, 27, 53, 19, 13, 355, 220, 14061, 1586, 11, 97, 2170, 19, 13, 144, 380, 1442, 19, 13, 144, 2, 299, 322, 6, 47, 646, 502, 19, 13, 144, 1012, 19, 13, 144, 4917, 578, 19, 13, 144, 15, 756, 578, 19, 13, 18, 76, 1586, 2630, 404, 1, 220, 14061, 9180, 1586, 97, 3723, 1370, 29, 449, 2, 1248, 6, 136, 1352, 913, 319, 337, 228, 366, 170]",1278.0,15143931,34
Surgical management of cholangiocarcinoma.,Seminars in liver disease,Semin. Liver Dis.,2004-05-01,"Biliary tract cancer affects approximately 7500 Americans each year. Tumors arising from the gallbladder are the most common; those of bile duct origin, or cholangiocarcinoma, are less frequently encountered, constituting approximately 2% of all reported cancers. Although cholangiocarcinoma can arise anywhere within the biliary tree, tumors involving the biliary confluence (i.e., hilar cholangiocarcinoma) represent the majority, accounting for 40 to 60% of all cases. Twenty to 30% of cholangiocarcinomas originate in the lower bile duct, and approximately 10% arise within the intrahepatic biliary tree and will present as an intrahepatic mass. Complete resection remains the most effective and only potentially curative therapy for cholangiocarcinoma. For all patients with intrahepatic cholangiocarcinoma and nearly all patients with hilar tumors, complete resection requires a major partial hepatectomy. Distal cholangiocarcinomas, on the other hand, are treated like all periampullary malignancies and typically require pancreaticoduodenectomy. Most patients with cholangiocarcinoma present with advanced disease that is not amenable to surgical treatment, and even with a complete resection, recurrence rates are high. Adjuvant therapy (chemotherapy and radiation therapy) has not been shown clearly to reduce recurrence risk.",Journal Article,5743.0,165.0,Biliary tract cancer affects approximately 7500 Americans each year Tumors arising from the are the most common those of duct origin or cholangiocarcinoma are less frequently encountered constituting approximately 2 of all reported cancers Although cholangiocarcinoma can arise anywhere within the biliary tree tumors involving the biliary confluence i.e. hilar cholangiocarcinoma represent the majority accounting for 40 to 60 of all cases Twenty to 30 of cholangiocarcinomas originate in the lower duct and approximately 10 arise within the intrahepatic biliary tree and will present as an intrahepatic mass Complete resection remains the most effective and only potentially curative therapy for cholangiocarcinoma For all patients with intrahepatic cholangiocarcinoma and nearly all patients with hilar tumors complete resection requires a major partial hepatectomy Distal cholangiocarcinomas on the other hand are treated like all periampullary malignancies and typically require pancreaticoduodenectomy Most patients with cholangiocarcinoma present with advanced disease that is not amenable to surgical treatment and even with a complete resection recurrence rates are high Adjuvant therapy chemotherapy and radiation therapy has not been shown clearly to reduce recurrence risk,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2532, 1696, 12, 2561, 705, 33288, 2731, 296, 111, 57, 2635, 29, 3, 32, 3, 96, 186, 135, 1, 2920, 1938, 15, 2126, 32, 299, 746, 3903, 14122, 705, 18, 1, 62, 210, 163, 242, 2126, 122, 3043, 17747, 262, 3, 2532, 4899, 57, 1267, 3, 2532, 15845, 70, 563, 4793, 2126, 1231, 3, 686, 3116, 9, 327, 6, 335, 1, 62, 140, 737, 6, 201, 1, 9386, 8838, 4, 3, 280, 2920, 2, 705, 79, 3043, 262, 3, 3022, 2532, 4899, 2, 303, 364, 22, 35, 3022, 782, 236, 170, 469, 3, 96, 323, 2, 158, 751, 1075, 36, 9, 2126, 9, 62, 7, 5, 3022, 2126, 2, 1857, 62, 7, 5, 4793, 57, 236, 170, 1706, 8, 458, 450, 2711, 2107, 9386, 23, 3, 127, 2833, 32, 73, 733, 62, 9180, 441, 2, 1969, 1353, 4104, 96, 7, 5, 2126, 364, 5, 131, 34, 17, 16, 44, 4070, 6, 221, 24, 2, 871, 5, 8, 236, 170, 146, 151, 32, 64, 249, 36, 56, 2, 121, 36, 71, 44, 85, 443, 2536, 6, 969, 146, 43]",1284.0,15192791,9
A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures.,The American journal of gastroenterology,Am. J. Gastroenterol.,2004-09-01,"The aim of this study was to assess the relative sensitivities and specificities of fluorescence in situ hybridization (FISH) and routine cytology for the detection of malignancy in biliary tract strictures. Bile duct brushing and aspirate specimens were collected from 131 patients being evaluated for possible malignant bile duct strictures. Both specimen types were assessed by FISH but only brushing specimens were assessed by cytology. The FISH assay used a mixture of fluorescently-labeled probes to the centromeres of chromosomes 3, 7, and 17 and chromosomal band 9p21 (Vysis UroVysion) to identify cells having chromosomal abnormalities. A case was considered positive for malignancy if five or more cells exhibited polysomy. Sixty-six of the 131 patients had surgical pathologic and/or clinical evidence of malignancy. Thirty-nine patients had cholangiocarcinoma, 19 had pancreatic carcinoma, and 8 had other types of malignancy. The sensitivity of cytology and FISH for the detection of malignancy in bile duct brushing specimens in these patients was 15% and 34% (p < 0.01), respectively. The sensitivity of FISH for the bile aspirate specimens was 23%, and the combined sensitivity of FISH for aspirate and brushing specimens was 35%. The specificity of FISH and cytology brushings were 91% and 98% (p= 0.06), respectively. FISH is significantly more sensitive than and nearly as specific as conventional cytology for the detection of malignant biliary strictures in biliary brushing specimens. FISH may improve the clinical management of patients who are being evaluated for malignancy in bile duct strictures.",Comparative Study,5620.0,259.0,The aim of this study was to assess the relative sensitivities and specificities of fluorescence in situ hybridization FISH and routine cytology for the detection of malignancy in biliary tract strictures duct brushing and aspirate specimens were collected from 131 patients being evaluated for possible malignant duct strictures Both specimen types were assessed by FISH but only brushing specimens were assessed by cytology The FISH assay used a mixture of fluorescently-labeled probes to the centromeres of chromosomes 3 7 and 17 and chromosomal band 9p21 Vysis UroVysion to identify cells having chromosomal abnormalities A case was considered positive for malignancy if five or more cells exhibited polysomy Sixty-six of the 131 patients had surgical pathologic and/or clinical evidence of malignancy Thirty-nine patients had cholangiocarcinoma 19 had carcinoma and 8 had other types of malignancy The sensitivity of cytology and FISH for the detection of malignancy in duct brushing specimens in these patients was 15 and 34 p 0.01 respectively The sensitivity of FISH for the aspirate specimens was 23 and the combined sensitivity of FISH for aspirate and brushing specimens was 35 The specificity of FISH and cytology brushings were 91 and 98 p= 0.06 respectively FISH is significantly more sensitive than and nearly as specific as conventional cytology for the detection of malignant biliary strictures in biliary brushing specimens FISH may improve the clinical management of patients who are being evaluated for malignancy in duct strictures,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 423, 3, 580, 6202, 2, 10571, 1, 1591, 4, 957, 1554, 1277, 2, 1311, 2045, 9, 3, 638, 1, 710, 4, 2532, 1696, 7860, 2920, 13607, 2, 8022, 623, 11, 786, 29, 2229, 7, 486, 194, 9, 899, 393, 2920, 7860, 110, 2360, 630, 11, 275, 20, 1277, 84, 158, 13607, 623, 11, 275, 20, 2045, 3, 1277, 719, 95, 8, 6972, 1, 12496, 2841, 3701, 6, 3, 43698, 1, 3560, 27, 67, 2, 269, 2, 1860, 7679, 9016, 23115, 12843, 6, 255, 37, 1041, 1860, 1171, 8, 473, 10, 515, 109, 9, 710, 492, 365, 15, 80, 37, 1416, 5882, 1746, 437, 1, 3, 2229, 7, 42, 221, 510, 2, 15, 38, 241, 1, 710, 977, 762, 7, 42, 2126, 326, 42, 134, 2, 66, 42, 127, 630, 1, 710, 3, 485, 1, 2045, 2, 1277, 9, 3, 638, 1, 710, 4, 2920, 13607, 623, 4, 46, 7, 10, 167, 2, 562, 19, 13, 355, 106, 3, 485, 1, 1277, 9, 3, 8022, 623, 10, 382, 2, 3, 397, 485, 1, 1277, 9, 8022, 2, 13607, 623, 10, 465, 3, 1121, 1, 1277, 2, 2045, 14515, 11, 970, 2, 1096, 19, 13, 1460, 106, 1277, 16, 97, 80, 745, 76, 2, 1857, 22, 112, 22, 809, 2045, 9, 3, 638, 1, 393, 2532, 7860, 4, 2532, 13607, 623, 1277, 68, 401, 3, 38, 284, 1, 7, 54, 32, 486, 194, 9, 710, 4, 2920, 7860]",1552.0,15330900,62
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.,Investigational new drugs,Invest New Drugs,2005-10-01,"Pancreaticobiliary malignancies respond poorly to conventional chemotherapy, and novel agents are needed. Dolatstatin-10 is a potent antimitotic pentapeptide isolated from the marine mollusk Dolabella auricularia that inhibits microtubule assembly. We conducted 2 parallel phase II trials of dolastatin-10 in patients with advanced hepatobiliary cancers and pancreatic adenocarcinoma. Eligible patients had histologically-confirmed metastatic pancreatic adenocarcinoma or metastatic, locally advanced or recurrent cancer of the liver, bile duct or gallbladder, and had received no prior chemotherapy for advanced disease. Dolastatin-10 400 microg/m(2) was administered intravenously by bolus every 21 days. Restaging CT scans were obtained every 2 cycles. Twenty-eight patients (16 hepatobiliary, including 7 hepatomas, 6 cholangiocarcinomas, 2 gallbladder carcinomas, and 12 pancreatic carcinomas) enrolled; 27 were evaluable for response. There were no objective responses. Grade 3/4 neutropenia occurred in 59% of patients and neutropenic fever in 18%. Median and 1-year survival were 5.0 months and 17% for the pancreatic cancer patients, and 3.0 months and 29% for the hepatobiliary patients. Median time to progression was 1.3 months for the pancreatic cancer patients and 1.6 months for the hepatobiliary patients. Dolastatin-10 is inactive against hepatobiliary and pancreatic carcinomas.","Clinical Trial, Phase II",5225.0,48.0,Pancreaticobiliary malignancies respond poorly to conventional chemotherapy and novel agents are needed Dolatstatin-10 is a potent antimitotic pentapeptide isolated from the marine mollusk Dolabella auricularia that inhibits microtubule assembly We conducted 2 parallel phase II trials of dolastatin-10 in patients with advanced hepatobiliary cancers and adenocarcinoma Eligible patients had histologically-confirmed metastatic adenocarcinoma or metastatic locally advanced or recurrent cancer of the duct or and had received no prior chemotherapy for advanced disease Dolastatin-10 400 microg/m 2 was administered intravenously by bolus every 21 days Restaging CT scans were obtained every 2 cycles Twenty-eight patients 16 hepatobiliary including 7 hepatomas 6 cholangiocarcinomas 2 carcinomas and 12 carcinomas enrolled 27 were evaluable for response There were no objective responses Grade 3/4 neutropenia occurred in 59 of patients and neutropenic fever in 18 Median and 1-year survival were 5.0 months and 17 for the cancer patients and 3.0 months and 29 for the hepatobiliary patients Median time to progression was 1.3 months for the cancer patients and 1.6 months for the hepatobiliary patients Dolastatin-10 is inactive against hepatobiliary and carcinomas,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[14581, 441, 1892, 1240, 6, 809, 56, 2, 229, 183, 32, 575, 55036, 79, 16, 8, 1157, 19035, 26429, 1355, 29, 3, 8178, 55037, 55038, 55039, 17, 1576, 4621, 7210, 21, 426, 18, 2755, 124, 215, 143, 1, 16686, 79, 4, 7, 5, 131, 4718, 163, 2, 449, 625, 7, 42, 2161, 557, 113, 449, 15, 113, 795, 131, 15, 387, 12, 1, 3, 2920, 15, 2, 42, 103, 77, 324, 56, 9, 131, 34, 16686, 79, 1524, 2440, 188, 18, 10, 468, 1672, 20, 3604, 454, 239, 162, 4275, 425, 1441, 11, 683, 454, 18, 410, 737, 659, 7, 245, 4718, 141, 67, 30324, 49, 9386, 18, 826, 2, 133, 826, 346, 428, 11, 859, 9, 51, 125, 11, 77, 461, 253, 88, 27, 39, 778, 489, 4, 728, 1, 7, 2, 3659, 2775, 4, 203, 52, 2, 14, 111, 25, 11, 33, 13, 53, 2, 269, 9, 3, 12, 7, 2, 27, 13, 53, 2, 462, 9, 3, 4718, 7, 52, 98, 6, 91, 10, 14, 27, 53, 9, 3, 12, 7, 2, 14, 49, 53, 9, 3, 4718, 7, 16686, 79, 16, 5002, 480, 4718, 2, 826]",1266.0,16133801,46
Clinical and pathologic features of proximal biliary strictures masquerading as hilar cholangiocarcinoma.,Journal of the American College of Surgeons,J. Am. Coll. Surg.,2005-10-13,"Nontraumatic inflammatory hilar strictures are uncommon, but are known to mimic malignancy. This study examines the clinical and pathologic features of benign idiopathic strictures. Patients without a history of trauma or earlier biliary operation treated for benign strictures were identified. Clinical information was obtained from the medical record and all resected specimens were reexamined. From January 1992 to July 2003, 275 patients with proximal biliary strictures were referred. Among these, 22 patients had a final histologic diagnosis of benign stricture, despite a suspected preoperative diagnosis of malignancy. All 22 patients underwent resection of the extrahepatic biliary tree, which in 10 patients was combined with en bloc partial hepatectomy. Histologic reexamination identified five different benign processes: lymphoplasmacytic sclerosing pancreatitis and cholangitis, primary sclerosing cholangitis, granulomatous disease, nonspecific fibrosis/inflammation, and stone disease. Major postoperative morbidity occurred in 6 (26%) patients but none died. No preoperative clinical or radiographic features were identified that could reliably distinguish patients with benign strictures from those with cancer. ""Malignant masquerade"" of the proximal bile duct results from several different underlying conditions, and differentiating benign strictures from cancer remains problematic. The treatment approach should continue to be resection for presumed malignancy.",Journal Article,5213.0,86.0,Nontraumatic inflammatory hilar strictures are uncommon but are known to mimic malignancy This study examines the clinical and pathologic features of benign idiopathic strictures Patients without a history of trauma or earlier biliary operation treated for benign strictures were identified Clinical information was obtained from the medical record and all resected specimens were reexamined From January 1992 to July 2003 275 patients with proximal biliary strictures were referred Among these 22 patients had a final histologic diagnosis of benign stricture despite a suspected preoperative diagnosis of malignancy All 22 patients underwent resection of the extrahepatic biliary tree which in 10 patients was combined with en bloc partial hepatectomy Histologic reexamination identified five different benign processes lymphoplasmacytic sclerosing pancreatitis and cholangitis primary sclerosing cholangitis granulomatous disease nonspecific fibrosis/inflammation and stone disease Major postoperative morbidity occurred in 6 26 patients but none died No preoperative clinical or radiographic features were identified that could reliably distinguish patients with benign strictures from those with cancer `` Malignant masquerade '' of the proximal duct results from several different underlying conditions and differentiating benign strictures from cancer remains problematic The treatment approach should continue to be resection for presumed malignancy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26459, 1291, 4793, 7860, 32, 2052, 84, 32, 440, 6, 5356, 710, 26, 45, 4468, 3, 38, 2, 510, 404, 1, 1002, 7540, 7860, 7, 187, 8, 532, 1, 11147, 15, 1677, 2532, 2589, 73, 9, 1002, 7860, 11, 108, 38, 487, 10, 683, 29, 3, 484, 3237, 2, 62, 1133, 623, 11, 20476, 29, 1024, 2846, 6, 2066, 1522, 5620, 7, 5, 2805, 2532, 7860, 11, 1995, 107, 46, 350, 7, 42, 8, 1457, 884, 147, 1, 1002, 6673, 550, 8, 2768, 498, 147, 1, 710, 62, 350, 7, 208, 170, 1, 3, 3710, 2532, 4899, 92, 4, 79, 7, 10, 397, 5, 4375, 5590, 450, 2711, 884, 33636, 108, 365, 338, 1002, 1849, 5325, 6782, 4535, 2, 8541, 86, 6782, 8541, 11186, 34, 5893, 3000, 1815, 2, 17290, 34, 458, 573, 787, 489, 4, 49, 432, 7, 84, 1292, 1016, 77, 498, 38, 15, 1580, 404, 11, 108, 17, 359, 4092, 3081, 7, 5, 1002, 7860, 29, 135, 5, 12, 393, 44169, 522, 1, 3, 2805, 2920, 99, 29, 392, 338, 1181, 1298, 2, 5209, 1002, 7860, 29, 12, 469, 6594, 3, 24, 353, 257, 1906, 6, 40, 170, 9, 5472, 710]",1456.0,16310689,1
Cancer characteristics in Swedish families fulfilling criteria for hereditary nonpolyposis colorectal cancer.,Gastroenterology,Gastroenterology,2005-12-01,"The present study quantified the prevalence of families that fulfill the Amsterdam or Bethesda criteria for hereditary nonpolyposis colorectal cancer (HNPCC) in the whole Swedish population and investigated the extent to which tumors in the classified families are HNPCC-related. The families of the Swedish Family-Cancer Database with at least 4 generations (N = 566,877) were classified according to the Amsterdam and the Bethesda criteria. Survival methods were used to assess the risk of cancer in the classified families, the prognosis of cancer patients, and the risk of subsequent malignancies after colorectal adenomas and after colorectal/endometrial adenocarcinomas. The Bethesda criteria identified 0.9% of all Swedish families and 11.2% of patients with colorectal cancer. Families that fulfilled the Bethesda criteria showed increased risks of cancer in the colorectum, endometrium, small bowel, ovary, stomach, bile ducts, renal pelvis, and ureter; members of Bethesda criteria families were at decreased risks of lung and cervical cancers. The prognosis of cancer in the ureter, renal pelvis, stomach, ovary, and colorectum, but not in the endometrium, was better in Bethesda criteria than in nonclassified families. Most malignancies in the classified families reflect typical features of HNPCC (association with subsequent malignancies, accelerated adenoma-carcinoma sequence, and better survival). The data presented in this study should help to define surveillance strategies for members of families that fulfill the criteria for HNPCC testing.",Journal Article,5164.0,33.0,"The present study quantified the prevalence of families that fulfill the Amsterdam or Bethesda criteria for hereditary nonpolyposis cancer HNPCC in the whole Swedish population and investigated the extent to which tumors in the classified families are HNPCC-related The families of the Swedish Family-Cancer Database with at least 4 generations N 566,877 were classified according to the Amsterdam and the Bethesda criteria Survival methods were used to assess the risk of cancer in the classified families the prognosis of cancer patients and the risk of subsequent malignancies after adenomas and after colorectal/endometrial adenocarcinomas The Bethesda criteria identified 0.9 of all Swedish families and 11.2 of patients with cancer Families that fulfilled the Bethesda criteria showed increased risks of cancer in the colorectum small bowel ovary ducts pelvis and ureter members of Bethesda criteria families were at decreased risks of and cancers The prognosis of cancer in the ureter pelvis ovary and colorectum but not in the was better in Bethesda criteria than in nonclassified families Most malignancies in the classified families reflect typical features of HNPCC association with subsequent malignancies accelerated adenoma-carcinoma sequence and better survival The data presented in this study should help to define surveillance strategies for members of families that fulfill the criteria for HNPCC testing",0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,"[3, 364, 45, 2790, 3, 1078, 1, 1954, 17, 11246, 3, 10531, 15, 8222, 371, 9, 2305, 10786, 12, 6232, 4, 3, 902, 14850, 266, 2, 565, 3, 1039, 6, 92, 57, 4, 3, 1373, 1954, 32, 6232, 139, 3, 1954, 1, 3, 14850, 607, 12, 609, 5, 28, 506, 39, 11083, 78, 14539, 17627, 11, 1373, 768, 6, 3, 10531, 2, 3, 8222, 371, 25, 636, 11, 95, 6, 423, 3, 43, 1, 12, 4, 3, 1373, 1954, 3, 356, 1, 12, 7, 2, 3, 43, 1, 706, 441, 50, 2751, 2, 50, 12863, 18442, 1586, 3, 8222, 371, 108, 13, 83, 1, 62, 14850, 1954, 2, 175, 18, 1, 7, 5, 12, 1954, 17, 9091, 3, 8222, 371, 224, 101, 1098, 1, 12, 4, 3, 12355, 302, 1659, 3631, 7310, 3270, 2, 9775, 1684, 1, 8222, 371, 1954, 11, 28, 340, 1098, 1, 2, 163, 3, 356, 1, 12, 4, 3, 9775, 3270, 3631, 2, 12355, 84, 44, 4, 3, 10, 380, 4, 8222, 371, 76, 4, 55198, 1954, 96, 441, 4, 3, 1373, 1954, 2694, 3476, 404, 1, 6232, 248, 5, 706, 441, 2241, 2434, 134, 1532, 2, 380, 25, 3, 74, 917, 4, 26, 45, 257, 987, 6, 1107, 617, 422, 9, 1684, 1, 1954, 17, 11246, 3, 371, 9, 6232, 471]",1423.0,16344057,21
"Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2006-03-01,"Biliary tract adenocarcinomas (BTAs), although anatomically related, arise through ill-defined and possibly different location-related pathogenetic pathways. This clinicopathologic study characterizes differences in cell cycle-regulatory protein expression across the spectrum of BTA. Tissue microarrays were prepared from paraffin-embedded surgical specimens with triplicate cores of BTA and benign tissue. Immunohistochemical expression of p53, cyclin D1, p21, Bcl2, p27, Mdm2, and Ki-67 was assessed, and the results were correlated with pathologic variables and survival. Hierarchical clustering was used to partition the data based on protein expression, and then the data were analyzed according to anatomic location. Tissue from 128 surgical patients (1992 to 2002) was obtained. Tumor sites of origin were intrahepatic cholangiocarcinoma (IH; n = 23), hilar cholangiocarcinoma (Hilar; n = 54), gallbladder (GB; n = 32), and distal bile duct (Distal; n = 19). p27 expression decreased progressively from proximal to distal in the biliary tree and correlated with location-related differences in outcome; cyclin D1 and Bcl2 overexpression also varied according to anatomic site. Aberrant p53 staining and cyclin D1 overexpression were lower in papillary tumors compared with the more common sclerosing tumors. The expression profiles of GB and Hilar were more similar to each other than either was to IH or Distal (86% clustering in the first partition). After an R0 resection, overexpression of Mdm2 (P = .0062) and absent p27 expression (P = .0165) independently predicted poor outcome. BTAs differentially express cell cycle-regulatory proteins based on tumor location and morphology. Prognostic roles were identified for Mdm2 and p27. Overlap in the pathogenesis of GB and Hilar tumors was suggested.",Journal Article,5074.0,65.0,Biliary tract adenocarcinomas BTAs although anatomically related arise through ill-defined and possibly different location-related pathogenetic pathways This clinicopathologic study characterizes differences in cell cycle-regulatory protein expression across the spectrum of BTA Tissue microarrays were prepared from paraffin-embedded surgical specimens with triplicate cores of BTA and benign tissue Immunohistochemical expression of p53 cyclin D1 p21 Bcl2 p27 Mdm2 and Ki-67 was assessed and the results were correlated with pathologic variables and survival Hierarchical clustering was used to partition the data based on protein expression and then the data were analyzed according to anatomic location Tissue from 128 surgical patients 1992 to 2002 was obtained Tumor sites of origin were intrahepatic cholangiocarcinoma IH n 23 hilar cholangiocarcinoma Hilar n 54 GB n 32 and distal duct Distal n 19 p27 expression decreased progressively from proximal to distal in the biliary tree and correlated with location-related differences in outcome cyclin D1 and Bcl2 overexpression also varied according to anatomic site Aberrant p53 staining and cyclin D1 overexpression were lower in papillary tumors compared with the more common sclerosing tumors The expression profiles of GB and Hilar were more similar to each other than either was to IH or Distal 86 clustering in the first partition After an R0 resection overexpression of Mdm2 P .0062 and absent p27 expression P .0165 independently predicted poor outcome BTAs differentially express cell cycle-regulatory proteins based on tumor location and morphology Prognostic roles were identified for Mdm2 and p27 Overlap in the pathogenesis of GB and Hilar tumors was suggested,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2532, 1696, 1586, 26488, 242, 9622, 139, 3043, 298, 4993, 395, 2, 2150, 338, 1147, 139, 10781, 460, 26, 1399, 45, 9239, 362, 4, 31, 417, 1253, 178, 55, 716, 3, 1873, 1, 24901, 246, 2774, 11, 4421, 29, 2487, 2505, 221, 623, 5, 17116, 4357, 1, 24901, 2, 1002, 246, 1382, 55, 1, 624, 1226, 2146, 2657, 3214, 2804, 3277, 2, 2311, 598, 10, 275, 2, 3, 99, 11, 438, 5, 510, 682, 2, 25, 4466, 3147, 10, 95, 6, 14812, 3, 74, 90, 23, 178, 55, 2, 818, 3, 74, 11, 311, 768, 6, 2745, 1147, 246, 29, 3990, 221, 7, 2846, 6, 1544, 10, 683, 30, 633, 1, 1938, 11, 3022, 2126, 14444, 78, 382, 4793, 2126, 4793, 78, 667, 7832, 78, 531, 2, 2107, 2920, 2107, 78, 326, 2804, 55, 340, 6696, 29, 2805, 6, 2107, 4, 3, 2532, 4899, 2, 438, 5, 1147, 139, 362, 4, 228, 1226, 2146, 2, 3214, 851, 120, 2051, 768, 6, 2745, 606, 1898, 624, 1029, 2, 1226, 2146, 851, 11, 280, 4, 1796, 57, 72, 5, 3, 80, 186, 6782, 57, 3, 55, 1241, 1, 7832, 2, 4793, 11, 80, 288, 6, 296, 127, 76, 361, 10, 6, 14444, 15, 2107, 868, 3147, 4, 3, 157, 14812, 50, 35, 2328, 170, 851, 1, 3277, 19, 26367, 2, 3269, 2804, 55, 19, 38119, 1042, 783, 334, 228, 26488, 2478, 1669, 31, 417, 1253, 652, 90, 23, 30, 1147, 2, 2567, 177, 1790, 11, 108, 9, 3277, 2, 2804, 4526, 4, 3, 1384, 1, 7832, 2, 4793, 57, 10, 1148]",1729.0,16505435,18
Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma.,Clinical lymphoma & myeloma,Clin Lymphoma Myeloma,2006-07-01,"Paraneoplastic cholestasis is an uncommon presenting symptom in Hodgkin's lymphoma (HL). Two distinct entities causing this clinical picture have been described: idiopathic cholestasis and vanishing bile duct syndrome (VBDS). We report a patient with idiopathic cholestasis and early-stage HL with favorable risk factors whose liver biopsy results were consistent with intrahepatic cholestasis and no ductopenia. Other causes for cholestatic jaundice were ruled out. He was treated with subtotal lymphoid irradiation and subsequently experienced a steady improvement in his liver function tests to near normal over 21 months. This case illustrates a rare paraneoplastic phenomenon, and a review of the available literature is included. We also discuss the differences between HL-related idiopathic cholestasis and VBDS. The distinction between these 2 diseases has prognostic implications: idiopathic cholestasis is usually reversible in early-stage HL after treatment, whereas patients who develop VBDS commonly die from their disease. There is no established approach to the management of paraneoplastic cholestasis. We postulate that single-modality radiation therapy alone should be considered a valid treatment alternative in early-stage HL with idiopathic cholestasis.",Case Reports,4952.0,19.0,Paraneoplastic cholestasis is an uncommon presenting symptom in 's HL Two distinct entities causing this clinical picture have been described idiopathic cholestasis and vanishing duct syndrome VBDS We report a patient with idiopathic cholestasis and early-stage HL with favorable risk factors whose biopsy results were consistent with intrahepatic cholestasis and no ductopenia Other causes for cholestatic jaundice were ruled out He was treated with subtotal lymphoid irradiation and subsequently experienced a steady improvement in his function tests to near normal over 21 months This case illustrates a rare paraneoplastic phenomenon and a review of the available literature is included We also discuss the differences between HL-related idiopathic cholestasis and VBDS The distinction between these 2 diseases has prognostic implications idiopathic cholestasis is usually reversible in early-stage HL after treatment whereas patients who develop VBDS commonly die from their disease There is no established approach to the management of paraneoplastic cholestasis We postulate that single-modality radiation therapy alone should be considered a valid treatment alternative in early-stage HL with idiopathic cholestasis,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6544, 19771, 16, 35, 2052, 1656, 934, 4, 292, 1718, 100, 834, 4613, 3440, 26, 38, 8951, 47, 85, 1027, 7540, 19771, 2, 34125, 2920, 681, 38227, 21, 414, 8, 69, 5, 7540, 19771, 2, 191, 82, 1718, 5, 913, 43, 130, 1310, 411, 99, 11, 925, 5, 3022, 19771, 2, 77, 55680, 127, 1626, 9, 24949, 7655, 11, 11901, 1205, 3174, 10, 73, 5, 5503, 2303, 1104, 2, 1611, 592, 8, 4152, 767, 4, 3224, 343, 895, 6, 1829, 295, 252, 239, 53, 26, 473, 6342, 8, 622, 6544, 3936, 2, 8, 206, 1, 3, 390, 789, 16, 159, 21, 120, 1139, 3, 362, 59, 1718, 139, 7540, 19771, 2, 38227, 3, 6628, 59, 46, 18, 1342, 71, 177, 1268, 7540, 19771, 16, 2082, 2786, 4, 191, 82, 1718, 50, 24, 547, 7, 54, 690, 38227, 841, 3384, 29, 136, 34, 125, 16, 77, 635, 353, 6, 3, 284, 1, 6544, 19771, 21, 12071, 17, 226, 1396, 121, 36, 279, 257, 40, 515, 8, 4406, 24, 1091, 4, 191, 82, 1718, 5, 7540, 19771]",1223.0,16879775,67
Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?,The oncologist,Oncologist,,"Worldwide, hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death. In the U.S., 18,510 new cancers of the liver and intrahepatic bile duct are expected in 2006, with an estimated 16,200 deaths. The incidence rates for HCC in the U.S. continued to rise steadily through 1998 and doubled during the period 1975-1995. Unresectable or metastatic HCC carries a poor prognosis, and systemic therapy with cytotoxic agents provides marginal benefit. A majority of HCC patients (>80%) presents with advanced or unresectable disease. Even for those with resected disease, the recurrence rate can be as high as 50% at 2 years. Because of the poor track record of systemic therapy in HCC, there has been a sense of nihilism for this disease in the oncology community for decades. However, with the arrival of newly developed molecularly targeted agents and the success of some of these agents in other traditionally challenging cancers, like renal cell carcinoma, there has recently been renewed interest in developing systemic therapy for HCC. This review attempts to concisely summarize the historical perspective and the current status of systemic therapy development in HCC.",Journal Article,,208.0,"Worldwide carcinoma HCC is the fifth most common cancer and the third most common cause of cancer-related death In the U.S. 18,510 new cancers of the and intrahepatic duct are expected in 2006 with an estimated 16,200 deaths The incidence rates for HCC in the U.S. continued to rise steadily through 1998 and doubled during the period 1975-1995 Unresectable or metastatic HCC carries a poor prognosis and systemic therapy with cytotoxic agents provides marginal benefit A majority of HCC patients 80 presents with advanced or unresectable disease Even for those with resected disease the recurrence rate can be as high as 50 at 2 years Because of the poor track record of systemic therapy in HCC there has been a sense of nihilism for this disease in the oncology community for decades However with the arrival of newly developed molecularly targeted agents and the success of some of these agents in other traditionally challenging cancers like cell carcinoma there has recently been renewed interest in developing systemic therapy for HCC This review attempts to concisely summarize the historical perspective and the current status of systemic therapy development in HCC",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2358, 134, 663, 16, 3, 5780, 96, 186, 12, 2, 3, 1282, 96, 186, 708, 1, 12, 139, 273, 4, 3, 1767, 695, 203, 10211, 217, 163, 1, 3, 2, 3022, 2920, 32, 1336, 4, 1324, 5, 35, 661, 245, 1250, 1043, 3, 287, 151, 9, 663, 4, 3, 1767, 695, 1351, 6, 3693, 7025, 298, 1850, 2, 8431, 190, 3, 727, 7585, 2323, 1468, 15, 113, 663, 4942, 8, 334, 356, 2, 403, 36, 5, 759, 183, 777, 3450, 247, 8, 686, 1, 663, 7, 493, 2740, 5, 131, 15, 1468, 34, 871, 9, 135, 5, 1133, 34, 3, 146, 116, 122, 40, 22, 64, 22, 212, 28, 18, 60, 408, 1, 3, 334, 7446, 3237, 1, 403, 36, 4, 663, 125, 71, 85, 8, 6091, 1, 21180, 9, 26, 34, 4, 3, 413, 1714, 9, 1968, 137, 5, 3, 13286, 1, 732, 276, 2372, 238, 183, 2, 3, 1825, 1, 476, 1, 46, 183, 4, 127, 4206, 1950, 163, 733, 31, 134, 125, 71, 761, 85, 8126, 1333, 4, 931, 403, 36, 9, 663, 26, 206, 4374, 6, 30983, 2479, 3, 2252, 3727, 2, 3, 291, 156, 1, 403, 36, 193, 4, 663]",1173.0,16880238,81
Differential diagnosis of proximal biliary obstruction.,Surgery,Surgery,2006-07-28,"Obstruction at the hepatic duct confluence is generally due to hilar cholangiocarcinoma (HCCA). However, in up to 15% of patients, hilar obstruction could be due to alternative diagnoses other than HCCA. The aim of this study was to determine preoperative criteria that could differentiate HCCA from the alternative diagnoses. All patients with hilar obstruction presumed to represent HCCA were included (1997-2001). The extent of disease was assessed preoperatively with computed tomography, magnetic resonance cholangiopancreatography, and Duplex ultrasonography, and these findings were correlated to the final histopathology. A total of 171 patients were included in the study, with HCCA being the most common diagnosis (141 patients [82.4%], group I). Alternative diagnoses other than HCCA were encountered in 30 patients (17.5%, group II) and included benign stricture (9 patients [5.2%]) and other malignancy (21 patients [12%]). There was a higher incidence of involvement of the second-order bile ducts in group I (26% vs 3% in group II, P<.01). Vascular involvement and lobar atrophy were more common in group I (58% and 41%) when compared with group II (16% and 6%, P<.005 and P<.002). The combination of these 2 findings (vascular invasion+lobar atrophy) was reliable for discriminating patients with HCCA from the alternative diagnoses. (38% in group I and 3.3% in group II, P<.001). Involvement of second-order bile ducts, vascular invasion, and lobar atrophy are more likely in patients with HCCA. The combination of vascular invasion and lobar atrophy significantly increases the diagnostic likelihood of HCCA. The absence of these findings should raise awareness of the possibility of an alternative diagnosis.",Journal Article,4925.0,42.0,Obstruction at the hepatic duct confluence is generally due to hilar cholangiocarcinoma HCCA However in up to 15 of patients hilar obstruction could be due to alternative diagnoses other than HCCA The aim of this study was to determine preoperative criteria that could differentiate HCCA from the alternative diagnoses All patients with hilar obstruction presumed to represent HCCA were included 1997-2001 The extent of disease was assessed preoperatively with computed tomography magnetic resonance cholangiopancreatography and Duplex ultrasonography and these findings were correlated to the final histopathology A total of 171 patients were included in the study with HCCA being the most common diagnosis 141 patients 82.4 group I Alternative diagnoses other than HCCA were encountered in 30 patients 17.5 group II and included benign stricture 9 patients 5.2 and other malignancy 21 patients 12 There was a higher incidence of involvement of the second-order ducts in group I 26 vs 3 in group II P .01 Vascular involvement and lobar atrophy were more common in group I 58 and 41 when compared with group II 16 and 6 P .005 and P .002 The combination of these 2 findings vascular invasion+lobar atrophy was reliable for discriminating patients with HCCA from the alternative diagnoses 38 in group I and 3.3 in group II P .001 Involvement of second-order ducts vascular invasion and lobar atrophy are more likely in patients with HCCA The combination of vascular invasion and lobar atrophy significantly increases the diagnostic likelihood of HCCA The absence of these findings should raise awareness of the possibility of an alternative diagnosis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3191, 28, 3, 939, 2920, 15845, 16, 1228, 520, 6, 4793, 2126, 9280, 137, 4, 126, 6, 167, 1, 7, 4793, 3191, 359, 40, 520, 6, 1091, 2403, 127, 76, 9280, 3, 1130, 1, 26, 45, 10, 6, 223, 498, 371, 17, 359, 3723, 9280, 29, 3, 1091, 2403, 62, 7, 5, 4793, 3191, 5472, 6, 1231, 9280, 11, 159, 2341, 1758, 3, 1039, 1, 34, 10, 275, 3888, 5, 1220, 872, 1484, 1535, 15476, 2, 18327, 4244, 2, 46, 272, 11, 438, 6, 3, 1457, 3831, 8, 181, 1, 5702, 7, 11, 159, 4, 3, 45, 5, 9280, 486, 3, 96, 186, 147, 4379, 7, 878, 39, 87, 70, 1091, 2403, 127, 76, 9280, 11, 3903, 4, 201, 7, 269, 33, 87, 215, 2, 159, 1002, 6673, 83, 7, 33, 18, 2, 127, 710, 239, 7, 133, 125, 10, 8, 142, 287, 1, 799, 1, 3, 419, 1732, 7310, 4, 87, 70, 432, 105, 27, 4, 87, 215, 19, 355, 756, 799, 2, 9919, 7637, 11, 80, 186, 4, 87, 70, 717, 2, 605, 198, 72, 5, 87, 215, 245, 2, 49, 19, 1614, 2, 19, 1111, 3, 150, 1, 46, 18, 272, 756, 578, 9919, 7637, 10, 2450, 9, 8059, 7, 5, 9280, 29, 3, 1091, 2403, 519, 4, 87, 70, 2, 27, 27, 4, 87, 215, 19, 144, 799, 1, 419, 1732, 7310, 756, 578, 2, 9919, 7637, 32, 80, 322, 4, 7, 5, 9280, 3, 150, 1, 756, 578, 2, 9919, 7637, 97, 1106, 3, 752, 1420, 1, 9280, 3, 1127, 1, 46, 272, 257, 5008, 3310, 1, 3, 2526, 1, 35, 1091, 147]",1649.0,17084718,82
Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy.,Critical reviews in oncology/hematology,Crit. Rev. Oncol. Hematol.,2007-01-01,"Adenocarcinomas of the gallbladder (GBC) and bile ducts (cholangiocarcinoma) (combined as biliary tract cancers, BTC) are uncommon tumors in the United States, but are endemic in parts of South America and Asia. BTC are aggressive tumors with poor survival. Published response rates to chemotherapy are less than 30% and no survival benefit has been demonstrated from palliative systemic therapy. Improved understanding of the biological characteristics and molecular carcinogenic mechanisms of these malignancies may lead to improved therapeutic regimens for patients.",Journal Article,4768.0,37.0,Adenocarcinomas of the GBC and ducts cholangiocarcinoma combined as biliary tract cancers BTC are uncommon tumors in the United States but are endemic in parts of South America and Asia BTC are aggressive tumors with poor survival Published response rates to chemotherapy are less than 30 and no survival benefit has been demonstrated from palliative systemic therapy Improved understanding of the biological characteristics and molecular carcinogenic mechanisms of these malignancies may lead to improved therapeutic regimens for patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1586, 1, 3, 6344, 2, 7310, 2126, 397, 22, 2532, 1696, 163, 8112, 32, 2052, 57, 4, 3, 1088, 907, 84, 32, 15483, 4, 6532, 1, 5452, 4010, 2, 5958, 8112, 32, 571, 57, 5, 334, 25, 983, 51, 151, 6, 56, 32, 299, 76, 201, 2, 77, 25, 247, 71, 85, 264, 29, 994, 403, 36, 231, 612, 1, 3, 1037, 374, 2, 219, 7483, 483, 1, 46, 441, 68, 1122, 6, 231, 189, 472, 9, 7]",539.0,17164111,85
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2007-02-02,"To examine the effect of adjuvant chemoradiation for adenocarcinoma of the distal common bile duct (DCBD) after pancreaticoduodenectomy (PD) on local control and survival. A total of 34 cases of adenocarcinoma of the DCBD were treated with PD and adjuvant chemoradiation at Johns Hopkins Hospital between 1994 and 2003. Median radiation dose was 5,040 cGy (range, 4,000-5,400 cGy). Concurrent 5-fluorouracil-based chemotherapy was given with radiation therapy, followed by maintenance chemotherapy. The median follow-up of patients alive at the time of analysis was 41 months. Death occurred in 21 of 34 patients (62%) during the follow-up period, all from progressive, distant metastatic disease. Median overall survival was 36.9 months, with a 5-year survival of 35%. On multivariate analysis, only nodal status significantly predicted survival (p < 0.02). For patients with negative and positive lymph nodes, 5-year survival was 100% and 24%, respectively. Actuarial 5-year local control was 70%. Compared with historical controls who underwent PD alone, patients who underwent surgery and adjuvant chemoradiation had significantly longer survival (36.9 months vs. 22 months; p < 0.05). Overall survival was significantly longer for both lymph node negative and lymph node positive patients (p < 0.05). Adjuvant chemoradiation after PD for adenocarcinoma of the DCBD may improve local control and overall survival. The predominant mode of failure is distant metastatic disease, highlighting the need for improved systemic therapy.",Journal Article,4736.0,82.0,"To examine the effect of adjuvant chemoradiation for adenocarcinoma of the distal common duct DCBD after pancreaticoduodenectomy PD on local control and survival A total of 34 cases of adenocarcinoma of the DCBD were treated with PD and adjuvant chemoradiation at Johns Hopkins Hospital between 1994 and 2003 Median radiation dose was 5,040 cGy range 4,000-5,400 cGy Concurrent 5-fluorouracil-based chemotherapy was given with radiation therapy followed by maintenance chemotherapy The median follow-up of patients alive at the time of analysis was 41 months Death occurred in 21 of 34 patients 62 during the follow-up period all from progressive distant metastatic disease Median overall survival was 36.9 months with a 5-year survival of 35 On multivariate analysis only nodal status significantly predicted survival p 0.02 For patients with negative and positive lymph nodes 5-year survival was 100 and 24 respectively Actuarial 5-year local control was 70 Compared with historical controls who underwent PD alone patients who underwent surgery and adjuvant chemoradiation had significantly longer survival 36.9 months vs. 22 months p 0.05 Overall survival was significantly longer for both lymph node negative and lymph node positive patients p 0.05 Adjuvant chemoradiation after PD for adenocarcinoma of the DCBD may improve local control and overall survival The predominant mode of failure is distant metastatic disease highlighting the need for improved systemic therapy",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1004, 3, 254, 1, 249, 975, 9, 449, 1, 3, 2107, 186, 2920, 38359, 50, 4104, 333, 23, 293, 182, 2, 25, 8, 181, 1, 562, 140, 1, 449, 1, 3, 38359, 11, 73, 5, 333, 2, 249, 975, 28, 5848, 5569, 702, 59, 3023, 2, 1522, 52, 121, 61, 10, 33, 6824, 3071, 184, 39, 984, 33, 1524, 3071, 750, 33, 1404, 90, 56, 10, 447, 5, 121, 36, 370, 20, 1146, 56, 3, 52, 166, 126, 1, 7, 1701, 28, 3, 98, 1, 65, 10, 605, 53, 273, 489, 4, 239, 1, 562, 7, 744, 190, 3, 166, 126, 727, 62, 29, 1014, 626, 113, 34, 52, 63, 25, 10, 511, 83, 53, 5, 8, 33, 111, 25, 1, 465, 23, 331, 65, 158, 779, 156, 97, 783, 25, 19, 13, 588, 9, 7, 5, 199, 2, 109, 263, 502, 33, 111, 25, 10, 394, 2, 259, 106, 2361, 33, 111, 293, 182, 10, 431, 72, 5, 2252, 535, 54, 208, 333, 279, 7, 54, 208, 152, 2, 249, 975, 42, 97, 589, 25, 511, 83, 53, 105, 350, 53, 19, 13, 474, 63, 25, 10, 97, 589, 9, 110, 263, 289, 199, 2, 263, 289, 109, 7, 19, 13, 474, 249, 975, 50, 333, 9, 449, 1, 3, 38359, 68, 401, 293, 182, 2, 63, 25, 3, 2750, 4530, 1, 496, 16, 626, 113, 34, 4051, 3, 594, 9, 231, 403, 36]",1478.0,17276614,107
"Lymph node dissection impact on staging and survival of extrahepatic cholangiocarcinomas, based on U.S. population data.",Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,J. Gastrointest. Surg.,2007-02-01,"Cholangiocarcinomas (CC) frequently demonstrate lymphatic spread. We investigated lymph node (LN) counts after resection of extrahepatic CC and survival based on the SEER 1973-2004 database. Out of 20,068 CC patients, 1,518 individuals were selected based on M0 stage and at least one LN examined. Primary cancer sites included gallbladder (29%), extrahepatic bile ducts (26%), and intrapancreatic/ampullary bile ducts (45%); 42% of patients were LN-positive. The median number of LNs examined was four (range 1-39). Median survival was 37 months for LN-negative and 16 months for LN-positive cancers. Multivariate prognostic variables were the number of positive LNs, primary site, age (all at p < 0.0001), gender (p = 0.002), size (p = 0.005), T category (p = 0.009), and total LN count (or number of negative LNs obtained, p = 0.01). The impact of total LN counts was seen in LN-negative (median survival, 1 vs 10 or more LNs examined: 27 vs 51 months, p = 0.002) and LN-positive disease (10 vs 22 months, p < 0.0001). Survival prediction of extrahepatic CCs is strongly influenced by total LN counts and numbers of negative LNs obtained. Although the resulting incremental benefit is small, dissection and examination of 10 or more LNs should be considered for curative intent resections.",Journal Article,4737.0,39.0,"Cholangiocarcinomas CC frequently demonstrate lymphatic spread We investigated lymph node LN counts after resection of extrahepatic CC and survival based on the SEER 1973-2004 database Out of 20,068 CC patients 1,518 individuals were selected based on M0 stage and at least one LN examined Primary cancer sites included 29 extrahepatic ducts 26 and intrapancreatic/ampullary ducts 45 42 of patients were LN-positive The median number of LNs examined was four range 1-39 Median survival was 37 months for LN-negative and 16 months for LN-positive cancers Multivariate prognostic variables were the number of positive LNs primary site age all at p 0.0001 gender p 0.002 size p 0.005 T category p 0.009 and total LN count or number of negative LNs obtained p 0.01 The impact of total LN counts was seen in LN-negative median survival 1 vs 10 or more LNs examined 27 vs 51 months p 0.002 and LN-positive disease 10 vs 22 months p 0.0001 Survival prediction of extrahepatic CCs is strongly influenced by total LN counts and numbers of negative LNs obtained Although the resulting incremental benefit is small dissection and examination of 10 or more LNs should be considered for curative intent resections",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[9386, 1951, 746, 608, 2936, 2579, 21, 565, 263, 289, 1763, 1911, 50, 170, 1, 3710, 1951, 2, 25, 90, 23, 3, 1605, 4756, 1131, 609, 1205, 1, 179, 13402, 1951, 7, 14, 10978, 869, 11, 715, 90, 23, 4591, 82, 2, 28, 506, 104, 1763, 409, 86, 12, 633, 159, 462, 3710, 7310, 432, 2, 38403, 6762, 7310, 512, 595, 1, 7, 11, 1763, 109, 3, 52, 207, 1, 2704, 409, 10, 294, 184, 14, 587, 52, 25, 10, 567, 53, 9, 1763, 199, 2, 245, 53, 9, 1763, 109, 163, 331, 177, 682, 11, 3, 207, 1, 109, 2704, 86, 606, 89, 62, 28, 19, 13, 488, 1632, 19, 13, 1111, 444, 19, 13, 1614, 102, 2169, 19, 13, 2376, 2, 181, 1763, 1276, 15, 207, 1, 199, 2704, 683, 19, 13, 355, 3, 345, 1, 181, 1763, 1911, 10, 527, 4, 1763, 199, 52, 25, 14, 105, 79, 15, 80, 2704, 409, 428, 105, 725, 53, 19, 13, 1111, 2, 1763, 109, 34, 79, 105, 350, 53, 19, 13, 488, 25, 1590, 1, 3710, 5688, 16, 1327, 2574, 20, 181, 1763, 1911, 2, 1870, 1, 199, 2704, 683, 242, 3, 1113, 3648, 247, 16, 302, 1161, 2, 1385, 1, 79, 15, 80, 2704, 257, 40, 515, 9, 1075, 1697, 2185]",1200.0,17390167,7
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.,Annals of surgery,Ann. Surg.,2007-05-01,"To assess long-term survival and prognostic factors in a large series of patients with bile duct cancer. The incidence of bile duct cancer is low but increasing. Determinants of survival vary in the literature, due to a lack of sufficient numbers of patients in most series. We studied 564 consecutive patients with bile duct cancer operated upon between 1973 and 2004. Patients were divided into intrahepatic, perihilar, and distal groups. Principle outcome measures were complications, 30-day mortality, and survival. Of the 564 patients, 44 (8%) had intrahepatic, 281 (50%) had perihilar, and 239 (42%) had distal tumors. Approximately half (294, 52%) were treated before 1995, while 270 (48%) were treated thereafter. The perioperative mortality rate was 4%. In log-rank analyses, survival was higher in the later time period (P = 0.002), in patients with intrahepatic disease (P = 0.001), with negative resection margins (P < 0.001), with well/moderately differentiated tumors (P < 0.001), and those with negative lymph nodal status (P < 0.001). In multivariate analysis, negative margins (P < 0.001), tumor differentiation (P < 0.001), and negative nodal status (P < 0.001), but not tumor diameter, were significant independent prognostic factors. In R0-resected patients, lymph node status (P < 0.001), but not tumor diameter, histology, or differentiation, further predicted survival. The median survivals for R0-resected intrahepatic, perihilar, and distal tumors were 80, 30, and 25 months, respectively, and the 5-year survivals were 63%, 30%, and 27%, respectively. R0 resection remains the best chance for long-term survival, and lymph node status is the most important prognostic factor following R0 resection.",Journal Article,4648.0,643.0,To assess long-term survival and prognostic factors in a large series of patients with duct cancer The incidence of duct cancer is low but increasing Determinants of survival vary in the literature due to a lack of sufficient numbers of patients in most series We studied 564 consecutive patients with duct cancer operated upon between 1973 and 2004 Patients were divided into intrahepatic perihilar and distal groups Principle outcome measures were complications 30-day mortality and survival Of the 564 patients 44 8 had intrahepatic 281 50 had perihilar and 239 42 had distal tumors Approximately half 294 52 were treated before 1995 while 270 48 were treated thereafter The perioperative mortality rate was 4 In log-rank analyses survival was higher in the later time period P 0.002 in patients with intrahepatic disease P 0.001 with negative resection margins P 0.001 with well/moderately differentiated tumors P 0.001 and those with negative lymph nodal status P 0.001 In multivariate analysis negative margins P 0.001 tumor differentiation P 0.001 and negative nodal status P 0.001 but not tumor diameter were significant independent prognostic factors In R0-resected patients lymph node status P 0.001 but not tumor diameter histology or differentiation further predicted survival The median survivals for R0-resected intrahepatic perihilar and distal tumors were 80 30 and 25 months respectively and the 5-year survivals were 63 30 and 27 respectively R0 resection remains the best chance for long-term survival and lymph node status is the most important prognostic factor following R0 resection,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 423, 319, 337, 25, 2, 177, 130, 4, 8, 375, 988, 1, 7, 5, 2920, 12, 3, 287, 1, 2920, 12, 16, 154, 84, 602, 3403, 1, 25, 2825, 4, 3, 789, 520, 6, 8, 926, 1, 1952, 1870, 1, 7, 4, 96, 988, 21, 656, 11090, 935, 7, 5, 2920, 12, 7297, 1548, 59, 4756, 2, 1131, 7, 11, 2176, 237, 3022, 9124, 2, 2107, 271, 4968, 228, 1018, 11, 521, 201, 218, 282, 2, 25, 1, 3, 11090, 7, 584, 66, 42, 3022, 8970, 212, 42, 9124, 2, 7141, 595, 42, 2107, 57, 705, 1303, 8375, 653, 11, 73, 348, 2323, 369, 6666, 576, 11, 73, 3972, 3, 1547, 282, 116, 10, 39, 4, 1066, 1026, 318, 25, 10, 142, 4, 3, 1559, 98, 727, 19, 13, 1111, 4, 7, 5, 3022, 34, 19, 13, 144, 5, 199, 170, 1012, 19, 13, 144, 5, 149, 3508, 1442, 57, 19, 13, 144, 2, 135, 5, 199, 263, 779, 156, 19, 13, 144, 4, 331, 65, 199, 1012, 19, 13, 144, 30, 910, 19, 13, 144, 2, 199, 779, 156, 19, 13, 144, 84, 44, 30, 2549, 11, 93, 306, 177, 130, 4, 2328, 1133, 7, 263, 289, 156, 19, 13, 144, 84, 44, 30, 2549, 784, 15, 910, 195, 783, 25, 3, 52, 3794, 9, 2328, 1133, 3022, 9124, 2, 2107, 57, 11, 493, 201, 2, 243, 53, 106, 2, 3, 33, 111, 3794, 11, 676, 201, 2, 428, 106, 2328, 170, 469, 3, 824, 3477, 9, 319, 337, 25, 2, 263, 289, 156, 16, 3, 96, 305, 177, 161, 366, 2328, 170]",1605.0,17457168,97
High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma.,American journal of surgery,Am. J. Surg.,2007-06-01,"Despite the use of radiologic, endoscopic, and laparoscopic staging techniques, the rate of nontherapeutic laparotomies in patients with hilar cholangiocarcinoma remains high. This study evaluated the accuracy of preoperative high-resolution computed tomography (HRCT) to determine resectability in this setting. Preoperative helical HRCT (2 contrast phases, rapid intravenous contrast bolus, 2.5-mm section thickness) for 32 consecutive patients who underwent laparotomy for the diagnosis of hilar cholangiocarcinoma from 2000 to 2005 were reviewed by a hepatobiliary radiologist. The accuracy of HRCT was determined by comparison of the imaging interpretation to intraoperative and pathologic findings. The chi-square test was used to identify imaging findings that best predicted unresectability. Fourteen of the 32 (44%) study patients were unresectable (extension along bile duct, 4; peritoneal metastases, 4; vascular encasement, 3; noncontiguous liver metastases, 2; N2 lymphadenopathy, 1). HRCT correctly predicted resectability in 17 of 18 patients who underwent therapeutic laparotomy (sensitivity = 94%). HRCT correctly predicted the inability to resect in 11 of the remaining 14 cases (specificity = 79%). In the 3 cases in which HRCT predicted resectability and the patient was unresectable, subcentimeter peritoneal disease, a subcentimeter liver metastasis, and distal bile duct involvement were responsible factors. The negative and positive predictive values of HRCT were 92% and 85%, respectively. Individual radiographic findings that best predicted unresectability were peritoneal spread (P = .015) and hepatic artery (P = .006) or portal vein (P = .002) involvement. Preoperative HRCT accurately predicts resectability in patients with hilar cholangiocarcinoma. Identification of specific radiographic features, in particular major vascular involvement and peritoneal abnormalities, is now used by our group to avoid unnecessary laparotomy.",Journal Article,4617.0,62.0,Despite the use of radiologic endoscopic and laparoscopic staging techniques the rate of nontherapeutic laparotomies in patients with hilar cholangiocarcinoma remains high This study evaluated the accuracy of preoperative high-resolution computed tomography HRCT to determine resectability in this setting Preoperative helical HRCT 2 contrast phases rapid intravenous contrast bolus 2.5-mm section thickness for 32 consecutive patients who underwent laparotomy for the diagnosis of hilar cholangiocarcinoma from 2000 to 2005 were reviewed by a hepatobiliary radiologist The accuracy of HRCT was determined by comparison of the imaging interpretation to intraoperative and pathologic findings The chi-square test was used to identify imaging findings that best predicted unresectability Fourteen of the 32 44 study patients were unresectable extension along duct 4 peritoneal metastases 4 vascular encasement 3 noncontiguous metastases 2 N2 lymphadenopathy 1 HRCT correctly predicted resectability in 17 of 18 patients who underwent therapeutic laparotomy sensitivity 94 HRCT correctly predicted the inability to resect in 11 of the remaining 14 cases specificity 79 In the 3 cases in which HRCT predicted resectability and the patient was unresectable subcentimeter peritoneal disease a subcentimeter metastasis and distal duct involvement were responsible factors The negative and positive predictive values of HRCT were 92 and 85 respectively Individual radiographic findings that best predicted unresectability were peritoneal spread P .015 and hepatic artery P .006 or portal vein P .002 involvement Preoperative HRCT accurately predicts resectability in patients with hilar cholangiocarcinoma Identification of specific radiographic features in particular major vascular involvement and peritoneal abnormalities is now used by our group to avoid unnecessary laparotomy,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[550, 3, 119, 1, 2812, 2056, 2, 1964, 632, 1092, 3, 116, 1, 15602, 18839, 4, 7, 5, 4793, 2126, 469, 64, 26, 45, 194, 3, 1190, 1, 498, 64, 2125, 1220, 872, 25009, 6, 223, 5150, 4, 26, 546, 498, 6638, 25009, 18, 748, 3523, 1321, 1262, 748, 3604, 18, 33, 321, 2917, 2903, 9, 531, 935, 7, 54, 208, 3274, 9, 3, 147, 1, 4793, 2126, 29, 1081, 6, 1242, 11, 446, 20, 8, 4718, 6247, 3, 1190, 1, 25009, 10, 509, 20, 1155, 1, 3, 270, 3037, 6, 1720, 2, 510, 272, 3, 3163, 3219, 412, 10, 95, 6, 255, 270, 272, 17, 824, 783, 16418, 3225, 1, 3, 531, 584, 45, 7, 11, 1468, 2401, 1510, 2920, 39, 1639, 196, 39, 756, 14229, 27, 28108, 196, 18, 3473, 4962, 14, 25009, 4911, 783, 5150, 4, 269, 1, 203, 7, 54, 208, 189, 3274, 485, 960, 25009, 4911, 783, 3, 4985, 6, 13798, 4, 175, 1, 3, 1844, 213, 140, 1121, 842, 4, 3, 27, 140, 4, 92, 25009, 783, 5150, 2, 3, 69, 10, 1468, 16262, 1639, 34, 8, 16262, 278, 2, 2107, 2920, 799, 11, 2327, 130, 3, 199, 2, 109, 464, 1030, 1, 25009, 11, 937, 2, 772, 106, 797, 1580, 272, 17, 824, 783, 16418, 11, 1639, 2579, 19, 3433, 2, 939, 2872, 19, 1861, 15, 3307, 2762, 19, 1111, 799, 498, 25009, 2141, 2623, 5150, 4, 7, 5, 4793, 2126, 911, 1, 112, 1580, 404, 4, 1454, 458, 756, 799, 2, 1639, 1171, 16, 1134, 95, 20, 114, 87, 6, 3085, 4224, 3274]",1873.0,17512280,86
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.,Digestive diseases and sciences,Dig. Dis. Sci.,2007-06-29,"There is no standard chemotherapy option for patients with biliary tract cancers. These patients present fairly ill and can have a rapid progression of disease. We conducted a multi-center, phase-II trial for patients with locally unresectable or metastatic bile duct or gallbladder adenocarcinomas using a modified regimen of gemcitabine and cisplatin to potentially improve tolerability. Patients received a 21-day treatment cycle of gemcitabine at 1,000 mg/m2 and cisplatin at 30 mg/m2 on days 1 and 8. To participate, 33 patients signed informed consent, and 30 patients received at least one dose of chemotherapy. By intention-to-treat analyses, 7 patients (21%) experienced a partial response and another 12 (36%) had stable disease for at least 12 weeks. The median progression-free survival was 6.3 months and median overall survival was 9.7 months. After 1 year, 39% of patients were alive. Most common grade 3-4 toxicities included neutropenia (33%), thrombocytopenia (23%), anemia (20%), nausea (20%), emesis (13%) and fatigue (10%). Of note, 52% of patients withdrew from study treatment, principally due to treatment-related adverse events. We concluded that this modified regimen appeared to have comparable activity to other gemcitabine and cisplatin regimens against advanced bile duct and gallbladder cancers, but there was still moderate toxicity in this patient population.","Clinical Trial, Phase II",4589.0,45.0,"There is no standard chemotherapy option for patients with biliary tract cancers These patients present fairly ill and can have a rapid progression of disease We conducted a multi-center phase-II trial for patients with locally unresectable or metastatic duct or adenocarcinomas using a modified regimen of gemcitabine and cisplatin to potentially improve tolerability Patients received a 21-day treatment cycle of gemcitabine at 1,000 mg/m2 and cisplatin at 30 mg/m2 on days 1 and 8 To participate 33 patients signed informed consent and 30 patients received at least one dose of chemotherapy By intention-to-treat analyses 7 patients 21 experienced a partial response and another 12 36 had stable disease for at least 12 weeks The median progression-free survival was 6.3 months and median overall survival was 9.7 months After 1 year 39 of patients were alive Most common grade 3-4 toxicities included neutropenia 33 thrombocytopenia 23 anemia 20 nausea 20 emesis 13 and fatigue 10 Of note 52 of patients withdrew from study treatment principally due to treatment-related adverse events We concluded that this modified regimen appeared to have comparable activity to other gemcitabine and cisplatin regimens against advanced duct and cancers but there was still moderate toxicity in this patient population",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[125, 16, 77, 260, 56, 1501, 9, 7, 5, 2532, 1696, 163, 46, 7, 364, 9971, 4993, 2, 122, 47, 8, 1321, 91, 1, 34, 21, 426, 8, 1414, 574, 124, 215, 160, 9, 7, 5, 795, 1468, 15, 113, 2920, 15, 1586, 75, 8, 1230, 477, 1, 679, 2, 540, 6, 751, 401, 1543, 7, 103, 8, 239, 218, 24, 417, 1, 679, 28, 14, 984, 81, 821, 2, 540, 28, 201, 81, 821, 23, 162, 14, 2, 66, 6, 3506, 466, 7, 7717, 2767, 3844, 2, 201, 7, 103, 28, 506, 104, 61, 1, 56, 20, 3205, 6, 943, 318, 67, 7, 239, 592, 8, 450, 51, 2, 1809, 133, 511, 42, 585, 34, 9, 28, 506, 133, 244, 3, 52, 91, 115, 25, 10, 49, 27, 53, 2, 52, 63, 25, 10, 83, 67, 53, 50, 14, 111, 587, 1, 7, 11, 1701, 96, 186, 88, 27, 39, 385, 159, 778, 466, 1340, 382, 1545, 179, 1218, 179, 6899, 233, 2, 613, 79, 1, 5739, 653, 1, 7, 7939, 29, 45, 24, 10257, 520, 6, 24, 139, 290, 281, 21, 4724, 17, 26, 1230, 477, 2121, 6, 47, 1279, 128, 6, 127, 679, 2, 540, 472, 480, 131, 2920, 2, 163, 84, 125, 10, 1234, 1163, 155, 4, 26, 69, 266]",1309.0,17597402,54
Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection.,Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,J. Gastrointest. Surg.,2007-09-11,"Re-resection for gallbladder carcinoma incidentally discovered after cholecystectomy is routinely advocated. However, the incidence of finding additional disease at the time of re-resection remains poorly defined. Between 1984 and 2006, 115 patients underwent re-resection at six major hepatobiliary centers for gallbladder carcinoma incidentally discovered during cholecystectomy. Data on clinicopathologic factors, operative details, TNM tumor stage, and outcome were collected and analyzed. Data on the incidence and location of residual/additional carcinoma discovered at the time of re-resection were also recorded. On pathologic analysis, T stage was T1 7.8%, T2 67.0%, and T3 25.2%. The median time from cholecystectomy to re-resection was 52 days. At the time of re-resection, hepatic surgery most often consisted of formal segmentectomy (64.9%). Patients underwent lymphadenectomy (LND) (50.5%) or LND + common bile duct resection (43.3%). The median number of lymph nodes harvested was 3 and did not differ between LND alone (n = 3) vs LND + common duct resection (n = 3) (P = 0.35). Pathology from the re-resection specimen noted residual/additional disease in 46.4% of patients. Of those patients staged as T1, T2, or T3, 0, 10.4, and 36.4%, respectively, had residual disease within the liver (P = 0.01). T stage was also associated with the risk of metastasis to locoregional lymph nodes (lymph node metastasis: T1 12.5%; T2 31.3%, T3 45.5%; P = 0.04). Cystic duct margin status predicted residual disease in the common bile duct (negative cystic duct, 4.3% vs positive cystic duct, 42.1%) (P = 0.01). Aggressive re-resection for incidental gallbladder carcinoma is warranted as the majority of patients have residual disease. Although common duct resection does not yield a greater lymph node count, it should be performed at the time of re-resection for patients with positive cystic duct margins because over one-third will have residual disease in the common bile duct.",Journal Article,4515.0,153.0,Re-resection for carcinoma incidentally discovered after cholecystectomy is routinely advocated However the incidence of finding additional disease at the time of re-resection remains poorly defined Between 1984 and 2006 115 patients underwent re-resection at six major hepatobiliary centers for carcinoma incidentally discovered during cholecystectomy Data on clinicopathologic factors operative details TNM tumor stage and outcome were collected and analyzed Data on the incidence and location of residual/additional carcinoma discovered at the time of re-resection were also recorded On pathologic analysis T stage was T1 7.8 T2 67.0 and T3 25.2 The median time from cholecystectomy to re-resection was 52 days At the time of re-resection hepatic surgery most often consisted of formal segmentectomy 64.9 Patients underwent lymphadenectomy LND 50.5 or LND common duct resection 43.3 The median number of lymph nodes harvested was 3 and did not differ between LND alone n 3 vs LND common duct resection n 3 P 0.35 Pathology from the re-resection specimen noted residual/additional disease in 46.4 of patients Of those patients staged as T1 T2 or T3 0 10.4 and 36.4 respectively had residual disease within the P 0.01 T stage was also associated with the risk of metastasis to locoregional lymph nodes lymph node metastasis T1 12.5 T2 31.3 T3 45.5 P 0.04 Cystic duct margin status predicted residual disease in the common duct negative cystic duct 4.3 vs positive cystic duct 42.1 P 0.01 Aggressive re-resection for incidental carcinoma is warranted as the majority of patients have residual disease Although common duct resection does not yield a greater lymph node count it should be performed at the time of re-resection for patients with positive cystic duct margins because over one-third will have residual disease in the common duct,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1491, 170, 9, 134, 5925, 2747, 50, 8493, 16, 3066, 8866, 137, 3, 287, 1, 1567, 402, 34, 28, 3, 98, 1, 1491, 170, 469, 1240, 395, 59, 6036, 2, 1324, 3670, 7, 208, 1491, 170, 28, 437, 458, 4718, 1168, 9, 134, 5925, 2747, 190, 8493, 74, 23, 1399, 130, 1208, 3791, 2918, 30, 82, 2, 228, 11, 786, 2, 311, 74, 23, 3, 287, 2, 1147, 1, 753, 402, 134, 2747, 28, 3, 98, 1, 1491, 170, 11, 120, 1872, 23, 510, 65, 102, 82, 10, 1534, 67, 66, 1786, 598, 13, 2, 2065, 243, 18, 3, 52, 98, 29, 8493, 6, 1491, 170, 10, 653, 162, 28, 3, 98, 1, 1491, 170, 939, 152, 96, 629, 1695, 1, 5057, 16767, 660, 83, 7, 208, 2048, 3400, 212, 33, 15, 3400, 186, 2920, 170, 601, 27, 3, 52, 207, 1, 263, 502, 6503, 10, 27, 2, 205, 44, 1505, 59, 3400, 279, 78, 27, 105, 3400, 186, 2920, 170, 78, 27, 19, 13, 465, 1117, 29, 3, 1491, 170, 2360, 1051, 753, 402, 34, 4, 641, 39, 1, 7, 1, 135, 7, 2930, 22, 1534, 1786, 15, 2065, 13, 79, 39, 2, 511, 39, 106, 42, 753, 34, 262, 3, 19, 13, 355, 102, 82, 10, 120, 41, 5, 3, 43, 1, 278, 6, 1325, 263, 502, 263, 289, 278, 1534, 133, 33, 1786, 456, 27, 2065, 512, 33, 19, 13, 755, 2965, 2920, 959, 156, 783, 753, 34, 4, 3, 186, 2920, 199, 2965, 2920, 39, 27, 105, 109, 2965, 2920, 595, 14, 19, 13, 355, 571, 1491, 170, 9, 4490, 134, 16, 1197, 22, 3, 686, 1, 7, 47, 753, 34, 242, 186, 2920, 170, 1097, 44, 2309, 8, 378, 263, 289, 1276, 192, 257, 40, 173, 28, 3, 98, 1, 1491, 170, 9, 7, 5, 109, 2965, 2920, 1012, 408, 252, 104, 1282, 303, 47, 753, 34, 4, 3, 186, 2920]",1840.0,17846848,33
Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?,Cancer,Cancer,2007-12-01,"To date, no consensus has been reached regarding which primary tumor subtypes are managed appropriately with hepatic metastectomy. Specifically, the role of hepatic resection for metastatic periampullary or pancreatic adenocarcinoma remains controversial. Between 1995 and 2005, 1563 patients underwent surgical resection for periampullary carcinoma (n=608 patients) or pancreatic adenocarcinoma (head, n=905 patients; tail, n=50 patients). Data on demographics, operative details, primary tumor status, and-when indicated-extent of hepatic metastasis were collected. Of the 1563 patients who underwent resection of periampullary or pancreatic adenocarcinoma, 22 patients (1.4%) underwent simultaneous hepatic resection for synchronous liver metastasis. The primary tumor site was ampullary (n=1 patient ), duodenal (n=2 patients), distal bile duct (n=2 patients), or pancreas (head, n=10 patients; tail, n=7 patients). The majority of patients (86.4%) had a solitary hepatic metastasis, and the median size of the largest lesion was 0.6 cm. Hepatic metastectomy included wedge resection (n=20 patients), segmentectomy (n=1 patient), and hemihepatectomy (n=1 patient). After matching patients on primary tumor histology and location, the median survival of patients who underwent hepatic resection of synchronous metastasis was 5.9 months compared with 5.6 months for patients who underwent palliative bypass alone (P=.46) and 14.2 months for patients with no metastatic disease who underwent primary tumor resection only (P<.001). Pancreatic (median, 5.9 months) versus nonpancreatic (median, 9.9 months) primary tumor histology was not associated with a difference in survival in patients who underwent resection of synchronous liver metastasis (P=.43). Even in well selected patients with low-volume metastatic liver disease, simultaneous resection of periampullary or pancreatic carcinoma with synchronous liver metastases did not result in long-term survival in the overwhelming majority of patients.",Journal Article,4434.0,99.0,To date no consensus has been reached regarding which primary tumor subtypes are managed appropriately with hepatic metastectomy Specifically the role of hepatic resection for metastatic periampullary or adenocarcinoma remains controversial Between 1995 and 2005 1563 patients underwent surgical resection for periampullary carcinoma n=608 patients or adenocarcinoma head n=905 patients tail n=50 patients Data on demographics operative details primary tumor status and-when indicated-extent of hepatic metastasis were collected Of the 1563 patients who underwent resection of periampullary or adenocarcinoma 22 patients 1.4 underwent simultaneous hepatic resection for synchronous metastasis The primary tumor site was ampullary n=1 patient duodenal n=2 patients distal duct n=2 patients or head n=10 patients tail n=7 patients The majority of patients 86.4 had a solitary hepatic metastasis and the median size of the largest lesion was 0.6 cm Hepatic metastectomy included wedge resection n=20 patients segmentectomy n=1 patient and hemihepatectomy n=1 patient After matching patients on primary tumor histology and location the median survival of patients who underwent hepatic resection of synchronous metastasis was 5.9 months compared with 5.6 months for patients who underwent palliative bypass alone P=.46 and 14.2 months for patients with no metastatic disease who underwent primary tumor resection only P .001 median 5.9 months versus nonpancreatic median 9.9 months primary tumor histology was not associated with a difference in survival in patients who underwent resection of synchronous metastasis P=.43 Even in well selected patients with low-volume metastatic disease simultaneous resection of periampullary or carcinoma with synchronous metastases did not result in long-term survival in the overwhelming majority of patients,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1244, 77, 1391, 71, 85, 1300, 666, 92, 86, 30, 814, 32, 2231, 4544, 5, 939, 28122, 1225, 3, 200, 1, 939, 170, 9, 113, 9180, 15, 449, 469, 2010, 59, 2323, 2, 1242, 44906, 7, 208, 221, 170, 9, 9180, 134, 78, 11768, 7, 15, 449, 718, 78, 13300, 7, 5809, 78, 212, 7, 74, 23, 2221, 1208, 3791, 86, 30, 156, 2, 198, 1103, 1039, 1, 939, 278, 11, 786, 1, 3, 44906, 7, 54, 208, 170, 1, 9180, 15, 449, 350, 7, 14, 39, 208, 2824, 939, 170, 9, 2734, 278, 3, 86, 30, 606, 10, 6762, 78, 14, 69, 4748, 78, 18, 7, 2107, 2920, 78, 18, 7, 15, 718, 78, 79, 7, 5809, 78, 67, 7, 3, 686, 1, 7, 868, 39, 42, 8, 3144, 939, 278, 2, 3, 52, 444, 1, 3, 2166, 1180, 10, 13, 49, 494, 939, 28122, 159, 8246, 170, 78, 179, 7, 16767, 78, 14, 69, 2, 22352, 78, 14, 69, 50, 2616, 7, 23, 86, 30, 784, 2, 1147, 3, 52, 25, 1, 7, 54, 208, 939, 170, 1, 2734, 278, 10, 33, 83, 53, 72, 5, 33, 49, 53, 9, 7, 54, 208, 994, 5481, 279, 19, 641, 2, 213, 18, 53, 9, 7, 5, 77, 113, 34, 54, 208, 86, 30, 170, 158, 19, 144, 52, 33, 83, 53, 185, 23093, 52, 83, 83, 53, 86, 30, 784, 10, 44, 41, 5, 8, 523, 4, 25, 4, 7, 54, 208, 170, 1, 2734, 278, 19, 601, 871, 4, 149, 715, 7, 5, 154, 433, 113, 34, 2824, 170, 1, 9180, 15, 134, 5, 2734, 196, 205, 44, 757, 4, 319, 337, 25, 4, 3, 10075, 686, 1, 7]",1843.0,17941009,21
Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer.,Annals of surgical oncology,Ann. Surg. Oncol.,2008-02-07,"The integration of biospecimens with reliable clinical data is critical to advance molecular findings from the laboratory to the clinic. We describe the development of an integrated pancreatic tissue bank (PTB) and clinical database for patients with pancreatic cancer and other pancreatic disorders. A clinical database and PTB were created in 1990 and 2000, respectively, to collect clinical information and biospecimens from patients with suspected or confirmed pancreatic cancer, other pancreatic diseases, and tumors of the duodenum, ampulla of Vater, and distal bile duct. Standard procedures for biospecimen collection and data entry were developed. From 2000 through 2006, the PTB collected 8,061 pancreatic tissue specimens from 620 patients. The most common histologies of pancreatic tumors were pancreatic ductal adenocarcinoma (55.3%) and neuroendocrine carcinoma (16.3%). The biospecimen collection also includes 431 plasma samples, 40 fine-needle aspiration samples, and a tissue microarray containing 85 pancreatic adenocarcinomas and matched normal tissue specimens. The clinical database contains information for 7,647 patients with pancreatic cancer, other pancreatic disorders, and duodenal, ampullary, or bile duct neoplasms. The data are arranged into nine modules: patient, presentation, risk factors, diagnostic imaging, treatment plan, surgery, pathology, postoperative complications, and follow-up. We have established a pancreatic cancer tissue bank with standardized procedures for collection of biospecimens along with a comprehensive multidisciplinary clinical database. The integrated biospecimen bank and clinical database for pancreatic cancer described here can serve as a model from which other groups may develop similar systems.",Journal Article,4366.0,48.0,"The integration of biospecimens with reliable clinical data is critical to advance molecular findings from the laboratory to the clinic We describe the development of an integrated tissue bank PTB and clinical database for patients with cancer and other disorders A clinical database and PTB were created in 1990 and 2000 respectively to collect clinical information and biospecimens from patients with suspected or confirmed cancer other diseases and tumors of the duodenum ampulla of Vater and distal duct Standard procedures for biospecimen collection and data entry were developed From 2000 through 2006 the PTB collected 8,061 tissue specimens from 620 patients The most common histologies of tumors were ductal adenocarcinoma 55.3 and neuroendocrine carcinoma 16.3 The biospecimen collection also includes 431 plasma samples 40 fine-needle aspiration samples and a tissue microarray containing 85 adenocarcinomas and matched normal tissue specimens The clinical database contains information for 7,647 patients with cancer other disorders and duodenal ampullary or duct neoplasms The data are arranged into nine modules patient presentation risk factors diagnostic imaging treatment plan surgery pathology postoperative complications and follow-up We have established a cancer tissue bank with standardized procedures for collection of biospecimens along with a comprehensive multidisciplinary clinical database The integrated biospecimen bank and clinical database for cancer described here can serve as a model from which other groups may develop similar systems",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2676, 1, 12419, 5, 2450, 38, 74, 16, 740, 6, 3148, 219, 272, 29, 3, 1624, 6, 3, 1188, 21, 897, 3, 193, 1, 35, 2102, 246, 10213, 31229, 2, 38, 609, 9, 7, 5, 12, 2, 127, 1997, 8, 38, 609, 2, 31229, 11, 2466, 4, 2289, 2, 1081, 106, 6, 6248, 38, 487, 2, 12419, 29, 7, 5, 2768, 15, 557, 12, 127, 1342, 2, 57, 1, 3, 8401, 12837, 1, 14777, 2, 2107, 2920, 260, 1369, 9, 13603, 2442, 2, 74, 3001, 11, 276, 29, 1081, 298, 1324, 3, 31229, 786, 66, 13500, 246, 623, 29, 10811, 7, 3, 96, 186, 3489, 1, 57, 11, 1258, 449, 614, 27, 2, 1542, 134, 245, 27, 3, 13603, 2442, 120, 1920, 10889, 554, 347, 327, 2924, 2177, 3256, 347, 2, 8, 246, 1727, 1101, 772, 1586, 2, 655, 295, 246, 623, 3, 38, 609, 4862, 487, 9, 67, 12315, 7, 5, 12, 127, 1997, 2, 4748, 6762, 15, 2920, 1179, 3, 74, 32, 18164, 237, 762, 11153, 69, 1031, 43, 130, 752, 270, 24, 2242, 152, 1117, 573, 521, 2, 166, 126, 21, 47, 635, 8, 12, 246, 10213, 5, 1670, 1369, 9, 2442, 1, 12419, 1510, 5, 8, 949, 1643, 38, 609, 3, 2102, 13603, 10213, 2, 38, 609, 9, 12, 1027, 467, 122, 1833, 22, 8, 202, 29, 92, 127, 271, 68, 690, 288, 1530]",1570.0,18256882,79
Systemic therapy for biliary tract cancers.,The oncologist,Oncologist,2008-04-01,"Biliary tract cancers (BTCs) are invasive carcinomas that arise from the epithelial lining of the gallbladder and bile ducts. These include intrahepatic, perihilar, and distal biliary tree cancers as well as carcinoma arising from the gallbladder. Complete surgical resection offers the only chance for cure; however, only 10% of patients present with early-stage disease and are considered surgical candidates. Among those patients who do undergo ""curative"" resection, recurrence rates are high; thus, for the majority of BTC patients, systemic chemotherapy is the mainstay of their treatment plan. Patients with unresectable or metastatic BTC have a poor prognosis, with a median overall survival time of <1 year. Despite a paucity of randomized phase III data, a consensus on first-line systemic therapy is emerging. In this review, we discuss the clinical experience with systemic treatment of BTC, focusing on the rationale for a first-line regimen as well as future directions in the field.",Journal Article,4312.0,169.0,Biliary tract cancers BTCs are invasive carcinomas that arise from the epithelial lining of the and ducts These include intrahepatic perihilar and distal biliary tree cancers as well as carcinoma arising from the Complete surgical resection offers the only chance for cure however only 10 of patients present with early-stage disease and are considered surgical candidates Among those patients who do undergo `` curative '' resection recurrence rates are high thus for the majority of BTC patients systemic chemotherapy is the mainstay of their treatment plan Patients with unresectable or metastatic BTC have a poor prognosis with a median overall survival time of 1 year Despite a paucity of randomized phase III data a consensus on first-line systemic therapy is emerging In this review we discuss the clinical experience with systemic treatment of BTC focusing on the rationale for a first-line regimen as well as future directions in the field,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2532, 1696, 163, 14636, 32, 416, 826, 17, 3043, 29, 3, 701, 10597, 1, 3, 2, 7310, 46, 643, 3022, 9124, 2, 2107, 2532, 4899, 163, 22, 149, 22, 134, 2635, 29, 3, 236, 221, 170, 2339, 3, 158, 3477, 9, 1722, 137, 158, 79, 1, 7, 364, 5, 191, 82, 34, 2, 32, 515, 221, 1931, 107, 135, 7, 54, 1022, 1251, 1075, 522, 170, 146, 151, 32, 64, 631, 9, 3, 686, 1, 8112, 7, 403, 56, 16, 3, 4041, 1, 136, 24, 2242, 7, 5, 1468, 15, 113, 8112, 47, 8, 334, 356, 5, 8, 52, 63, 25, 98, 1, 14, 111, 550, 8, 4832, 1, 384, 124, 316, 74, 8, 1391, 23, 157, 328, 403, 36, 16, 1478, 4, 26, 206, 21, 1139, 3, 38, 730, 5, 403, 24, 1, 8112, 3312, 23, 3, 1728, 9, 8, 157, 328, 477, 22, 149, 22, 508, 3540, 4, 3, 1067]",948.0,18448556,33
Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures.,The American journal of gastroenterology,Am. J. Gastroenterol.,2008-05-01,"Standard techniques for evaluating bile duct strictures have poor sensitivity for detection of malignancy. Newer imaging modalities, such as intraductal ultrasound (IDUS), and advanced cytologic techniques, such as digital image analysis (DIA) and fluorescence in situ hybridization (FISH), identify chromosomal abnormalities, and may improve sensitivity while maintaining high specificity. Our aim was to prospectively evaluate the accuracy of these techniques in patients with indeterminate biliary strictures. Cholangiography, routine cytology (RC), intraductal biopsy, DIA, FISH, and IDUS were performed in 86 patients with indeterminate biliary strictures. Patients were stratified based on the presence or absence of primary sclerosing cholangitis (PSC). RC provided low sensitivity (7-33%) but high specificity (95-100%) for PSC and non-PSC patients. The composite DIA/FISH results (when considering trisomy-7 [Tri-7] as a marker of benign disease) yielded a 100% specificity and increased sensitivity one- to fivefold in PSC patients versus RC, and two- to fivefold in patients without PSC, depending on how suspicious cytology results were interpreted. For the most difficult-to-manage patients with negative cytology and histology who were later proven to have malignancy (N = 21), DIA, FISH, composite DIA/FISH, and IDUS were able to predict malignant diagnoses in 14%, 62%, 67%, and 86%, respectively. DIA, FISH, and IDUS enhance the accuracy of standard techniques in evaluation of indeterminate bile duct strictures, allowing diagnosis of malignancy in a substantial number of patients with false-negative cytology and histology. These findings support the routine use of these newer diagnostic modalities in patients with indeterminate biliary strictures.",Comparative Study,4282.0,128.0,Standard techniques for evaluating duct strictures have poor sensitivity for detection of malignancy Newer imaging modalities such as intraductal ultrasound IDUS and advanced cytologic techniques such as digital image analysis DIA and fluorescence in situ hybridization FISH identify chromosomal abnormalities and may improve sensitivity while maintaining high specificity Our aim was to prospectively evaluate the accuracy of these techniques in patients with indeterminate biliary strictures Cholangiography routine cytology RC intraductal biopsy DIA FISH and IDUS were performed in 86 patients with indeterminate biliary strictures Patients were stratified based on the presence or absence of primary sclerosing cholangitis PSC RC provided low sensitivity 7-33 but high specificity 95-100 for PSC and non-PSC patients The composite DIA/FISH results when considering trisomy-7 Tri-7 as a marker of benign disease yielded a 100 specificity and increased sensitivity one- to fivefold in PSC patients versus RC and two- to fivefold in patients without PSC depending on how suspicious cytology results were interpreted For the most difficult-to-manage patients with negative cytology and histology who were later proven to have malignancy N 21 DIA FISH composite DIA/FISH and IDUS were able to predict malignant diagnoses in 14 62 67 and 86 respectively DIA FISH and IDUS enhance the accuracy of standard techniques in evaluation of indeterminate duct strictures allowing diagnosis of malignancy in a substantial number of patients with false-negative cytology and histology These findings support the routine use of these newer diagnostic modalities in patients with indeterminate biliary strictures,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[260, 1092, 9, 1435, 2920, 7860, 47, 334, 485, 9, 638, 1, 710, 2246, 270, 1558, 225, 22, 4851, 1945, 34463, 2, 131, 4195, 1092, 225, 22, 3271, 1482, 65, 11201, 2, 1591, 4, 957, 1554, 1277, 255, 1860, 1171, 2, 68, 401, 485, 369, 3284, 64, 1121, 114, 1130, 10, 6, 1143, 376, 3, 1190, 1, 46, 1092, 4, 7, 5, 5167, 2532, 7860, 21954, 1311, 2045, 2724, 4851, 411, 11201, 1277, 2, 34463, 11, 173, 4, 868, 7, 5, 5167, 2532, 7860, 7, 11, 1173, 90, 23, 3, 463, 15, 1127, 1, 86, 6782, 8541, 5417, 2724, 1052, 154, 485, 67, 466, 84, 64, 1121, 48, 394, 9, 5417, 2, 220, 5417, 7, 3, 3308, 11201, 1277, 99, 198, 3075, 6317, 67, 11181, 67, 22, 8, 952, 1, 1002, 34, 2178, 8, 394, 1121, 2, 101, 485, 104, 6, 19529, 4, 5417, 7, 185, 2724, 2, 100, 6, 19529, 4, 7, 187, 5417, 3221, 23, 832, 3230, 2045, 99, 11, 5047, 9, 3, 96, 1740, 6, 4001, 7, 5, 199, 2045, 2, 784, 54, 11, 1559, 1930, 6, 47, 710, 78, 239, 11201, 1277, 3308, 11201, 1277, 2, 34463, 11, 1665, 6, 678, 393, 2403, 4, 213, 744, 598, 2, 868, 106, 11201, 1277, 2, 34463, 1304, 3, 1190, 1, 260, 1092, 4, 451, 1, 5167, 2920, 7860, 2952, 147, 1, 710, 4, 8, 1281, 207, 1, 7, 5, 2133, 199, 2045, 2, 784, 46, 272, 538, 3, 1311, 119, 1, 46, 2246, 752, 1558, 4, 7, 5, 5167, 2532, 7860]",1698.0,18477350,44
Autoimmune pancreatitis and concurrent small lymphocytic lymphoma: not just a coincidence?,Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,J. Gastrointest. Surg.,2008-05-28,"A 76-year-old gentleman presented with painless jaundice, weight loss, and anorexia. Computed tomography imaging revealed fullness of the pancreatic head and multiple enlarged retroperitoneal lymph nodes. Cholangiogram revealed a distal common bile duct stricture. Due to concerns of malignancy, the patient underwent operative exploration. Several enlarged lymph nodes in the aortocaval region and a firm hard mass in the pancreatic head were found. Frozen section from one of the lymph nodes was suspicious for low-grade lymphoma. A pancreaticoduodenectomy was performed. Histologic analysis of the pancreatic head revealed a lymphoplasmacytic infiltrate with stromal fibrosis consistent with autoimmune pancreatitis. The retroperitoneal lymph nodes were involved by small lymphocytic lymphoma. Autoimmune pancreatitis is the most common benign diagnosis after pancreatic resection for presumed malignancy. It has a well-documented association with autoimmune conditions, such as Sjgren's syndrome, inflammatory bowel disease, and sclerosing cholangitis. Additionally, chronic lymphocytic leukemia-small lymphocytic lymphoma is often associated with autoimmune phenomena, most notably autoimmune hemolytic anemia. However, an association between autoimmune pancreatitis and small lymphocytic lymphoma has not been previously described. To our knowledge, this is the first reported case of a patient with concurrent autoimmune pancreatitis and small lymphocytic lymphoma.",Case Reports,4255.0,20.0,A 76-year-old gentleman presented with painless jaundice weight loss and anorexia Computed tomography imaging revealed fullness of the head and multiple enlarged retroperitoneal lymph nodes Cholangiogram revealed a distal common duct stricture Due to concerns of malignancy the patient underwent operative exploration Several enlarged lymph nodes in the aortocaval region and a firm hard mass in the head were found Frozen section from one of the lymph nodes was suspicious for low-grade A pancreaticoduodenectomy was performed Histologic analysis of the head revealed a lymphoplasmacytic infiltrate with stromal fibrosis consistent with autoimmune pancreatitis The retroperitoneal lymph nodes were involved by small lymphocytic Autoimmune pancreatitis is the most common benign diagnosis after resection for presumed malignancy It has a well-documented association with autoimmune conditions such as Sjgren 's syndrome inflammatory bowel disease and sclerosing cholangitis Additionally chronic lymphocytic leukemia-small lymphocytic is often associated with autoimmune phenomena most notably autoimmune hemolytic anemia However an association between autoimmune pancreatitis and small lymphocytic has not been previously described To our knowledge this is the first reported case of a patient with concurrent autoimmune pancreatitis and small lymphocytic,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[8, 846, 111, 1095, 28444, 917, 5, 14963, 7655, 924, 407, 2, 3373, 1220, 872, 270, 553, 30803, 1, 3, 718, 2, 232, 7547, 2591, 263, 502, 28026, 553, 8, 2107, 186, 2920, 6673, 520, 6, 2061, 1, 710, 3, 69, 208, 1208, 3370, 392, 7547, 263, 502, 4, 3, 17414, 1053, 2, 8, 10851, 9327, 782, 4, 3, 718, 11, 204, 3015, 2917, 29, 104, 1, 3, 263, 502, 10, 3230, 9, 154, 88, 8, 4104, 10, 173, 884, 65, 1, 3, 718, 553, 8, 5325, 5172, 5, 1126, 3000, 925, 5, 3445, 4535, 3, 2591, 263, 502, 11, 646, 20, 302, 1193, 3445, 4535, 16, 3, 96, 186, 1002, 147, 50, 170, 9, 5472, 710, 192, 71, 8, 149, 1405, 248, 5, 3445, 1298, 225, 22, 26707, 292, 681, 1291, 1659, 34, 2, 6782, 8541, 1724, 442, 1193, 2647, 302, 1193, 16, 629, 41, 5, 3445, 11549, 96, 2552, 3445, 10425, 1545, 137, 35, 248, 59, 3445, 4535, 2, 302, 1193, 71, 44, 85, 373, 1027, 6, 114, 922, 26, 16, 3, 157, 210, 473, 1, 8, 69, 5, 750, 3445, 4535, 2, 302, 1193]",1356.0,18506547,2
Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma.,Annals of surgical oncology,Ann. Surg. Oncol.,2008-06-10,"Frozen section analysis of bile duct margins is often used to guide the extent of surgical resection for hilar cholangiocarcinoma (HCCA), but the usefulness of this practice is unknown. The association between disease-specific survival (DSS) and pathologic margin status determined during and after surgical resection for HCCA was assessed retrospectively for 101 patients between 1992 and 2005. Final histopathology identified three subgroups on the basis of resection margin status: wide margin (bile duct and specimen margins negative for adenocarcinoma), narrow margin (bile duct margin negative but specimen margins positive), and positive margin (bile duct and specimen margins positive). On the basis of frozen section analysis alone, 90 patients were thought to have a disease-negative bile duct margin intraoperatively. Final histopathology showed that eight patients (9%) had invasive adenocarcinoma in the cuff of bile duct submitted for frozen section analysis. Of the 82 patients with negative final bile duct margins, 54 patients were categorized as having wide margins, and 28 patients had narrow margins. The median DSS for patients with wide margins was 56 months compared with 38 months for patients with narrow margins and 32 months for margin-positive patients (P = .01). Frozen section analysis of the proximal bile duct margin is misleading in 9% of patients. Among patients with HCCA who are determined to have negative duct margins intraoperatively, only 60% will have margins adequately wide enough to be associated with an improvement in DSS.",Comparative Study,4242.0,79.0,Frozen section analysis of duct margins is often used to guide the extent of surgical resection for hilar cholangiocarcinoma HCCA but the usefulness of this practice is unknown The association between disease-specific survival DSS and pathologic margin status determined during and after surgical resection for HCCA was assessed retrospectively for 101 patients between 1992 and 2005 Final histopathology identified three subgroups on the basis of resection margin status wide margin duct and specimen margins negative for adenocarcinoma narrow margin duct margin negative but specimen margins positive and positive margin duct and specimen margins positive On the basis of frozen section analysis alone 90 patients were thought to have a disease-negative duct margin intraoperatively Final histopathology showed that eight patients 9 had invasive adenocarcinoma in the cuff of duct submitted for frozen section analysis Of the 82 patients with negative final duct margins 54 patients were categorized as having wide margins and 28 patients had narrow margins The median DSS for patients with wide margins was 56 months compared with 38 months for patients with narrow margins and 32 months for margin-positive patients P .01 Frozen section analysis of the proximal duct margin is misleading in 9 of patients Among patients with HCCA who are determined to have negative duct margins intraoperatively only 60 will have margins adequately wide enough to be associated with an improvement in DSS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3015, 2917, 65, 1, 2920, 1012, 16, 629, 95, 6, 1597, 3, 1039, 1, 221, 170, 9, 4793, 2126, 9280, 84, 3, 5235, 1, 26, 758, 16, 860, 3, 248, 59, 34, 112, 25, 1788, 2, 510, 959, 156, 509, 190, 2, 50, 221, 170, 9, 9280, 10, 275, 894, 9, 2338, 7, 59, 2846, 2, 1242, 1457, 3831, 108, 169, 1453, 23, 3, 877, 1, 170, 959, 156, 1019, 959, 2920, 2, 2360, 1012, 199, 9, 449, 6958, 959, 2920, 959, 199, 84, 2360, 1012, 109, 2, 109, 959, 2920, 2, 2360, 1012, 109, 23, 3, 877, 1, 3015, 2917, 65, 279, 424, 7, 11, 2739, 6, 47, 8, 34, 199, 2920, 959, 6595, 1457, 3831, 224, 17, 659, 7, 83, 42, 416, 449, 4, 3, 11445, 1, 2920, 5118, 9, 3015, 2917, 65, 1, 3, 878, 7, 5, 199, 1457, 2920, 1012, 667, 7, 11, 2320, 22, 1041, 1019, 1012, 2, 339, 7, 42, 6958, 1012, 3, 52, 1788, 9, 7, 5, 1019, 1012, 10, 664, 53, 72, 5, 519, 53, 9, 7, 5, 6958, 1012, 2, 531, 53, 9, 959, 109, 7, 19, 355, 3015, 2917, 65, 1, 3, 2805, 2920, 959, 16, 12533, 4, 83, 1, 7, 107, 7, 5, 9280, 54, 32, 509, 6, 47, 199, 2920, 1012, 6595, 158, 335, 303, 47, 1012, 4215, 1019, 5151, 6, 40, 41, 5, 35, 767, 4, 1788]",1492.0,18543039,24
Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence.,Annals of surgery,Ann. Surg.,2008-08-01,"Hilar cholangiocarcinoma is an uncommon tumor with a poor prognosis. We sought to evaluate recurrence patterns and prognostic factors for disease-specific and disease-free survival in patients with surgically resected hilar cholangiocarcinoma in a single institution over the last 21 years. From 1985 to 2006, all patients with hilar cholangiocarcinoma referred to a tertiary surgical clinic were evaluated. Demographic data, tumor characteristics, and outcome were analyzed retrospectively. Outcome was compared in patients treated in a recent era (1995-2006) compared with an earlier era (1985-1994). Of 91 patients evaluated, 22 patients (24%) had unresectable disease at presentation. Of the 69 patients submitted to laparotomy, resection was possible in 55% and the curative (R0) resection rate was 63%. In patients submitted to exploration, the operative (60 day) morbidity and mortality rates were 26% and 3%. Median disease-specific (DSS) and disease-free survival (DFS) were 29 and 20 months, respectively (median FU, 29 months.). In patients undergoing R0 resection, the median survival was prolonged (65 months). In the more recent era, resectability rates improved (69% vs. 17%; P = 0.0002), and this was associated with an improvement in median survival (30 vs. 4 months; P < 0.001). Factors predictive of improved disease-specific and disease-free survival included negative histologic margins, concomitant hepatic lobectomy, lack of nodal disease, well-differentiated histology, and an earlier tumor stage (P < 0.05). Concomitant liver resection was associated with a higher R0 resection rate (P = 0.006) and improved DSS and DFS (P = 0.005). In addition, concomitant liver resection was associated with a decreased incidence of initial recurrence in liver (P = 0.031). In patients with hilar cholangiocarcinoma, concomitant hepatic resection is associated with improved DFS, DSS, and decreased hepatic recurrence. Therefore, hepatectomy combined with bile duct resection should be considered standard treatment.",Journal Article,4190.0,128.0,Hilar cholangiocarcinoma is an uncommon tumor with a poor prognosis We sought to evaluate recurrence patterns and prognostic factors for disease-specific and disease-free survival in patients with surgically resected hilar cholangiocarcinoma in a single institution over the last 21 years From 1985 to 2006 all patients with hilar cholangiocarcinoma referred to a tertiary surgical clinic were evaluated Demographic data tumor characteristics and outcome were analyzed retrospectively Outcome was compared in patients treated in a recent era 1995-2006 compared with an earlier era 1985-1994 Of 91 patients evaluated 22 patients 24 had unresectable disease at presentation Of the 69 patients submitted to laparotomy resection was possible in 55 and the curative R0 resection rate was 63 In patients submitted to exploration the operative 60 day morbidity and mortality rates were 26 and 3 Median disease-specific DSS and disease-free survival DFS were 29 and 20 months respectively median FU 29 months In patients undergoing R0 resection the median survival was prolonged 65 months In the more recent era resectability rates improved 69 vs. 17 P 0.0002 and this was associated with an improvement in median survival 30 vs. 4 months P 0.001 Factors predictive of improved disease-specific and disease-free survival included negative histologic margins concomitant hepatic lobectomy lack of nodal disease well-differentiated histology and an earlier tumor stage P 0.05 Concomitant resection was associated with a higher R0 resection rate P 0.006 and improved DSS and DFS P 0.005 In addition concomitant resection was associated with a decreased incidence of initial recurrence in P 0.031 In patients with hilar cholangiocarcinoma concomitant hepatic resection is associated with improved DFS DSS and decreased hepatic recurrence Therefore hepatectomy combined with duct resection should be considered standard treatment,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4793, 2126, 16, 35, 2052, 30, 5, 8, 334, 356, 21, 990, 6, 376, 146, 764, 2, 177, 130, 9, 34, 112, 2, 34, 115, 25, 4, 7, 5, 2350, 1133, 4793, 2126, 4, 8, 226, 731, 252, 3, 1060, 239, 60, 29, 4675, 6, 1324, 62, 7, 5, 4793, 2126, 1995, 6, 8, 2557, 221, 1188, 11, 194, 1540, 74, 30, 374, 2, 228, 11, 311, 894, 228, 10, 72, 4, 7, 73, 4, 8, 435, 1713, 2323, 1324, 72, 5, 35, 1677, 1713, 4675, 3023, 1, 970, 7, 194, 350, 7, 259, 42, 1468, 34, 28, 1031, 1, 3, 790, 7, 5118, 6, 3274, 170, 10, 899, 4, 614, 2, 3, 1075, 2328, 170, 116, 10, 676, 4, 7, 5118, 6, 3370, 3, 1208, 335, 218, 787, 2, 282, 151, 11, 432, 2, 27, 52, 34, 112, 1788, 2, 34, 115, 25, 1010, 11, 462, 2, 179, 53, 106, 52, 1296, 462, 53, 4, 7, 479, 2328, 170, 3, 52, 25, 10, 1069, 556, 53, 4, 3, 80, 435, 1713, 5150, 151, 231, 790, 105, 269, 19, 13, 3531, 2, 26, 10, 41, 5, 35, 767, 4, 52, 25, 201, 105, 39, 53, 19, 13, 144, 130, 464, 1, 231, 34, 112, 2, 34, 115, 25, 159, 199, 884, 1012, 1781, 939, 3258, 926, 1, 779, 34, 149, 1442, 784, 2, 35, 1677, 30, 82, 19, 13, 474, 1781, 170, 10, 41, 5, 8, 142, 2328, 170, 116, 19, 13, 1861, 2, 231, 1788, 2, 1010, 19, 13, 1614, 4, 352, 1781, 170, 10, 41, 5, 8, 340, 287, 1, 388, 146, 4, 19, 13, 5304, 4, 7, 5, 4793, 2126, 1781, 939, 170, 16, 41, 5, 231, 1010, 1788, 2, 340, 939, 146, 673, 2711, 397, 5, 2920, 170, 257, 40, 515, 260, 24]",1916.0,18650638,84
Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone.,Annals of surgical oncology,Ann. Surg. Oncol.,2008-08-27,"Patients with resected extrahepatic bile duct adenocarcinoma who have microscopically positive resection margins and/or pathologic locoregional nodal involvement (R1pN1) have a high-risk of locoregional recurrence, and therefore, we advocate the use of adjuvant chemoradiation. To evaluate the safety and effectiveness of this treatment, we compared survival and side effects outcomes between such patients and patients with negative resection margins and pathologically negative nodes (R0pN0) who did not receive adjuvant treatment. Between 1984 and 2005, 65 patients were treated with curative-intended resection for extrahepatic bile duct adenocarcinoma. Patients with tumors arising in the gallbladder and periampullary region were excluded. Pathology and diagnostic images were centrally reviewed. Overall survival and locoregional recurrence outcomes for patients with standard-risk R0pN0 (surgery alone, or S group, n = 23) were compared with those of patients with high locoregional recurrence risk, R1 and/or pN1 (R1pN1) status who received adjuvant chemoradiation (S-CRT group, n = 42). The median follow-up for the entire group was 31 months. Patients in the S-CRT and S groups had a similar 5-year overall survival (36% vs. 42%, P = .6) and locoregional recurrence (5-year rate: 38% vs. 37%, P = .13). In the S-CRT group, three patients (7%) experienced an acute (grade 3 or more) side effect. Our finding of a lack of a survival difference between the S and S-CRT groups suggests that for patients with extrahepatic bile duct adenocarcinoma at high risk for locoregional recurrence (i.e., R1 resection or pN1 disease), adjuvant chemoradiation provides an equivalent overall survival despite of these worse prognostic features.",Journal Article,4164.0,58.0,Patients with resected extrahepatic duct adenocarcinoma who have microscopically positive resection margins and/or pathologic locoregional nodal involvement R1pN1 have a high-risk of locoregional recurrence and therefore we advocate the use of adjuvant chemoradiation To evaluate the safety and effectiveness of this treatment we compared survival and side effects outcomes between such patients and patients with negative resection margins and pathologically negative nodes R0pN0 who did not receive adjuvant treatment Between 1984 and 2005 65 patients were treated with curative-intended resection for extrahepatic duct adenocarcinoma Patients with tumors arising in the and periampullary region were excluded Pathology and diagnostic images were centrally reviewed Overall survival and locoregional recurrence outcomes for patients with standard-risk R0pN0 surgery alone or S group n 23 were compared with those of patients with high locoregional recurrence risk R1 and/or pN1 R1pN1 status who received adjuvant chemoradiation S-CRT group n 42 The median follow-up for the entire group was 31 months Patients in the S-CRT and S groups had a similar 5-year overall survival 36 vs. 42 P .6 and locoregional recurrence 5-year rate 38 vs. 37 P .13 In the S-CRT group three patients 7 experienced an acute grade 3 or more side effect Our finding of a lack of a survival difference between the S and S-CRT groups suggests that for patients with extrahepatic duct adenocarcinoma at high risk for locoregional recurrence i.e. R1 resection or pN1 disease adjuvant chemoradiation provides an equivalent overall survival despite of these worse prognostic features,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 1133, 3710, 2920, 449, 54, 47, 7187, 109, 170, 1012, 2, 15, 510, 1325, 779, 799, 45243, 47, 8, 64, 43, 1, 1325, 146, 2, 673, 21, 8912, 3, 119, 1, 249, 975, 6, 376, 3, 367, 2, 1236, 1, 26, 24, 21, 72, 25, 2, 1152, 176, 123, 59, 225, 7, 2, 7, 5, 199, 170, 1012, 2, 2998, 199, 502, 45244, 54, 205, 44, 560, 249, 24, 59, 6036, 2, 1242, 556, 7, 11, 73, 5, 1075, 4081, 170, 9, 3710, 2920, 449, 7, 5, 57, 2635, 4, 3, 2, 9180, 1053, 11, 1800, 1117, 2, 752, 1572, 11, 4604, 446, 63, 25, 2, 1325, 146, 123, 9, 7, 5, 260, 43, 45244, 152, 279, 15, 695, 87, 78, 382, 11, 72, 5, 135, 1, 7, 5, 64, 1325, 146, 43, 3239, 2, 15, 7945, 45243, 156, 54, 103, 249, 975, 695, 1089, 87, 78, 595, 3, 52, 166, 126, 9, 3, 1797, 87, 10, 456, 53, 7, 4, 3, 695, 1089, 2, 695, 271, 42, 8, 288, 33, 111, 63, 25, 511, 105, 595, 19, 49, 2, 1325, 146, 33, 111, 116, 519, 105, 567, 19, 233, 4, 3, 695, 1089, 87, 169, 7, 67, 592, 35, 286, 88, 27, 15, 80, 1152, 254, 114, 1567, 1, 8, 926, 1, 8, 25, 523, 59, 3, 695, 2, 695, 1089, 271, 844, 17, 9, 7, 5, 3710, 2920, 449, 28, 64, 43, 9, 1325, 146, 70, 563, 3239, 170, 15, 7945, 34, 249, 975, 777, 35, 2017, 63, 25, 550, 1, 46, 639, 177, 404]",1655.0,18754070,8
Analysis of the extent of resection for adenocarcinoma of the gallbladder.,Annals of surgical oncology,Ann. Surg. Oncol.,2008-11-05,"Gallbladder cancer has historically been considered an incurable malignancy; although, extended resection has been associated with cure in selected patients. However, the optimal extent of resection is unknown. The objective of this study was to analyze the impact of the extent of resection for gallbladder adenocarcinoma on disease-specific survival (DSS) and perioperative morbidity. Analysis of a prospective hepatobiliary surgery database identified patients undergoing surgical resection for gallbladder adenocarcinoma from 1990 to 2002. Clinicopathologic factors including extent of resection were analyzed for their association with DSS and perioperative morbidity. Long-term outcome was evaluable in 104 patients. With median follow-up of 58 months for survivors, the actuarial 5-year DSS was 42%. Thirty-six patients (35%) underwent major hepatectomy, but in 15 this was not mandatory to clear all disease. Sixty-eight patients (65%) underwent common bile duct (CBD) excision, but 32 were performed empirically. Twenty-one patients (20%) underwent en bloc resection of adjacent organs other than the liver. The performance of a major hepatectomy or a CBD excision was not associated with other clinicopathologic variables or long-term survival. Resection of adjacent organs were associated with advanced T stage but not with survival. T stage, N stage, histologic differentiation, and CBD involvement were independently associated with survival. Major hepatectomy and CBD excision were significantly associated with perioperative morbidity. We conclude that tumor biology and stage, rather than extent of resection, predict outcome after resection for gallbladder cancer. Major hepatic resections, including major hepatectomy and CBD excision, are appropriate when necessary to clear disease but are not mandatory in all cases.",Journal Article,4094.0,116.0,cancer has historically been considered an incurable malignancy although extended resection has been associated with cure in selected patients However the optimal extent of resection is unknown The objective of this study was to analyze the impact of the extent of resection for adenocarcinoma on disease-specific survival DSS and perioperative morbidity Analysis of a prospective hepatobiliary surgery database identified patients undergoing surgical resection for adenocarcinoma from 1990 to 2002 Clinicopathologic factors including extent of resection were analyzed for their association with DSS and perioperative morbidity Long-term outcome was evaluable in 104 patients With median follow-up of 58 months for survivors the actuarial 5-year DSS was 42 Thirty-six patients 35 underwent major hepatectomy but in 15 this was not mandatory to clear all disease Sixty-eight patients 65 underwent common duct CBD excision but 32 were performed empirically Twenty-one patients 20 underwent en bloc resection of adjacent organs other than the The performance of a major hepatectomy or a CBD excision was not associated with other clinicopathologic variables or long-term survival Resection of adjacent organs were associated with advanced T stage but not with survival T stage N stage histologic differentiation and CBD involvement were independently associated with survival Major hepatectomy and CBD excision were significantly associated with perioperative morbidity We conclude that tumor biology and stage rather than extent of resection predict outcome after resection for cancer Major hepatic resections including major hepatectomy and CBD excision are appropriate when necessary to clear disease but are not mandatory in all cases,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12, 71, 3578, 85, 515, 35, 2641, 710, 242, 1747, 170, 71, 85, 41, 5, 1722, 4, 715, 7, 137, 3, 665, 1039, 1, 170, 16, 860, 3, 461, 1, 26, 45, 10, 6, 1992, 3, 345, 1, 3, 1039, 1, 170, 9, 449, 23, 34, 112, 25, 1788, 2, 1547, 787, 65, 1, 8, 482, 4718, 152, 609, 108, 7, 479, 221, 170, 9, 449, 29, 2289, 6, 1544, 1399, 130, 141, 1039, 1, 170, 11, 311, 9, 136, 248, 5, 1788, 2, 1547, 787, 319, 337, 228, 10, 859, 4, 3407, 7, 5, 52, 166, 126, 1, 717, 53, 9, 332, 3, 2361, 33, 111, 1788, 10, 595, 977, 437, 7, 465, 208, 458, 2711, 84, 4, 167, 26, 10, 44, 7322, 6, 885, 62, 34, 1746, 659, 7, 556, 208, 186, 2920, 14624, 1366, 84, 531, 11, 173, 9654, 737, 104, 7, 179, 208, 4375, 5590, 170, 1, 2086, 2285, 127, 76, 3, 3, 528, 1, 8, 458, 2711, 15, 8, 14624, 1366, 10, 44, 41, 5, 127, 1399, 682, 15, 319, 337, 25, 170, 1, 2086, 2285, 11, 41, 5, 131, 102, 82, 84, 44, 5, 25, 102, 82, 78, 82, 884, 910, 2, 14624, 799, 11, 1042, 41, 5, 25, 458, 2711, 2, 14624, 1366, 11, 97, 41, 5, 1547, 787, 21, 2060, 17, 30, 891, 2, 82, 1832, 76, 1039, 1, 170, 678, 228, 50, 170, 9, 12, 458, 939, 2185, 141, 458, 2711, 2, 14624, 1366, 32, 870, 198, 1493, 6, 885, 34, 84, 32, 44, 7322, 4, 62, 140]",1735.0,18985272,67
"The role of postoperative radiation therapy (PORT) in the treatment of extrahepatic bile duct cancer: a surveillance, epidemiology, and end results (SEER) population-based investigation.",Journal of gastrointestinal cancer,J Gastrointest Cancer,2009-01-21,"Extrahepatic bile duct cancers (EBDC) are aggressive cancers for which the importance of the use of postoperative radiation therapy (PORT) in potentially curative cases remains the subject of clinical investigation. The 1973-2004 National Cancer Institute Surveillance Epidemiology and End Results (SEER) database was analyzed for patients with EBDC who had undergone cancer-directed surgery. Patients who died <3 months after surgery were excluded from analysis. Patients with distant metastases, with unknown stage or interventions, or benign histologies were excluded. Nine hundred fifty-six patients were selected. Tumor-related factors, such as regional (vs. local) disease and an increasing number of lymph nodes predicted for the delivery of PORT. In unadjusted univariate analysis, patients treated from 1973 to 2004 who fit the selection criteria had a lower 3-year survival rate if they received PORT vs. no PORT (3 year survival 31.3% vs. 39.6%, p = 0.04), but this improvement did not hold in multivariate survival analysis or in univariate analysis of patient subsets. Based on analysis of the SEER database, there was no definitive evidence for improved survival with the addition of PORT to radical surgery. This analysis should be approached with caution given its observational and retrospective nature. In addition, it should be remembered that the SEER database lacks information on the use of chemotherapy, radiation technique, and the completeness of resection.",Journal Article,4017.0,3.0,Extrahepatic duct cancers EBDC are aggressive cancers for which the importance of the use of postoperative radiation therapy PORT in potentially curative cases remains the subject of clinical investigation The 1973-2004 National Cancer Institute Surveillance Epidemiology and End Results SEER database was analyzed for patients with EBDC who had undergone cancer-directed surgery Patients who died 3 months after surgery were excluded from analysis Patients with distant metastases with unknown stage or interventions or benign histologies were excluded Nine hundred fifty-six patients were selected Tumor-related factors such as regional vs. local disease and an increasing number of lymph nodes predicted for the delivery of PORT In unadjusted univariate analysis patients treated from 1973 to 2004 who fit the selection criteria had a lower 3-year survival rate if they received PORT vs. no PORT 3 year survival 31.3 vs. 39.6 p 0.04 but this improvement did not hold in multivariate survival analysis or in univariate analysis of patient subsets Based on analysis of the SEER database there was no definitive evidence for improved survival with the addition of PORT to radical surgery This analysis should be approached with caution given its observational and retrospective nature In addition it should be remembered that the SEER database lacks information on the use of chemotherapy radiation technique and the completeness of resection,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3710, 2920, 163, 45403, 32, 571, 163, 9, 92, 3, 1187, 1, 3, 119, 1, 573, 121, 36, 3083, 4, 751, 1075, 140, 469, 3, 2974, 1, 38, 940, 3, 4756, 1131, 657, 12, 1377, 617, 1284, 2, 396, 99, 1605, 609, 10, 311, 9, 7, 5, 45403, 54, 42, 1989, 12, 1166, 152, 7, 54, 1016, 27, 53, 50, 152, 11, 1800, 29, 65, 7, 5, 626, 196, 5, 860, 82, 15, 1151, 15, 1002, 3489, 11, 1800, 762, 1128, 1461, 437, 7, 11, 715, 30, 139, 130, 225, 22, 951, 105, 293, 34, 2, 35, 602, 207, 1, 263, 502, 783, 9, 3, 989, 1, 3083, 4, 4487, 880, 65, 7, 73, 29, 4756, 6, 1131, 54, 2975, 3, 881, 371, 42, 8, 280, 27, 111, 25, 116, 492, 491, 103, 3083, 105, 77, 3083, 27, 111, 25, 456, 27, 105, 587, 49, 19, 13, 755, 84, 26, 767, 205, 44, 4164, 4, 331, 25, 65, 15, 4, 880, 65, 1, 69, 1890, 90, 23, 65, 1, 3, 1605, 609, 125, 10, 77, 1057, 241, 9, 231, 25, 5, 3, 352, 1, 3083, 6, 711, 152, 26, 65, 257, 40, 5738, 5, 5526, 447, 211, 2495, 2, 459, 2202, 4, 352, 192, 257, 40, 26083, 17, 3, 1605, 609, 6856, 487, 23, 3, 119, 1, 56, 121, 1312, 2, 3, 7507, 1, 170]",1442.0,19156542,12
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.,Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2009-04-28,"Advanced cancers of the bile duct and gallbladder carry an ominous prognosis. Rebeccamycin analogue (RA) is a novel antitumor antibiotic where phase I trials suggested clinical efficacy in patients with biliary cancers. The primary objective was to determine the response rate to RA in patients with advanced gallbladder and bile duct tumors. Secondary endpoints were survival and pharmacokinetic characterization. RA was given at a dose 165 mg/(m(2) day) x 5 days every 3 weeks. Forty-six patients were enrolled. Nine patients were removed from study before their first planned imaging study for response. Two patients had partial responses and 16 had stable disease. On an intent-to-treat analysis the median survival was 6.3 months. A >20% drop in CA19.9 was seen in 43% of patients with initial high levels. Grade 4 neutropenia and thrombocytopenia were seen in 35 and 5% of patients, respectively. Febrile neutropenia occurred in 16% of patients. The pharmacokinetic profile of this trial closely resembles those of prior phase I trials. Measured biliary concentrations of RA were as much as 100x greater than simultaneous plasma concentration. Although RA has a response rate of 5% in advanced biliary cancers, it is associated with significant numbers of patients experiencing prolonged stable disease. Biliary concentrations of RA are significantly greater than plasma concentrations.","Clinical Trial, Phase II",3920.0,9.0,Advanced cancers of the duct and carry an ominous prognosis Rebeccamycin analogue RA is a novel antitumor antibiotic where phase I trials suggested clinical efficacy in patients with biliary cancers The primary objective was to determine the response rate to RA in patients with advanced and duct tumors Secondary endpoints were survival and pharmacokinetic characterization RA was given at a dose 165 mg/ m 2 day x 5 days every 3 weeks Forty-six patients were enrolled Nine patients were removed from study before their first planned imaging study for response Two patients had partial responses and 16 had stable disease On an intent-to-treat analysis the median survival was 6.3 months A 20 drop in CA19.9 was seen in 43 of patients with initial high levels Grade 4 neutropenia and thrombocytopenia were seen in 35 and 5 of patients respectively Febrile neutropenia occurred in 16 of patients The pharmacokinetic profile of this trial closely resembles those of prior phase I trials Measured biliary concentrations of RA were as much as 100x greater than simultaneous plasma concentration Although RA has a response rate of 5 in advanced biliary cancers it is associated with significant numbers of patients experiencing prolonged stable disease Biliary concentrations of RA are significantly greater than plasma concentrations,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[131, 163, 1, 3, 2920, 2, 3542, 35, 17173, 356, 22160, 4696, 4631, 16, 8, 229, 579, 5210, 1257, 124, 70, 143, 1148, 38, 209, 4, 7, 5, 2532, 163, 3, 86, 461, 10, 6, 223, 3, 51, 116, 6, 4631, 4, 7, 5, 131, 2, 2920, 57, 568, 1387, 11, 25, 2, 1456, 2136, 4631, 10, 447, 28, 8, 61, 4966, 81, 188, 18, 218, 1006, 33, 162, 454, 27, 244, 1213, 437, 7, 11, 346, 762, 7, 11, 2264, 29, 45, 348, 136, 157, 1465, 270, 45, 9, 51, 100, 7, 42, 450, 253, 2, 245, 42, 585, 34, 23, 35, 1697, 6, 943, 65, 3, 52, 25, 10, 49, 27, 53, 8, 179, 7215, 4, 6058, 83, 10, 527, 4, 601, 1, 7, 5, 388, 64, 148, 88, 39, 778, 2, 1340, 11, 527, 4, 465, 2, 33, 1, 7, 106, 2498, 778, 489, 4, 245, 1, 7, 3, 1456, 800, 1, 26, 160, 3210, 13270, 135, 1, 324, 124, 70, 143, 644, 2532, 1003, 1, 4631, 11, 22, 1802, 22, 37540, 378, 76, 2824, 554, 1227, 242, 4631, 71, 8, 51, 116, 1, 33, 4, 131, 2532, 163, 192, 16, 41, 5, 93, 1870, 1, 7, 2985, 1069, 585, 34, 2532, 1003, 1, 4631, 32, 97, 378, 76, 554, 1003]",1330.0,19399502,57
Evolving treatment strategies for gallbladder cancer.,Annals of surgical oncology,Ann. Surg. Oncol.,2009-06-03,"Gallbladder cancer is an uncommon cancer that has traditionally been associated with a poor prognosis. In the era of laparoscopic cholecystectomy, incidental gallbladder cancer has dramatically increased and now constitutes the major way patients present with gallbladder cancer. While patients with incidental gallbladder cancer have a better survival than patients with nonincidental gallbladder cancer, incidental gallbladder cancer can be associated with a varied prognosis. Imaging with computed tomography (CT), magnetic resonance imaging (MRI), and [18]F-fluorodeoxyglucose (FDG) positron emission tomography (PET), as well as diagnostic laparoscopy, all have varying roles in the workup of patients with incidental gallbladder cancer. For patients with T1b, T2, and T3 incidental gallbladder cancer re-resection is generally recommended. At re-exploration, many patients with incidental gallbladder cancer will have residual disease. Definitive oncologic management requires re-resection of the liver, portal lymphadenectomy, and attention to the common bile duct. The extent of the hepatic resection should be dictated by the ability to achieve a microscopically negative (R0) margin. Routine resection of the common bile duct is unnecessary but should be undertaken in the setting of a positive cystic duct margin. If an incidental gallbladder cancer is discovered at the time of surgery, whether the surgeon should directly proceed with a more definitive oncologic operation should depend on the surgeon's skill-set and experience. Gallbladder cancer has a propensity to recur. Although data for adjuvant therapy following resection are limited, some data do suggest a survival benefit for adjuvant chemoradiation therapy. Management of patients with gallbladder cancer requires a multidisciplinary approach with input from a surgeon skilled in hepatobiliary surgery.",Journal Article,3884.0,98.0,cancer is an uncommon cancer that has traditionally been associated with a poor prognosis In the era of laparoscopic cholecystectomy incidental cancer has dramatically increased and now constitutes the major way patients present with cancer While patients with incidental cancer have a better survival than patients with nonincidental cancer incidental cancer can be associated with a varied prognosis Imaging with computed tomography CT magnetic resonance imaging MRI and 18 F-fluorodeoxyglucose FDG positron emission tomography PET as well as diagnostic laparoscopy all have varying roles in the workup of patients with incidental cancer For patients with T1b T2 and T3 incidental cancer re-resection is generally recommended At re-exploration many patients with incidental cancer will have residual disease Definitive oncologic management requires re-resection of the portal lymphadenectomy and attention to the common duct The extent of the hepatic resection should be dictated by the ability to achieve a microscopically negative R0 margin Routine resection of the common duct is unnecessary but should be undertaken in the setting of a positive cystic duct margin If an incidental cancer is discovered at the time of surgery whether the surgeon should directly proceed with a more definitive oncologic operation should depend on the surgeon 's skill-set and experience cancer has a propensity to recur Although data for adjuvant therapy following resection are limited some data do suggest a survival benefit for adjuvant chemoradiation therapy Management of patients with cancer requires a multidisciplinary approach with input from a surgeon skilled in hepatobiliary surgery,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12, 16, 35, 2052, 12, 17, 71, 4206, 85, 41, 5, 8, 334, 356, 4, 3, 1713, 1, 1964, 8493, 4490, 12, 71, 2729, 101, 2, 1134, 6788, 3, 458, 2255, 7, 364, 5, 12, 369, 7, 5, 4490, 12, 47, 8, 380, 25, 76, 7, 5, 45570, 12, 4490, 12, 122, 40, 41, 5, 8, 2051, 356, 270, 5, 1220, 872, 425, 1484, 1535, 270, 704, 2, 203, 1068, 4085, 1285, 1900, 1799, 872, 495, 22, 149, 22, 752, 3553, 62, 47, 2990, 1790, 4, 3, 4755, 1, 7, 5, 4490, 12, 9, 7, 5, 6142, 1786, 2, 2065, 4490, 12, 1491, 170, 16, 1228, 793, 28, 1491, 3370, 445, 7, 5, 4490, 12, 303, 47, 753, 34, 1057, 1998, 284, 1706, 1491, 170, 1, 3, 3307, 2048, 2, 2111, 6, 3, 186, 2920, 3, 1039, 1, 3, 939, 170, 257, 40, 10575, 20, 3, 801, 6, 1359, 8, 7187, 199, 2328, 959, 1311, 170, 1, 3, 186, 2920, 16, 4224, 84, 257, 40, 2789, 4, 3, 546, 1, 8, 109, 2965, 2920, 959, 492, 35, 4490, 12, 16, 2747, 28, 3, 98, 1, 152, 317, 3, 1897, 257, 1606, 6174, 5, 8, 80, 1057, 1998, 2589, 257, 4533, 23, 3, 1897, 292, 11180, 916, 2, 730, 12, 71, 8, 1925, 6, 5609, 242, 74, 9, 249, 36, 366, 170, 32, 383, 476, 74, 1022, 309, 8, 25, 247, 9, 249, 975, 36, 284, 1, 7, 5, 12, 1706, 8, 1643, 353, 5, 5772, 29, 8, 1897, 11918, 4, 4718, 152]",1682.0,19495882,72
Preemptive surgery for premalignant foregut lesions.,Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,J. Gastrointest. Surg.,2009-06-10,"Preemptive surgery is the prophylactic removal of an organ at high risk for malignant transformation or the resection of a precancerous or ""early"" malignant neoplasm in an individual with a hereditary predisposition to cancer. Recent advances in molecular diagnostic techniques have improved our understanding of the biologic behavior of these conditions. Predictive testing is an emerging field that attempts to assess the potential risk of cancer development in predisposed individuals. Despite substantial improvement in these forms of testing, all results are imperfect. This information often becomes an important tool that is used by healthcare providers to evaluate the risk-benefit ratio of various risk modifying strategies (i.e., intensive surveillance or preemptive surgery). A systematic literature review was performed using Medline and the bibliographies of all referenced publications to identify articles relating to preemptive surgery for premalignant foregut lesions. In this review, we outline the controversies surrounding predictive risk assessment, surveillance strategies, and preemptive surgery in the management of high-grade dysplasia (HGD) in Barrett's esophagus (BE), hereditary diffuse gastric cancer (HDGC), bile duct cysts, primary sclerosing cholangitis (PSC), and pancreatic cystic neoplasms. Resection of BE is supported by the progressive nature of the disease, the risk of occult carcinoma, and the lethality of esophageal cancer. Prophylactic total gastrectomy for HDGC appears reasonable in the absence of accurate screening tests but must be balanced by the impact of surgical complications and altered quality of life. Surgical resection of biliary cysts theoretically eliminates the exposed epithelium to decrease the lifetime risk of cholangiocarcinoma. Liver transplantation for PSC remains controversial given the scarcity of donor organs and inability to accurately identify high-risk individuals. Given the uncertain natural history of pancreatic cystic neoplasms, the merits of selective versus obligatory resection will continue to be debated. Preemptive operations require optimal judgment and surgical precision to maximize function and enhance survival. Ultimately, balancing the risk of surgical intervention with less invasive interventions or observation must be individualized on a case-by-case basis.",Journal Article,3877.0,8.0,Preemptive surgery is the prophylactic removal of an organ at high risk for malignant transformation or the resection of a precancerous or `` early '' malignant neoplasm in an individual with a hereditary predisposition to cancer Recent advances in molecular diagnostic techniques have improved our understanding of the biologic behavior of these conditions Predictive testing is an emerging field that attempts to assess the potential risk of cancer development in predisposed individuals Despite substantial improvement in these forms of testing all results are imperfect This information often becomes an important tool that is used by healthcare providers to evaluate the risk-benefit ratio of various risk modifying strategies i.e. intensive surveillance or preemptive surgery A systematic literature review was performed using Medline and the bibliographies of all referenced publications to identify articles relating to preemptive surgery for premalignant foregut lesions In this review we outline the controversies surrounding predictive risk assessment surveillance strategies and preemptive surgery in the management of high-grade dysplasia HGD in Barrett 's BE hereditary diffuse cancer HDGC duct cysts primary sclerosing cholangitis PSC and cystic neoplasms Resection of BE is supported by the progressive nature of the disease the risk of occult carcinoma and the lethality of cancer Prophylactic total gastrectomy for HDGC appears reasonable in the absence of accurate screening tests but must be balanced by the impact of surgical complications and altered quality of life Surgical resection of biliary cysts theoretically eliminates the exposed epithelium to decrease the lifetime risk of cholangiocarcinoma transplantation for PSC remains controversial given the scarcity of donor organs and inability to accurately identify high-risk individuals Given the uncertain natural history of cystic neoplasms the merits of selective versus obligatory resection will continue to be debated Preemptive operations require optimal judgment and surgical precision to maximize function and enhance survival Ultimately balancing the risk of surgical intervention with less invasive interventions or observation must be individualized on a case-by-case basis,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,"[15332, 152, 16, 3, 1862, 2829, 1, 35, 1259, 28, 64, 43, 9, 393, 1392, 15, 3, 170, 1, 8, 6605, 15, 191, 522, 393, 2131, 4, 35, 797, 5, 8, 2305, 2863, 6, 12, 435, 954, 4, 219, 752, 1092, 47, 231, 114, 612, 1, 3, 1283, 1710, 1, 46, 1298, 464, 471, 16, 35, 1478, 1067, 17, 4374, 6, 423, 3, 174, 43, 1, 12, 193, 4, 11072, 869, 550, 1281, 767, 4, 46, 2377, 1, 471, 62, 99, 32, 13613, 26, 487, 629, 5366, 35, 305, 1515, 17, 16, 95, 20, 2819, 1994, 6, 376, 3, 43, 247, 197, 1, 747, 43, 4898, 422, 70, 563, 1686, 617, 15, 15332, 152, 8, 1556, 789, 206, 10, 173, 75, 3388, 2, 3, 21080, 1, 62, 13365, 4463, 6, 255, 2384, 7750, 6, 15332, 152, 9, 4343, 20481, 406, 4, 26, 206, 21, 5277, 3, 6613, 2976, 464, 43, 455, 617, 422, 2, 15332, 152, 4, 3, 284, 1, 64, 88, 2253, 6623, 4, 4366, 292, 40, 2305, 1388, 12, 21972, 2920, 4395, 86, 6782, 8541, 5417, 2, 2965, 1179, 170, 1, 40, 16, 2708, 20, 3, 1014, 2202, 1, 3, 34, 3, 43, 1, 2879, 134, 2, 3, 3266, 1, 12, 1862, 181, 3577, 9, 21972, 1233, 3203, 4, 3, 1127, 1, 1481, 453, 895, 84, 1642, 40, 4115, 20, 3, 345, 1, 221, 521, 2, 1495, 372, 1, 358, 221, 170, 1, 2532, 4395, 9662, 10794, 3, 2234, 2781, 6, 775, 3, 2898, 43, 1, 2126, 497, 9, 5417, 469, 2010, 447, 3, 16074, 1, 1488, 2285, 2, 4985, 6, 2141, 255, 64, 43, 869, 447, 3, 2717, 1504, 532, 1, 2965, 1179, 3, 4986, 1, 1094, 185, 23107, 170, 303, 1906, 6, 40, 7755, 15332, 3867, 1353, 665, 8671, 2, 221, 2720, 6, 4116, 343, 2, 1304, 25, 2050, 13013, 3, 43, 1, 221, 788, 5, 299, 416, 1151, 15, 1664, 1642, 40, 2596, 23, 8, 473, 20, 473, 877]",2262.0,19513795,5
Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma.,Surgery,Surgery,2009-08-01,"The American Joint Committee on Cancer (AJCC) T classification system for cholangiocarcinoma does not take into account the unique pathologic features of the bile duct. As such, the current AJCC T classification for distal cholangiocarcinoma may be inaccurate. A total of 147 patients with distal cholangiocarcinoma were identified from a single institution database. The prognostic importance of depth of tumor invasion relative to the AJCC T classification system was assessed. The AJCC T classification was T1 (n = 11, 7.5%), T2 (n = 6, 4.1%), T3 (n = 73, 49.7%), or T4 (n = 57, 38.8%). When cases were analyzed according to depth of tumor invasion, most lesions were > or =5 mm (<5 mm, 9.5%; range, 5-12, 51.0%; >12 mm, 39.5%). The AJCC T classification was not associated with survival outcome (median survival, T1, 40.1 months; T2, 14.8 months; T3, 16.5 months; T4, 20.2 months; P = .17). In contrast, depth of tumor invasion was associated with a worse outcome as tumor depth increased (median survival, <5 mm, not reached; range, 5-12, 28.9 months; >12 mm, 12.9 months; P = .001). On multivariate analyses, tumor depth remained the factor most associated with outcome (<5 mm; hazard ratio [HR] = referent vs 5-12 mm; HR = 3.8 vs >12 mm; HR = 6.7 mm; P = .001). The AJCC T classification for distal cholangiocarcinoma does not accurately predict prognosis. Depth of the bile duct carcinoma invasion is a better alternative method to determine prognosis and should be incorporated into the pathologic assessment of resected distal cholangiocarcinoma.",Journal Article,3825.0,66.0,The American Joint Committee on Cancer AJCC T classification system for cholangiocarcinoma does not take into account the unique pathologic features of the duct As such the current AJCC T classification for distal cholangiocarcinoma may be inaccurate A total of 147 patients with distal cholangiocarcinoma were identified from a single institution database The prognostic importance of depth of tumor invasion relative to the AJCC T classification system was assessed The AJCC T classification was T1 n 11 7.5 T2 n 6 4.1 T3 n 73 49.7 or T4 n 57 38.8 When cases were analyzed according to depth of tumor invasion most lesions were or =5 mm 5 mm 9.5 range 5-12 51.0 12 mm 39.5 The AJCC T classification was not associated with survival outcome median survival T1 40.1 months T2 14.8 months T3 16.5 months T4 20.2 months P .17 In contrast depth of tumor invasion was associated with a worse outcome as tumor depth increased median survival 5 mm not reached range 5-12 28.9 months 12 mm 12.9 months P .001 On multivariate analyses tumor depth remained the factor most associated with outcome 5 mm hazard ratio HR referent vs 5-12 mm HR 3.8 vs 12 mm HR 6.7 mm P .001 The AJCC T classification for distal cholangiocarcinoma does not accurately predict prognosis Depth of the duct carcinoma invasion is a better alternative method to determine prognosis and should be incorporated into the pathologic assessment of resected distal cholangiocarcinoma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 597, 2093, 2002, 23, 12, 2271, 102, 947, 398, 9, 2126, 1097, 44, 3585, 237, 1967, 3, 991, 510, 404, 1, 3, 2920, 22, 225, 3, 291, 2271, 102, 947, 9, 2107, 2126, 68, 40, 8791, 8, 181, 1, 4961, 7, 5, 2107, 2126, 11, 108, 29, 8, 226, 731, 609, 3, 177, 1187, 1, 2436, 1, 30, 578, 580, 6, 3, 2271, 102, 947, 398, 10, 275, 3, 2271, 102, 947, 10, 1534, 78, 175, 67, 33, 1786, 78, 49, 39, 14, 2065, 78, 803, 739, 67, 15, 2463, 78, 696, 519, 66, 198, 140, 11, 311, 768, 6, 2436, 1, 30, 578, 96, 406, 11, 15, 33, 321, 33, 321, 83, 33, 184, 33, 133, 725, 13, 133, 321, 587, 33, 3, 2271, 102, 947, 10, 44, 41, 5, 25, 228, 52, 25, 1534, 327, 14, 53, 1786, 213, 66, 53, 2065, 245, 33, 53, 2463, 179, 18, 53, 19, 269, 4, 748, 2436, 1, 30, 578, 10, 41, 5, 8, 639, 228, 22, 30, 2436, 101, 52, 25, 33, 321, 44, 1300, 184, 33, 133, 339, 83, 53, 133, 321, 133, 83, 53, 19, 144, 23, 331, 318, 30, 2436, 958, 3, 161, 96, 41, 5, 228, 33, 321, 360, 197, 168, 9881, 105, 33, 133, 321, 168, 27, 66, 105, 133, 321, 168, 49, 67, 321, 19, 144, 3, 2271, 102, 947, 9, 2107, 2126, 1097, 44, 2141, 678, 356, 2436, 1, 3, 2920, 134, 578, 16, 8, 380, 1091, 596, 6, 223, 356, 2, 257, 40, 2449, 237, 3, 510, 455, 1, 1133, 2107, 2126]",1442.0,19628081,38
The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium.,Investigational new drugs,Invest New Drugs,2009-08-11,"Hepatobiliary cancers respond poorly to cytotoxic chemotherapy. We evaluated the activity and safety of ixabepilone, an epothilone B analogue which stabilizes microtubules, in a phase II trial in patients with advanced cancers of the gallbladder, bile duct, and liver. Eligible patients had previously-untreated, histologically-proven unresectable hepatobiliary cancer. Ixabepilone, 40 mg/m(2), was administered intravenously over 3 h every 21 days. Between January 2002 and April 2005, 54 patients (19 hepatocelluar carcinoma, 13 cholangiocarcinomas, 22 gallbladder carcinomas) were enrolled; 47 patients were evaluable for efficacy. The objective response rate was 8.5%; 51% had stable disease. Median overall survival was 7.0 months (95% CI, 5.0 to 10.8 months) and median progression-free survival was 2.6 months (95% CI, 1.4 to 4.1 months). Grade 3/4 toxicities included neutropenia (39%), fatigue (9%), allergic/hypersensitivity reaction (4%) and sensory neuropathy (4%). Single agent ixabepilone has limited activity in advanced hepatobiliary cancers.","Clinical Trial, Phase II",3815.0,5.0,Hepatobiliary cancers respond poorly to cytotoxic chemotherapy We evaluated the activity and safety of ixabepilone an epothilone B analogue which stabilizes microtubules in a phase II trial in patients with advanced cancers of the duct and Eligible patients had previously-untreated histologically-proven unresectable hepatobiliary cancer Ixabepilone 40 mg/m 2 was administered intravenously over 3 h every 21 days Between January 2002 and April 2005 54 patients 19 hepatocelluar carcinoma 13 cholangiocarcinomas 22 carcinomas were enrolled 47 patients were evaluable for efficacy The objective response rate was 8.5 51 had stable disease Median overall survival was 7.0 months 95 CI 5.0 to 10.8 months and median progression-free survival was 2.6 months 95 CI 1.4 to 4.1 months Grade 3/4 toxicities included neutropenia 39 fatigue 9 allergic/hypersensitivity reaction 4 and sensory neuropathy 4 Single agent ixabepilone has limited activity in advanced hepatobiliary cancers,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4718, 163, 1892, 1240, 6, 759, 56, 21, 194, 3, 128, 2, 367, 1, 3514, 35, 10202, 132, 4696, 92, 11019, 9870, 4, 8, 124, 215, 160, 4, 7, 5, 131, 163, 1, 3, 2920, 2, 625, 7, 42, 373, 1278, 2161, 1930, 1468, 4718, 12, 3514, 327, 81, 188, 18, 10, 468, 1672, 252, 27, 555, 454, 239, 162, 59, 1024, 1544, 2, 2292, 1242, 667, 7, 326, 45647, 134, 233, 9386, 350, 826, 11, 346, 662, 7, 11, 859, 9, 209, 3, 461, 51, 116, 10, 66, 33, 725, 42, 585, 34, 52, 63, 25, 10, 67, 13, 53, 48, 58, 33, 13, 6, 79, 66, 53, 2, 52, 91, 115, 25, 10, 18, 49, 53, 48, 58, 14, 39, 6, 39, 14, 53, 88, 27, 39, 385, 159, 778, 587, 613, 83, 7465, 4034, 1329, 39, 2, 4148, 1751, 39, 226, 420, 3514, 71, 383, 128, 4, 131, 4718, 163]",975.0,19669700,9
Elevated cancer mortality in the relatives of patients with pancreatic cancer.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2009-10-20,"Most inherited cancer syndromes are characterized by the familial clustering of cancers at several organ sites. To determine if cancers, other than pancreatic cancer, cluster in pancreatic cancer kindreds, we examined mortality patterns among the relatives of National Familial Pancreatic Tumor Registry probands. Over 200,000 person-years of follow-up from 8,564 first-degree relatives of probands and 1,007 spouse controls were included in these analyses. We compared mortality rates of National Familial Pancreatic Tumor Registry participants to US population rates using weighed standardized mortality ratios (wSMR). Analyses were stratified by family history of pancreatic cancer (sporadic versus familial), family history of young onset pancreatic cancer (<50 years), and family history score. Cancer mortality was increased in both the relatives of sporadic probands [wSMR 1.55, 95% confidence interval (95% CI) 1.39-1.73] and familial probands (wSMR 1.41, 95% CI 1.26-1.58). Relatives of familial probands had a significantly increased risk of dying from breast (wSMR 1.66, 95% CI 1.15-2.34), ovarian (wSMR 2.05, 95% CI 1.10-3.49), and bile duct cancers (wSMR 2.89, 95% CI 1.04-6.39). Relatives of sporadic probands were at increased risk of dying from bile duct cancer (wSMR 3.01, 95% CI 1.09-6.67). Relatives of young onset probands were at higher risk of dying from cancers of the breast (wSMR 1.98, 95% CI 1.01-3.52), colon (wSMR 2.31, 95% CI 1.30-3.81) and prostate (wSMR 2.31, 95% CI 1.14-4.20). Increased cancer mortality was not observed in the spouse controls. Our results show that relatives of pancreatic cancer patients are at higher risk of developing cancers at other sites and highlight the importance of complete family history in clinical risk assessment.",Journal Article,3745.0,45.0,"Most inherited cancer syndromes are characterized by the familial clustering of cancers at several organ sites To determine if cancers other than cancer cluster in cancer kindreds we examined mortality patterns among the relatives of National Familial Tumor Registry probands Over 200,000 person-years of follow-up from 8,564 first-degree relatives of probands and 1,007 spouse controls were included in these analyses We compared mortality rates of National Familial Tumor Registry participants to US population rates using weighed standardized mortality ratios wSMR Analyses were stratified by family history of cancer sporadic versus familial family history of young onset cancer 50 years and family history score Cancer mortality was increased in both the relatives of sporadic probands wSMR 1.55 95 confidence interval 95 CI 1.39-1.73 and familial probands wSMR 1.41 95 CI 1.26-1.58 Relatives of familial probands had a significantly increased risk of dying from wSMR 1.66 95 CI 1.15-2.34 wSMR 2.05 95 CI 1.10-3.49 and duct cancers wSMR 2.89 95 CI 1.04-6.39 Relatives of sporadic probands were at increased risk of dying from duct cancer wSMR 3.01 95 CI 1.09-6.67 Relatives of young onset probands were at higher risk of dying from cancers of the wSMR 1.98 95 CI 1.01-3.52 wSMR 2.31 95 CI 1.30-3.81 and wSMR 2.31 95 CI 1.14-4.20 Increased cancer mortality was not observed in the spouse controls Our results show that relatives of cancer patients are at higher risk of developing cancers at other sites and highlight the importance of complete family history in clinical risk assessment",1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[96, 2986, 12, 2040, 32, 765, 20, 3, 2200, 3147, 1, 163, 28, 392, 1259, 633, 6, 223, 492, 163, 127, 76, 12, 3132, 4, 12, 10141, 21, 409, 282, 764, 107, 3, 3335, 1, 657, 2200, 30, 1608, 4916, 252, 1250, 984, 2719, 60, 1, 166, 126, 29, 66, 11090, 157, 1444, 3335, 1, 4916, 2, 14, 1999, 10568, 535, 11, 159, 4, 46, 318, 21, 72, 282, 151, 1, 657, 2200, 30, 1608, 776, 6, 843, 266, 151, 75, 10271, 1670, 282, 1137, 22570, 318, 11, 1173, 20, 607, 532, 1, 12, 1928, 185, 2200, 607, 532, 1, 1169, 1707, 12, 212, 60, 2, 607, 532, 368, 12, 282, 10, 101, 4, 110, 3, 3335, 1, 1928, 4916, 22570, 14, 614, 48, 307, 268, 48, 58, 14, 587, 14, 803, 2, 2200, 4916, 22570, 14, 605, 48, 58, 14, 432, 14, 717, 3335, 1, 2200, 4916, 42, 8, 97, 101, 43, 1, 4536, 29, 22570, 14, 700, 48, 58, 14, 167, 18, 562, 22570, 18, 474, 48, 58, 14, 79, 27, 739, 2, 2920, 163, 22570, 18, 887, 48, 58, 14, 755, 49, 587, 3335, 1, 1928, 4916, 11, 28, 101, 43, 1, 4536, 29, 2920, 12, 22570, 27, 355, 48, 58, 14, 1730, 49, 598, 3335, 1, 1169, 1707, 4916, 11, 28, 142, 43, 1, 4536, 29, 163, 1, 3, 22570, 14, 1096, 48, 58, 14, 355, 27, 653, 22570, 18, 456, 48, 58, 14, 201, 27, 865, 2, 22570, 18, 456, 48, 58, 14, 213, 39, 179, 101, 12, 282, 10, 44, 164, 4, 3, 10568, 535, 114, 99, 514, 17, 3335, 1, 12, 7, 32, 28, 142, 43, 1, 931, 163, 28, 127, 633, 2, 1817, 3, 1187, 1, 236, 607, 532, 4, 38, 43, 455]",1591.0,19843679,87
Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature.,Digestive diseases and sciences,Dig. Dis. Sci.,2010-01-27,"Alagille syndrome is a multi-system developmental disorder associated with paucity of interlobular bile ducts and cholestasis, rarely associated with hepatocellular carcinoma. Associated syndromic co-morbidities may complicate surgical management. As such, we herein review the modern management of a large hepatocellular carcinoma in an adult patient with Alagille syndrome and review the literature of adult Alagille patients with hepatocellular carcinoma. A 29-year-old woman with a history of Alagille syndrome was referred with biopsy-proven 128cm hepatocellular carcinoma replacing her right liver. Biopsy of the contralateral liver demonstrated findings consistent with Alagille syndrome, but no underlying cirrhosis. CT volumetrics demonstrated a future liver remnant of 40%. Extensive hematologic and cardiac work-up was performed pre-operatively, given the syndrome's associated bleeding dyscrasias and cardiac abnormalities. The patient underwent a margin-negative right hepatectomy using the ""hanging"" technique through a thoracoabdominal approach. The patient developed a transient hyperbilirubinemia but no hepatic insufficiency and did well post-operatively. Since Alagille syndrome affects multiple organ systems, preoperative evaluation of cardiac, hematologic, and hepatic function should be considered. This case illustrates the peri-operative management of an Alagille patient, and highlights several key technical points that contributed to a successful resection.",Case Reports,3646.0,15.0,Alagille syndrome is a multi-system developmental disorder associated with paucity of interlobular ducts and cholestasis rarely associated with carcinoma Associated syndromic co-morbidities may complicate surgical management As such we herein review the modern management of a large carcinoma in an adult patient with Alagille syndrome and review the literature of adult Alagille patients with carcinoma A 29-year-old woman with a history of Alagille syndrome was referred with biopsy-proven 12 8 cm carcinoma replacing her right Biopsy of the contralateral demonstrated findings consistent with Alagille syndrome but no underlying cirrhosis CT volumetrics demonstrated a future remnant of 40 Extensive hematologic and work-up was performed pre-operatively given the syndrome 's associated bleeding dyscrasias and abnormalities The patient underwent a margin-negative right hepatectomy using the `` hanging '' technique through a thoracoabdominal approach The patient developed a transient hyperbilirubinemia but no hepatic insufficiency and did well post-operatively Since Alagille syndrome affects multiple organ systems preoperative evaluation of hematologic and hepatic function should be considered This case illustrates the peri-operative management of an Alagille patient and highlights several key technical points that contributed to a successful resection,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,"[25227, 681, 16, 8, 1414, 398, 4566, 2645, 41, 5, 4832, 1, 45858, 7310, 2, 19771, 2416, 41, 5, 134, 41, 14201, 1269, 5655, 68, 11157, 221, 284, 22, 225, 21, 1986, 206, 3, 2366, 284, 1, 8, 375, 134, 4, 35, 780, 69, 5, 25227, 681, 2, 206, 3, 789, 1, 780, 25227, 7, 5, 134, 8, 462, 111, 1095, 2854, 5, 8, 532, 1, 25227, 681, 10, 1995, 5, 411, 1930, 133, 66, 494, 134, 9574, 1084, 1913, 411, 1, 3, 2138, 264, 272, 925, 5, 25227, 681, 84, 77, 1181, 3563, 425, 31574, 264, 8, 508, 5644, 1, 327, 1344, 813, 2, 1357, 126, 10, 173, 671, 9433, 447, 3, 681, 292, 41, 2294, 17162, 2, 1171, 3, 69, 208, 8, 959, 199, 1913, 2711, 75, 3, 58594, 522, 1312, 298, 8, 22007, 353, 3, 69, 276, 8, 2473, 7236, 84, 77, 939, 4360, 2, 205, 149, 539, 9433, 1192, 25227, 681, 2561, 232, 1259, 1530, 498, 451, 1, 813, 2, 939, 343, 257, 40, 515, 26, 473, 6342, 3, 6164, 1208, 284, 1, 35, 25227, 69, 2, 2527, 392, 825, 3359, 862, 17, 3447, 6, 8, 1401, 170]",1365.0,20108035,41
Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma.,Annals of surgery,Ann. Surg.,2010-04-01,"To examine the importance of adequate lymph node sampling in staging of extrahepatic bile duct cancer (EHBDCA). The American Joint Committee on Cancer staging manual (sixth edition) states that histologic examination of at least 3 lymph nodes is required for adequate N stage determination for EHBDCA. This recommendation has not been validated; however, there has been no comparative assessment of the proximal versus distal bile duct cancer. A total of 257 patients (144 hilar cholangiocarcinoma [HCCA] and 113 distal bile duct adenocarcinoma [DBDCA]) who underwent curative intent resection (1987-2007) were analyzed; patients with gallbladder cancer were excluded. Final disease staging, including lymph node status and total number of nodes examined (total lymph node count), was obtained from the final pathology report. Differences in disease-specific survival, according to nodal status, were compared using the log-rank test. R1 resections (n = 51) were excluded from this analysis. Metastasis to regional lymph nodes was noted in 89 patients (34.6%) and was an independent prognostic factor of poor survival (median disease-specific survival N0 vs. N1: 53.5 vs. 19.3 months, P < 0.0001, hazard ratio = 2.1 [95% CI: 1.4-3.2]). The median total lymph node count was 6 (range: 0-42), and was significantly lower for HCCA compared with DBDCA (median = 3 [range: 0-16] vs. 12 [range: 1-42], P < 0.001, respectively). For the entire cohort, patients who underwent R0 resection and were classified as N0, based on total lymph node count <11, had a disease-specific survival that was significantly worse than that of patients classified as N0 based on total lymph node count >or=11 (52.6 +/- 9.8 months vs. not reached, P = 0.008). The estimated optimal total lymph node count for HCCA differed from that of DBDCA (n = 7 vs. n = 11, respectively). Adequate lymph nodes assessment of EHBDCA, based on the current AJCC recommendations, results in understaging of these tumors. With respect to the optimal total lymph node count, HCCA, and DBDCA should be considered separately.",Journal Article,3582.0,92.0,To examine the importance of adequate lymph node sampling in staging of extrahepatic duct cancer EHBDCA The American Joint Committee on Cancer staging manual sixth edition states that histologic examination of at least 3 lymph nodes is required for adequate N stage determination for EHBDCA This recommendation has not been validated however there has been no comparative assessment of the proximal versus distal duct cancer A total of 257 patients 144 hilar cholangiocarcinoma HCCA and 113 distal duct adenocarcinoma DBDCA who underwent curative intent resection 1987-2007 were analyzed patients with cancer were excluded Final disease staging including lymph node status and total number of nodes examined total lymph node count was obtained from the final pathology report Differences in disease-specific survival according to nodal status were compared using the log-rank test R1 resections n 51 were excluded from this analysis Metastasis to regional lymph nodes was noted in 89 patients 34.6 and was an independent prognostic factor of poor survival median disease-specific survival N0 vs. N1 53.5 vs. 19.3 months P 0.0001 hazard ratio 2.1 95 CI 1.4-3.2 The median total lymph node count was 6 range 0-42 and was significantly lower for HCCA compared with DBDCA median 3 range 0-16 vs. 12 range 1-42 P 0.001 respectively For the entire cohort patients who underwent R0 resection and were classified as N0 based on total lymph node count 11 had a disease-specific survival that was significantly worse than that of patients classified as N0 based on total lymph node count or=11 52.6 +/- 9.8 months vs. not reached P 0.008 The estimated optimal total lymph node count for HCCA differed from that of DBDCA n 7 vs. n 11 respectively Adequate lymph nodes assessment of EHBDCA based on the current AJCC recommendations results in understaging of these tumors With respect to the optimal total lymph node count HCCA and DBDCA should be considered separately,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1004, 3, 1187, 1, 1658, 263, 289, 2874, 4, 632, 1, 3710, 2920, 12, 39270, 3, 597, 2093, 2002, 23, 12, 632, 4590, 7462, 3580, 907, 17, 884, 1385, 1, 28, 506, 27, 263, 502, 16, 616, 9, 1658, 78, 82, 3104, 9, 39270, 26, 3347, 71, 44, 85, 938, 137, 125, 71, 85, 77, 2352, 455, 1, 3, 2805, 185, 2107, 2920, 12, 8, 181, 1, 7941, 7, 4415, 4793, 2126, 9280, 2, 4259, 2107, 2920, 449, 34851, 54, 208, 1075, 1697, 170, 5450, 1307, 11, 311, 7, 5, 12, 11, 1800, 1457, 34, 632, 141, 263, 289, 156, 2, 181, 207, 1, 502, 409, 181, 263, 289, 1276, 10, 683, 29, 3, 1457, 1117, 414, 362, 4, 34, 112, 25, 768, 6, 779, 156, 11, 72, 75, 3, 1066, 1026, 412, 3239, 2185, 78, 725, 11, 1800, 29, 26, 65, 278, 6, 951, 263, 502, 10, 1051, 4, 887, 7, 562, 49, 2, 10, 35, 306, 177, 161, 1, 334, 25, 52, 34, 112, 25, 3394, 105, 3192, 699, 33, 105, 326, 27, 53, 19, 13, 488, 360, 197, 18, 14, 48, 58, 14, 39, 27, 18, 3, 52, 181, 263, 289, 1276, 10, 49, 184, 13, 595, 2, 10, 97, 280, 9, 9280, 72, 5, 34851, 52, 27, 184, 13, 245, 105, 133, 184, 14, 595, 19, 13, 144, 106, 9, 3, 1797, 180, 7, 54, 208, 2328, 170, 2, 11, 1373, 22, 3394, 90, 23, 181, 263, 289, 1276, 175, 42, 8, 34, 112, 25, 17, 10, 97, 639, 76, 17, 1, 7, 1373, 22, 3394, 90, 23, 181, 263, 289, 1276, 15, 175, 653, 49, 83, 66, 53, 105, 44, 1300, 19, 13, 2155, 3, 661, 665, 181, 263, 289, 1276, 9, 9280, 2512, 29, 17, 1, 34851, 78, 67, 105, 78, 175, 106, 1658, 263, 502, 455, 1, 39270, 90, 23, 3, 291, 2271, 883, 99, 4, 18228, 1, 46, 57, 5, 2184, 6, 3, 665, 181, 263, 289, 1276, 9280, 2, 34851, 257, 40, 515, 3582]",1957.0,20224368,45
Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation.,"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2010-05-21,"Fibrolamellar carcinoma is a rare malignant primary liver neoplasm with characteristic histological features that typically arises in young patients without viral hepatitis or cirrhosis. Previous studies on this entity have been limited by small numbers of patients. In contrast to classical hepatocellular carcinoma, individual cases of fibrolamellar carcinoma have been reported to express cytokeratin 7. In addition, ultrastructural and serological studies have suggested that fibrolamellar carcinoma may show neuroendocrine differentiation. The cellular differentiation of fibrolamellar carcinoma has not been studied and little is reported about its immunohistochemical profile. We studied 26 cases of fibrolamellar carcinoma and 62 cases of classical hepatocellular carcinoma by immunohistochemistry for HepPar1, glypican-3, pCEA, CD10, alpha-fetoprotein, cytokeratin 20, neuroendocrine markers, and surrogate markers for biliary differentiation (cytokeratin 7, cytokeratin 19, epithelial membrane antigen, EpCAM, mCEA, B72.3, and CA19.9). In situ hybridization for albumin mRNA was also performed. Tumor cells of fibrolamellar carcinoma and hepatocellular carcinoma showed positive signals for albumin mRNA by in situ hybridization in all cases. Both tumor types stained uniformly positively with HepPar1 and most showed a canalicular staining pattern for pCEA, confirming their hepatocellular differentiation. In addition, 39% of hepatocellular carcinoma cases and 59% of fibrolamellar carcinoma cases were positive for glypican-3. All 22 fibrolamellar carcinoma cases tested showed positive staining for cytokeratin 7 and epithelial membrane antigen, whereas less than one-third of hepatocellular carcinoma cases were positive for these markers (P<0.0001). Further, 36% of fibrolamellar carcinoma cases showed staining for B72.3, cytokeratin 19, EpCAM, or mCEA. Minimal evidence of neuroendocrine differentiation in either tumor was found with any of the usual immunohistochemical markers used for this purpose. Therefore, cytokeratin 7 and epithelial membrane antigen may be useful to differentiate between fibrolamellar carcinoma and hepatocellular carcinoma. On the basis of immunohistochemistry, fibrolamellar carcinoma seems to show both hepatocellular and bile duct differentiation.",Journal Article,3532.0,62.0,Fibrolamellar carcinoma is a rare malignant primary neoplasm with characteristic histological features that typically arises in young patients without viral hepatitis or cirrhosis Previous studies on this entity have been limited by small numbers of patients In contrast to classical carcinoma individual cases of fibrolamellar carcinoma have been reported to express cytokeratin 7 In addition ultrastructural and serological studies have suggested that fibrolamellar carcinoma may show neuroendocrine differentiation The cellular differentiation of fibrolamellar carcinoma has not been studied and little is reported about its immunohistochemical profile We studied 26 cases of fibrolamellar carcinoma and 62 cases of classical carcinoma by immunohistochemistry for HepPar1 glypican-3 pCEA CD10 alpha-fetoprotein cytokeratin 20 neuroendocrine markers and surrogate markers for biliary differentiation cytokeratin 7 cytokeratin 19 epithelial membrane antigen EpCAM mCEA B72.3 and CA19.9 In situ hybridization for albumin mRNA was also performed Tumor cells of fibrolamellar carcinoma and carcinoma showed positive signals for albumin mRNA by in situ hybridization in all cases Both tumor types stained uniformly positively with HepPar1 and most showed a canalicular staining pattern for pCEA confirming their differentiation In addition 39 of carcinoma cases and 59 of fibrolamellar carcinoma cases were positive for glypican-3 All 22 fibrolamellar carcinoma cases tested showed positive staining for cytokeratin 7 and epithelial membrane antigen whereas less than one-third of carcinoma cases were positive for these markers P 0.0001 Further 36 of fibrolamellar carcinoma cases showed staining for B72.3 cytokeratin 19 EpCAM or mCEA Minimal evidence of neuroendocrine differentiation in either tumor was found with any of the usual immunohistochemical markers used for this purpose Therefore cytokeratin 7 and epithelial membrane antigen may be useful to differentiate between fibrolamellar carcinoma and carcinoma On the basis of immunohistochemistry fibrolamellar carcinoma seems to show both and duct differentiation,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[9686, 134, 16, 8, 622, 393, 86, 2131, 5, 2037, 1831, 404, 17, 1969, 6053, 4, 1169, 7, 187, 1667, 3002, 15, 3563, 698, 94, 23, 26, 2983, 47, 85, 383, 20, 302, 1870, 1, 7, 4, 748, 6, 3781, 134, 797, 140, 1, 9686, 134, 47, 85, 210, 6, 1669, 4292, 67, 4, 352, 13755, 2, 14132, 94, 47, 1148, 17, 9686, 134, 68, 514, 1542, 910, 3, 763, 910, 1, 9686, 134, 71, 44, 85, 656, 2, 1215, 16, 210, 545, 211, 1382, 800, 21, 656, 432, 140, 1, 9686, 134, 2, 744, 140, 1, 3781, 134, 20, 888, 9, 34900, 17206, 27, 22615, 6289, 950, 6607, 4292, 179, 1542, 525, 2, 2592, 525, 9, 2532, 910, 4292, 67, 4292, 326, 701, 1905, 448, 6820, 46052, 31634, 27, 2, 6058, 83, 4, 957, 1554, 9, 2799, 956, 10, 120, 173, 30, 37, 1, 9686, 134, 2, 134, 224, 109, 2312, 9, 2799, 956, 20, 4, 957, 1554, 4, 62, 140, 110, 30, 630, 3386, 4254, 2375, 5, 34900, 2, 96, 224, 8, 18186, 1029, 1177, 9, 22615, 5030, 136, 910, 4, 352, 587, 1, 134, 140, 2, 728, 1, 9686, 134, 140, 11, 109, 9, 17206, 27, 62, 350, 9686, 134, 140, 650, 224, 109, 1029, 9, 4292, 67, 2, 701, 1905, 448, 547, 299, 76, 104, 1282, 1, 134, 140, 11, 109, 9, 46, 525, 19, 13, 488, 195, 511, 1, 9686, 134, 140, 224, 1029, 9, 31634, 27, 4292, 326, 6820, 15, 46052, 1048, 241, 1, 1542, 910, 4, 361, 30, 10, 204, 5, 500, 1, 3, 3521, 1382, 525, 95, 9, 26, 743, 673, 4292, 67, 2, 701, 1905, 448, 68, 40, 999, 6, 3723, 59, 9686, 134, 2, 134, 23, 3, 877, 1, 888, 9686, 134, 2744, 6, 514, 110, 2, 2920, 910]",2120.0,20495535,105
Intrahepatic cholangiocarcinoma.,The Surgical clinics of North America,Surg. Clin. North Am.,2010-08-01,"Intrahepatic cholangiocarcinoma (ICC) is a primary cancer of the bile ducts, arising from malignant transformation of the epithelial cells that line the biliary apparatus. ICC is relatively uncommon, but its incidence is on the increase. ICC is frequently discovered as an incidental, indeterminate liver mass. Surgical resection of ICC represents the only potentially curative therapeutic option. The role of routine hilar lymphadenectomy is controversial, but should be considered to optimize staging. Although adjuvant chemotherapy and radiotherapy is probably not supported by current data, each should strongly be considered in patients with lymph node metastasis or an R1 resection. For those patients with inoperable disease, locoregional therapy with transarterial chemoembolization can be considered.",Journal Article,3460.0,73.0,Intrahepatic cholangiocarcinoma ICC is a primary cancer of the ducts arising from malignant transformation of the epithelial cells that line the biliary apparatus ICC is relatively uncommon but its incidence is on the increase ICC is frequently discovered as an incidental indeterminate mass Surgical resection of ICC represents the only potentially curative therapeutic option The role of routine hilar lymphadenectomy is controversial but should be considered to optimize staging Although adjuvant chemotherapy and radiotherapy is probably not supported by current data each should strongly be considered in patients with lymph node metastasis or an R1 resection For those patients with inoperable disease locoregional therapy with transarterial chemoembolization can be considered,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3022, 2126, 2259, 16, 8, 86, 12, 1, 3, 7310, 2635, 29, 393, 1392, 1, 3, 701, 37, 17, 328, 3, 2532, 10180, 2259, 16, 1352, 2052, 84, 211, 287, 16, 23, 3, 344, 2259, 16, 746, 2747, 22, 35, 4490, 5167, 782, 221, 170, 1, 2259, 1449, 3, 158, 751, 1075, 189, 1501, 3, 200, 1, 1311, 4793, 2048, 16, 2010, 84, 257, 40, 515, 6, 2465, 632, 242, 249, 56, 2, 310, 16, 4061, 44, 2708, 20, 291, 74, 296, 257, 1327, 40, 515, 4, 7, 5, 263, 289, 278, 15, 35, 3239, 170, 9, 135, 7, 5, 3874, 34, 1325, 36, 5, 7671, 6056, 122, 40, 515]",783.0,20637950,18
Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis.,Journal of surgical oncology,J Surg Oncol,2010-09-01,"The management of patients with peri-ampullary liver metastasis remains controversial. We sought to assess the safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. Between 1993 and 2009, 40 patients underwent curative intent surgery (resection and/or radiofrequency ablation (RFA)) for peri-ampullary liver metastasis. Clinicopathologic and outcome data were collected and analyzed. Location of the primary tumor was pancreas head (n = 20), ampulla of Vater (n = 10), distal bile duct (n = 5), or duodenum (n = 5). Most patients (n = 27) presented with synchronous disease, while 13 patients presented with metachronous disease following a median disease-free interval of 22 months. Most patients (n = 25) presented with hepatic metastasis from pancreaticobiliary origin (pancreatic or distal common bile duct) compared with 15 patients who had metastasis from an intestinal-type primary (ampullary or duodenal). There were no differences in metastatic tumor number or size between these groups (P > 0.05). Post-operative morbidity and mortality was 30% and 5% respectively. Overall 1- and 3-year survival was 55% and 18%. Patients who underwent resection of liver metastasis from intestinal-type tumors experienced a longer survival compared with patients who had pancreaticobiliary lesions (median: 13 months vs. 23 months; P = 0.05). Curative intent surgery for peri-ampullary liver metastasis was associated with post-operative morbidity and a 5% mortality rate. Although the overall survival benefit was modest, patients with liver metastasis from intestinal-type tumors experienced improved survival following resection of liver metastasis compared with pancreaticobiliary lesions.",Journal Article,3429.0,35.0,The management of patients with peri-ampullary metastasis remains controversial We sought to assess the safety and efficacy of curative intent surgery for peri-ampullary metastasis Between 1993 and 2009 40 patients underwent curative intent surgery resection and/or radiofrequency ablation RFA for peri-ampullary metastasis Clinicopathologic and outcome data were collected and analyzed Location of the primary tumor was head n 20 ampulla of Vater n 10 distal duct n 5 or duodenum n 5 Most patients n 27 presented with synchronous disease while 13 patients presented with metachronous disease following a median disease-free interval of 22 months Most patients n 25 presented with hepatic metastasis from pancreaticobiliary origin or distal common duct compared with 15 patients who had metastasis from an intestinal-type primary ampullary or duodenal There were no differences in metastatic tumor number or size between these groups P 0.05 Post-operative morbidity and mortality was 30 and 5 respectively Overall 1- and 3-year survival was 55 and 18 Patients who underwent resection of metastasis from intestinal-type tumors experienced a longer survival compared with patients who had pancreaticobiliary lesions median 13 months vs. 23 months P 0.05 Curative intent surgery for peri-ampullary metastasis was associated with post-operative morbidity and a 5 mortality rate Although the overall survival benefit was modest patients with metastasis from intestinal-type tumors experienced improved survival following resection of metastasis compared with pancreaticobiliary lesions,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 284, 1, 7, 5, 6164, 6762, 278, 469, 2010, 21, 990, 6, 423, 3, 367, 2, 209, 1, 1075, 1697, 152, 9, 6164, 6762, 278, 59, 3343, 2, 1238, 327, 7, 208, 1075, 1697, 152, 170, 2, 15, 5567, 1650, 3463, 9, 6164, 6762, 278, 1399, 2, 228, 74, 11, 786, 2, 311, 1147, 1, 3, 86, 30, 10, 718, 78, 179, 12837, 1, 14777, 78, 79, 2107, 2920, 78, 33, 15, 8401, 78, 33, 96, 7, 78, 428, 917, 5, 2734, 34, 369, 233, 7, 917, 5, 4796, 34, 366, 8, 52, 34, 115, 268, 1, 350, 53, 96, 7, 78, 243, 917, 5, 939, 278, 29, 14581, 1938, 15, 2107, 186, 2920, 72, 5, 167, 7, 54, 42, 278, 29, 35, 3077, 267, 86, 6762, 15, 4748, 125, 11, 77, 362, 4, 113, 30, 207, 15, 444, 59, 46, 271, 19, 13, 474, 539, 1208, 787, 2, 282, 10, 201, 2, 33, 106, 63, 14, 2, 27, 111, 25, 10, 614, 2, 203, 7, 54, 208, 170, 1, 278, 29, 3077, 267, 57, 592, 8, 589, 25, 72, 5, 7, 54, 42, 14581, 406, 52, 233, 53, 105, 382, 53, 19, 13, 474, 1075, 1697, 152, 9, 6164, 6762, 278, 10, 41, 5, 539, 1208, 787, 2, 8, 33, 282, 116, 242, 3, 63, 25, 247, 10, 1721, 7, 5, 278, 29, 3077, 267, 57, 592, 231, 25, 366, 170, 1, 278, 72, 5, 14581, 406]",1580.0,20740584,23
"Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries.",Journal of the American College of Surgeons,J. Am. Coll. Surg.,2010-11-12,"Gallbladder cancer (GBCA) is a rare malignancy with a variable incidence worldwide. This study analyzed GBCA patients treated at centers in 3 countries. The aim was to assess for location-specific differences in presentation and outcomes, which might suggest differences in pathogenesis or disease biology. Data for consecutive patients submitted to operation at Instituto Oncolgico Fundacin Arturo Lpez Prez (FALP, Chile), Yokohama City University (YCU, Japan), and Memorial Sloan-Kettering Cancer Center (MSKCC, USA) between 1999 and 2007 were studied retrospectively. Patient demographics, disease- and treatment-related variables and outcomes were analyzed by chi-square, Kruskal-Wallis, and log-rank test. Two hundred sixty-one patients (MSKCC, 130; FALP, 85; YCU, 46) underwent exploration, and 160 (MSKCC, 91; FALP, 33; YCU, 36) underwent R0 resection. Patients treated at FALP were younger (median 57 years, p < 0.001) and more often female (80%, p < 0.005); at YCU there were fewer patients with incidental tumors (19.5% compared with more than 60% at FALP and MSKCC, p < 0.001). En bloc liver and bile duct resections were performed more commonly at MSKCC and YCU (p < 0.001). Patients treated at FALP had more advanced tumor stage compared with those treated at MSKCC and YCU (p < 0.001). Disease-specific survival (DSS) was not different among the groups when patients submitted to an R0 resection were analyzed (p = 0.12). On multivariate analysis, T-stage, nodal involvement, and bile duct involvement were predictors of DSS; center was not significant. Despite some differences in presentation, disease extent, and surgical treatment, DSS after curative intent resection was similar among all 3 groups. The most important predictors of outcomes were related to tumor extent rather than country of origin.",Comparative Study,3357.0,68.0,cancer GBCA is a rare malignancy with a variable incidence worldwide This study analyzed GBCA patients treated at centers in 3 countries The aim was to assess for location-specific differences in presentation and outcomes which might suggest differences in pathogenesis or disease biology Data for consecutive patients submitted to operation at Instituto Oncolgico Fundacin Arturo Lpez Prez FALP Chile Yokohama City University YCU Japan and Memorial Sloan-Kettering Cancer Center MSKCC USA between 1999 and 2007 were studied retrospectively Patient demographics disease- and treatment-related variables and outcomes were analyzed by chi-square Kruskal-Wallis and log-rank test Two hundred sixty-one patients MSKCC 130 FALP 85 YCU 46 underwent exploration and 160 MSKCC 91 FALP 33 YCU 36 underwent R0 resection Patients treated at FALP were younger median 57 years p 0.001 and more often female 80 p 0.005 at YCU there were fewer patients with incidental tumors 19.5 compared with more than 60 at FALP and MSKCC p 0.001 En bloc and duct resections were performed more commonly at MSKCC and YCU p 0.001 Patients treated at FALP had more advanced tumor stage compared with those treated at MSKCC and YCU p 0.001 Disease-specific survival DSS was not different among the groups when patients submitted to an R0 resection were analyzed p 0.12 On multivariate analysis T-stage nodal involvement and duct involvement were predictors of DSS center was not significant Despite some differences in presentation disease extent and surgical treatment DSS after curative intent resection was similar among all 3 groups The most important predictors of outcomes were related to tumor extent rather than country of origin,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12, 9894, 16, 8, 622, 710, 5, 8, 1347, 287, 2358, 26, 45, 311, 9894, 7, 73, 28, 1168, 4, 27, 2115, 3, 1130, 10, 6, 423, 9, 1147, 112, 362, 4, 1031, 2, 123, 92, 822, 309, 362, 4, 1384, 15, 34, 891, 74, 9, 935, 7, 5118, 6, 2589, 28, 34364, 59535, 46322, 46323, 46324, 39473, 23881, 15222, 46325, 7235, 1652, 19920, 6157, 2, 2563, 2783, 2784, 12, 574, 4191, 2706, 59, 2043, 2, 1307, 11, 656, 894, 69, 2221, 34, 2, 24, 139, 682, 2, 123, 11, 311, 20, 3163, 3219, 8800, 8875, 2, 1066, 1026, 412, 100, 1128, 1746, 104, 7, 4191, 3431, 23881, 772, 19920, 641, 208, 3370, 2, 3457, 4191, 970, 23881, 466, 19920, 511, 208, 2328, 170, 7, 73, 28, 23881, 11, 773, 52, 696, 60, 19, 13, 144, 2, 80, 629, 1061, 493, 19, 13, 1614, 28, 19920, 125, 11, 1497, 7, 5, 4490, 57, 326, 33, 72, 5, 80, 76, 335, 28, 23881, 2, 4191, 19, 13, 144, 4375, 5590, 2, 2920, 2185, 11, 173, 80, 841, 28, 4191, 2, 19920, 19, 13, 144, 7, 73, 28, 23881, 42, 80, 131, 30, 82, 72, 5, 135, 73, 28, 4191, 2, 19920, 19, 13, 144, 34, 112, 25, 1788, 10, 44, 338, 107, 3, 271, 198, 7, 5118, 6, 35, 2328, 170, 11, 311, 19, 13, 133, 23, 331, 65, 102, 82, 779, 799, 2, 2920, 799, 11, 674, 1, 1788, 574, 10, 44, 93, 550, 476, 362, 4, 1031, 34, 1039, 2, 221, 24, 1788, 50, 1075, 1697, 170, 10, 288, 107, 62, 27, 271, 3, 96, 305, 674, 1, 123, 11, 139, 6, 30, 1039, 1832, 76, 5978, 1, 1938]",1710.0,21075015,84
New staging system and a registry for perihilar cholangiocarcinoma.,"Hepatology (Baltimore, Md.)",Hepatology,2011-04-01,"Perihilar cholangiocarcinoma is one of the most challenging diseases with poor overall survival. The major problem for anyone trying to convincingly compare studies among centers or over time is the lack of a reliable staging system. The most commonly used system is the Bismuth-Corlette classification of bile duct involvement, which, however, does not include crucial information such as vascular encasement and distant metastases. Other systems are rarely used because they do not provide several key pieces of information guiding therapy. Therefore, we have designed a new system reporting the size of the tumor, the extent of the disease in the biliary system, the involvement of the hepatic artery and portal vein, the involvement of lymph nodes, distant metastases, and the volume of the putative remnant liver after resection. The aim of this system is the standardization of the reporting of perihilar cholangiocarcinoma so that relevant information regarding resectability, indications for liver transplantation, and prognosis can be provided. With this tool, we have created a new registry enabling every center to prospectively enter data on their patients with hilar cholangiocarcinoma (www.cholangioca.org). The availability of such standardized and multicenter data will enable us to identify the critical criteria guiding therapy.",Journal Article,3217.0,166.0,Perihilar cholangiocarcinoma is one of the most challenging diseases with poor overall survival The major problem for anyone trying to convincingly compare studies among centers or over time is the lack of a reliable staging system The most commonly used system is the Bismuth-Corlette classification of duct involvement which however does not include crucial information such as vascular encasement and distant metastases Other systems are rarely used because they do not provide several key pieces of information guiding therapy Therefore we have designed a new system reporting the size of the tumor the extent of the disease in the biliary system the involvement of the hepatic artery and portal vein the involvement of lymph nodes distant metastases and the volume of the putative remnant after resection The aim of this system is the standardization of the reporting of perihilar cholangiocarcinoma so that relevant information regarding resectability indications for transplantation and prognosis can be provided With this tool we have created a new registry enabling every center to prospectively enter data on their patients with hilar cholangiocarcinoma www.cholangioca.org The availability of such standardized and multicenter data will enable us to identify the critical criteria guiding therapy,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[9124, 2126, 16, 104, 1, 3, 96, 1950, 1342, 5, 334, 63, 25, 3, 458, 2497, 9, 39612, 14453, 6, 16274, 932, 94, 107, 1168, 15, 252, 98, 16, 3, 926, 1, 8, 2450, 632, 398, 3, 96, 841, 95, 398, 16, 3, 22291, 46531, 947, 1, 2920, 799, 92, 137, 1097, 44, 643, 2653, 487, 225, 22, 756, 14229, 2, 626, 196, 127, 1530, 32, 2416, 95, 408, 491, 1022, 44, 377, 392, 825, 21181, 1, 487, 5972, 36, 673, 21, 47, 1114, 8, 217, 398, 1760, 3, 444, 1, 3, 30, 3, 1039, 1, 3, 34, 4, 3, 2532, 398, 3, 799, 1, 3, 939, 2872, 2, 3307, 2762, 3, 799, 1, 263, 502, 626, 196, 2, 3, 433, 1, 3, 2743, 5644, 50, 170, 3, 1130, 1, 26, 398, 16, 3, 6213, 1, 3, 1760, 1, 9124, 2126, 1743, 17, 867, 487, 666, 5150, 2406, 9, 497, 2, 356, 122, 40, 1052, 5, 26, 1515, 21, 47, 2466, 8, 217, 1608, 5257, 454, 574, 6, 1143, 7058, 74, 23, 136, 7, 5, 4793, 2126, 3064, 60013, 5598, 3, 2550, 1, 225, 1670, 2, 1570, 74, 303, 3047, 843, 6, 255, 3, 740, 371, 5972, 36]",1307.0,21480336,102
Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment.,Annals of surgery,Ann. Surg.,2011-08-01,"This study evaluates the significance of tumor involvement of the liver in early T-stage tumors and lymph node (LN) metastases on outcome after R0 resection of gallbladder cancer (GBCA). A prospectively maintained database, supplemented with review of the medical record, was used to identify patients who underwent a complete (R0) resection for GBCA. All patients underwent definitive surgical treatment at the initial operation (1 stage) or after initial noncurative cholecystectomy (incidental tumors, 2 stage), including partial hepatectomy and portal LN dissection, with or without bile duct and/or adjacent organ resection. Clinicopathological variables, including TNM stage, histologic tumor involvement of liver (residual or direct extension in the GB fossa or discontiguous disease), and the total number of regional LNs assessed were analyzed for their association with outcome. One hundred twenty-two patients were identified and analyzed. The median follow up period was 23 months. Liver and nodal involvement by GBCA were observed in 61 (50%) and 41(34%) patients, respectively. Among patients with T2 tumors (n = 53), 48 (91%) were incidental. Liver involvement was present in 26%, and this factor was associated with decreased recurrence-free (RFS) and disease-specific survival (DSS) compared with patients with T2 tumors without liver involvement (median RFS, 12 months vs. not reached, P = 0.004, median DSS 25 months versus not reached, P = 0.003); T1b tumors (n = 10) were not associated with liver involvement. The median total lymph node count (TLNC) was 3 (range 0-20). For the entire cohort, survival of patients classified as N0 based on TLNC < 6 was significantly worse than that of N0 patients based on TLNC  6 (median RFS, 22 months versus not reached, P < 0.001, median DSS 41 months versus not reached, P < 0.001). Liver involvement and TLNC remained significant prognostic factors in a multivariate model that included TNM stage. Resection and histologic evaluation of at least 6 lymph nodes improves risk-stratification after resection of GBCA. Incidental T2 tumors are often associated with residual liver disease and should be reclassified to reflect the adverse outcome. The data suggests a need for standardized minimum requirements for adequate surgical treatment and pathological examination.",Comparative Study,3095.0,97.0,This study evaluates the significance of tumor involvement of the in early T-stage tumors and lymph node LN metastases on outcome after R0 resection of cancer GBCA A prospectively maintained database supplemented with review of the medical record was used to identify patients who underwent a complete R0 resection for GBCA All patients underwent definitive surgical treatment at the initial operation 1 stage or after initial noncurative cholecystectomy incidental tumors 2 stage including partial hepatectomy and portal LN dissection with or without duct and/or adjacent organ resection Clinicopathological variables including TNM stage histologic tumor involvement of residual or direct extension in the GB fossa or discontiguous disease and the total number of regional LNs assessed were analyzed for their association with outcome One hundred twenty-two patients were identified and analyzed The median follow up period was 23 months and nodal involvement by GBCA were observed in 61 50 and 41 34 patients respectively Among patients with T2 tumors n 53 48 91 were incidental involvement was present in 26 and this factor was associated with decreased recurrence-free RFS and disease-specific survival DSS compared with patients with T2 tumors without involvement median RFS 12 months vs. not reached P 0.004 median DSS 25 months versus not reached P 0.003 T1b tumors n 10 were not associated with involvement The median total lymph node count TLNC was 3 range 0-20 For the entire cohort survival of patients classified as N0 based on TLNC 6 was significantly worse than that of N0 patients based on TLNC  6 median RFS 22 months versus not reached P 0.001 median DSS 41 months versus not reached P 0.001 involvement and TLNC remained significant prognostic factors in a multivariate model that included TNM stage Resection and histologic evaluation of at least 6 lymph nodes improves risk-stratification after resection of GBCA Incidental T2 tumors are often associated with residual disease and should be reclassified to reflect the adverse outcome The data suggests a need for standardized minimum requirements for adequate surgical treatment and pathological examination,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26, 45, 4941, 3, 724, 1, 30, 799, 1, 3, 4, 191, 102, 82, 57, 2, 263, 289, 1763, 196, 23, 228, 50, 2328, 170, 1, 12, 9894, 8, 1143, 1955, 609, 7687, 5, 206, 1, 3, 484, 3237, 10, 95, 6, 255, 7, 54, 208, 8, 236, 2328, 170, 9, 9894, 62, 7, 208, 1057, 221, 24, 28, 3, 388, 2589, 14, 82, 15, 50, 388, 15957, 8493, 4490, 57, 18, 82, 141, 450, 2711, 2, 3307, 1763, 1161, 5, 15, 187, 2920, 2, 15, 2086, 1259, 170, 2721, 682, 141, 2918, 82, 884, 30, 799, 1, 753, 15, 1196, 2401, 4, 3, 7832, 5100, 15, 33214, 34, 2, 3, 181, 207, 1, 951, 2704, 275, 11, 311, 9, 136, 248, 5, 228, 104, 1128, 737, 100, 7, 11, 108, 2, 311, 3, 52, 166, 126, 727, 10, 382, 53, 2, 779, 799, 20, 9894, 11, 164, 4, 713, 212, 2, 605, 562, 7, 106, 107, 7, 5, 1786, 57, 78, 699, 576, 970, 11, 4490, 799, 10, 364, 4, 432, 2, 26, 161, 10, 41, 5, 340, 146, 115, 1272, 2, 34, 112, 25, 1788, 72, 5, 7, 5, 1786, 57, 187, 799, 52, 1272, 133, 53, 105, 44, 1300, 19, 13, 1520, 52, 1788, 243, 53, 185, 44, 1300, 19, 13, 1421, 6142, 57, 78, 79, 11, 44, 41, 5, 799, 3, 52, 181, 263, 289, 1276, 29160, 10, 27, 184, 13, 179, 9, 3, 1797, 180, 25, 1, 7, 1373, 22, 3394, 90, 23, 29160, 49, 10, 97, 639, 76, 17, 1, 3394, 7, 90, 23, 29160, 749, 49, 52, 1272, 350, 53, 185, 44, 1300, 19, 13, 144, 52, 1788, 605, 53, 185, 44, 1300, 19, 13, 144, 799, 2, 29160, 958, 93, 177, 130, 4, 8, 331, 202, 17, 159, 2918, 82, 170, 2, 884, 451, 1, 28, 506, 49, 263, 502, 1804, 43, 1541, 50, 170, 1, 9894, 4490, 1786, 57, 32, 629, 41, 5, 753, 34, 2, 257, 40, 7864, 6, 2694, 3, 290, 228, 3, 74, 844, 8, 594, 9, 1670, 2499, 4230, 9, 1658, 221, 24, 2, 1301, 1385]",2179.0,21617582,99
Resection of perihilar biliary schwannoma.,Surgical oncology,Surg Oncol,2011-06-12,"Schwannomas are usually benign nerve sheath tumors, which typically arise in the head, neck, spinal cord and extremities. Schwannoma of the biliary tract is an extremely rare finding. Patients generally lack symptoms and seek medical attention when tumor growth causes obstructive jaundice. Preoperative diagnosis is difficult and resection is the treatment of choice. A 54 year-old female with history of back and right labia minor melanoma for which she underwent complete excision and right inguinal lymph node dissection more than 10 years ago, was evaluated for new onset gastroesophageal reflux symptoms and found to have markedly abnormal liver enzymes. Imagining studies revealed intrahepatic ductal dilatation and a 5.2 cm mass in the porta hepatis that was not consistent with cholangiocarcinoma or hepatocellular carcinoma. Multiple percutaneous biopsies of the mass failed to provide a definitive diagnosis. With a high clinical suspicion of metastatic melanoma and no other evident sites of disease, operative intervention was undertaken for diagnosis and definitive treatment. Diagnostic laparoscopy was performed initially, but access to the mass was difficult, given its location. Subsequently, the patient underwent laparotomy, with tumor excision, common bile duct resection and hepato-jejunostomy. Pathologic examination and analysis were consistent with cellular schwannoma. Postoperatively, the patient recovered uneventfully, and liver function studies returned to normal. Schwannomas are uncommon tumors, which very rarely arise from the biliary tract and cause biliary obstruction. Exploration is indicated in order to establish the diagnosis and to render definitive treatment.",Case Reports,3145.0,5.0,Schwannomas are usually benign nerve sheath tumors which typically arise in the head spinal cord and extremities Schwannoma of the biliary tract is an extremely rare finding Patients generally lack symptoms and seek medical attention when tumor growth causes obstructive jaundice Preoperative diagnosis is difficult and resection is the treatment of choice A 54 year-old female with history of back and right labia minor for which she underwent complete excision and right inguinal lymph node dissection more than 10 years ago was evaluated for new onset gastroesophageal reflux symptoms and found to have markedly abnormal enzymes Imagining studies revealed intrahepatic ductal dilatation and a 5.2 cm mass in the porta hepatis that was not consistent with cholangiocarcinoma or carcinoma Multiple percutaneous biopsies of the mass failed to provide a definitive diagnosis With a high clinical suspicion of metastatic and no other evident sites of disease operative intervention was undertaken for diagnosis and definitive treatment Diagnostic laparoscopy was performed initially but access to the mass was difficult given its location Subsequently the patient underwent laparotomy with tumor excision common duct resection and hepato-jejunostomy Pathologic examination and analysis were consistent with cellular schwannoma Postoperatively the patient recovered uneventfully and function studies returned to normal Schwannomas are uncommon tumors which very rarely arise from the biliary tract and cause biliary obstruction Exploration is indicated in order to establish the diagnosis and to render definitive treatment,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[9672, 32, 2082, 1002, 2476, 7280, 57, 92, 1969, 3043, 4, 3, 718, 1499, 1885, 2, 6387, 9601, 1, 3, 2532, 1696, 16, 35, 2938, 622, 1567, 7, 1228, 926, 507, 2, 6606, 484, 2111, 198, 30, 129, 1626, 6937, 7655, 498, 147, 16, 1740, 2, 170, 16, 3, 24, 1, 1866, 8, 667, 111, 1095, 1061, 5, 532, 1, 4636, 2, 1913, 60224, 2278, 9, 92, 3109, 208, 236, 1366, 2, 1913, 4907, 263, 289, 1161, 80, 76, 79, 60, 5028, 10, 194, 9, 217, 1707, 3227, 9657, 507, 2, 204, 6, 47, 2195, 1668, 3039, 39682, 94, 553, 3022, 1258, 12799, 2, 8, 33, 18, 494, 782, 4, 3, 18918, 21188, 17, 10, 44, 925, 5, 2126, 15, 134, 232, 3720, 1154, 1, 3, 782, 1551, 6, 377, 8, 1057, 147, 5, 8, 64, 38, 5782, 1, 113, 2, 77, 127, 2853, 633, 1, 34, 1208, 788, 10, 2789, 9, 147, 2, 1057, 24, 752, 3553, 10, 173, 1625, 84, 1655, 6, 3, 782, 10, 1740, 447, 211, 1147, 1611, 3, 69, 208, 3274, 5, 30, 1366, 186, 2920, 170, 2, 17970, 17144, 510, 1385, 2, 65, 11, 925, 5, 763, 9601, 3541, 3, 69, 5784, 30535, 2, 343, 94, 5157, 6, 295, 9672, 32, 2052, 57, 92, 923, 2416, 3043, 29, 3, 2532, 1696, 2, 708, 2532, 3191, 3370, 16, 1103, 4, 1732, 6, 1811, 3, 147, 2, 6, 7873, 1057, 24]",1620.0,21665464,55
Hilar cholangiocarcinoma: tumor depth as a predictor of outcome.,"Archives of surgery (Chicago, Ill. : 1960)",Arch Surg,2011-06-01,"The American Joint Committee on Cancer staging system for hilar cholangiocarcinoma may be inaccurate because the bile duct lacks discrete tissue boundaries. To examine the accuracy of the American Joint Committee on Cancer staging schemes and to determine the prognostic implications of tumor depth. From January 1, 1987, through December 31, 2009, there were 106 patients who underwent resection of hilar cholangiocarcinoma who had pathologic slides available for re-review. Tumor depth and overall survival. Overall median survival was 19.9 months. The 6th and 7th editions of the T-classification criteria were unable to discriminate among T1, T2, and T3 lesions (P > .05 for all). Median survival was associated with the invasion depth of the tumor (5 mm vs <5 mm): 18 months vs 30 months (P = .01). On multivariate analysis, tumor depth remained predictive of disease-specific death (hazard ratio, 1.70; P = .03). The American Joint Committee on Cancer T-classification criteria did not stratify patients with regard to prognosis. Depth of tumor invasion is a better predictor of long-term outcome.",Journal Article,3156.0,28.0,The American Joint Committee on Cancer staging system for hilar cholangiocarcinoma may be inaccurate because the duct lacks discrete tissue boundaries To examine the accuracy of the American Joint Committee on Cancer staging schemes and to determine the prognostic implications of tumor depth From January 1 1987 through December 31 2009 there were 106 patients who underwent resection of hilar cholangiocarcinoma who had pathologic slides available for re-review Tumor depth and overall survival Overall median survival was 19.9 months The 6th and 7th editions of the T-classification criteria were unable to discriminate among T1 T2 and T3 lesions P .05 for all Median survival was associated with the invasion depth of the tumor 5 mm vs 5 mm 18 months vs 30 months P .01 On multivariate analysis tumor depth remained predictive of disease-specific death hazard ratio 1.70 P .03 The American Joint Committee on Cancer T-classification criteria did not stratify patients with regard to prognosis Depth of tumor invasion is a better predictor of long-term outcome,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 597, 2093, 2002, 23, 12, 632, 398, 9, 4793, 2126, 68, 40, 8791, 408, 3, 2920, 6856, 5447, 246, 9692, 6, 1004, 3, 1190, 1, 3, 597, 2093, 2002, 23, 12, 632, 7103, 2, 6, 223, 3, 177, 1268, 1, 30, 2436, 29, 1024, 14, 5450, 298, 1397, 456, 1238, 125, 11, 3251, 7, 54, 208, 170, 1, 4793, 2126, 54, 42, 510, 3830, 390, 9, 1491, 206, 30, 2436, 2, 63, 25, 63, 52, 25, 10, 326, 83, 53, 3, 10865, 2, 7283, 17465, 1, 3, 102, 947, 371, 11, 4253, 6, 5696, 107, 1534, 1786, 2, 2065, 406, 19, 474, 9, 62, 52, 25, 10, 41, 5, 3, 578, 2436, 1, 3, 30, 4126, 321, 105, 33, 321, 203, 53, 105, 201, 53, 19, 355, 23, 331, 65, 30, 2436, 958, 464, 1, 34, 112, 273, 360, 197, 14, 431, 19, 680, 3, 597, 2093, 2002, 23, 12, 102, 947, 371, 205, 44, 3570, 7, 5, 2539, 6, 356, 2436, 1, 30, 578, 16, 8, 380, 980, 1, 319, 337, 228]",1064.0,21690446,82
High-grade dysplasia of the cystic duct margin in the absence of malignancy after cholecystectomy.,HPB : the official journal of the International Hepato Pancreato Biliary Association,HPB (Oxford),2011-10-10,"A total of 750,000 cholecystectomies are performed annually in the USA. No data exist on patients with microscopic high-grade dysplasia at the cystic duct margin and the associated incidence of cholangiocarcinoma. Pathology reports for 1992-2010 were reviewed for patients with high-grade dysplasia of the cystic duct margin in the absence of invasive gallbladder cancer. Clinical data were obtained from chart review. Five patients with high-grade dysplasia at the cystic duct margin without evidence of malignancy were identified. Radiologic imaging was abnormal in two patients. The cystic duct stump was abnormally dilated in both patients and one patient had an enlarged portacaval lymph node. All five patients underwent exploration and resection of either the cystic duct stump or the bile duct. Specimens in four of the patients showed no evidence of malignancy or dysplasia. One patient was found to have a node-positive adenocarcinoma of the cystic duct. High-grade dysplasia at the cystic duct margin without evidence of invasive gallbladder cancer is rare. Patients with this finding should undergo cross-sectional imaging and a diagnosis of an underlying cholangiocarcinoma should be considered, especially if imaging reveals any abnormalities.",Journal Article,3025.0,9.0,"A total of 750,000 cholecystectomies are performed annually in the USA No data exist on patients with microscopic high-grade dysplasia at the cystic duct margin and the associated incidence of cholangiocarcinoma Pathology reports for 1992-2010 were reviewed for patients with high-grade dysplasia of the cystic duct margin in the absence of invasive cancer Clinical data were obtained from chart review Five patients with high-grade dysplasia at the cystic duct margin without evidence of malignancy were identified Radiologic imaging was abnormal in two patients The cystic duct stump was abnormally dilated in both patients and one patient had an enlarged portacaval lymph node All five patients underwent exploration and resection of either the cystic duct stump or the duct Specimens in four of the patients showed no evidence of malignancy or dysplasia One patient was found to have a node-positive adenocarcinoma of the cystic duct High-grade dysplasia at the cystic duct margin without evidence of invasive cancer is rare Patients with this finding should undergo cross-sectional imaging and a diagnosis of an underlying cholangiocarcinoma should be considered especially if imaging reveals any abnormalities",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 181, 1, 4506, 984, 34686, 32, 173, 4226, 4, 3, 2706, 77, 74, 1923, 23, 7, 5, 2984, 64, 88, 2253, 28, 3, 2965, 2920, 959, 2, 3, 41, 287, 1, 2126, 1117, 1198, 9, 2846, 1120, 11, 446, 9, 7, 5, 64, 88, 2253, 1, 3, 2965, 2920, 959, 4, 3, 1127, 1, 416, 12, 38, 74, 11, 683, 29, 2937, 206, 365, 7, 5, 64, 88, 2253, 28, 3, 2965, 2920, 959, 187, 241, 1, 710, 11, 108, 2812, 270, 10, 1668, 4, 100, 7, 3, 2965, 2920, 14645, 10, 11749, 11536, 4, 110, 7, 2, 104, 69, 42, 35, 7547, 46882, 263, 289, 62, 365, 7, 208, 3370, 2, 170, 1, 361, 3, 2965, 2920, 14645, 15, 3, 2920, 623, 4, 294, 1, 3, 7, 224, 77, 241, 1, 710, 15, 2253, 104, 69, 10, 204, 6, 47, 8, 289, 109, 449, 1, 3, 2965, 2920, 64, 88, 2253, 28, 3, 2965, 2920, 959, 187, 241, 1, 416, 12, 16, 622, 7, 5, 26, 1567, 257, 1251, 1383, 2832, 270, 2, 8, 147, 1, 35, 1181, 2126, 257, 40, 515, 1093, 492, 270, 4054, 500, 1171]",1215.0,22081921,74
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.,The oncologist,Oncologist,2011-12-16,"Cancers of origin in the gallbladder and bile ducts are rarely curable with current modalities of cancer treatment. Our clinical application of broad-based mutational profiling for patients diagnosed with a gastrointestinal malignancy has led to the novel discovery of mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) in tumors from a subset of patients with cholangiocarcinoma. A total of 287 tumors from gastrointestinal cancer patients (biliary tract, colorectal, gastroesophageal, liver, pancreatic, and small intestine carcinoma) were tested during routine clinical evaluation for 130 site-specific mutations within 15 cancer genes. Mutations were identified within a number of genes, including KRAS (35%), TP53 (22%), PIK3CA (10%), BRAF (7%), APC (6%), NRAS (3%), AKT1 (1%), CTNNB1 (1%), and PTEN (1%). Although mutations in the metabolic enzyme IDH1 were rare in the other common gastrointestinal malignancies in this series (2%), they were found in three tumors (25%) of an initial series of 12 biliary tract carcinomas. To better define IDH1 and IDH2 mutational status, an additional 75 gallbladder and bile duct cancers were examined. Combining these cohorts of biliary cancers, mutations in IDH1 and IDH2 were found only in cholangiocarcinomas of intrahepatic origin (nine of 40, 23%) and in none of the 22 extrahepatic cholangiocarcinomas and none of the 25 gallbladder carcinomas. In an analysis of frozen tissue specimens, IDH1 mutation was associated with highly elevated tissue levels of the enzymatic product 2-hydroxyglutarate. Thus, IDH1 mutation is a molecular feature of cholangiocarcinomas of intrahepatic origin. These findings define a specific metabolic abnormality in this largely incurable type of gastrointestinal cancer and present a potentially new target for therapy.",Journal Article,2958.0,374.0,Cancers of origin in the and ducts are rarely curable with current modalities of cancer treatment Our clinical application of broad-based mutational profiling for patients diagnosed with a malignancy has led to the novel discovery of mutations in the gene encoding isocitrate dehydrogenase 1 IDH1 in tumors from a subset of patients with cholangiocarcinoma A total of 287 tumors from cancer patients biliary tract gastroesophageal and small intestine carcinoma were tested during routine clinical evaluation for 130 site-specific mutations within 15 cancer genes Mutations were identified within a number of genes including KRAS 35 TP53 22 PIK3CA 10 BRAF 7 APC 6 NRAS 3 AKT1 1 CTNNB1 1 and PTEN 1 Although mutations in the metabolic enzyme IDH1 were rare in the other common malignancies in this series 2 they were found in three tumors 25 of an initial series of 12 biliary tract carcinomas To better define IDH1 and IDH2 mutational status an additional 75 and duct cancers were examined Combining these cohorts of biliary cancers mutations in IDH1 and IDH2 were found only in cholangiocarcinomas of intrahepatic origin nine of 40 23 and in none of the 22 extrahepatic cholangiocarcinomas and none of the 25 carcinomas In an analysis of frozen tissue specimens IDH1 mutation was associated with highly elevated tissue levels of the enzymatic product 2-hydroxyglutarate Thus IDH1 mutation is a molecular feature of cholangiocarcinomas of intrahepatic origin These findings define a specific metabolic abnormality in this largely incurable type of cancer and present a potentially new target for therapy,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[163, 1, 1938, 4, 3, 2, 7310, 32, 2416, 4151, 5, 291, 1558, 1, 12, 24, 114, 38, 1581, 1, 2094, 90, 1619, 1080, 9, 7, 265, 5, 8, 710, 71, 836, 6, 3, 229, 1574, 1, 138, 4, 3, 145, 2362, 5795, 2374, 14, 2662, 4, 57, 29, 8, 697, 1, 7, 5, 2126, 8, 181, 1, 8488, 57, 29, 12, 7, 2532, 1696, 3227, 2, 302, 6844, 134, 11, 650, 190, 1311, 38, 451, 9, 3431, 606, 112, 138, 262, 167, 12, 214, 138, 11, 108, 262, 8, 207, 1, 214, 141, 723, 465, 1206, 350, 1506, 79, 566, 67, 2528, 49, 2845, 27, 4958, 14, 4485, 14, 2, 820, 14, 242, 138, 4, 3, 1436, 1644, 2662, 11, 622, 4, 3, 127, 186, 441, 4, 26, 988, 18, 491, 11, 204, 4, 169, 57, 243, 1, 35, 388, 988, 1, 133, 2532, 1696, 826, 6, 380, 1107, 2662, 2, 4520, 1619, 156, 35, 402, 481, 2, 2920, 163, 11, 409, 1525, 46, 736, 1, 2532, 163, 138, 4, 2662, 2, 4520, 11, 204, 158, 4, 9386, 1, 3022, 1938, 762, 1, 327, 382, 2, 4, 1292, 1, 3, 350, 3710, 9386, 2, 1292, 1, 3, 243, 826, 4, 35, 65, 1, 3015, 246, 623, 2662, 258, 10, 41, 5, 561, 804, 246, 148, 1, 3, 5226, 2821, 18, 10774, 631, 2662, 258, 16, 8, 219, 2705, 1, 9386, 1, 3022, 1938, 46, 272, 1107, 8, 112, 1436, 3698, 4, 26, 1733, 2641, 267, 1, 12, 2, 364, 8, 751, 217, 283, 9, 36]",1602.0,22180306,1
Development and preliminary testing of a translational model of hepatocellular carcinoma for MR imaging and interventional oncologic investigations.,Journal of vascular and interventional radiology : JVIR,J Vasc Interv Radiol,2012-01-20,"To develop a translational rat hepatocellular carcinoma (HCC) disease model for magnetic resonance (MR) imaging and image-guided interventional oncologic investigations. Male rats underwent sham control surgery (n = 6), selective bile duct ligation (SBDL; n = 4), or common bile duct ligation (CBDL; n = 6), with procedure optimization in four rats and N1S1 hepatoma cell injection into two or three sites in the livers of 12 rats. All rats subsequently underwent MR imaging to assess tumor establishment and volume. Mesenteric angiography and percutaneous MR-guided laser ablation of the liver were performed in a subgroup of animals (n = 4). Animal weight and liver test results were monitored. After harvesting, the livers were subjected to gross and microscopic analysis. Tumor volume and laboratory parameters were assessed between ligation groups. MR imaging demonstrated hyperintense T2 and hypointense T1 lesions with tumor induction in five of 10 (50.0%), seven of eight (87.5%), and 12 of 12 (100%) sites in the control, SBDL, and CBDL groups, respectively. Tumor volumes differed significantly by group (P < .02). Mesenteric angiography demonstrated an enhancing tumor stain. Clinical and laboratory assessment revealed a significant decrease in weight (P = .01) and albumin level (P < .01) and an increase in total bilirubin level (P = .02) in CBDL rats but not SBDL rats (P = 1.0). Histologic examination showed high-grade HCCs with local and vascular invasion within the context of early fibrosis in CBDL and SBDL rats. MR-guided laser ablation generated a 1-2-cm ablation zone with histologic findings consistent with reversible and irreversible injury. A biologically relevant rat HCC disease model has been developed for MR imaging and preliminary interventional oncologic applications.",Journal Article,2923.0,18.0,To develop a translational rat carcinoma HCC disease model for magnetic resonance MR imaging and image-guided interventional oncologic investigations Male rats underwent sham control surgery n 6 selective duct ligation SBDL n 4 or common duct ligation CBDL n 6 with procedure optimization in four rats and N1S1 hepatoma cell injection into two or three sites in the livers of 12 rats All rats subsequently underwent MR imaging to assess tumor establishment and volume Mesenteric angiography and percutaneous MR-guided laser ablation of the were performed in a subgroup of animals n 4 Animal weight and test results were monitored After harvesting the livers were subjected to gross and microscopic analysis Tumor volume and laboratory parameters were assessed between ligation groups MR imaging demonstrated hyperintense T2 and hypointense T1 lesions with tumor induction in five of 10 50.0 seven of eight 87.5 and 12 of 12 100 sites in the control SBDL and CBDL groups respectively Tumor volumes differed significantly by group P .02 Mesenteric angiography demonstrated an enhancing tumor stain Clinical and laboratory assessment revealed a significant decrease in weight P .01 and albumin level P .01 and an increase in total bilirubin level P .02 in CBDL rats but not SBDL rats P 1.0 Histologic examination showed high-grade HCCs with local and vascular invasion within the context of early fibrosis in CBDL and SBDL rats MR-guided laser ablation generated a 1-2-cm ablation zone with histologic findings consistent with reversible and irreversible injury A biologically relevant rat HCC disease model has been developed for MR imaging and preliminary interventional oncologic applications,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 690, 8, 2460, 4008, 134, 663, 34, 202, 9, 1484, 1535, 1638, 270, 2, 1482, 1808, 6182, 1998, 2492, 1045, 3765, 208, 8836, 182, 152, 78, 49, 1094, 2920, 5307, 35278, 78, 39, 15, 186, 2920, 5307, 35279, 78, 49, 5, 1299, 3980, 4, 294, 3765, 2, 22718, 13822, 31, 1754, 237, 100, 15, 169, 633, 4, 3, 8868, 1, 133, 3765, 62, 3765, 1611, 208, 1638, 270, 6, 423, 30, 5346, 2, 433, 5719, 8078, 2, 3720, 1638, 1808, 3555, 1650, 1, 3, 11, 173, 4, 8, 1363, 1, 2258, 78, 39, 2026, 924, 2, 412, 99, 11, 2909, 50, 17700, 3, 8868, 11, 4325, 6, 1789, 2, 2984, 65, 30, 433, 2, 1624, 1038, 11, 275, 59, 5307, 271, 1638, 270, 264, 13223, 1786, 2, 22719, 1534, 406, 5, 30, 504, 4, 365, 1, 79, 212, 13, 648, 1, 659, 912, 33, 2, 133, 1, 133, 394, 633, 4, 3, 182, 35278, 2, 35279, 271, 106, 30, 2225, 2512, 97, 20, 87, 19, 588, 5719, 8078, 264, 35, 2430, 30, 8763, 38, 2, 1624, 455, 553, 8, 93, 775, 4, 924, 19, 355, 2, 2799, 301, 19, 355, 2, 35, 344, 4, 181, 5009, 301, 19, 588, 4, 35279, 3765, 84, 44, 35278, 3765, 19, 14, 13, 884, 1385, 224, 64, 88, 6400, 5, 293, 2, 756, 578, 262, 3, 1533, 1, 191, 3000, 4, 35279, 2, 35278, 3765, 1638, 1808, 3555, 1650, 1419, 8, 14, 18, 494, 1650, 3614, 5, 884, 272, 925, 5, 2786, 2, 4422, 2730, 8, 2665, 867, 4008, 663, 34, 202, 71, 85, 276, 9, 1638, 270, 2, 1676, 6182, 1998, 2911]",1692.0,22265247,24
Surgical management of proximal bile duct cancers.,Langenbeck's archives of surgery,Langenbecks Arch Surg,2012-03-06,"Tumors arising from the proximal biliary tree remain particularly challenging with respect to their evaluation and treatment. Complete resection with negative histologic margins is the most effective treatment modality. However, the majority of patients are not candidates for surgery.                                                                        Over the last decades, advances have evolved to improve resectability and morbidity after major liver and bile duct resection. However, these disease processes still pose a management challenge. Herein, we provide an overview of proximal bile duct cancers, hilar cholangiocarcinoma (HCCa) and intrahepatic cholangiocarcinoma (ICCa).",Journal Article,2877.0,16.0,Tumors arising from the proximal biliary tree remain particularly challenging with respect to their evaluation and treatment Complete resection with negative histologic margins is the most effective treatment modality However the majority of patients are not candidates for surgery Over the last decades advances have evolved to improve resectability and morbidity after major and duct resection However these disease processes still pose a management challenge Herein we provide an overview of proximal duct cancers hilar cholangiocarcinoma HCCa and intrahepatic cholangiocarcinoma ICCa,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[57, 2635, 29, 3, 2805, 2532, 4899, 918, 823, 1950, 5, 2184, 6, 136, 451, 2, 24, 236, 170, 5, 199, 884, 1012, 16, 3, 96, 323, 24, 1396, 137, 3, 686, 1, 7, 32, 44, 1931, 9, 152, 252, 3, 1060, 1968, 954, 47, 3937, 6, 401, 5150, 2, 787, 50, 458, 2, 2920, 170, 137, 46, 34, 1849, 1234, 6015, 8, 284, 1745, 1986, 21, 377, 35, 2901, 1, 2805, 2920, 163, 4793, 2126, 9280, 2, 3022, 2126, 14038]",587.0,22391776,109
The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases.,Cancer,Cancer,2012-03-13,"BACKGROUND. Surgical strategy for hilar cholangiocarcinoma often includes hepatectomy, but the role of portal vein resection (PVR) remains controversial. In this study, the authors sought to identify factors associated with outcome after surgical management of hilar cholangiocarcinoma and examined the impact of PVR on survival. Three hundred five patients who underwent curative-intent surgery for hilar cholangiocarcinoma between 1984 and 2010 were identified from an international, multi-institutional database. Clinicopathologic data were evaluated using univariate and multivariate analyses. Most patients had hilar cholangiocarcinoma with tumors classified as T3/T4 (51.1%) and Bismuth-Corlette type II/III (60.9%). Resection involved extrahepatic bile duct resection (EHBR) alone (26.6%); or hepatectomy and EHBR without PVR (56.7%); or combined hepatectomy, EHBR, and PVR (16.7%). Negative resection (R0) margin status was higher among the patients who underwent hepatectomy plus EHBR (without PVR, 64.2%; with PVR, 66.7%) versus EHBR alone (54.3%; P < .001). The median number of lymph nodes assessed was higher among the patients who underwent hepatectomy plus EHBR (without PVR, 6 lymph nodes; with PVR, 4 lymph nodes) versus EHBR alone (2 lymph nodes; P < .001). The 90-day mortality rate was lower for patients who underwent EHBR alone (1.2%) compared with the rate for patients who underwent hepatectomy plus EHBR (without PVR, 10.6%, with PVR, 17.6%; P < .001). The overall 5-year survival rate was 20.2%. Factors that were associated with an adverse prognosis included lymph node metastasis (hazard ratio [HR], 1.79; P = .002) and R1 margin status (HR, 1.81; P < .001). Microscopic vascular invasion did not influence survival (HR, 1.23; P = .19). Among the patients who underwent hepatectomy plus EHBR, PVR was not associated with a worse long-term outcome (P = .76). EHBR alone was associated with a greater risk of positive surgical margins and worse lymph node clearance. The current results indicated that hepatectomy should be considered the standard treatment for hilar cholangiocarcinoma, and PVR should be undertaken when necessary to extirpate all disease. Combined hepatectomy, EHBR, and PVR can offer long-term survival in some patients with advanced hilar cholangiocarcinoma.",Comparative Study,2870.0,102.0,BACKGROUND Surgical strategy for hilar cholangiocarcinoma often includes hepatectomy but the role of portal vein resection PVR remains controversial In this study the authors sought to identify factors associated with outcome after surgical management of hilar cholangiocarcinoma and examined the impact of PVR on survival Three hundred five patients who underwent curative-intent surgery for hilar cholangiocarcinoma between 1984 and 2010 were identified from an international multi-institutional database Clinicopathologic data were evaluated using univariate and multivariate analyses Most patients had hilar cholangiocarcinoma with tumors classified as T3/T4 51.1 and Bismuth-Corlette type II/III 60.9 Resection involved extrahepatic duct resection EHBR alone 26.6 or hepatectomy and EHBR without PVR 56.7 or combined hepatectomy EHBR and PVR 16.7 Negative resection R0 margin status was higher among the patients who underwent hepatectomy plus EHBR without PVR 64.2 with PVR 66.7 versus EHBR alone 54.3 P .001 The median number of lymph nodes assessed was higher among the patients who underwent hepatectomy plus EHBR without PVR 6 lymph nodes with PVR 4 lymph nodes versus EHBR alone 2 lymph nodes P .001 The 90-day mortality rate was lower for patients who underwent EHBR alone 1.2 compared with the rate for patients who underwent hepatectomy plus EHBR without PVR 10.6 with PVR 17.6 P .001 The overall 5-year survival rate was 20.2 Factors that were associated with an adverse prognosis included lymph node metastasis hazard ratio HR 1.79 P .002 and R1 margin status HR 1.81 P .001 Microscopic vascular invasion did not influence survival HR 1.23 P .19 Among the patients who underwent hepatectomy plus EHBR PVR was not associated with a worse long-term outcome P .76 EHBR alone was associated with a greater risk of positive surgical margins and worse lymph node clearance The current results indicated that hepatectomy should be considered the standard treatment for hilar cholangiocarcinoma and PVR should be undertaken when necessary to extirpate all disease Combined hepatectomy EHBR and PVR can offer long-term survival in some patients with advanced hilar cholangiocarcinoma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2426, 221, 692, 9, 4793, 2126, 629, 1920, 2711, 84, 3, 200, 1, 3307, 2762, 170, 11524, 469, 2010, 4, 26, 45, 3, 738, 990, 6, 255, 130, 41, 5, 228, 50, 221, 284, 1, 4793, 2126, 2, 409, 3, 345, 1, 11524, 23, 25, 169, 1128, 365, 7, 54, 208, 1075, 1697, 152, 9, 4793, 2126, 59, 6036, 2, 1120, 11, 108, 29, 35, 944, 1414, 1115, 609, 1399, 74, 11, 194, 75, 880, 2, 331, 318, 96, 7, 42, 4793, 2126, 5, 57, 1373, 22, 2065, 2463, 725, 14, 2, 22291, 46531, 267, 215, 316, 335, 83, 170, 646, 3710, 2920, 170, 20767, 279, 432, 49, 15, 2711, 2, 20767, 187, 11524, 664, 67, 15, 397, 2711, 20767, 2, 11524, 245, 67, 199, 170, 2328, 959, 156, 10, 142, 107, 3, 7, 54, 208, 2711, 349, 20767, 187, 11524, 660, 18, 5, 11524, 700, 67, 185, 20767, 279, 667, 27, 19, 144, 3, 52, 207, 1, 263, 502, 275, 10, 142, 107, 3, 7, 54, 208, 2711, 349, 20767, 187, 11524, 49, 263, 502, 5, 11524, 39, 263, 502, 185, 20767, 279, 18, 263, 502, 19, 144, 3, 424, 218, 282, 116, 10, 280, 9, 7, 54, 208, 20767, 279, 14, 18, 72, 5, 3, 116, 9, 7, 54, 208, 2711, 349, 20767, 187, 11524, 79, 49, 5, 11524, 269, 49, 19, 144, 3, 63, 33, 111, 25, 116, 10, 179, 18, 130, 17, 11, 41, 5, 35, 290, 356, 159, 263, 289, 278, 360, 197, 168, 14, 842, 19, 1111, 2, 3239, 959, 156, 168, 14, 865, 19, 144, 2984, 756, 578, 205, 44, 1054, 25, 168, 14, 382, 19, 326, 107, 3, 7, 54, 208, 2711, 349, 20767, 11524, 10, 44, 41, 5, 8, 639, 319, 337, 228, 19, 846, 20767, 279, 10, 41, 5, 8, 378, 43, 1, 109, 221, 1012, 2, 639, 263, 289, 1960, 3, 291, 99, 1103, 17, 2711, 257, 40, 515, 3, 260, 24, 9, 4793, 2126, 2, 11524, 257, 40, 2789, 198, 1493, 6, 37638, 62, 34, 397, 2711, 20767, 2, 11524, 122, 1918, 319, 337, 25, 4, 476, 7, 5, 131, 4793, 2126]",2190.0,22415526,95
Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?,"Hepatology (Baltimore, Md.)",Hepatology,2012-08-27,"Intraductal papillary neoplasm of the bile duct (IPNB) is a variant of bile duct carcinoma characterized by intraductal growth and better outcome compared with the more common nodular-sclerosing type. IPNB is a recognized precursor of invasive carcinoma, but its pathogenesis and natural history are ill-defined. This study examines the clinicopathologic features and outcomes of IPNB. A consecutive cohort of patients with bile duct cancer (hilar, intrahepatic, or distal) was reviewed, and those with papillary histologic features identified. Histopathologic findings and immunohistochemical staining for tumor markers and for cytokeratin and mucin proteins were used to classify IPNB into subtypes. Survival data were analyzed and correlated with clinical and pathologic parameters. Thirty-nine IPNBs were identified in hilar (23/144), intrahepatic (4/86), and distal (12/113) bile duct specimens between 1991 and 2010. Histopathologic examination revealed 27 pancreatobiliary, four gastric, two intestinal, and six oncocytic subtypes; results of cytokeratin and mucin staining were similar to those of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Invasive carcinoma was seen in 29/39 (74%) IPNBs. Overall median survival was 62 months and was not different between IPNB locations or subtypes. Factors associated with a worse median survival included presence and depth of tumor invasion, margin-positive resection, and expression of MUC1 and CEA. IPNBs are an uncommon variant of bile duct cancer, representing approximately 10% of all resectable cases. They occur throughout the biliary tract, share some histologic and clinical features with IPMNs of the pancreas, and may represent a carcinogenesis pathway different from that of conventional bile duct carcinomas arising from flat dysplasia. Given their significant risk of harboring invasive carcinoma, they should be treated with complete resection.",Comparative Study,2703.0,134.0,Intraductal papillary neoplasm of the duct IPNB is a variant of duct carcinoma characterized by intraductal growth and better outcome compared with the more common nodular-sclerosing type IPNB is a recognized precursor of invasive carcinoma but its pathogenesis and natural history are ill-defined This study examines the clinicopathologic features and outcomes of IPNB A consecutive cohort of patients with duct cancer hilar intrahepatic or distal was reviewed and those with papillary histologic features identified Histopathologic findings and immunohistochemical staining for tumor markers and for cytokeratin and mucin proteins were used to classify IPNB into subtypes Survival data were analyzed and correlated with clinical and pathologic parameters Thirty-nine IPNBs were identified in hilar 23/144 intrahepatic 4/86 and distal 12/113 duct specimens between 1991 and 2010 Histopathologic examination revealed 27 pancreatobiliary four two intestinal and six oncocytic subtypes results of cytokeratin and mucin staining were similar to those of intraductal papillary mucinous neoplasm IPMN of the Invasive carcinoma was seen in 29/39 74 IPNBs Overall median survival was 62 months and was not different between IPNB locations or subtypes Factors associated with a worse median survival included presence and depth of tumor invasion margin-positive resection and expression of MUC1 and CEA IPNBs are an uncommon variant of duct cancer representing approximately 10 of all resectable cases They occur throughout the biliary tract share some histologic and clinical features with IPMNs of the and may represent a carcinogenesis pathway different from that of conventional duct carcinomas arising from flat dysplasia Given their significant risk of harboring invasive carcinoma they should be treated with complete resection,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,"[4851, 1796, 2131, 1, 3, 2920, 27175, 16, 8, 1142, 1, 2920, 134, 765, 20, 4851, 129, 2, 380, 228, 72, 5, 3, 80, 186, 4481, 6782, 267, 27175, 16, 8, 1904, 2765, 1, 416, 134, 84, 211, 1384, 2, 1504, 532, 32, 4993, 395, 26, 45, 4468, 3, 1399, 404, 2, 123, 1, 27175, 8, 935, 180, 1, 7, 5, 2920, 12, 4793, 3022, 15, 2107, 10, 446, 2, 135, 5, 1796, 884, 404, 108, 2630, 272, 2, 1382, 1029, 9, 30, 525, 2, 9, 4292, 2, 5258, 652, 11, 95, 6, 4896, 27175, 237, 814, 25, 74, 11, 311, 2, 438, 5, 38, 2, 510, 1038, 977, 762, 25432, 11, 108, 4, 4793, 382, 4415, 3022, 39, 868, 2, 2107, 133, 4259, 2920, 623, 59, 3372, 2, 1120, 2630, 1385, 553, 428, 9206, 294, 100, 3077, 2, 437, 17287, 814, 99, 1, 4292, 2, 5258, 1029, 11, 288, 6, 135, 1, 4851, 1796, 2391, 2131, 4398, 1, 3, 416, 134, 10, 527, 4, 462, 587, 794, 25432, 63, 52, 25, 10, 744, 53, 2, 10, 44, 338, 59, 27175, 4069, 15, 814, 130, 41, 5, 8, 639, 52, 25, 159, 463, 2, 2436, 1, 30, 578, 959, 109, 170, 2, 55, 1, 4994, 2, 3088, 25432, 32, 35, 2052, 1142, 1, 2920, 12, 2861, 705, 79, 1, 62, 1899, 140, 491, 1271, 2432, 3, 2532, 1696, 4349, 476, 884, 2, 38, 404, 5, 5884, 1, 3, 2, 68, 1231, 8, 1719, 308, 338, 29, 17, 1, 809, 2920, 826, 2635, 29, 7767, 2253, 447, 136, 93, 43, 1, 2105, 416, 134, 491, 257, 40, 73, 5, 236, 170]",1826.0,22504729,9
GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct.,HPB : the official journal of the International Hepato Pancreato Biliary Association,HPB (Oxford),2012-06-18,"Activating point mutations of GNAS at codon 201 have been detected in approximately two thirds of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Intraductal papillary neoplasms of the bile ducts (IPNBs) morphologically resemble pancreatic IPMNs. This study sought to assess the mutational status of GNAS at codon 201 in IPNBs. Thirty-four patients were included. DNA from microdissected IPNBs was subjected to a polymerase chain reaction and ligation method for the detection of GNAS mutations at codon 201 and of KRAS mutations at codon 12. Mutational status was compared with clinical and pathologic data. The IPNBs had a median diameter of 3.5 cm and were located intrahepatically (n= 6), extrahepatically (n= 13), both intra- and extrahepatically (n= 4) or in the gallbladder (intracystic papillary neoplasms, n= 11). Most exhibited pancreatobiliary differentiation (n= 20), high-grade dysplasia (n= 26) and an associated adenocarcinoma (n= 20). Analysis of GNAS codon 201 identified only one mutant sample in a multifocal intestinal subtype intrahepatic IPNB with high-grade dysplasia. Six lesions harboured a KRAS codon 12 mutation. GNAS codon 201 mutations are uncommon in IPNBs, by contrast with pancreatic IPMNs. More comprehensive molecular profiling is needed to uncover the pathways involved in IPNB development.",Journal Article,2773.0,31.0,Activating point mutations of GNAS at codon 201 have been detected in approximately two thirds of intraductal papillary mucinous neoplasms IPMNs of the Intraductal papillary neoplasms of the ducts IPNBs morphologically resemble IPMNs This study sought to assess the mutational status of GNAS at codon 201 in IPNBs Thirty-four patients were included DNA from microdissected IPNBs was subjected to a polymerase chain reaction and ligation method for the detection of GNAS mutations at codon 201 and of KRAS mutations at codon 12 Mutational status was compared with clinical and pathologic data The IPNBs had a median diameter of 3.5 cm and were located intrahepatically n= 6 extrahepatically n= 13 both intra- and extrahepatically n= 4 or in the intracystic papillary neoplasms n= 11 Most exhibited pancreatobiliary differentiation n= 20 high-grade dysplasia n= 26 and an associated adenocarcinoma n= 20 Analysis of GNAS codon 201 identified only one mutant sample in a multifocal intestinal subtype intrahepatic IPNB with high-grade dysplasia Six lesions harboured a KRAS codon 12 mutation GNAS codon 201 mutations are uncommon in IPNBs by contrast with IPMNs More comprehensive molecular profiling is needed to uncover the pathways involved in IPNB development,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1616, 741, 138, 1, 8624, 28, 3673, 4766, 47, 85, 530, 4, 705, 100, 5438, 1, 4851, 1796, 2391, 1179, 5884, 1, 3, 4851, 1796, 1179, 1, 3, 7310, 25432, 6204, 8247, 5884, 26, 45, 990, 6, 423, 3, 1619, 156, 1, 8624, 28, 3673, 4766, 4, 25432, 977, 294, 7, 11, 159, 261, 29, 9418, 25432, 10, 4325, 6, 8, 1451, 1260, 1329, 2, 5307, 596, 9, 3, 638, 1, 8624, 138, 28, 3673, 4766, 2, 1, 723, 138, 28, 3673, 133, 1619, 156, 10, 72, 5, 38, 2, 510, 74, 3, 25432, 42, 8, 52, 2549, 1, 27, 33, 494, 2, 11, 2308, 61838, 78, 49, 47380, 78, 233, 110, 2392, 2, 47380, 78, 39, 15, 4, 3, 23158, 1796, 1179, 78, 175, 96, 1416, 9206, 910, 78, 179, 64, 88, 2253, 78, 432, 2, 35, 41, 449, 78, 179, 65, 1, 8624, 3673, 4766, 108, 158, 104, 620, 1000, 4, 8, 3492, 3077, 875, 3022, 27175, 5, 64, 88, 2253, 437, 406, 19257, 8, 723, 3673, 133, 258, 8624, 3673, 4766, 138, 32, 2052, 4, 25432, 20, 748, 5, 5884, 80, 949, 219, 1080, 16, 575, 6, 6281, 3, 460, 646, 4, 27175, 193]",1260.0,22954004,4
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.,The oncologist,Oncologist,2012-12-07,"Presentation of the Case A 37-year-old woman presented at 35 weeks of gestation with her third child with failure to adequately gain weight and was noted by her obstetrician to have delay in the growth of her baby. Ultrasound of the abdomen incidentally revealed the presence of a liver lesion. After additional evaluation, she ultimately delivered her daughter at 36 weeks uneventfully. She subsequently underwent additional evaluation. Liver magnetic resonance imaging (MRI) revealed a 5-cm solitary solid mass in segment 4A of the liver, concerning for malignancy. Serum -fetoprotein, carcinoembryonic antigen, cancer antigen (CA)19-9, CA15-3, and CA125 were all normal. Liver biopsy was positive for adenocarcinoma. The tumor cells demonstrated a phenotype suggesting a possible breast primary, although the immunohistochemistry did not support that diagnosis and the tumor was negative for mammaglobin, gross cystic disease fluid protein (GCDFP)-15, estrogen receptor (ER), and progesterone receptor (PR) (Table 1). The tumor was also CDX2 and cardiotrophin-1 negative, but cytokeratin (CK) 19 positive. Her endoscopic retrograde cholangiopancreatography, upper endoscopy, colonoscopy, breast mammogram, and breast MRI were completely normal. A positron emission tomography-computed tomography scan showed a fluorodeoxyglucose-avid 5.8-cm  6.0-cm hypoattenuating lesion with peripheral enhancement involving segment 4 and segment 8 at the dome. In addition, central necrosis within the lesion was noted. The left main portal vein was mildly attenuated by the mass. She eventually underwent a left hepatectomy en bloc with caudate resection, portal lymphadenectomy, cholecystectomy, and omental pedicle flap. On exploration of the abdomen, no additional disease was noted. The final pathology revealed a 9.4-cm moderately to poorly differentiated adenocarcinoma of the intrahepatic bile ducts. Venous invasion was present. Perineural invasion was absent. The margins were negative. Thirteen lymph nodes were obtained, all of which were negative, consistent with a stage T2, N0, MX intrahepatic cholangiocarcinoma. The tumor was positive for CK7, CK19, and CA19-9 and negative for CK20, CDX2, CA125, ER, PR, GCDFP-15, synaptophysin, and chromogranin (Table 1). The uninvolved liver was unremarkable and a trichrome stain showed no fibrosis. Following an uneventful postoperative recovery, she was referred for consideration of adjuvant therapy.",Case Reports,2601.0,14.0,Presentation of the Case A 37-year-old woman presented at 35 weeks of gestation with her third child with failure to adequately gain weight and was noted by her obstetrician to have delay in the growth of her baby Ultrasound of the abdomen incidentally revealed the presence of a lesion After additional evaluation she ultimately delivered her daughter at 36 weeks uneventfully She subsequently underwent additional evaluation magnetic resonance imaging MRI revealed a 5-cm solitary solid mass in segment 4A of the concerning for malignancy Serum -fetoprotein carcinoembryonic antigen cancer antigen CA 19-9 CA15-3 and CA125 were all normal biopsy was positive for adenocarcinoma The tumor cells demonstrated a phenotype suggesting a possible primary although the immunohistochemistry did not support that diagnosis and the tumor was negative for mammaglobin gross cystic disease fluid protein GCDFP -15 estrogen receptor ER and progesterone receptor PR Table 1 The tumor was also CDX2 and cardiotrophin-1 negative but cytokeratin CK 19 positive Her endoscopic retrograde cholangiopancreatography upper endoscopy colonoscopy mammogram and MRI were completely normal A positron emission tomography-computed tomography scan showed a fluorodeoxyglucose-avid 5.8-cm 6.0-cm hypoattenuating lesion with peripheral enhancement involving segment 4 and segment 8 at the dome In addition central necrosis within the lesion was noted The left main portal vein was mildly attenuated by the mass She eventually underwent a left hepatectomy en bloc with caudate resection portal lymphadenectomy cholecystectomy and omental pedicle flap On exploration of the abdomen no additional disease was noted The final pathology revealed a 9.4-cm moderately to poorly differentiated adenocarcinoma of the intrahepatic ducts Venous invasion was present Perineural invasion was absent The margins were negative Thirteen lymph nodes were obtained all of which were negative consistent with a stage T2 N0 MX intrahepatic cholangiocarcinoma The tumor was positive for CK7 CK19 and CA19-9 and negative for CK20 CDX2 CA125 ER PR GCDFP-15 synaptophysin and chromogranin Table 1 The uninvolved was unremarkable and a trichrome stain showed no fibrosis Following an uneventful postoperative recovery she was referred for consideration of adjuvant therapy,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1031, 1, 3, 473, 8, 567, 111, 1095, 2854, 917, 28, 465, 244, 1, 13250, 5, 1084, 1282, 2566, 5, 496, 6, 4215, 1803, 924, 2, 10, 1051, 20, 1084, 23084, 6, 47, 1984, 4, 3, 129, 1, 1084, 25200, 1945, 1, 3, 4036, 5925, 553, 3, 463, 1, 8, 1180, 50, 402, 451, 3109, 2050, 1623, 1084, 15254, 28, 511, 244, 30535, 3109, 1611, 208, 402, 451, 1484, 1535, 270, 704, 553, 8, 33, 494, 3144, 537, 782, 4, 4610, 14820, 1, 3, 4243, 9, 710, 524, 2014, 6607, 5139, 448, 12, 448, 1568, 326, 83, 18367, 27, 2, 3188, 11, 62, 295, 411, 10, 109, 9, 449, 3, 30, 37, 264, 8, 1005, 802, 8, 899, 86, 242, 3, 888, 205, 44, 538, 17, 147, 2, 3, 30, 10, 199, 9, 16093, 1789, 2965, 34, 2357, 178, 14935, 167, 808, 153, 516, 2, 2143, 153, 998, 7016, 14, 3, 30, 10, 120, 9934, 2, 62177, 14, 199, 84, 4292, 4925, 326, 109, 1084, 2056, 10583, 15476, 1726, 4199, 3996, 5129, 2, 704, 11, 2500, 295, 8, 1900, 1799, 872, 1220, 872, 1657, 224, 8, 4085, 5189, 33, 66, 494, 49, 13, 494, 28516, 1180, 5, 672, 2461, 1267, 4610, 39, 2, 4610, 66, 28, 3, 15553, 4, 352, 854, 1523, 262, 3, 1180, 10, 1051, 3, 1712, 1895, 3307, 2762, 10, 9443, 2656, 20, 3, 782, 3109, 3124, 208, 8, 1712, 2711, 4375, 5590, 5, 10199, 170, 3307, 2048, 8493, 2, 11404, 9253, 3942, 23, 3370, 1, 3, 4036, 77, 402, 34, 10, 1051, 3, 1457, 1117, 553, 8, 83, 39, 494, 3508, 6, 1240, 1442, 449, 1, 3, 3022, 7310, 2167, 578, 10, 364, 4917, 578, 10, 3269, 3, 1012, 11, 199, 3170, 263, 502, 11, 683, 62, 1, 92, 11, 199, 925, 5, 8, 82, 1786, 3394, 10684, 3022, 2126, 3, 30, 10, 109, 9, 12097, 13815, 2, 6058, 83, 2, 199, 9, 10821, 9934, 3188, 516, 998, 14935, 167, 12161, 2, 8931, 7016, 14, 3, 7377, 10, 20197, 2, 8, 33539, 8763, 224, 77, 3000, 366, 35, 16742, 573, 1602, 3109, 10, 1995, 9, 2415, 1, 249, 36]",2320.0,23220842,15
2564 resected periampullary adenocarcinomas at a single institution: trends over three decades.,HPB : the official journal of the International Hepato Pancreato Biliary Association,HPB (Oxford),2013-03-08,"This study was carried out to determine relative survival rates and trends in outcomes in patients who underwent resection of periampullary adenocarcinomas (PACs) with curative intent at a single institution over the last three decades. From 1980 to 2011, 2564 pancreaticoduodenectomies (PDs) were performed for PACs. Pathological diagnosis, therapy and survival were retrospectively analysed. The primary sites included the pancreas (66%), ampulla (16%), bile duct (12%) and duodenum (6%). Operation volume increased from 11 per year in the 1980s to 135 per year in the 2000s (P < 0.001). Patients in the 1980s were younger (median age: 64 years; range: 33-90 years) than those in the 1990s (median age: 68 years; range: 31-103 years) and 2000s (median age: 68 years; range: 24-93 years) (P < 0.001). Over time, the frequency of a diagnosis of pancreatic cancer arising from intraductal papillary mucinous neoplasm increased from 2% in the 1980s to 8% in the 2000s (P < 0.001). The rate of 30-day mortality after surgery in the 1980s was 2%, which was similar to rates in the 1990s (1%) and 2000s (1%). Survival in each type of PAC did not change over time. Pancreatic cancer was associated with the worst survival (median survival: 19 months) compared with adenocarcinomas of the ampulla (median survival: 47 months), bile duct (median survival: 23 months) and duodenum (median survival: 54 months) (P < 0.001). There are significant differences among PACs in longterm survival following PD. Although the numbers of patients undergoing safe resection have increased, overall longterm outcomes have not improved significantly.",Comparative Study,2510.0,105.0,This study was carried out to determine relative survival rates and trends in outcomes in patients who underwent resection of periampullary adenocarcinomas PACs with curative intent at a single institution over the last three decades From 1980 to 2011 2564 pancreaticoduodenectomies PDs were performed for PACs Pathological diagnosis therapy and survival were retrospectively analysed The primary sites included the 66 ampulla 16 duct 12 and duodenum 6 Operation volume increased from 11 per year in the 1980s to 135 per year in the 2000s P 0.001 Patients in the 1980s were younger median age 64 years range 33-90 years than those in the 1990s median age 68 years range 31-103 years and 2000s median age 68 years range 24-93 years P 0.001 Over time the frequency of a diagnosis of cancer arising from intraductal papillary mucinous neoplasm increased from 2 in the 1980s to 8 in the 2000s P 0.001 The rate of 30-day mortality after surgery in the 1980s was 2 which was similar to rates in the 1990s 1 and 2000s 1 Survival in each type of PAC did not change over time cancer was associated with the worst survival median survival 19 months compared with adenocarcinomas of the ampulla median survival 47 months duct median survival 23 months and duodenum median survival 54 months P 0.001 There are significant differences among PACs in longterm survival following PD Although the numbers of patients undergoing safe resection have increased overall longterm outcomes have not improved significantly,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26, 45, 10, 2629, 1205, 6, 223, 580, 25, 151, 2, 1963, 4, 123, 4, 7, 54, 208, 170, 1, 9180, 1586, 27264, 5, 1075, 1697, 28, 8, 226, 731, 252, 3, 1060, 169, 1968, 29, 4376, 6, 1132, 62550, 28529, 5680, 11, 173, 9, 27264, 1301, 147, 36, 2, 25, 11, 894, 3141, 3, 86, 633, 159, 3, 700, 12837, 245, 2920, 133, 2, 8401, 49, 2589, 433, 101, 29, 175, 379, 111, 4, 3, 8361, 6, 3978, 379, 111, 4, 3, 17373, 19, 13, 144, 7, 4, 3, 8361, 11, 773, 52, 89, 660, 60, 184, 466, 424, 60, 76, 135, 4, 3, 7524, 52, 89, 806, 60, 184, 456, 3283, 60, 2, 17373, 52, 89, 806, 60, 184, 259, 966, 60, 19, 13, 144, 252, 98, 3, 675, 1, 8, 147, 1, 12, 2635, 29, 4851, 1796, 2391, 2131, 101, 29, 18, 4, 3, 8361, 6, 66, 4, 3, 17373, 19, 13, 144, 3, 116, 1, 201, 218, 282, 50, 152, 4, 3, 8361, 10, 18, 92, 10, 288, 6, 151, 4, 3, 7524, 14, 2, 17373, 14, 25, 4, 296, 267, 1, 6100, 205, 44, 707, 252, 98, 12, 10, 41, 5, 3, 4066, 25, 52, 25, 326, 53, 72, 5, 1586, 1, 3, 12837, 52, 25, 662, 53, 2920, 52, 25, 382, 53, 2, 8401, 52, 25, 667, 53, 19, 13, 144, 125, 32, 93, 362, 107, 27264, 4, 16328, 25, 366, 333, 242, 3, 1870, 1, 7, 479, 1165, 170, 47, 101, 63, 16328, 123, 47, 44, 231, 97]",1498.0,23472829,100
Irreversible electroporation ablation of the liver can be detected with ultrasound B-mode and elastography.,Surgery,Surgery,2013-03-13,"Irreversible electroporation (IRE) is a novel ablation technique that induces permanent membrane permeability and cell death. We are interested in ultrasound B-mode and elastography to monitor IRE ablation in the liver. Yorkshire pigs underwent IRE ablation of the liver and were imaged with ultrasound B-mode and elastography. Histologic evaluation of cell death by triphenyltetrazolium chloride and hematoxylin and eosin staining was performed. Elastography showed that liver ablated by IRE exhibited increased tissue stiffness with a peak strain ratio of 2.22. The IRE lesion had a discrete border without bubble artifact, and the lesion size significantly correlated with area of cell death on histology. IRE ablation was unaffected by presence of large blood vessels or bile ducts. IRE ablation led to increased tissue stiffness that was detectable by elastography and indicative of cell death. Elastography may complement B-mode ultrasonography to monitor IRE ablation of the liver.",Journal Article,2505.0,17.0,Irreversible electroporation IRE is a novel ablation technique that induces permanent membrane permeability and cell death We are interested in ultrasound B-mode and elastography to monitor IRE ablation in the Yorkshire pigs underwent IRE ablation of the and were imaged with ultrasound B-mode and elastography Histologic evaluation of cell death by triphenyltetrazolium chloride and hematoxylin and eosin staining was performed Elastography showed that ablated by IRE exhibited increased tissue stiffness with a peak strain ratio of 2.22 The IRE lesion had a discrete border without bubble artifact and the lesion size significantly correlated with area of cell death on histology IRE ablation was unaffected by presence of large blood vessels or ducts IRE ablation led to increased tissue stiffness that was detectable by elastography and indicative of cell death Elastography may complement B-mode ultrasonography to monitor IRE ablation of the,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4422, 15690, 11525, 16, 8, 229, 1650, 1312, 17, 1516, 4377, 1905, 4757, 2, 31, 273, 21, 32, 7420, 4, 1945, 132, 4530, 2, 15057, 6, 3334, 11525, 1650, 4, 3, 62579, 40302, 208, 11525, 1650, 1, 3, 2, 11, 5903, 5, 1945, 132, 4530, 2, 15057, 884, 451, 1, 31, 273, 20, 44786, 12086, 2, 6209, 2, 5975, 1029, 10, 173, 15057, 224, 17, 9463, 20, 11525, 1416, 101, 246, 9815, 5, 8, 2944, 5041, 197, 1, 18, 350, 3, 11525, 1180, 42, 8, 5447, 11793, 187, 25969, 14759, 2, 3, 1180, 444, 97, 438, 5, 965, 1, 31, 273, 23, 784, 11525, 1650, 10, 4585, 20, 463, 1, 375, 315, 3102, 15, 7310, 11525, 1650, 836, 6, 101, 246, 9815, 17, 10, 2083, 20, 15057, 2, 5572, 1, 31, 273, 15057, 68, 3731, 132, 4530, 4244, 6, 3334, 11525, 1650, 1, 3]",947.0,23489942,74
Use of EUS-FNA in diagnosing pancreatic neoplasm without a definitive mass on CT.,Gastrointestinal endoscopy,Gastrointest. Endosc.,2013-03-21,"Diagnosis of pancreatic neoplasm is challenging in patients with inconclusive findings on pancreatic multidetector row CT (MDCT). To determine the diagnostic accuracy and to identify predictors of pancreatic neoplasm by EUS with FNA in this setting. Retrospective chart review during the study period of January 2002 to December 2010. Tertiary referral center. Of the 1046 patients who underwent pancreatic EUS, 116 patients were selected because their clinical presentation was suspicious for pancreatic malignancy, but their MDCT findings were inconclusive. EUS with FNA. Diagnostic yield of malignancy and significance of clinical variables. When surgical pathology or subsequent clinical course was used as the criterion standard, EUS with FNA had a sensitivity, specificity, positive predictive value, and accuracy of 87.3%, 98.3%, 98.5%, and 92.1%, respectively, in diagnosing a pancreatic neoplasm that was indeterminate on MDCT. Factors significantly associated with EUS detection of pancreatic ductal adenocarcinoma were total bilirubin level greater than 2 mg/dL (P < .001), CT finding of pancreatic duct dilation (P < .001), bile duct stricture (P < .001), and tumor size 1.5 cm or larger detected by EUS (P = .004). Among them, pancreatic duct dilation on CT (odds ratio 4.10; 95% confidence interval, 1.52-11.05), and tumor size 1.5 cm or larger detected by EUS (odds ratio 8.46; 95% confidence interval, 2.02-35.45) were independent risk factors. Retrospective design and patient referral bias. When MDCT is indeterminate, EUS is a highly sensitive and accurate modality for the detection of pancreatic neoplasm, especially when the tumor is smaller than 2.0 cm.",Journal Article,2497.0,,Diagnosis of neoplasm is challenging in patients with inconclusive findings on multidetector row CT MDCT To determine the diagnostic accuracy and to identify predictors of neoplasm by EUS with FNA in this setting Retrospective chart review during the study period of January 2002 to December 2010 Tertiary referral center Of the 1046 patients who underwent EUS 116 patients were selected because their clinical presentation was suspicious for malignancy but their MDCT findings were inconclusive EUS with FNA Diagnostic yield of malignancy and significance of clinical variables When surgical pathology or subsequent clinical course was used as the criterion standard EUS with FNA had a sensitivity specificity positive predictive value and accuracy of 87.3 98.3 98.5 and 92.1 respectively in diagnosing a neoplasm that was indeterminate on MDCT Factors significantly associated with EUS detection of ductal adenocarcinoma were total bilirubin level greater than 2 mg/dL P .001 CT finding of duct dilation P .001 duct stricture P .001 and tumor size 1.5 cm or larger detected by EUS P .004 Among them duct dilation on CT odds ratio 4.10 95 confidence interval 1.52-11.05 and tumor size 1.5 cm or larger detected by EUS odds ratio 8.46 95 confidence interval 2.02-35.45 were independent risk factors Retrospective design and patient referral bias When MDCT is indeterminate EUS is a highly sensitive and accurate modality for the detection of neoplasm especially when the tumor is smaller than 2.0 cm,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[147, 1, 2131, 16, 1950, 4, 7, 5, 6791, 272, 23, 21994, 23657, 425, 16233, 6, 223, 3, 752, 1190, 2, 6, 255, 674, 1, 2131, 20, 3626, 5, 4064, 4, 26, 546, 459, 2937, 206, 190, 3, 45, 727, 1, 1024, 1544, 6, 1397, 1120, 2557, 2096, 574, 1, 3, 29394, 7, 54, 208, 3626, 3790, 7, 11, 715, 408, 136, 38, 1031, 10, 3230, 9, 710, 84, 136, 16233, 272, 11, 6791, 3626, 5, 4064, 752, 2309, 1, 710, 2, 724, 1, 38, 682, 198, 221, 1117, 15, 706, 38, 906, 10, 95, 22, 3, 4643, 260, 3626, 5, 4064, 42, 8, 485, 1121, 109, 464, 549, 2, 1190, 1, 912, 27, 1096, 27, 1096, 33, 2, 937, 14, 106, 4, 5798, 8, 2131, 17, 10, 5167, 23, 16233, 130, 97, 41, 5, 3626, 638, 1, 1258, 449, 11, 181, 5009, 301, 378, 76, 18, 81, 1826, 19, 144, 425, 1567, 1, 2920, 8062, 19, 144, 2920, 6673, 19, 144, 2, 30, 444, 14, 33, 494, 15, 1077, 530, 20, 3626, 19, 1520, 107, 1370, 2920, 8062, 23, 425, 610, 197, 39, 79, 48, 307, 268, 14, 653, 175, 474, 2, 30, 444, 14, 33, 494, 15, 1077, 530, 20, 3626, 610, 197, 66, 641, 48, 307, 268, 18, 588, 465, 512, 11, 306, 43, 130, 459, 771, 2, 69, 2096, 2947, 198, 16233, 16, 5167, 3626, 16, 8, 561, 745, 2, 1481, 1396, 9, 3, 638, 1, 2131, 1093, 198, 3, 30, 16, 2170, 76, 18, 13, 494]",1499.0,23523302,50
Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases.,Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,J Oncol Pharm Pract,2013-05-14,"Limited clinical data are available regarding the safety of docetaxel in metastatic breast cancer patients with liver dysfunction. Eligible patients had breast cancer with impaired liver function secondary to hepatic metastases and were candidates for docetaxel therapy. They were assigned to one of five groups on the basis of total bilirubin, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels. All other causes of liver dysfunction were excluded, and bile duct obstruction was corrected, if possible, prior to study entry. Patients received docetaxel every three weeks. The chemotherapy dose was chosen on the basis of the patient's level of hepatic dysfunction and escalated as tolerated. The primary outcome of this study was safety. The secondary outcomes were pharmacokinetic data and efficacy in terms of time to disease progression. Twenty-three patients were enrolled. No unexpected toxicities occurred. Grade 3/4 fatigue (65%), neutropenia (30%), myalgias (26%), neutropenic fever (26%), vomiting (9%), and rash (9%) were the most common serious adverse events. The median time to progression was three months (range 1-18 months). Pharmacokinetic results indicated that patients with more severe hepatic dysfunction may have been underdosed based on our conservative dosing strategy. Docetaxel can be administered to patients with metastatic breast cancer and liver dysfunction after dose attenuation. However, because of a narrow therapeutic index in this clinical setting, therapy should be closely monitored with subsequent dose escalation when possible.",Journal Article,2443.0,9.0,Limited clinical data are available regarding the safety of docetaxel in metastatic cancer patients with dysfunction Eligible patients had cancer with impaired function secondary to hepatic metastases and were candidates for docetaxel therapy They were assigned to one of five groups on the basis of total bilirubin alanine aminotransferase aspartate aminotransferase and alkaline phosphatase levels All other causes of dysfunction were excluded and duct obstruction was corrected if possible prior to study entry Patients received docetaxel every three weeks The chemotherapy dose was chosen on the basis of the patient 's level of hepatic dysfunction and escalated as tolerated The primary outcome of this study was safety The secondary outcomes were pharmacokinetic data and efficacy in terms of time to disease progression Twenty-three patients were enrolled No unexpected toxicities occurred Grade 3/4 fatigue 65 neutropenia 30 myalgias 26 neutropenic fever 26 vomiting 9 and rash 9 were the most common serious adverse events The median time to progression was three months range 1-18 months Pharmacokinetic results indicated that patients with more severe hepatic dysfunction may have been underdosed based on our conservative dosing strategy Docetaxel can be administered to patients with metastatic cancer and dysfunction after dose attenuation However because of a narrow therapeutic index in this clinical setting therapy should be closely monitored with subsequent dose escalation when possible,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[383, 38, 74, 32, 390, 666, 3, 367, 1, 621, 4, 113, 12, 7, 5, 1527, 625, 7, 42, 12, 5, 2364, 343, 568, 6, 939, 196, 2, 11, 1931, 9, 621, 36, 491, 11, 896, 6, 104, 1, 365, 271, 23, 3, 877, 1, 181, 5009, 5411, 4597, 6308, 4597, 2, 5355, 2577, 148, 62, 127, 1626, 1, 1527, 11, 1800, 2, 2920, 3191, 10, 3848, 492, 899, 324, 6, 45, 3001, 7, 103, 621, 454, 169, 244, 3, 56, 61, 10, 4695, 23, 3, 877, 1, 3, 69, 292, 301, 1, 939, 1527, 2, 2842, 22, 421, 3, 86, 228, 1, 26, 45, 10, 367, 3, 568, 123, 11, 1456, 74, 2, 209, 4, 1794, 1, 98, 6, 34, 91, 737, 169, 7, 11, 346, 77, 3792, 385, 489, 88, 27, 39, 613, 556, 778, 201, 11571, 432, 3659, 2775, 432, 1966, 83, 2, 1641, 83, 11, 3, 96, 186, 1762, 290, 281, 3, 52, 98, 6, 91, 10, 169, 53, 184, 14, 203, 53, 1456, 99, 1103, 17, 7, 5, 80, 905, 939, 1527, 68, 47, 85, 24977, 90, 23, 114, 4476, 1280, 692, 621, 122, 40, 468, 6, 7, 5, 113, 12, 2, 1527, 50, 61, 5349, 137, 408, 1, 8, 6958, 189, 558, 4, 26, 38, 546, 36, 257, 40, 3210, 2909, 5, 706, 61, 1125, 198, 899]",1506.0,23676510,62
Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome.,PloS one,PLoS ONE,2013-06-11,"Adenocarcinomas of the ampulla of Vater are classified as biliary cancers, though the exact epithelium of origin for these cancers is not known. We sought to molecularly classify ampullary adenocarcinomas in comparison to known adenocarcinomas of the pancreas, bile duct, and duodenum by gene expression analysis. We analyzed 32 fresh-frozen resected, untreated periampullary adenocarcinomas (8 pancreatic, 2 extrahepatic biliary, 8 duodenal, and 14 ampullary) using the Affymetrix U133 Plus 2.0 genome array. Unsupervised and supervised hierarchical clustering identified two subtypes of ampullary carcinomas that were molecularly and histologically characterized. Hierarchical clustering of periampullary carcinomas segregated ampullary carcinomas into two subgroups, which were distinctly different from pancreatic carcinomas. Non-pancreatic periampullary adenocarcinomas were segregated into two subgroups with differing prognoses: 5 year RFS (77% vs. 0%, p=0.007) and 5 year OS (100% vs. 35%, p=0.005). Unsupervised clustering analysis of the 14 ampullary samples also identified two subgroups: a good prognosis intestinal-like subgroup and a poor prognosis biliary-like subgroup with 5 year OS of 70% vs. 28%, P=0.09. Expression of CK7+/CK20- but not CDX-2 correlated with these two subgroups. Activation of the AKT and MAPK pathways were both increased in the poor prognostic biliary-like subgroup. In an independent 80 patient ampullary validation dataset only histological subtype (intestinal vs. pancreaticobiliary) was significantly associated with OS in both univariate (p=0.006) and multivariate analysis (P=0.04). Gene expression analysis discriminated pancreatic adenocarcinomas from other periampullary carcinomas and identified two prognostically relevant subgroups of ampullary adenocarcinomas. Histological subtype was an independent prognostic factor in ampullary adenocarcinomas.",Journal Article,2415.0,32.0,Adenocarcinomas of the ampulla of Vater are classified as biliary cancers though the exact epithelium of origin for these cancers is not known We sought to molecularly classify ampullary adenocarcinomas in comparison to known adenocarcinomas of the duct and duodenum by gene expression analysis We analyzed 32 fresh-frozen resected untreated periampullary adenocarcinomas 8 2 extrahepatic biliary 8 duodenal and 14 ampullary using the Affymetrix U133 Plus 2.0 genome array Unsupervised and supervised hierarchical clustering identified two subtypes of ampullary carcinomas that were molecularly and histologically characterized Hierarchical clustering of periampullary carcinomas segregated ampullary carcinomas into two subgroups which were distinctly different from carcinomas Non-pancreatic periampullary adenocarcinomas were segregated into two subgroups with differing prognoses 5 year RFS 77 vs. 0 p 0.007 and 5 year OS 100 vs. 35 p 0.005 Unsupervised clustering analysis of the 14 ampullary samples also identified two subgroups a good prognosis intestinal-like subgroup and a poor prognosis biliary-like subgroup with 5 year OS of 70 vs. 28 P 0.09 Expression of CK7+/CK20- but not CDX-2 correlated with these two subgroups Activation of the AKT and MAPK pathways were both increased in the poor prognostic biliary-like subgroup In an independent 80 patient ampullary validation dataset only histological subtype intestinal vs. pancreaticobiliary was significantly associated with OS in both univariate p 0.006 and multivariate analysis P 0.04 Gene expression analysis discriminated adenocarcinomas from other periampullary carcinomas and identified two prognostically relevant subgroups of ampullary adenocarcinomas Histological subtype was an independent prognostic factor in ampullary adenocarcinomas,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1586, 1, 3, 12837, 1, 14777, 32, 1373, 22, 2532, 163, 2471, 3, 2472, 2781, 1, 1938, 9, 46, 163, 16, 44, 440, 21, 990, 6, 2372, 4896, 6762, 1586, 4, 1155, 6, 440, 1586, 1, 3, 2920, 2, 8401, 20, 145, 55, 65, 21, 311, 531, 4329, 3015, 1133, 1278, 9180, 1586, 66, 18, 3710, 2532, 66, 4748, 2, 213, 6762, 75, 3, 5318, 17316, 349, 18, 13, 898, 1926, 6512, 2, 7762, 4466, 3147, 108, 100, 814, 1, 6762, 826, 17, 11, 2372, 2, 2161, 765, 4466, 3147, 1, 9180, 826, 11324, 6762, 826, 237, 100, 1453, 92, 11, 9452, 338, 29, 826, 220, 14061, 9180, 1586, 11, 11324, 237, 100, 1453, 5, 5276, 5362, 33, 111, 1272, 849, 105, 13, 19, 13, 1999, 2, 33, 111, 118, 394, 105, 465, 19, 13, 1614, 6512, 3147, 65, 1, 3, 213, 6762, 347, 120, 108, 100, 1453, 8, 1178, 356, 3077, 733, 1363, 2, 8, 334, 356, 2532, 733, 1363, 5, 33, 111, 118, 1, 431, 105, 339, 19, 13, 1730, 55, 1, 12097, 10821, 84, 44, 12417, 18, 438, 5, 46, 100, 1453, 363, 1, 3, 649, 2, 1748, 460, 11, 110, 101, 4, 3, 334, 177, 2532, 733, 1363, 4, 35, 306, 493, 69, 6762, 929, 3014, 158, 1831, 875, 3077, 105, 14581, 10, 97, 41, 5, 118, 4, 110, 880, 19, 13, 1861, 2, 331, 65, 19, 13, 755, 145, 55, 65, 8752, 1586, 29, 127, 9180, 826, 2, 108, 100, 7848, 867, 1453, 1, 6762, 1586, 1831, 875, 10, 35, 306, 177, 161, 4, 6762, 1586]",1810.0,23776447,15
Early detection of metachronous bile duct cancer in Lynch syndrome: report of a case.,Surgery today,Surg. Today,2013-07-31,"Lynch syndrome is an autosomal dominant disease associated with a high incidence of colorectal, endometrial, stomach, ovarian, pancreatic, ureter and renal pelvis, bile duct and brain tumors. The syndrome can also include sebaceous gland adenomas and keratoacanthomas, and carcinoma of the small bowel. The lifetime risk for bile duct cancer in patients with Lynch syndrome is approximately 2 %. The present report describes a case of Lynch syndrome with metachronous bile duct cancer diagnosed at an early stage. The patient was a 73-year-old Japanese male who underwent a successful left lobectomy of the liver, and there was no sign of recurrence for 2 years postoperative. However, this patient harbored a germline mutation in MLH1, which prompted diagnostic examinations for noncolorectal tumors when a periodic surveillance blood examination showed abnormal values of hepatobiliary enzymes. Although most patients with bile duct cancer are diagnosed at an advanced stage, the bile duct cancer was diagnosed at an early stage in the present patient due to the observation of the gene mutation and the preceding liver tumor. This case illustrates the importance of continuous surveillance for extracolonic tumors, including bile duct cancer, in patients with Lynch syndrome.",Case Reports,2365.0,4.0,Lynch syndrome is an autosomal dominant disease associated with a high incidence of ureter and pelvis duct and brain tumors The syndrome can also include sebaceous gland adenomas and keratoacanthomas and carcinoma of the small bowel The lifetime risk for duct cancer in patients with Lynch syndrome is approximately 2 The present report describes a case of Lynch syndrome with metachronous duct cancer diagnosed at an early stage The patient was a 73-year-old Japanese male who underwent a successful left lobectomy of the and there was no sign of recurrence for 2 years postoperative However this patient harbored a germline mutation in MLH1 which prompted diagnostic examinations for noncolorectal tumors when a periodic surveillance blood examination showed abnormal values of hepatobiliary enzymes Although most patients with duct cancer are diagnosed at an advanced stage the duct cancer was diagnosed at an early stage in the present patient due to the observation of the gene mutation and the preceding tumor This case illustrates the importance of continuous surveillance for extracolonic tumors including duct cancer in patients with Lynch syndrome,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,"[3546, 681, 16, 35, 6084, 2156, 34, 41, 5, 8, 64, 287, 1, 9775, 2, 3270, 2920, 2, 342, 57, 3, 681, 122, 120, 643, 8621, 2326, 2751, 2, 16091, 2, 134, 1, 3, 302, 1659, 3, 2898, 43, 9, 2920, 12, 4, 7, 5, 3546, 681, 16, 705, 18, 3, 364, 414, 2677, 8, 473, 1, 3546, 681, 5, 4796, 2920, 12, 265, 28, 35, 191, 82, 3, 69, 10, 8, 803, 111, 1095, 5256, 1045, 54, 208, 8, 1401, 1712, 3258, 1, 3, 2, 125, 10, 77, 7636, 1, 146, 9, 18, 60, 573, 137, 26, 69, 3253, 8, 1009, 258, 4, 3321, 92, 4140, 752, 4209, 9, 17766, 57, 198, 8, 9086, 617, 315, 1385, 224, 1668, 1030, 1, 4718, 3039, 242, 96, 7, 5, 2920, 12, 32, 265, 28, 35, 131, 82, 3, 2920, 12, 10, 265, 28, 35, 191, 82, 4, 3, 364, 69, 520, 6, 3, 1664, 1, 3, 145, 258, 2, 3, 5892, 30, 26, 473, 6342, 3, 1187, 1, 1314, 617, 9, 18178, 57, 141, 2920, 12, 4, 7, 5, 3546, 681]",1157.0,23896635,22
Marital status and survival in patients with cancer.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2013-09-23,"To examine the impact of marital status on stage at diagnosis, use of definitive therapy, and cancer-specific mortality among each of the 10 leading causes of cancer-related death in the United States. We used the Surveillance, Epidemiology and End Results program to identify 1,260,898 patients diagnosed in 2004 through 2008 with lung, colorectal, breast, pancreatic, prostate, liver/intrahepatic bile duct, non-Hodgkin lymphoma, head/neck, ovarian, or esophageal cancer. We used multivariable logistic and Cox regression to analyze the 734,889 patients who had clinical and follow-up information available. Married patients were less likely to present with metastatic disease (adjusted odds ratio [OR], 0.83; 95% CI, 0.82 to 0.84; P < .001), more likely to receive definitive therapy (adjusted OR, 1.53; 95% CI, 1.51 to 1.56; P < .001), and less likely to die as a result of their cancer after adjusting for demographics, stage, and treatment (adjusted hazard ratio, 0.80; 95% CI, 0.79 to 0.81; P < .001) than unmarried patients. These associations remained significant when each individual cancer was analyzed (P < .05 for all end points for each malignancy). The benefit associated with marriage was greater in males than females for all outcome measures analyzed (P < .001 in all cases). For prostate, breast, colorectal, esophageal, and head/neck cancers, the survival benefit associated with marriage was larger than the published survival benefit of chemotherapy. Even after adjusting for known confounders, unmarried patients are at significantly higher risk of presentation with metastatic cancer, undertreatment, and death resulting from their cancer. This study highlights the potentially significant impact that social support can have on cancer detection, treatment, and survival.",Journal Article,2311.0,384.0,"To examine the impact of marital status on stage at diagnosis use of definitive therapy and cancer-specific mortality among each of the 10 leading causes of cancer-related death in the United States We used the Surveillance Epidemiology and End Results program to identify 1,260,898 patients diagnosed in 2004 through 2008 with liver/intrahepatic duct head/neck or cancer We used multivariable logistic and Cox regression to analyze the 734,889 patients who had clinical and follow-up information available Married patients were less likely to present with metastatic disease adjusted odds ratio OR 0.83 95 CI 0.82 to 0.84 P .001 more likely to receive definitive therapy adjusted OR 1.53 95 CI 1.51 to 1.56 P .001 and less likely to die as a result of their cancer after adjusting for demographics stage and treatment adjusted hazard ratio 0.80 95 CI 0.79 to 0.81 P .001 than unmarried patients These associations remained significant when each individual cancer was analyzed P .05 for all end points for each malignancy The benefit associated with marriage was greater in males than females for all outcome measures analyzed P .001 in all cases For and head/neck cancers the survival benefit associated with marriage was larger than the published survival benefit of chemotherapy Even after adjusting for known confounders unmarried patients are at significantly higher risk of presentation with metastatic cancer undertreatment and death resulting from their cancer This study highlights the potentially significant impact that social support can have on cancer detection treatment and survival",1,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[6, 1004, 3, 345, 1, 5345, 156, 23, 82, 28, 147, 119, 1, 1057, 36, 2, 12, 112, 282, 107, 296, 1, 3, 79, 1049, 1626, 1, 12, 139, 273, 4, 3, 1088, 907, 21, 95, 3, 617, 1284, 2, 396, 99, 1243, 6, 255, 14, 6398, 16449, 7, 265, 4, 1131, 298, 1375, 5, 4094, 3022, 2920, 718, 4606, 15, 12, 21, 95, 658, 812, 2, 418, 320, 6, 1992, 3, 12641, 13993, 7, 54, 42, 38, 2, 166, 126, 487, 390, 5365, 7, 11, 299, 322, 6, 364, 5, 113, 34, 586, 610, 197, 15, 13, 852, 48, 58, 13, 878, 6, 13, 874, 19, 144, 80, 322, 6, 560, 1057, 36, 586, 15, 14, 699, 48, 58, 14, 725, 6, 14, 664, 19, 144, 2, 299, 322, 6, 3384, 22, 8, 757, 1, 136, 12, 50, 1358, 9, 2221, 82, 2, 24, 586, 360, 197, 13, 493, 48, 58, 13, 842, 6, 13, 865, 19, 144, 76, 8491, 7, 46, 685, 958, 93, 198, 296, 797, 12, 10, 311, 19, 474, 9, 62, 396, 862, 9, 296, 710, 3, 247, 41, 5, 14822, 10, 378, 4, 2296, 76, 2451, 9, 62, 228, 1018, 311, 19, 144, 4, 62, 140, 9, 2, 718, 4606, 163, 3, 25, 247, 41, 5, 14822, 10, 1077, 76, 3, 983, 25, 247, 1, 56, 871, 50, 1358, 9, 440, 4423, 8491, 7, 32, 28, 97, 142, 43, 1, 1031, 5, 113, 12, 13127, 2, 273, 1113, 29, 136, 12, 26, 45, 2527, 3, 751, 93, 345, 17, 2032, 538, 122, 47, 23, 12, 638, 24, 2, 25]",1597.0,24062405,62
Systematic use of an intraoperative air leak test at the time of major liver resection reduces the rate of postoperative biliary complications.,Journal of the American College of Surgeons,J. Am. Coll. Surg.,2013-12-01,"After hepatectomy, bile leaks remain a major cause of morbidity, cost, and disability. This study was designed to determine if a novel intraoperative air leak test (ALT) would reduce the incidence of post-hepatectomy biliary complications. Rates of postoperative biliary complications were compared among 103 patients who underwent ALT and 120 matched patients operated on before ALT was used. All study patients underwent major hepatectomy without bile duct resection at 3 high-volume hepatobiliary centers between 2008 and 2012. The ALT was performed by placement of a transcystic cholangiogram catheter to inject air into the biliary tree, the upper abdomen was filled with saline, and the distal common bile duct was manually occluded. Uncontrolled bile ducts were identified by localization of air bubbles at the transection surface and were directly repaired. The 2 groups were similar in diagnosis, chemotherapy use, tumor number and size, resection extent, surgery duration, and blood loss (all, p > 0.05). Single or multiple uncontrolled bile ducts were intraoperatively detected and repaired in 62.1% of ALT vs 8.3% of non-ALT patients (p < 0.001). This resulted in a lower rate of postoperative bile leaks in ALT (1.9%) vs non-ALT patients (10.8%; p = 0.008). Independent risk factors for postoperative bile leaks included extended hepatectomy (p = 0.031), caudate resection (p = 0.02), and not performing ALT (p = 0.002) (odds ratio = 3.8; 95% CI, 1.3-11.8; odds ratio = 4.0; 95% CI, 1.1-14.3; and odds ratio = 11.8; 95% CI, 2.4-58.8, respectively). The ALT is an easily reproducible test that is highly effective for intraoperative detection and repair of open bile ducts, reducing the rate of postoperative bile leaks.",Controlled Clinical Trial,2242.0,39.0,After hepatectomy leaks remain a major cause of morbidity cost and disability This study was designed to determine if a novel intraoperative air leak test ALT would reduce the incidence of post-hepatectomy biliary complications Rates of postoperative biliary complications were compared among 103 patients who underwent ALT and 120 matched patients operated on before ALT was used All study patients underwent major hepatectomy without duct resection at 3 high-volume hepatobiliary centers between 2008 and 2012 The ALT was performed by placement of a transcystic cholangiogram catheter to inject air into the biliary tree the upper abdomen was filled with saline and the distal common duct was manually occluded Uncontrolled ducts were identified by localization of air bubbles at the transection surface and were directly repaired The 2 groups were similar in diagnosis chemotherapy use tumor number and size resection extent surgery duration and blood loss all p 0.05 Single or multiple uncontrolled ducts were intraoperatively detected and repaired in 62.1 of ALT vs 8.3 of non-ALT patients p 0.001 This resulted in a lower rate of postoperative leaks in ALT 1.9 vs non-ALT patients 10.8 p 0.008 Independent risk factors for postoperative leaks included extended hepatectomy p 0.031 caudate resection p 0.02 and not performing ALT p 0.002 odds ratio 3.8 95 CI 1.3-11.8 odds ratio 4.0 95 CI 1.1-14.3 and odds ratio 11.8 95 CI 2.4-58.8 respectively The ALT is an easily reproducible test that is highly effective for intraoperative detection and repair of open ducts reducing the rate of postoperative leaks,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[50, 2711, 9674, 918, 8, 458, 708, 1, 787, 835, 2, 5868, 26, 45, 10, 1114, 6, 223, 492, 8, 229, 1720, 6909, 4238, 412, 4548, 688, 969, 3, 287, 1, 539, 2711, 2532, 521, 151, 1, 573, 2532, 521, 11, 72, 107, 3283, 7, 54, 208, 4548, 2, 2031, 655, 7, 7297, 23, 348, 4548, 10, 95, 62, 45, 7, 208, 458, 2711, 187, 2920, 170, 28, 27, 64, 433, 4718, 1168, 59, 1375, 2, 1195, 3, 4548, 10, 173, 20, 2613, 1, 8, 63624, 28026, 3925, 6, 37989, 6909, 237, 3, 2532, 4899, 3, 1726, 4036, 10, 11948, 5, 5969, 2, 3, 2107, 186, 2920, 10, 8474, 31685, 6180, 7310, 11, 108, 20, 2145, 1, 6909, 27157, 28, 3, 13575, 1255, 2, 11, 1606, 18437, 3, 18, 271, 11, 288, 4, 147, 56, 119, 30, 207, 2, 444, 170, 1039, 152, 654, 2, 315, 407, 62, 19, 13, 474, 226, 15, 232, 6180, 7310, 11, 6595, 530, 2, 18437, 4, 744, 14, 1, 4548, 105, 66, 27, 1, 220, 4548, 7, 19, 13, 144, 26, 627, 4, 8, 280, 116, 1, 573, 9674, 4, 4548, 14, 83, 105, 220, 4548, 7, 79, 66, 19, 13, 2155, 306, 43, 130, 9, 573, 9674, 159, 1747, 2711, 19, 13, 5304, 10199, 170, 19, 13, 588, 2, 44, 3620, 4548, 19, 13, 1111, 610, 197, 27, 66, 48, 58, 14, 27, 175, 66, 610, 197, 39, 13, 48, 58, 14, 14, 213, 27, 2, 610, 197, 175, 66, 48, 58, 18, 39, 717, 66, 106, 3, 4548, 16, 35, 4697, 4172, 412, 17, 16, 561, 323, 9, 1720, 638, 2, 972, 1, 1020, 7310, 1818, 3, 116, 1, 573, 9674]",1609.0,24246619,90
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.,Clinical colorectal cancer,Clin Colorectal Cancer,2014-01-04,"Patients with advanced biliary tract cancers have limited therapeutic options. Preclinical data suggest that proteasome inhibition may be an effective therapeutic strategy. We thus evaluated the clinical efficacy of bortezomib in advanced biliary tract cancers. Patients with locally advanced or metastatic cholangiocarcinoma or gallbladder adenocarcinoma who had received 0 to 2 previous therapies received bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 of a 21-day cycle. The primary end point was objective response rate. A Simon 2-stage design was used (null response rate of < 5% and response rate of  20% of interest). Twenty patients enrolled (bile duct/gallbladder cancer [14/6] and previous treatments 0/1/2 [10/6/3]). The trial was discontinued early because of lack of confirmed partial responses. No unanticipated adverse events were noted. There was 1 unconfirmed partial response. Ten patients achieved stable disease as best response. Median time to progression was 5.8 months (95% confidence interval [CI], 0.7-77.6 months). Median survival was 9 months (95% CI, 4.6-18.5 months). The 6-month and 1-year survival rates were 70% and 38%, respectively. There was no difference in survival based on primary disease site. Single-agent bortezomib does not result in objective responses in biliary tract cancers. However, the rate of stable disease and time to progression benchmark is encouraging. Further development of bortezomib in combination with other therapies in this disease setting should be considered.","Clinical Trial, Phase II",2208.0,12.0,Patients with advanced biliary tract cancers have limited therapeutic options Preclinical data suggest that proteasome inhibition may be an effective therapeutic strategy We thus evaluated the clinical efficacy of bortezomib in advanced biliary tract cancers Patients with locally advanced or metastatic cholangiocarcinoma or adenocarcinoma who had received 0 to 2 previous therapies received bortezomib 1.3 mg/m 2 on days 1 4 8 and 11 of a 21-day cycle The primary end point was objective response rate A Simon 2-stage design was used null response rate of 5 and response rate of  20 of interest Twenty patients enrolled duct/gallbladder cancer 14/6 and previous treatments 0/1/2 10/6/3 The trial was discontinued early because of lack of confirmed partial responses No unanticipated adverse events were noted There was 1 unconfirmed partial response Ten patients achieved stable disease as best response Median time to progression was 5.8 months 95 confidence interval CI 0.7-77.6 months Median survival was 9 months 95 CI 4.6-18.5 months The 6-month and 1-year survival rates were 70 and 38 respectively There was no difference in survival based on primary disease site Single-agent bortezomib does not result in objective responses in biliary tract cancers However the rate of stable disease and time to progression benchmark is encouraging Further development of bortezomib in combination with other therapies in this disease setting should be considered,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 131, 2532, 1696, 163, 47, 383, 189, 838, 693, 74, 309, 17, 1694, 297, 68, 40, 35, 323, 189, 692, 21, 631, 194, 3, 38, 209, 1, 819, 4, 131, 2532, 1696, 163, 7, 5, 795, 131, 15, 113, 2126, 15, 449, 54, 42, 103, 13, 6, 18, 698, 235, 103, 819, 14, 27, 81, 188, 18, 23, 162, 14, 39, 66, 2, 175, 1, 8, 239, 218, 417, 3, 86, 396, 741, 10, 461, 51, 116, 8, 7385, 18, 82, 771, 10, 95, 3505, 51, 116, 1, 33, 2, 51, 116, 1, 749, 179, 1, 1333, 737, 7, 346, 2920, 48193, 12, 213, 49, 2, 698, 640, 13, 14, 18, 79, 49, 27, 3, 160, 10, 2402, 191, 408, 1, 926, 1, 557, 450, 253, 77, 12580, 290, 281, 11, 1051, 125, 10, 14, 5971, 450, 51, 1618, 7, 513, 585, 34, 22, 824, 51, 52, 98, 6, 91, 10, 33, 66, 53, 48, 307, 268, 58, 13, 67, 849, 49, 53, 52, 25, 10, 83, 53, 48, 58, 39, 49, 203, 33, 53, 3, 49, 811, 2, 14, 111, 25, 151, 11, 431, 2, 519, 106, 125, 10, 77, 523, 4, 25, 90, 23, 86, 34, 606, 226, 420, 819, 1097, 44, 757, 4, 461, 253, 4, 2532, 1696, 163, 137, 3, 116, 1, 585, 34, 2, 98, 6, 91, 7330, 16, 2269, 195, 193, 1, 819, 4, 150, 5, 127, 235, 4, 26, 34, 546, 257, 40, 515]",1460.0,24512954,68
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.,"Hepatology (Baltimore, Md.)",Hepatology,2014-02-28,"Hepatocellular carcinoma (HCC) is the most rapidly increasing cause of cancer-related mortality in the United States. Because of the lack of viable treatment options for HCC, prevention in high-risk patients has been proposed as an alternative strategy. The main risk factor for HCC is cirrhosis and several lines of evidence implicate epidermal growth factor (EGF) in the progression of cirrhosis and development of HCC. We therefore examined the effects of the EGF receptor (EGFR) inhibitor erlotinib on liver fibrogenesis and hepatocellular transformation in three different animal models of progressive cirrhosis: a rat model induced by repeated, low-dose injections of diethylnitrosamine (DEN), a mouse model induced by carbon tetrachloride (CCl4 ), and a rat model induced by bile duct ligation (BDL). Erlotinib reduced EGFR phosphorylation in hepatic stellate cells (HSC) and reduced the total number of activated HSC. Erlotinib also decreased hepatocyte proliferation and liver injury. Consistent with all these findings, pharmacological inhibition of EGFR signaling effectively prevented the progression of cirrhosis and regressed fibrosis in some animals. Moreover, by alleviating the underlying liver disease, erlotinib blocked the development of HCC and its therapeutic efficacy could be monitored with a previously reported gene expression signature predictive of HCC risk in human cirrhosis patients. These data suggest that EGFR inhibition using Food and Drug Administration-approved inhibitors provides a promising therapeutic approach for reduction of fibrogenesis and prevention of HCC in high-risk cirrhosis patients who can be identified and monitored by gene expression signatures.",Journal Article,2153.0,145.0,carcinoma HCC is the most rapidly increasing cause of cancer-related mortality in the United States Because of the lack of viable treatment options for HCC prevention in high-risk patients has been proposed as an alternative strategy The main risk factor for HCC is cirrhosis and several lines of evidence implicate epidermal growth factor EGF in the progression of cirrhosis and development of HCC We therefore examined the effects of the EGF receptor EGFR inhibitor erlotinib on fibrogenesis and transformation in three different animal models of progressive cirrhosis a rat model induced by repeated low-dose injections of diethylnitrosamine DEN a mouse model induced by carbon tetrachloride CCl4 and a rat model induced by duct ligation BDL Erlotinib reduced EGFR phosphorylation in hepatic stellate cells HSC and reduced the total number of activated HSC Erlotinib also decreased proliferation and injury Consistent with all these findings pharmacological inhibition of EGFR signaling effectively prevented the progression of cirrhosis and regressed fibrosis in some animals Moreover by alleviating the underlying disease erlotinib blocked the development of HCC and its therapeutic efficacy could be monitored with a previously reported gene expression signature predictive of HCC risk in human cirrhosis patients These data suggest that EGFR inhibition using Food and Drug Administration-approved inhibitors provides a promising therapeutic approach for reduction of fibrogenesis and prevention of HCC in high-risk cirrhosis patients who can be identified and monitored by gene expression signatures,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[134, 663, 16, 3, 96, 1755, 602, 708, 1, 12, 139, 282, 4, 3, 1088, 907, 408, 1, 3, 926, 1, 2663, 24, 838, 9, 663, 1070, 4, 64, 43, 7, 71, 85, 1587, 22, 35, 1091, 692, 3, 1895, 43, 161, 9, 663, 16, 3563, 2, 392, 285, 1, 241, 5545, 829, 129, 161, 3114, 4, 3, 91, 1, 3563, 2, 193, 1, 663, 21, 673, 409, 3, 176, 1, 3, 3114, 153, 227, 230, 962, 23, 40664, 2, 1392, 4, 169, 338, 2026, 274, 1, 1014, 3563, 8, 4008, 202, 277, 20, 2113, 154, 61, 4344, 1, 26799, 32263, 8, 830, 202, 277, 20, 5183, 35780, 12660, 2, 8, 4008, 202, 277, 20, 2920, 5307, 27357, 962, 405, 227, 982, 4, 939, 9528, 37, 5596, 2, 405, 3, 181, 207, 1, 735, 5596, 962, 120, 340, 457, 2, 2730, 925, 5, 62, 46, 272, 3419, 297, 1, 227, 314, 1856, 3902, 3, 91, 1, 3563, 2, 12579, 3000, 4, 476, 2258, 1393, 20, 12956, 3, 1181, 34, 962, 2582, 3, 193, 1, 663, 2, 211, 189, 209, 359, 40, 2909, 5, 8, 373, 210, 145, 55, 1651, 464, 1, 663, 43, 4, 171, 3563, 7, 46, 74, 309, 17, 227, 297, 75, 1773, 2, 234, 634, 850, 222, 777, 8, 721, 189, 353, 9, 628, 1, 40664, 2, 1070, 1, 663, 4, 64, 43, 3563, 7, 54, 122, 40, 108, 2, 2909, 20, 145, 55, 2210]",1606.0,24677197,46
"Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.",PloS one,PLoS ONE,2014-04-07,"Brivanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) tyrosine kinases, which are both involved in mechanisms of liver fibrosis. We hypothesized that inhibition of VEGFR and FGFR by brivanib would inhibit liver fibrosis. We therefore examined the effect of brivanib on liver fibrosis in three mouse models of fibrosis. In vivo, we induced liver fibrosis by bile duct ligation (BDL), chronic carbon tetrachloride (CCl4), and chronic thioacetamide (TAA) administration. Liver fibrosis was examined by immunohistochemistry and Western immunoblotting. In vitro, we used LX-2 human hepatic stellate cells (HSCs) to assess the effect of brivanib on stellate cell proliferation and activation. After in vivo induction with BDL, CCl4, and TAA, mice treated with brivanib showed reduced liver fibrosis and decreased expression of collagen I1 and -smooth muscle actin in the liver. In vitro, brivanib decreased proliferation of HSCs induced by platelet-derived growth factor (PDGF), VEGF, and FGF. Brivanib also decreased stellate cell viability and inhibited PDGFBB-induced phosphorylation of its cognate receptor. Brivanib reduces liver fibrosis in three different animal models and decreases human hepatic stellate cell activation. Brivanib may represent a novel therapeutic approach to treatment of liver fibrosis and prevention of liver cancer.",Journal Article,2115.0,32.0,Brivanib is a selective inhibitor of vascular endothelial growth factor receptor VEGFR and fibroblast growth factor receptor FGFR tyrosine kinases which are both involved in mechanisms of fibrosis We hypothesized that inhibition of VEGFR and FGFR by brivanib would inhibit fibrosis We therefore examined the effect of brivanib on fibrosis in three mouse models of fibrosis In vivo we induced fibrosis by duct ligation BDL chronic carbon tetrachloride CCl4 and chronic thioacetamide TAA administration fibrosis was examined by immunohistochemistry and Western immunoblotting In vitro we used LX-2 human hepatic stellate cells HSCs to assess the effect of brivanib on stellate cell proliferation and activation After in vivo induction with BDL CCl4 and TAA mice treated with brivanib showed reduced fibrosis and decreased expression of collagen I1 and -smooth muscle actin in the In vitro brivanib decreased proliferation of HSCs induced by platelet-derived growth factor PDGF VEGF and FGF Brivanib also decreased stellate cell viability and inhibited PDGFBB-induced phosphorylation of its cognate receptor Brivanib reduces fibrosis in three different animal models and decreases human hepatic stellate cell activation Brivanib may represent a novel therapeutic approach to treatment of fibrosis and prevention of cancer,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[9827, 16, 8, 1094, 230, 1, 756, 845, 129, 161, 153, 2134, 2, 3758, 129, 161, 153, 4453, 564, 1549, 92, 32, 110, 646, 4, 483, 1, 3000, 21, 1237, 17, 297, 1, 2134, 2, 4453, 20, 9827, 688, 1433, 3000, 21, 673, 409, 3, 254, 1, 9827, 23, 3000, 4, 169, 830, 274, 1, 3000, 4, 386, 21, 277, 3000, 20, 2920, 5307, 27357, 442, 5183, 35780, 12660, 2, 442, 48287, 12469, 634, 3000, 10, 409, 20, 888, 2, 1521, 5293, 4, 439, 21, 95, 64173, 18, 171, 939, 9528, 37, 6185, 6, 423, 3, 254, 1, 9827, 23, 9528, 31, 457, 2, 363, 50, 4, 386, 504, 5, 27357, 12660, 2, 12469, 399, 73, 5, 9827, 224, 405, 3000, 2, 340, 55, 1, 3945, 64174, 2, 2014, 5774, 1502, 5525, 4, 3, 4, 439, 9827, 340, 457, 1, 6185, 277, 20, 1596, 526, 129, 161, 4546, 618, 2, 6517, 9827, 120, 340, 9528, 31, 2120, 2, 879, 64175, 277, 982, 1, 211, 8903, 153, 9827, 2389, 3000, 4, 169, 338, 2026, 274, 2, 2140, 171, 939, 9528, 31, 363, 9827, 68, 1231, 8, 229, 189, 353, 6, 24, 1, 3000, 2, 1070, 1, 12]",1320.0,24710173,0
Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis.,JAMA surgery,JAMA Surg,2014-06-01,"Data on outcomes following surgical management of intrahepatic cholangiocarcinoma (ICC) are limited. The incidence of ICC is increasing and it has a poor prognosis. No consensus has been reached regarding the optimal treatment modalities. To systematically review and synthesize the available evidence regarding treatment and prognosis in patients with ICC. The PubMed database was searched for relevant articles published between January 1, 2000, and April 1, 2013. Only studies assessing predictors of survival or recurrence in patients undergoing curative-intent surgical treatment of ICC were included. Small series, studies reporting on mixed types of cholangiocarcinoma, or exclusively on hepatolithiasis-associated cholangiocarcinoma, and those published in a language other than English, French, German, Italian, or Greek, were excluded. Fifty-seven of 960 articles were therefore analyzed. Data on preoperative, intraoperative, and postoperative variables were extracted by 3 independent reviewers. Multiple studies reporting on the same population were excluded. Data were pooled using a random-effects model. We hypothesized that preoperative variables and tumor characteristics affect patient survival. The outcomes of the study were overall survival and recurrence-free survival. The hypothesis was formulated before data collection. Fifty-seven studies (4756 patients) were included in the review. Median patient age ranged from 49 to 67 years, and 57% were male. Most patients had a solitary (69%), large (median size, 4.5-8.0 cm) tumor of the mass-forming type (86%). Approximately one-third of the patients had lymph node metastasis (34%) or vascular (38%), perineural (29%), or biliary invasion (29%). Most underwent a major hepatectomy (82%), often accompanied by lymphadenectomy (67%) and sometimes by extrahepatic bile duct resection (23%). Median and 5-year overall survival (OS) generally were approximately 28 months (range, 9-53 months) and 30% (range, 5%-56%), respectively; factors predicting shorter OS included large tumor size, multiple tumors, lymph node metastasis, and vascular invasion. Adjuvant chemotherapy or radiotherapy did not appear to be beneficial. Seven studies (2132 patients) provided data for the meta-analysis. Factors associated with shorter OS included older age (pooled hazard ratio, 1.10; 95% CI, 1.03-1.17), larger tumor size (1.09; 1.02-1.16), presence of multiple tumors (1.70; 1.43-2.02), lymph node metastasis (2.09; 1.80-2.43), vascular invasion (1.87; 1.44-2.42), and poor tumor differentiation (1.41; 1.17-1.71). The prognosis of ICC is dictated mainly by tumor factors. Future research could focus on the usefulness of adjuvant treatment as well as other multidisciplinary treatment modalities.",Journal Article,2060.0,196.0,Data on outcomes following surgical management of intrahepatic cholangiocarcinoma ICC are limited The incidence of ICC is increasing and it has a poor prognosis No consensus has been reached regarding the optimal treatment modalities To systematically review and synthesize the available evidence regarding treatment and prognosis in patients with ICC The PubMed database was searched for relevant articles published between January 1 2000 and April 1 2013 Only studies assessing predictors of survival or recurrence in patients undergoing curative-intent surgical treatment of ICC were included Small series studies reporting on mixed types of cholangiocarcinoma or exclusively on hepatolithiasis-associated cholangiocarcinoma and those published in a language other than English French German Italian or Greek were excluded Fifty-seven of 960 articles were therefore analyzed Data on preoperative intraoperative and postoperative variables were extracted by 3 independent reviewers Multiple studies reporting on the same population were excluded Data were pooled using a random-effects model We hypothesized that preoperative variables and tumor characteristics affect patient survival The outcomes of the study were overall survival and recurrence-free survival The hypothesis was formulated before data collection Fifty-seven studies 4756 patients were included in the review Median patient age ranged from 49 to 67 years and 57 were male Most patients had a solitary 69 large median size 4.5-8.0 cm tumor of the mass-forming type 86 Approximately one-third of the patients had lymph node metastasis 34 or vascular 38 perineural 29 or biliary invasion 29 Most underwent a major hepatectomy 82 often accompanied by lymphadenectomy 67 and sometimes by extrahepatic duct resection 23 Median and 5-year overall survival OS generally were approximately 28 months range 9-53 months and 30 range 5 -56 respectively factors predicting shorter OS included large tumor size multiple tumors lymph node metastasis and vascular invasion Adjuvant chemotherapy or radiotherapy did not appear to be beneficial Seven studies 2132 patients provided data for the meta-analysis Factors associated with shorter OS included older age pooled hazard ratio 1.10 95 CI 1.03-1.17 larger tumor size 1.09 1.02-1.16 presence of multiple tumors 1.70 1.43-2.02 lymph node metastasis 2.09 1.80-2.43 vascular invasion 1.87 1.44-2.42 and poor tumor differentiation 1.41 1.17-1.71 The prognosis of ICC is dictated mainly by tumor factors Future research could focus on the usefulness of adjuvant treatment as well as other multidisciplinary treatment modalities,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[74, 23, 123, 366, 221, 284, 1, 3022, 2126, 2259, 32, 383, 3, 287, 1, 2259, 16, 602, 2, 192, 71, 8, 334, 356, 77, 1391, 71, 85, 1300, 666, 3, 665, 24, 1558, 6, 3390, 206, 2, 11254, 3, 390, 241, 666, 24, 2, 356, 4, 7, 5, 2259, 3, 3161, 609, 10, 3080, 9, 867, 2384, 983, 59, 1024, 14, 1081, 2, 2292, 14, 1346, 158, 94, 1977, 674, 1, 25, 15, 146, 4, 7, 479, 1075, 1697, 221, 24, 1, 2259, 11, 159, 302, 988, 94, 1760, 23, 1739, 630, 1, 2126, 15, 4437, 23, 34380, 41, 2126, 2, 135, 983, 4, 8, 4794, 127, 76, 4201, 9254, 10842, 10215, 15, 27327, 11, 1800, 1461, 648, 1, 8809, 2384, 11, 673, 311, 74, 23, 498, 1720, 2, 573, 682, 11, 2484, 20, 27, 306, 7171, 232, 94, 1760, 23, 3, 827, 266, 11, 1800, 74, 11, 1830, 75, 8, 2324, 176, 202, 21, 1237, 17, 498, 682, 2, 30, 374, 1158, 69, 25, 3, 123, 1, 3, 45, 11, 63, 25, 2, 146, 115, 25, 3, 1492, 10, 7495, 348, 74, 2442, 1461, 648, 94, 64189, 7, 11, 159, 4, 3, 206, 52, 69, 89, 1869, 29, 739, 6, 598, 60, 2, 696, 11, 1045, 96, 7, 42, 8, 3144, 790, 375, 52, 444, 39, 33, 66, 13, 494, 30, 1, 3, 782, 4525, 267, 868, 705, 104, 1282, 1, 3, 7, 42, 263, 289, 278, 562, 15, 756, 519, 4917, 462, 15, 2532, 578, 462, 96, 208, 8, 458, 2711, 878, 629, 2756, 20, 2048, 598, 2, 5164, 20, 3710, 2920, 170, 382, 52, 2, 33, 111, 63, 25, 118, 1228, 11, 705, 339, 53, 184, 83, 699, 53, 2, 201, 184, 33, 664, 106, 130, 1434, 985, 118, 159, 375, 30, 444, 232, 57, 263, 289, 278, 2, 756, 578, 249, 56, 15, 310, 205, 44, 1322, 6, 40, 2524, 648, 94, 64190, 7, 1052, 74, 9, 3, 1742, 65, 130, 41, 5, 985, 118, 159, 434, 89, 1830, 360, 197, 14, 79, 48, 58, 14, 680, 14, 269, 1077, 30, 444, 14, 1730, 14, 588, 14, 245, 463, 1, 232, 57, 14, 431, 14, 601, 18, 588, 263, 289, 278, 18, 1730, 14, 493, 18, 601, 756, 578, 14, 912, 14, 584, 18, 595, 2, 334, 30, 910, 14, 605, 14, 269, 14, 792, 3, 356, 1, 2259, 16, 10575, 2615, 20, 30, 130, 508, 389, 359, 1222, 23, 3, 5235, 1, 249, 24, 22, 149, 22, 127, 1643, 24, 1558]",2629.0,24718873,79
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.,Human pathology,Hum. Pathol.,2014-04-13,"Patients with cholangiocarcinoma often present with locally advanced or metastatic disease. There is a need for effective therapeutic strategies for advanced stage cholangiocarcinoma. Recently, FGFR2 translocations have been identified as a potential target for tyrosine kinase inhibitor therapies. This study evaluated 152 cholangiocarcinomas and 4 intraductal papillary biliary neoplasms of the bile duct for presence of FGFR2 translocations by fluorescence in situ hybridization and characterized the clinicopathologic features of cases with FGFR2 translocations. Thirteen (10 women, 3 men; 8%) of 156 biliary tumors harbored FGFR2 translocations, including 12 intrahepatic cholangiocarcinomas (12/96; 13%) and 1 intraductal papillary neoplasm of the bile duct. Histologically, cholangiocarcinomas with FGFR2 translocations displayed prominent intraductal growth (62%) or anastomosing tubular glands with desmoplasia (38%). Immunohistochemically, the tumors with FGFR2 translocations frequently showed weak and patchy expression of CK19 (77%). Markers of the stem cell phenotype in cholangiocarcinoma, HepPar1 and CK20, were negative in all cases. The median cancer-specific survival for patients whose tumors harbored FGFR2 translocations was 123 months compared to 37 months for cases without FGFR2 translocations (P = .039). This study also assessed 100 cholangiocarcinomas for ERBB2 amplification and ROS1 translocations. Of the cases tested, 3% and 1% were positive for ERBB2 amplification and ROS1 translocation, respectively. These results confirm that FGFR2, ERRB2, and ROS1 alterations are potential therapeutic targets for intrahepatic cholangiocarcinoma. ",Journal Article,2109.0,88.0,Patients with cholangiocarcinoma often present with locally advanced or metastatic disease There is a need for effective therapeutic strategies for advanced stage cholangiocarcinoma Recently FGFR2 translocations have been identified as a potential target for tyrosine kinase inhibitor therapies This study evaluated 152 cholangiocarcinomas and 4 intraductal papillary biliary neoplasms of the duct for presence of FGFR2 translocations by fluorescence in situ hybridization and characterized the clinicopathologic features of cases with FGFR2 translocations Thirteen 10 women 3 men 8 of 156 biliary tumors harbored FGFR2 translocations including 12 intrahepatic cholangiocarcinomas 12/96 13 and 1 intraductal papillary neoplasm of the duct Histologically cholangiocarcinomas with FGFR2 translocations displayed prominent intraductal growth 62 or anastomosing tubular glands with desmoplasia 38 Immunohistochemically the tumors with FGFR2 translocations frequently showed weak and patchy expression of CK19 77 Markers of the stem cell phenotype in cholangiocarcinoma HepPar1 and CK20 were negative in all cases The median cancer-specific survival for patients whose tumors harbored FGFR2 translocations was 123 months compared to 37 months for cases without FGFR2 translocations P .039 This study also assessed 100 cholangiocarcinomas for ERBB2 amplification and ROS1 translocations Of the cases tested 3 and 1 were positive for ERBB2 amplification and ROS1 translocation respectively These results confirm that FGFR2 ERRB2 and ROS1 alterations are potential therapeutic targets for intrahepatic cholangiocarcinoma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 2126, 629, 364, 5, 795, 131, 15, 113, 34, 125, 16, 8, 594, 9, 323, 189, 422, 9, 131, 82, 2126, 761, 5273, 3262, 47, 85, 108, 22, 8, 174, 283, 9, 564, 216, 230, 235, 26, 45, 194, 5370, 9386, 2, 39, 4851, 1796, 2532, 1179, 1, 3, 2920, 9, 463, 1, 5273, 3262, 20, 1591, 4, 957, 1554, 2, 765, 3, 1399, 404, 1, 140, 5, 5273, 3262, 3170, 79, 117, 27, 325, 66, 1, 5693, 2532, 57, 3253, 5273, 3262, 141, 133, 3022, 9386, 133, 921, 233, 2, 14, 4851, 1796, 2131, 1, 3, 2920, 2161, 9386, 5, 5273, 3262, 2507, 3689, 4851, 129, 744, 15, 31642, 6360, 3966, 5, 19633, 519, 6347, 3, 57, 5, 5273, 3262, 746, 224, 4241, 2, 17750, 55, 1, 13815, 849, 525, 1, 3, 452, 31, 1005, 4, 2126, 34900, 2, 10821, 11, 199, 4, 62, 140, 3, 52, 12, 112, 25, 9, 7, 1310, 57, 3253, 5273, 3262, 10, 2698, 53, 72, 6, 567, 53, 9, 140, 187, 5273, 3262, 19, 5955, 26, 45, 120, 275, 394, 9386, 9, 2186, 1073, 2, 3581, 3262, 1, 3, 140, 650, 27, 2, 14, 11, 109, 9, 2186, 1073, 2, 3581, 2006, 106, 46, 99, 1843, 17, 5273, 48361, 2, 3581, 593, 32, 174, 189, 637, 9, 3022, 2126]",1612.0,24837095,10
Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma.,American journal of clinical oncology,Am. J. Clin. Oncol.,2016-06-01,"The aim of this was to determine survival after starting neoadjuvant therapy for patients who became ineligible for orthotopic liver transplantation (OLT). Since January 1993, 215 patients with unresectable cholangiocarcinoma began treatment with planned OLT. Treatment included external-beam radiation therapy (EBRT) with fluorouracil, bile duct brachytherapy, and postradiotherapy fluorouracil or capecitabine before OLT. Adverse findings at the staging operation, death, and other factors precluded OLT in 63 patients (29%), of whom 61 completed neoadjuvant chemoradiation. By October 2012, 56 (89%) of the 63 patients unable to undergo OLT had died. Twenty-two patients (35%) became ineligible for OLT before the staging operation, 38 (60%) at the staging operation, and 3 (5%) after staging. From the date of diagnosis, median overall survival was 12.3 months. Survival was 17% at 18 months and 7% at 24 months. Median survival after fallout was 6.8 months. Median survival after the staging operation was 6 months. Two patients lived for 3.7 and 8.7 years before dying of cancer or liver failure caused by persistent biliary stricture at the site of the original cancer, respectively. Univariate analysis showed that time from diagnosis to fallout correlated with overall survival (P=0.04). In highly selected patients initially suitable for OLT, the mortality rate for cholangiocarcinoma was high in patients who became ineligible for OLT. Their survival, however, was comparable to expected survival for patients with locally advanced or metastatic disease treated with nontransplant therapies. The most common reason for patient fallout was adverse findings at the staging operation.",Journal Article,1329.0,3.0,The aim of this was to determine survival after starting neoadjuvant therapy for patients who became ineligible for orthotopic transplantation OLT Since January 1993 215 patients with unresectable cholangiocarcinoma began treatment with planned OLT Treatment included external-beam radiation therapy EBRT with fluorouracil duct brachytherapy and postradiotherapy fluorouracil or capecitabine before OLT Adverse findings at the staging operation death and other factors precluded OLT in 63 patients 29 of whom 61 completed neoadjuvant chemoradiation By October 2012 56 89 of the 63 patients unable to undergo OLT had died Twenty-two patients 35 became ineligible for OLT before the staging operation 38 60 at the staging operation and 3 5 after staging From the date of diagnosis median overall survival was 12.3 months Survival was 17 at 18 months and 7 at 24 months Median survival after fallout was 6.8 months Median survival after the staging operation was 6 months Two patients lived for 3.7 and 8.7 years before dying of cancer or failure caused by persistent biliary stricture at the site of the original cancer respectively Univariate analysis showed that time from diagnosis to fallout correlated with overall survival P=0.04 In highly selected patients initially suitable for OLT the mortality rate for cholangiocarcinoma was high in patients who became ineligible for OLT Their survival however was comparable to expected survival for patients with locally advanced or metastatic disease treated with nontransplant therapies The most common reason for patient fallout was adverse findings at the staging operation,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1130, 1, 26, 10, 6, 223, 25, 50, 1723, 536, 36, 9, 7, 54, 3451, 3773, 9, 2157, 497, 10112, 1192, 1024, 3343, 6511, 7, 5, 1468, 2126, 4603, 24, 5, 1465, 10112, 24, 159, 1455, 1345, 121, 36, 1883, 5, 1404, 2920, 1536, 2, 15619, 1404, 15, 1629, 348, 10112, 290, 272, 28, 3, 632, 2589, 273, 2, 127, 130, 8035, 10112, 4, 676, 7, 462, 1, 953, 713, 781, 536, 975, 20, 2551, 1195, 664, 887, 1, 3, 676, 7, 4253, 6, 1251, 10112, 42, 1016, 737, 100, 7, 465, 3451, 3773, 9, 10112, 348, 3, 632, 2589, 519, 335, 28, 3, 632, 2589, 2, 27, 33, 50, 632, 29, 3, 1244, 1, 147, 52, 63, 25, 10, 133, 27, 53, 25, 10, 269, 28, 203, 53, 2, 67, 28, 259, 53, 52, 25, 50, 35828, 10, 49, 66, 53, 52, 25, 50, 3, 632, 2589, 10, 49, 53, 100, 7, 4813, 9, 27, 67, 2, 66, 67, 60, 348, 4536, 1, 12, 15, 496, 1546, 20, 1882, 2532, 6673, 28, 3, 606, 1, 3, 2279, 12, 106, 880, 65, 224, 17, 98, 29, 147, 6, 35828, 438, 5, 63, 25, 19, 13, 755, 4, 561, 715, 7, 1625, 2884, 9, 10112, 3, 282, 116, 9, 2126, 10, 64, 4, 7, 54, 3451, 3773, 9, 10112, 136, 25, 137, 10, 1279, 6, 1336, 25, 9, 7, 5, 795, 131, 15, 113, 34, 73, 5, 21364, 235, 3, 96, 186, 3852, 9, 69, 35828, 10, 290, 272, 28, 3, 632, 2589]",1623.0,24921218,102
Multimodal treatment strategies for advanced hilar cholangiocarcinoma.,Langenbeck's archives of surgery,Langenbecks Arch Surg,2014-06-25,"Cholangiocarcinoma (CCA) is the second most common primary malignancy of the liver arising from malignant transformation and growth of biliary ductal epithelium. Approximately 50-70 % of CCAs arise at the hilar plate of the biliary tree, which are termed hilar cholangiocarcinoma (HC). Various staging systems are currently employed to classify HCs and determine resectability. Depending on the pre-operative staging, the mainstays of treatment include surgery, chemotherapy, radiation therapy, and photodynamic therapy. Surgical resection offers the only chance for cure of HC and achieving an R0 resection has demonstrated improved overall survival. However, obtaining longitudinal and radial surgical margins that are free of tumor can be difficult and frequently requires extensive resections, particularly for advanced HCs. Pre-operative interventions may be necessary to prepare patients for major hepatic resections, including endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangiography, and portal vein embolization. Multimodal therapy that combines chemotherapy with external beam radiation, stereotactic body radiation therapy, bile duct brachytherapy, and/or photodynamic therapy are all possible strategies for advanced HC prior to resection. Orthotopic liver transplantation is another therapeutic option that can achieve complete extirpation of locally advanced HC in judiciously selected patients following standardized neoadjuvant protocols.",Journal Article,2036.0,14.0,Cholangiocarcinoma CCA is the second most common primary malignancy of the arising from malignant transformation and growth of biliary ductal epithelium Approximately 50-70 of CCAs arise at the hilar plate of the biliary tree which are termed hilar cholangiocarcinoma HC Various staging systems are currently employed to classify HCs and determine resectability Depending on the pre-operative staging the mainstays of treatment include surgery chemotherapy radiation therapy and photodynamic therapy Surgical resection offers the only chance for cure of HC and achieving an R0 resection has demonstrated improved overall survival However obtaining longitudinal and radial surgical margins that are free of tumor can be difficult and frequently requires extensive resections particularly for advanced HCs Pre-operative interventions may be necessary to prepare patients for major hepatic resections including endoscopic retrograde cholangiopancreatography percutaneous transhepatic cholangiography and portal vein embolization Multimodal therapy that combines chemotherapy with external beam radiation stereotactic body radiation therapy duct brachytherapy and/or photodynamic therapy are all possible strategies for advanced HC prior to resection Orthotopic transplantation is another therapeutic option that can achieve complete extirpation of locally advanced HC in judiciously selected patients following standardized neoadjuvant protocols,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2126, 4317, 16, 3, 419, 96, 186, 86, 710, 1, 3, 2635, 29, 393, 1392, 2, 129, 1, 2532, 1258, 2781, 705, 212, 431, 1, 24750, 3043, 28, 3, 4793, 9656, 1, 3, 2532, 4899, 92, 32, 4183, 4793, 2126, 7487, 747, 632, 1530, 32, 694, 2516, 6, 4896, 21799, 2, 223, 5150, 3221, 23, 3, 671, 1208, 632, 3, 19093, 1, 24, 643, 152, 56, 121, 36, 2, 6910, 36, 221, 170, 2339, 3, 158, 3477, 9, 1722, 1, 7487, 2, 1785, 35, 2328, 170, 71, 264, 231, 63, 25, 137, 5244, 2380, 2, 6471, 221, 1012, 17, 32, 115, 1, 30, 122, 40, 1740, 2, 746, 1706, 1344, 2185, 823, 9, 131, 21799, 671, 1208, 1151, 68, 40, 1493, 6, 12113, 7, 9, 458, 939, 2185, 141, 2056, 10583, 15476, 3720, 18865, 21954, 2, 3307, 2762, 4232, 4122, 36, 17, 6705, 56, 5, 1455, 1345, 121, 1729, 642, 121, 36, 2920, 1536, 2, 15, 6910, 36, 32, 62, 899, 422, 9, 131, 7487, 324, 6, 170, 2157, 497, 16, 1809, 189, 1501, 17, 122, 1359, 236, 11945, 1, 795, 131, 7487, 4, 21121, 715, 7, 366, 1670, 536, 2189]",1442.0,24962146,24
Residual disease predicts outcomes after definitive resection for incidental gallbladder cancer.,Journal of the American College of Surgeons,J. Am. Coll. Surg.,2014-05-16,"Residual disease (RD) at definitive resection of incidental gallbladder cancer (IGBCA) influences outcome, but its clinical relevance with respect to anatomic site is incompletely characterized. Consecutive patients with IGBCA undergoing re-exploration from 1998 to 2009 were identified; those submitted to a complete resection were analyzed. Demographics and tumor- and treatment-related variables were correlated with RD and survival. Cancer-specific survival was stratified by site of RD (local [gallbladder bed]; regional [bile duct, lymph nodes]; distant [discontiguous liver, port site, peritoneal]). Of the 135 patients submitted to re-exploration, RD was found in 82 (61%) overall and in 63 (54%) of 116 patients submitted to resection; the most common site was regional (n=27, 43%). The T stage of the gallbladder specimen was the only independent predictor of RD (T1b= 35.7%, T2= 48.3%, T3= 70%, p= 0.015). The presence of RD at any site dramatically reduced median disease-free survival (DFS) (11.2 vs 93.4 months, p < 0.0001) and disease-specific survival (DSS) (25.2 months vs not reached, p < 0.0001) compared with no RD, respectively. Disease-specific survival did not differ according to RD location, with all anatomic sites being equally poor (p= 0.87). Residual disease at any site predicted DFS (hazard ratio [HR] 3.3, 95% CI 1.9 to 5.7, p= 0.0003) and DSS (HR 2.4, 95% CI 1.2 to 4.6, p= 0.01), independent of all other tumor-related variables. Survival in patients with RD at local or regional sites was not significantly different than that seen in stage IV disease, with neither subgroup clearly benefiting from reoperation. Outcomes were poor in all patients with RD, regardless of location.",Journal Article,2076.0,29.0,Residual disease RD at definitive resection of incidental cancer IGBCA influences outcome but its clinical relevance with respect to anatomic site is incompletely characterized Consecutive patients with IGBCA undergoing re-exploration from 1998 to 2009 were identified those submitted to a complete resection were analyzed Demographics and tumor- and treatment-related variables were correlated with RD and survival Cancer-specific survival was stratified by site of RD local bed regional duct lymph nodes distant discontiguous port site peritoneal Of the 135 patients submitted to re-exploration RD was found in 82 61 overall and in 63 54 of 116 patients submitted to resection the most common site was regional n 27 43 The T stage of the specimen was the only independent predictor of RD T1b 35.7 T2 48.3 T3 70 p 0.015 The presence of RD at any site dramatically reduced median disease-free survival DFS 11.2 vs 93.4 months p 0.0001 and disease-specific survival DSS 25.2 months vs not reached p 0.0001 compared with no RD respectively Disease-specific survival did not differ according to RD location with all anatomic sites being equally poor p 0.87 Residual disease at any site predicted DFS hazard ratio HR 3.3 95 CI 1.9 to 5.7 p 0.0003 and DSS HR 2.4 95 CI 1.2 to 4.6 p 0.01 independent of all other tumor-related variables Survival in patients with RD at local or regional sites was not significantly different than that seen in stage IV disease with neither subgroup clearly benefiting from reoperation Outcomes were poor in all patients with RD regardless of location,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[753, 34, 3089, 28, 1057, 170, 1, 4490, 12, 48505, 3859, 228, 84, 211, 38, 2088, 5, 2184, 6, 2745, 606, 16, 5252, 765, 935, 7, 5, 48505, 479, 1491, 3370, 29, 1850, 6, 1238, 11, 108, 135, 5118, 6, 8, 236, 170, 11, 311, 2221, 2, 30, 2, 24, 139, 682, 11, 438, 5, 3089, 2, 25, 12, 112, 25, 10, 1173, 20, 606, 1, 3089, 293, 2929, 951, 2920, 263, 502, 626, 33214, 3083, 606, 1639, 1, 3, 3978, 7, 5118, 6, 1491, 3370, 3089, 10, 204, 4, 878, 713, 63, 2, 4, 676, 667, 1, 3790, 7, 5118, 6, 170, 3, 96, 186, 606, 10, 951, 78, 428, 601, 3, 102, 82, 1, 3, 2360, 10, 3, 158, 306, 980, 1, 3089, 6142, 465, 67, 1786, 576, 27, 2065, 431, 19, 13, 3433, 3, 463, 1, 3089, 28, 500, 606, 2729, 405, 52, 34, 115, 25, 1010, 175, 18, 105, 966, 39, 53, 19, 13, 488, 2, 34, 112, 25, 1788, 243, 18, 53, 105, 44, 1300, 19, 13, 488, 72, 5, 77, 3089, 106, 34, 112, 25, 205, 44, 1505, 768, 6, 3089, 1147, 5, 62, 2745, 633, 486, 4142, 334, 19, 13, 912, 753, 34, 28, 500, 606, 783, 1010, 360, 197, 168, 27, 27, 48, 58, 14, 83, 6, 33, 67, 19, 13, 4418, 2, 1788, 168, 18, 39, 48, 58, 14, 18, 6, 39, 49, 19, 13, 355, 306, 1, 62, 127, 30, 139, 682, 25, 4, 7, 5, 3089, 28, 293, 15, 951, 633, 10, 44, 97, 338, 76, 17, 527, 4, 82, 478, 34, 5, 2174, 1363, 2536, 15251, 29, 5077, 123, 11, 334, 4, 62, 7, 5, 3089, 1583, 1, 1147]",1577.0,25087941,60
"Hepatobiliary cancers, version 2.2014.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2014-08-01,"Hepatobiliary cancers include a spectrum of invasive carcinomas arising in the liver (hepatocellular carcinoma), gall bladder, and bile ducts (cholangiocarcinomas). Gallbladder cancer and cholangiocarcinomas are collectively known as biliary tract cancers. Gallbladder cancer is the most common and aggressive type of all the biliary tract cancers. Cholangiocarcinomas are diagnosed throughout the biliary tree and are typically classified as either intrahepatic or extrahepatic cholangiocarcinoma. Extrahepatic cholangiocarcinomas are more common than intrahepatic cholangiocarcinomas. This manuscript focuses on the clinical management of patients with gallbladder cancer and cholangiocarcinomas (intrahepatic and extrahepatic). ",Journal Article,1999.0,39.0,Hepatobiliary cancers include a spectrum of invasive carcinomas arising in the carcinoma gall and ducts cholangiocarcinomas cancer and cholangiocarcinomas are collectively known as biliary tract cancers cancer is the most common and aggressive type of all the biliary tract cancers Cholangiocarcinomas are diagnosed throughout the biliary tree and are typically classified as either intrahepatic or extrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinomas are more common than intrahepatic cholangiocarcinomas This manuscript focuses on the clinical management of patients with cancer and cholangiocarcinomas intrahepatic and extrahepatic,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[4718, 163, 643, 8, 1873, 1, 416, 826, 2635, 4, 3, 134, 23298, 2, 7310, 9386, 12, 2, 9386, 32, 2535, 440, 22, 2532, 1696, 163, 12, 16, 3, 96, 186, 2, 571, 267, 1, 62, 3, 2532, 1696, 163, 9386, 32, 265, 2432, 3, 2532, 4899, 2, 32, 1969, 1373, 22, 361, 3022, 15, 3710, 2126, 3710, 9386, 32, 80, 186, 76, 3022, 9386, 26, 5825, 3026, 23, 3, 38, 284, 1, 7, 5, 12, 2, 9386, 3022, 2, 3710]",646.0,25099447,95
The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology.,Annals of surgical oncology,Ann. Surg. Oncol.,2014-12-18,"Intrahepatic cholangiocarcinoma (ICC) often is a diagnosis determined by exclusion. Distinguishing ICC from other metastatic adenocarcinomas based on histopathologic or immunohistochemical analysis often is difficult and requires an extensive workup. This study aimed to determine whether albumin, whose expression is restricted to the liver, has potential as a biomarker for ICC using a novel and highly sensitive RNA in situ hybridization (ISH) platform. Modified branched DNA probes were developed for albumin RNA ISH. The study evaluated 467 patient samples of primary and metastatic lesions. Of the 467 samples evaluated, 83 were ICCs, 42 were hepatocellular carcinomas (HCCs), and 332 were nonhepatic carcinomas including tumors arising from the perihilar region and bile duct, pancreas, stomach, esophagus, colon, breast, ovary, endometrium, kidney, and urinary bladder. Albumin RNA ISH was highly sensitive for cancers of liver origin, staining positive in 82 (99 %) of 83 ICCs and in 42 HCCs (100 %). Perihilar and distal bile duct carcinomas as well as carcinomas arising at other sites tested negative for albumin. Notably, 6 (22 %) of 27 intrahepatic tumors previously diagnosed as carcinomas of undetermined origin tested positive for albumin. Albumin RNA ISH is a sensitive and highly specific diagnostic tool for distinguishing ICC from metastatic adenocarcinoma to the liver or carcinoma of unknown origin. Albumin RNA ISH could replace the extensive diagnostic workup, leading to timely confirmation of the ICC diagnosis. Additionally, the assay could serve as a guide to distinguish ICC from perihilar adenocarcinoma.",Journal Article,1860.0,31.0,Intrahepatic cholangiocarcinoma ICC often is a diagnosis determined by exclusion Distinguishing ICC from other metastatic adenocarcinomas based on histopathologic or immunohistochemical analysis often is difficult and requires an extensive workup This study aimed to determine whether albumin whose expression is restricted to the has potential as a biomarker for ICC using a novel and highly sensitive RNA in situ hybridization ISH platform Modified branched DNA probes were developed for albumin RNA ISH The study evaluated 467 patient samples of primary and metastatic lesions Of the 467 samples evaluated 83 were ICCs 42 were carcinomas HCCs and 332 were nonhepatic carcinomas including tumors arising from the perihilar region and duct ovary and urinary Albumin RNA ISH was highly sensitive for cancers of origin staining positive in 82 99 of 83 ICCs and in 42 HCCs 100 Perihilar and distal duct carcinomas as well as carcinomas arising at other sites tested negative for albumin Notably 6 22 of 27 intrahepatic tumors previously diagnosed as carcinomas of undetermined origin tested positive for albumin Albumin RNA ISH is a sensitive and highly specific diagnostic tool for distinguishing ICC from metastatic adenocarcinoma to the or carcinoma of unknown origin Albumin RNA ISH could replace the extensive diagnostic workup leading to timely confirmation of the ICC diagnosis Additionally the assay could serve as a guide to distinguish ICC from perihilar adenocarcinoma,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,"[3022, 2126, 2259, 629, 16, 8, 147, 509, 20, 4721, 4508, 2259, 29, 127, 113, 1586, 90, 23, 2630, 15, 1382, 65, 629, 16, 1740, 2, 1706, 35, 1344, 4755, 26, 45, 1295, 6, 223, 317, 2799, 1310, 55, 16, 2016, 6, 3, 71, 174, 22, 8, 901, 9, 2259, 75, 8, 229, 2, 561, 745, 893, 4, 957, 1554, 6321, 2243, 1230, 14088, 261, 3701, 11, 276, 9, 2799, 893, 6321, 3, 45, 194, 10993, 69, 347, 1, 86, 2, 113, 406, 1, 3, 10993, 347, 194, 852, 11, 17417, 595, 11, 826, 6400, 2, 10651, 11, 40936, 826, 141, 57, 2635, 29, 3, 9124, 1053, 2, 2920, 3631, 2, 1660, 2799, 893, 6321, 10, 561, 745, 9, 163, 1, 1938, 1029, 109, 4, 878, 1058, 1, 852, 17417, 2, 4, 595, 6400, 394, 9124, 2, 2107, 2920, 826, 22, 149, 22, 826, 2635, 28, 127, 633, 650, 199, 9, 2799, 2552, 49, 350, 1, 428, 3022, 57, 373, 265, 22, 826, 1, 5206, 1938, 650, 109, 9, 2799, 2799, 893, 6321, 16, 8, 745, 2, 561, 112, 752, 1515, 9, 4508, 2259, 29, 113, 449, 6, 3, 15, 134, 1, 860, 1938, 2799, 893, 6321, 359, 7195, 3, 1344, 752, 4755, 1049, 6, 4225, 3551, 1, 3, 2259, 147, 1724, 3, 719, 359, 1833, 22, 8, 1597, 6, 3081, 2259, 29, 9124, 449]",1477.0,25519926,57
IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism.,"Hepatology (Baltimore, Md.)",Hepatology,2015-03-20,"Cholangiocarcinoma (CCA) is a lethal hepatobiliary neoplasm originating from the biliary apparatus. In humans, CCA risk factors include hepatobiliary inflammation and fibrosis. The recently identified interleukin (IL)-1 family member, IL-33, has been shown to be a biliary mitogen which also promotes liver inflammation and fibrosis. Our aim was to generate a mouse model of CCA mimicking the human disease. Ectopic oncogene expression in the biliary tract was accomplished by the Sleeping Beauty transposon transfection system with transduction of constitutively active AKT (myr-AKT) and Yes-associated protein. Intrabiliary instillation of the transposon-transposase complex was coupled with lobar bile duct ligation in C57BL/6 mice, followed by administration of IL-33 for 3 consecutive days. Tumors developed in 72% of the male mice receiving both oncogenes plus IL-33 by 10 weeks but in only 20% of the male mice transduced with the oncogenes alone. Tumors expressed SOX9 and pancytokeratin (features of CCA) but were negative for HepPar1 (a marker of hepatocellular carcinoma). Substantive overlap with human CCA specimens was revealed by RNA profiling. Not only did IL-33 induce IL-6 expression by human cholangiocytes but it likely facilitated tumor development in vivo by an IL-6-sensitive process as tumor development was significantly attenuated in Il-6(-/-) male animals. Furthermore, tumor formation occurred at a similar rate when IL-6 was substituted for IL-33 in this model. The transposase-mediated transduction of constitutively active AKT and Yes-associated protein in the biliary epithelium coupled with lobar obstruction and IL-33 administration results in the development of CCA with morphological and biochemical features of the human disease; this model highlights the role of inflammatory cytokines in CCA oncogenesis.",Journal Article,1768.0,62.0,Cholangiocarcinoma CCA is a lethal hepatobiliary neoplasm originating from the biliary apparatus In humans CCA risk factors include hepatobiliary inflammation and fibrosis The recently identified interleukin IL -1 family member IL-33 has been shown to be a biliary mitogen which also promotes inflammation and fibrosis Our aim was to generate a mouse model of CCA mimicking the human disease Ectopic oncogene expression in the biliary tract was accomplished by the Sleeping Beauty transposon transfection system with transduction of constitutively active AKT myr-AKT and Yes-associated protein Intrabiliary instillation of the transposon-transposase complex was coupled with lobar duct ligation in C57BL/6 mice followed by administration of IL-33 for 3 consecutive days Tumors developed in 72 of the male mice receiving both oncogenes plus IL-33 by 10 weeks but in only 20 of the male mice transduced with the oncogenes alone Tumors expressed SOX9 and pancytokeratin features of CCA but were negative for HepPar1 a marker of carcinoma Substantive overlap with human CCA specimens was revealed by RNA profiling Not only did IL-33 induce IL-6 expression by human cholangiocytes but it likely facilitated tumor development in vivo by an IL-6-sensitive process as tumor development was significantly attenuated in Il-6 -/- male animals Furthermore tumor formation occurred at a similar rate when IL-6 was substituted for IL-33 in this model The transposase-mediated transduction of constitutively active AKT and Yes-associated protein in the biliary epithelium coupled with lobar obstruction and IL-33 administration results in the development of CCA with morphological and biochemical features of the human disease this model highlights the role of inflammatory cytokines in CCA oncogenesis,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2126, 4317, 16, 8, 2266, 4718, 2131, 6794, 29, 3, 2532, 10180, 4, 3218, 4317, 43, 130, 643, 4718, 1815, 2, 3000, 3, 761, 108, 1603, 501, 14, 607, 2693, 501, 466, 71, 85, 443, 6, 40, 8, 2532, 2625, 92, 120, 2148, 1815, 2, 3000, 114, 1130, 10, 6, 2562, 8, 830, 202, 1, 4317, 8191, 3, 171, 34, 3647, 1836, 55, 4, 3, 2532, 1696, 10, 5741, 20, 3, 13358, 16570, 14042, 3789, 398, 5, 2761, 1, 2818, 544, 649, 34624, 649, 2, 7073, 41, 178, 47950, 13561, 1, 3, 14042, 18066, 840, 10, 3332, 5, 9919, 2920, 5307, 4, 7049, 49, 399, 370, 20, 634, 1, 501, 466, 9, 27, 935, 162, 57, 276, 4, 720, 1, 3, 1045, 399, 357, 110, 3326, 349, 501, 466, 20, 79, 244, 84, 4, 158, 179, 1, 3, 1045, 399, 5042, 5, 3, 3326, 279, 57, 570, 8428, 2, 23508, 404, 1, 4317, 84, 11, 199, 9, 34900, 8, 952, 1, 134, 14940, 4526, 5, 171, 4317, 623, 10, 553, 20, 893, 1080, 44, 158, 205, 501, 466, 1290, 501, 49, 55, 20, 171, 24166, 84, 192, 322, 4667, 30, 193, 4, 386, 20, 35, 501, 49, 745, 1129, 22, 30, 193, 10, 97, 2656, 4, 501, 49, 1045, 2258, 798, 30, 1264, 489, 28, 8, 288, 116, 198, 501, 49, 10, 10536, 9, 501, 466, 4, 26, 202, 3, 18066, 517, 2761, 1, 2818, 544, 649, 2, 7073, 41, 178, 4, 3, 2532, 2781, 3332, 5, 9919, 3191, 2, 501, 466, 634, 99, 4, 3, 193, 1, 4317, 5, 4268, 2, 1487, 404, 1, 3, 171, 34, 26, 202, 2527, 3, 200, 1, 1291, 1886, 4, 4317, 4503]",1787.0,25580681,1
Intraductal papillary mucinous neoplasm of the liver: GI image.,Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,J. Gastrointest. Surg.,2015-01-24,"Intraductal papillary mucinous neoplasms (IPMNs) are rare, mucin-producing, predominantly noninvasive tumors arising from epithelial cells. Most IPMNs arise from the pancreas. There exists a subset of IPMN of the biliary tract (BT-IPMN). IPMNs regardless of origin produce large amounts of mucin relative to scant amounts of epithelial cells, leading to mass effect disturbances in bile flow. Affected bile ducts exhibit marked dilatation. The majority of IPMN patients present with a non-malignant neoplasm. Because of potential for transformation, surgery is the treatment of choice. Bronchobiliary fistulas can present as congenital defects, following thoracoabodominal trauma, or as rare complications of diseases of the biliary tract such as BT-IPMN. There are no reported cases in the literature of bronchobiliary fistula associated with BT-IPMN, but there is a clear theoretical risk. ",Case Reports,1823.0,3.0,Intraductal papillary mucinous neoplasms IPMNs are rare mucin-producing predominantly noninvasive tumors arising from epithelial cells Most IPMNs arise from the There exists a subset of IPMN of the biliary tract BT-IPMN IPMNs regardless of origin produce large amounts of mucin relative to scant amounts of epithelial cells leading to mass effect disturbances in flow Affected ducts exhibit marked dilatation The majority of IPMN patients present with a non-malignant neoplasm Because of potential for transformation surgery is the treatment of choice Bronchobiliary fistulas can present as congenital defects following thoracoabodominal trauma or as rare complications of diseases of the biliary tract such as BT-IPMN There are no reported cases in the literature of bronchobiliary fistula associated with BT-IPMN but there is a clear theoretical risk,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4851, 1796, 2391, 1179, 5884, 32, 622, 5258, 3787, 2117, 2957, 57, 2635, 29, 701, 37, 96, 5884, 3043, 29, 3, 125, 2481, 8, 697, 1, 4398, 1, 3, 2532, 1696, 3641, 4398, 5884, 1583, 1, 1938, 2410, 375, 4939, 1, 5258, 580, 6, 11578, 4939, 1, 701, 37, 1049, 6, 782, 254, 6741, 4, 1412, 1424, 7310, 2239, 2003, 12799, 3, 686, 1, 4398, 7, 364, 5, 8, 220, 393, 2131, 408, 1, 174, 9, 1392, 152, 16, 3, 24, 1, 1866, 48813, 13244, 122, 364, 22, 6711, 2945, 366, 65536, 11147, 15, 22, 622, 521, 1, 1342, 1, 3, 2532, 1696, 225, 22, 3641, 4398, 125, 32, 77, 210, 140, 4, 3, 789, 1, 48813, 4920, 41, 5, 3641, 4398, 84, 125, 16, 8, 885, 7060, 43]",852.0,25617079,112
Analysis of free-form radiology dictations for completeness and clarity for pancreatic cancer staging.,Abdominal imaging,Abdom Imaging,2015-10-01,"To assess the completeness and clarity of current free-form radiology reports for pancreatic cancer staging by evaluating them against the elements of the RSNA CT oncology primary pancreas mass dictation template. This retrospective study was approved by our Institutional Review Board (IRB). 295 free-form computed tomography (CT) reports for baseline staging of pancreatic cancer (PC) generated between August 2008 and December 2010 were evaluated by one of two radiologists with expertise in pancreatic cancer imaging. Reports which indicated that metastatic disease was present were excluded. The completeness and clarity of the reports were analyzed against the elements of the RSNA CT pancreas mass dictation template. Fisher's exact tests were used to analyze differences by year and type of radiologist. Primary lesion location, size, and effect on bile duct (BD) were provided in 93.9% (277/295), 69.8% (206/295), and 67.5% (199/295) of reports, respectively. Standard terms to describe vascular involvement were used in 47.5% (140/295) of reports. In 20.3% (60/295), the resectability status could not be defined based on the report alone. In 36.9% (109/295) of reports, review of CT images was necessary to understand vascular involvement. Radiologists expert in pancreatic oncology had a higher proportion of reports using standardized terminology and reports in which vascular involvement was understood without revisiting the images. Free-form reports were more likely to use ambiguous terminology and/or require review of the actual images for understanding resectability status. The use of a standardized reporting template may improve the usefulness of pancreatic cancer staging reports.",Journal Article,1573.0,26.0,To assess the completeness and clarity of current free-form radiology reports for cancer staging by evaluating them against the elements of the RSNA CT oncology primary mass dictation template This retrospective study was approved by our Institutional Review Board IRB 295 free-form computed tomography CT reports for baseline staging of cancer PC generated between August 2008 and December 2010 were evaluated by one of two radiologists with expertise in cancer imaging Reports which indicated that metastatic disease was present were excluded The completeness and clarity of the reports were analyzed against the elements of the RSNA CT mass dictation template Fisher 's exact tests were used to analyze differences by year and type of radiologist Primary lesion location size and effect on duct BD were provided in 93.9 277/295 69.8 206/295 and 67.5 199/295 of reports respectively Standard terms to describe vascular involvement were used in 47.5 140/295 of reports In 20.3 60/295 the resectability status could not be defined based on the report alone In 36.9 109/295 of reports review of CT images was necessary to understand vascular involvement Radiologists expert in oncology had a higher proportion of reports using standardized terminology and reports in which vascular involvement was understood without revisiting the images Free-form reports were more likely to use ambiguous terminology and/or require review of the actual images for understanding resectability status The use of a standardized reporting template may improve the usefulness of cancer staging reports,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 423, 3, 7507, 2, 12901, 1, 291, 115, 1297, 4003, 1198, 9, 12, 632, 20, 1435, 1370, 480, 3, 2531, 1, 3, 15426, 425, 413, 86, 782, 32429, 5932, 26, 459, 45, 10, 850, 20, 114, 1115, 206, 2620, 5880, 7051, 115, 1297, 1220, 872, 425, 1198, 9, 330, 632, 1, 12, 1341, 1419, 59, 2480, 1375, 2, 1397, 1120, 11, 194, 20, 104, 1, 100, 3915, 5, 4935, 4, 12, 270, 1198, 92, 1103, 17, 113, 34, 10, 364, 11, 1800, 3, 7507, 2, 12901, 1, 3, 1198, 11, 311, 480, 3, 2531, 1, 3, 15426, 425, 782, 32429, 5932, 3135, 292, 2472, 895, 11, 95, 6, 1992, 362, 20, 111, 2, 267, 1, 6247, 86, 1180, 1147, 444, 2, 254, 23, 2920, 7942, 11, 1052, 4, 966, 83, 7996, 7051, 790, 66, 5956, 7051, 2, 598, 33, 5840, 7051, 1, 1198, 106, 260, 1794, 6, 897, 756, 799, 11, 95, 4, 662, 33, 3304, 7051, 1, 1198, 4, 179, 27, 335, 7051, 3, 5150, 156, 359, 44, 40, 395, 90, 23, 3, 414, 279, 4, 511, 83, 3486, 7051, 1, 1198, 206, 1, 425, 1572, 10, 1493, 6, 1640, 756, 799, 3915, 2005, 4, 413, 42, 8, 142, 920, 1, 1198, 75, 1670, 3462, 2, 1198, 4, 92, 756, 799, 10, 1784, 187, 34588, 3, 1572, 115, 1297, 1198, 11, 80, 322, 6, 119, 11286, 3462, 2, 15, 1353, 206, 1, 3, 3480, 1572, 9, 612, 5150, 156, 3, 119, 1, 8, 1670, 1760, 5932, 68, 401, 3, 5235, 1, 12, 632, 1198]",1581.0,25906341,58
Biliary tract cancers: understudied and poorly understood.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-04-27,"Biliary tract cancers are a heterogeneous group of cancers that arise in either the intra- or extrahepatic bile ducts or the gallbladder. Local therapy with surgical resection and perhaps radiation therapy is used for localized disease. There is no known effective adjuvant therapy, although various combinations have been used clinically without definitive data showing a benefit. The most standard chemotherapy for metastatic disease is gemcitabine plus cisplatin based on a single positive randomized trial. Genetic mutations that may lead to better, targeted therapy choices are being identified, albeit with variable frequency. Early studies of targeted agents have been negative, but these were in unselected patients where it was unknown whether the target was activated in any individual patient. Careful selection of patients enrolling onto trials of targeted agents will make the subsets of biliary tract cancers even smaller but is likely necessary to improve outcomes from these deadly diseases. ",Journal Article,1730.0,43.0,Biliary tract cancers are a heterogeneous group of cancers that arise in either the intra- or extrahepatic ducts or the Local therapy with surgical resection and perhaps radiation therapy is used for localized disease There is no known effective adjuvant therapy although various combinations have been used clinically without definitive data showing a benefit The most standard chemotherapy for metastatic disease is gemcitabine plus cisplatin based on a single positive randomized trial Genetic mutations that may lead to better targeted therapy choices are being identified albeit with variable frequency Early studies of targeted agents have been negative but these were in unselected patients where it was unknown whether the target was activated in any individual patient Careful selection of patients enrolling onto trials of targeted agents will make the subsets of biliary tract cancers even smaller but is likely necessary to improve outcomes from these deadly diseases,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2532, 1696, 163, 32, 8, 1564, 87, 1, 163, 17, 3043, 4, 361, 3, 2392, 15, 3710, 7310, 15, 3, 293, 36, 5, 221, 170, 2, 4434, 121, 36, 16, 95, 9, 909, 34, 125, 16, 77, 440, 323, 249, 36, 242, 747, 1247, 47, 85, 95, 505, 187, 1057, 74, 2069, 8, 247, 3, 96, 260, 56, 9, 113, 34, 16, 679, 349, 540, 90, 23, 8, 226, 109, 384, 160, 336, 138, 17, 68, 1122, 6, 380, 238, 36, 5218, 32, 486, 108, 5993, 5, 1347, 675, 191, 94, 1, 238, 183, 47, 85, 199, 84, 46, 11, 4, 3594, 7, 1257, 192, 10, 860, 317, 3, 283, 10, 735, 4, 500, 797, 69, 3465, 881, 1, 7, 6280, 3301, 143, 1, 238, 183, 303, 2378, 3, 1890, 1, 2532, 1696, 163, 871, 2170, 84, 16, 322, 1493, 6, 401, 123, 29, 46, 6610, 1342]",979.0,25918294,79
Presentation and Clinical Outcomes of Choledochal Cysts in Children and Adults: A Multi-institutional Analysis.,JAMA surgery,JAMA Surg,2015-06-01,"Choledochal cysts (CCs) are rare, with risk of infection and cancer. To characterize the natural history, management, and long-term implications of CC disease. A total of 394 patients who underwent resection of a CC between January 1, 1972, and April 11, 2014, were identified from an international multi-institutional database. Patients were followed up through September 27, 2014. Clinicopathologic characteristics, operative details, and outcome data were analyzed from May 1, 2014, to October 14, 2014. Resection of CC. Management, morbidity, and overall survival. Among 394 patients, there were 135 children (34.3%) and 318 women (80.7%). Adults were more likely to present with abdominal pain (71.8% vs 40.7%; P<.001) and children were more likely to have jaundice (31.9% vs 11.6%; P<.001). Preoperative interventions were more commonly performed in adults (64.5% vs 31.1%; P<.001), including endoscopic retrograde pancreatography (55.6% vs 27.4%; P<.001), percutaneous transhepatic cholangiography (17.4% vs 5.9%; P<.001), and endobiliary stenting (18.1% vs 4.4%; P<.001)). Type I CCs were more often seen in children vs adults (79.7% vs 64.9%; P=.003); type IV CCs predominated in the adult population (23.9% vs 12.0%; P=.006). Extrahepatic bile duct resection with hepaticoenterostomy was the most frequently performed procedure in both age groups (80.3%). Perioperative morbidity was higher in adults (35.1% vs 16.3%; P<.001). On pathologic examination, 10 patients (2.5%) had cholangiocarcinoma. After a median follow-up of 28 months, 5-year overall survival was 95.5%. On follow-up, 13 patients (3.3%), presented with biliary cancer. Presentation of CC varied between children and adults, and resection was associated with a degree of morbidity. Although concomitant cancer was uncommon, it occurred in 3.0% of the patients. Long-term surveillance is indicated given the possibility of future development of biliary cancer after CC resection.",Journal Article,1695.0,34.0,Choledochal cysts CCs are rare with risk of infection and cancer To characterize the natural history management and long-term implications of CC disease A total of 394 patients who underwent resection of a CC between January 1 1972 and April 11 2014 were identified from an international multi-institutional database Patients were followed up through September 27 2014 Clinicopathologic characteristics operative details and outcome data were analyzed from May 1 2014 to October 14 2014 Resection of CC Management morbidity and overall survival Among 394 patients there were 135 children 34.3 and 318 women 80.7 Adults were more likely to present with abdominal pain 71.8 vs 40.7 P .001 and children were more likely to have jaundice 31.9 vs 11.6 P .001 Preoperative interventions were more commonly performed in adults 64.5 vs 31.1 P .001 including endoscopic retrograde pancreatography 55.6 vs 27.4 P .001 percutaneous transhepatic cholangiography 17.4 vs 5.9 P .001 and endobiliary stenting 18.1 vs 4.4 P .001 Type I CCs were more often seen in children vs adults 79.7 vs 64.9 P .003 type IV CCs predominated in the adult population 23.9 vs 12.0 P .006 Extrahepatic duct resection with hepaticoenterostomy was the most frequently performed procedure in both age groups 80.3 Perioperative morbidity was higher in adults 35.1 vs 16.3 P .001 On pathologic examination 10 patients 2.5 had cholangiocarcinoma After a median follow-up of 28 months 5-year overall survival was 95.5 On follow-up 13 patients 3.3 presented with biliary cancer Presentation of CC varied between children and adults and resection was associated with a degree of morbidity Although concomitant cancer was uncommon it occurred in 3.0 of the patients Long-term surveillance is indicated given the possibility of future development of biliary cancer after CC resection,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[14001, 4395, 5688, 32, 622, 5, 43, 1, 930, 2, 12, 6, 1507, 3, 1504, 532, 284, 2, 319, 337, 1268, 1, 1951, 34, 8, 181, 1, 9273, 7, 54, 208, 170, 1, 8, 1951, 59, 1024, 14, 14451, 2, 2292, 175, 1409, 11, 108, 29, 35, 944, 1414, 1115, 609, 7, 11, 370, 126, 298, 2636, 428, 1409, 1399, 374, 1208, 3791, 2, 228, 74, 11, 311, 29, 68, 14, 1409, 6, 2551, 213, 1409, 170, 1, 1951, 284, 787, 2, 63, 25, 107, 9273, 7, 125, 11, 3978, 541, 562, 27, 2, 8797, 117, 493, 67, 857, 11, 80, 322, 6, 364, 5, 1467, 559, 792, 66, 105, 327, 67, 19, 144, 2, 541, 11, 80, 322, 6, 47, 7655, 456, 83, 105, 175, 49, 19, 144, 498, 1151, 11, 80, 841, 173, 4, 857, 660, 33, 105, 456, 14, 19, 144, 141, 2056, 10583, 66050, 614, 49, 105, 428, 39, 19, 144, 3720, 18865, 21954, 269, 39, 105, 33, 83, 19, 144, 2, 47686, 17911, 203, 14, 105, 39, 39, 19, 144, 267, 70, 5688, 11, 80, 629, 527, 4, 541, 105, 857, 842, 67, 105, 660, 83, 19, 1421, 267, 478, 5688, 16244, 4, 3, 780, 266, 382, 83, 105, 133, 13, 19, 1861, 3710, 2920, 170, 5, 66051, 10, 3, 96, 746, 173, 1299, 4, 110, 89, 271, 493, 27, 1547, 787, 10, 142, 4, 857, 465, 14, 105, 245, 27, 19, 144, 23, 510, 1385, 79, 7, 18, 33, 42, 2126, 50, 8, 52, 166, 126, 1, 339, 53, 33, 111, 63, 25, 10, 48, 33, 23, 166, 126, 233, 7, 27, 27, 917, 5, 2532, 12, 1031, 1, 1951, 2051, 59, 541, 2, 857, 2, 170, 10, 41, 5, 8, 1444, 1, 787, 242, 1781, 12, 10, 2052, 192, 489, 4, 27, 13, 1, 3, 7, 319, 337, 617, 16, 1103, 447, 3, 2526, 1, 508, 193, 1, 2532, 12, 50, 1951, 170]",1839.0,25923827,91
Gallbladder cancer: expert consensus statement.,HPB : the official journal of the International Hepato Pancreato Biliary Association,HPB (Oxford),2015-08-01,"An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists was convened on 15 January 2014 to review current evidence on the management of gallbladder carcinoma in order to establish practice guidelines. In summary, within high incidence areas, the assessment of routine gallbladder specimens should include the microscopic evaluation of a minimum of three sections and the cystic duct margin; specimens with dysplasia or proven cancer should be extensively sampled. Provided the patient is medically fit for surgery, data support the resection of all gallbladder polyps of >1.0cm in diameter and those with imaging evidence of vascular stalks. The minimum staging evaluation of patients with suspected or proven gallbladder cancer includes contrasted cross-sectional imaging and diagnostic laparoscopy. Adequate lymphadenectomy includes assessment of any suspicious regional nodes, evaluation of the aortocaval nodal basin, and a goal recovery of at least six nodes. Patients with confirmed metastases to N2 nodal stations do not benefit from radical resection and should receive systemic and/or palliative treatments. Primary resection of patients with early T-stage (T1b-2) disease should include en bloc resection of adjacent liver parenchyma. Patients with T1b, T2 or T3 disease that is incidentally identified in a cholecystectomy specimen should undergo re-resection unless this is contraindicated by advanced disease or poor performance status. Re-resection should include complete portal lymphadenectomy and bile duct resection only when needed to achieve a negative margin (R0) resection. Patients with preoperatively staged T3 or T4 N1 disease should be considered for clinical trials of neoadjuvant chemotherapy. Following R0 resection of T2-4 disease in N1 gallbladder cancer, patients should be considered for adjuvant systemic chemotherapy and/or chemoradiotherapy. ",Journal Article,1634.0,110.0,An American Hepato-Pancreato-Biliary Association AHPBA -sponsored consensus meeting of expert panellists was convened on 15 January 2014 to review current evidence on the management of carcinoma in order to establish practice guidelines In summary within high incidence areas the assessment of routine specimens should include the microscopic evaluation of a minimum of three sections and the cystic duct margin specimens with dysplasia or proven cancer should be extensively sampled Provided the patient is medically fit for surgery data support the resection of all polyps of 1.0 cm in diameter and those with imaging evidence of vascular stalks The minimum staging evaluation of patients with suspected or proven cancer includes contrasted cross-sectional imaging and diagnostic laparoscopy Adequate lymphadenectomy includes assessment of any suspicious regional nodes evaluation of the aortocaval nodal basin and a goal recovery of at least six nodes Patients with confirmed metastases to N2 nodal stations do not benefit from radical resection and should receive systemic and/or palliative treatments Primary resection of patients with early T-stage T1b-2 disease should include en bloc resection of adjacent parenchyma Patients with T1b T2 or T3 disease that is incidentally identified in a cholecystectomy specimen should undergo re-resection unless this is contraindicated by advanced disease or poor performance status Re-resection should include complete portal lymphadenectomy and duct resection only when needed to achieve a negative margin R0 resection Patients with preoperatively staged T3 or T4 N1 disease should be considered for clinical trials of neoadjuvant chemotherapy Following R0 resection of T2-4 disease in N1 cancer patients should be considered for adjuvant systemic chemotherapy and/or chemoradiotherapy,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[35, 597, 17970, 25456, 2532, 248, 41148, 5537, 1391, 2238, 1, 2005, 25590, 10, 4440, 23, 167, 1024, 1409, 6, 206, 291, 241, 23, 3, 284, 1, 134, 4, 1732, 6, 1811, 758, 677, 4, 1962, 262, 64, 287, 1361, 3, 455, 1, 1311, 623, 257, 643, 3, 2984, 451, 1, 8, 2499, 1, 169, 3013, 2, 3, 2965, 2920, 959, 623, 5, 2253, 15, 1930, 12, 257, 40, 3576, 5919, 1052, 3, 69, 16, 4381, 2975, 9, 152, 74, 538, 3, 170, 1, 62, 3742, 1, 14, 13, 494, 4, 2549, 2, 135, 5, 270, 241, 1, 756, 66457, 3, 2499, 632, 451, 1, 7, 5, 2768, 15, 1930, 12, 1920, 13257, 1383, 2832, 270, 2, 752, 3553, 1658, 2048, 1920, 455, 1, 500, 3230, 951, 502, 451, 1, 3, 17414, 779, 6969, 2, 8, 1326, 1602, 1, 28, 506, 437, 502, 7, 5, 557, 196, 6, 3473, 779, 9105, 1022, 44, 247, 29, 711, 170, 2, 257, 560, 403, 2, 15, 994, 640, 86, 170, 1, 7, 5, 191, 102, 82, 6142, 18, 34, 257, 643, 4375, 5590, 170, 1, 2086, 5388, 7, 5, 6142, 1786, 15, 2065, 34, 17, 16, 5925, 108, 4, 8, 8493, 2360, 257, 1251, 1491, 170, 6179, 26, 16, 11387, 20, 131, 34, 15, 334, 528, 156, 1491, 170, 257, 643, 236, 3307, 2048, 2, 2920, 170, 158, 198, 575, 6, 1359, 8, 199, 959, 2328, 170, 7, 5, 3888, 2930, 2065, 15, 2463, 3192, 34, 257, 40, 515, 9, 38, 143, 1, 536, 56, 366, 2328, 170, 1, 1786, 39, 34, 4, 3192, 12, 7, 257, 40, 515, 9, 249, 403, 56, 2, 15, 1464]",1832.0,26172135,51
Hilar cholangiocarcinoma: expert consensus statement.,HPB : the official journal of the International Hepato Pancreato Biliary Association,HPB (Oxford),2015-08-01,"An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of hilar cholangiocarcinoma in order to establish practice guidelines and to agree consensus statements. It was established that the treatment of patients with hilar cholangiocarcinoma requires a coordinated, multidisciplinary approach to optimize the chances for both durable survival and effective palliation. An adequate diagnostic and staging work-up includes high-quality cross-sectional imaging; however, pathologic confirmation is not required prior to resection or initiation of a liver transplant trimodal treatment protocol. The ideal treatment for suitable patients with resectable hilar malignancy is resection of the intra- and extrahepatic bile ducts, as well as resection of the involved ipsilateral liver. Preoperative biliary drainage is best achieved with percutaneous transhepatic approaches and may be indicated for patients with cholangitis, malnutrition or hepatic insufficiency. Portal vein embolization is a safe and effective strategy for increasing the future liver remnant (FLR) and is particularly useful for patients with an FLR of <30%. Selected patients with unresectable hilar cholangiocarcinoma should be evaluated for a standard trimodal protocol incorporating external beam and endoluminal radiation therapy, systemic chemotherapy and liver transplantation. Post-resection chemoradiation should be offered to patients who show high-risk features on surgical pathology. Chemoradiation is also recommended for patients with locally advanced, unresectable hilar cancers. For patients with locally recurrent or metastatic hilar cholangiocarcinoma, first-line chemotherapy with gemcitabine and cisplatin is recommended based on multiple Phase II trials and a large randomized controlled trial including a heterogeneous population of patients with biliary cancers. ",Journal Article,1634.0,93.0,An American Hepato-Pancreato-Biliary Association AHPBA -sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of hilar cholangiocarcinoma in order to establish practice guidelines and to agree consensus statements It was established that the treatment of patients with hilar cholangiocarcinoma requires a coordinated multidisciplinary approach to optimize the chances for both durable survival and effective palliation An adequate diagnostic and staging work-up includes high-quality cross-sectional imaging however pathologic confirmation is not required prior to resection or initiation of a transplant trimodal treatment protocol The ideal treatment for suitable patients with resectable hilar malignancy is resection of the intra- and extrahepatic ducts as well as resection of the involved ipsilateral Preoperative biliary drainage is best achieved with percutaneous transhepatic approaches and may be indicated for patients with cholangitis malnutrition or hepatic insufficiency Portal vein embolization is a safe and effective strategy for increasing the future remnant FLR and is particularly useful for patients with an FLR of 30 Selected patients with unresectable hilar cholangiocarcinoma should be evaluated for a standard trimodal protocol incorporating external beam and endoluminal radiation therapy systemic chemotherapy and transplantation Post-resection chemoradiation should be offered to patients who show high-risk features on surgical pathology Chemoradiation is also recommended for patients with locally advanced unresectable hilar cancers For patients with locally recurrent or metastatic hilar cholangiocarcinoma first-line chemotherapy with gemcitabine and cisplatin is recommended based on multiple Phase II trials and a large randomized controlled trial including a heterogeneous population of patients with biliary cancers,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[35, 597, 17970, 25456, 2532, 248, 41148, 5537, 1391, 2238, 1, 2005, 25590, 543, 23, 167, 1024, 1409, 6, 206, 291, 241, 23, 3, 284, 1, 4793, 2126, 4, 1732, 6, 1811, 758, 677, 2, 6, 10473, 1391, 7072, 192, 10, 635, 17, 3, 24, 1, 7, 5, 4793, 2126, 1706, 8, 5725, 1643, 353, 6, 2465, 3, 10726, 9, 110, 1480, 25, 2, 323, 3695, 35, 1658, 752, 2, 632, 1357, 126, 1920, 64, 372, 1383, 2832, 270, 137, 510, 3551, 16, 44, 616, 324, 6, 170, 15, 1118, 1, 8, 941, 13990, 24, 1182, 3, 3662, 24, 9, 2884, 7, 5, 1899, 4793, 710, 16, 170, 1, 3, 2392, 2, 3710, 7310, 22, 149, 22, 170, 1, 3, 646, 2880, 498, 2532, 3528, 16, 824, 513, 5, 3720, 18865, 611, 2, 68, 40, 1103, 9, 7, 5, 8541, 12860, 15, 939, 4360, 3307, 2762, 4232, 16, 8, 1165, 2, 323, 692, 9, 602, 3, 508, 5644, 7660, 2, 16, 823, 999, 9, 7, 5, 35, 7660, 1, 201, 715, 7, 5, 1468, 4793, 2126, 257, 40, 194, 9, 8, 260, 13990, 1182, 2570, 1455, 1345, 2, 28915, 121, 36, 403, 56, 2, 497, 539, 170, 975, 257, 40, 2216, 6, 7, 54, 514, 64, 43, 404, 23, 221, 1117, 975, 16, 120, 793, 9, 7, 5, 795, 131, 1468, 4793, 163, 9, 7, 5, 795, 387, 15, 113, 4793, 2126, 157, 328, 56, 5, 679, 2, 540, 16, 793, 90, 23, 232, 124, 215, 143, 2, 8, 375, 384, 1149, 160, 141, 8, 1564, 266, 1, 7, 5, 2532, 163]",1915.0,26172136,37
Preoperative biliary drainage in perihilar cholangiocarcinoma: identifying patients who require percutaneous drainage after failed endoscopic drainage.,Endoscopy,Endoscopy,2015-09-18,"Preoperative biliary drainage is often initiated with endoscopic retrograde cholangiopancreatography (ERCP) in patients with potentially resectable perihilar cholangiocarcinoma (PHC), but additional percutaneous transhepatic catheter (PTC) drainage is frequently required. This study aimed to develop and validate a prediction model to identify patients with a high risk of inadequate ERCP drainage. Patients with potentially resectable PHC and (attempted) preoperative ERCP drainage were included from two specialty center cohorts between 2001 and 2013. Indications for additional PTC drainage were failure to place an endoscopic stent, failure to relieve jaundice, cholangitis, or insufficient drainage of the future liver remnant. A prediction model was derived from the European cohort and externally validated in the USA cohort. Of the 288 patients, 108 (38%) required additional preoperative PTC drainage after inadequate ERCP drainage. Independent risk factors for additional PTC drainage were proximal biliary obstruction on preoperative imaging (Bismuth 3 or 4) and predrainage total bilirubin level. The prediction model identified three subgroups: patients with low risk (7%), moderate risk (40%), and high risk (62%). The high-risk group consisted of patients with a total bilirubin level above 150 mol/L and Bismuth 3a or 4 tumors, who typically require preoperative drainage of the angulated left bile ducts. The prediction model had good discrimination (area under the curve 0.74) and adequate calibration in the external validation cohort. Selected patients with potentially resectable PHC have a high risk (62%) of inadequate preoperative ERCP drainage requiring additional PTC drainage. These patients might do better with initial PTC drainage instead of ERCP.",Journal Article,1586.0,15.0,Preoperative biliary drainage is often initiated with endoscopic retrograde cholangiopancreatography ERCP in patients with potentially resectable perihilar cholangiocarcinoma PHC but additional percutaneous transhepatic catheter PTC drainage is frequently required This study aimed to develop and validate a prediction model to identify patients with a high risk of inadequate ERCP drainage Patients with potentially resectable PHC and attempted preoperative ERCP drainage were included from two specialty center cohorts between 2001 and 2013 Indications for additional PTC drainage were failure to place an endoscopic stent failure to relieve jaundice cholangitis or insufficient drainage of the future remnant A prediction model was derived from the European cohort and externally validated in the USA cohort Of the 288 patients 108 38 required additional preoperative PTC drainage after inadequate ERCP drainage Independent risk factors for additional PTC drainage were proximal biliary obstruction on preoperative imaging Bismuth 3 or 4 and predrainage total bilirubin level The prediction model identified three subgroups patients with low risk 7 moderate risk 40 and high risk 62 The high-risk group consisted of patients with a total bilirubin level above 150 mol/L and Bismuth 3a or 4 tumors who typically require preoperative drainage of the angulated left ducts The prediction model had good discrimination area under the curve 0.74 and adequate calibration in the external validation cohort Selected patients with potentially resectable PHC have a high risk 62 of inadequate preoperative ERCP drainage requiring additional PTC drainage These patients might do better with initial PTC drainage instead of ERCP,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[498, 2532, 3528, 16, 629, 1917, 5, 2056, 10583, 15476, 12020, 4, 7, 5, 751, 1899, 9124, 2126, 9615, 84, 402, 3720, 18865, 3925, 3748, 3528, 16, 746, 616, 26, 45, 1295, 6, 690, 2, 2183, 8, 1590, 202, 6, 255, 7, 5, 8, 64, 43, 1, 3358, 12020, 3528, 7, 5, 751, 1899, 9615, 2, 4098, 498, 12020, 3528, 11, 159, 29, 100, 5852, 574, 736, 59, 1758, 2, 1346, 2406, 9, 402, 3748, 3528, 11, 496, 6, 3536, 35, 2056, 7601, 496, 6, 9635, 7655, 8541, 15, 3027, 3528, 1, 3, 508, 5644, 8, 1590, 202, 10, 526, 29, 3, 1865, 180, 2, 7753, 938, 4, 3, 2706, 180, 1, 3, 8603, 7, 3590, 519, 616, 402, 498, 3748, 3528, 50, 3358, 12020, 3528, 306, 43, 130, 9, 402, 3748, 3528, 11, 2805, 2532, 3191, 23, 498, 270, 22291, 27, 15, 39, 2, 66818, 181, 5009, 301, 3, 1590, 202, 108, 169, 1453, 7, 5, 154, 43, 67, 1163, 43, 327, 2, 64, 43, 744, 3, 64, 43, 87, 1695, 1, 7, 5, 8, 181, 5009, 301, 2090, 1577, 27474, 805, 2, 22291, 6981, 15, 39, 57, 54, 1969, 1353, 498, 3528, 1, 3, 66819, 1712, 7310, 3, 1590, 202, 42, 1178, 3520, 965, 669, 3, 1496, 13, 794, 2, 1658, 4821, 4, 3, 1455, 929, 180, 715, 7, 5, 751, 1899, 9615, 47, 8, 64, 43, 744, 1, 3358, 498, 12020, 3528, 1888, 402, 3748, 3528, 46, 7, 822, 1022, 380, 5, 388, 3748, 3528, 3496, 1, 12020]",1720.0,26382308,6
Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection.,Journal of the American College of Surgeons,J. Am. Coll. Surg.,2015-09-15,"The aim of this study was to investigate the rate and pattern of recurrence after curative intent resection of perihilar cholangiocarcinoma (PHC). Patients were included from 2 prospectively maintained databases. Recurrences were categorized by site. Time to recurrence and recurrence-free survival (RFS) were estimated using the Kaplan-Meier method. Cox proportional hazards modeling was used to identify independent poor prognostic factors. Between 1991 and 2012, 306 consecutive patients met inclusion criteria. Median overall survival was 40 months. A recurrence was diagnosed in 177 patients (58%). An initial local recurrence was found in 26% of patients: liver hilum (11%), hepaticojejunostomy (8%), liver resection margin (8%), or distal bile duct remnant (2%). An initial distant recurrence was observed in 40% of patients: retroperitoneal lymph nodes (14%), intrahepatic away from the resection margin (13%), peritoneum (12%), and lungs (8%). Only 18% of patients had an isolated initial local recurrence. The estimated overall recurrence rate was 76% at 8 years. After a recurrence-free period of 5 years, 28% of patients developed a recurrence in the next 3 years. Median RFS was 26 months. Independent prognostic factors for RFS were resection margin, lymph node status, and tumor differentiation. Only node-positive PHC precluded RFS beyond 7 years. Perihilar cholangiocarcinoma will recur in most patients (76%) after resection, emphasizing the need for better adjuvant strategies. The high recurrence rate of up to 8 years justifies prolonged surveillance. Only patients with an isolated initial local recurrence (18%) may have benefited from a more extensive resection or liver transplantation. Node-positive PHC appears incurable.",Journal Article,1589.0,39.0,The aim of this study was to investigate the rate and pattern of recurrence after curative intent resection of perihilar cholangiocarcinoma PHC Patients were included from 2 prospectively maintained databases Recurrences were categorized by site Time to recurrence and recurrence-free survival RFS were estimated using the Kaplan-Meier method Cox proportional hazards modeling was used to identify independent poor prognostic factors Between 1991 and 2012 306 consecutive patients met inclusion criteria Median overall survival was 40 months A recurrence was diagnosed in 177 patients 58 An initial local recurrence was found in 26 of patients hilum 11 hepaticojejunostomy 8 resection margin 8 or distal duct remnant 2 An initial distant recurrence was observed in 40 of patients retroperitoneal lymph nodes 14 intrahepatic away from the resection margin 13 peritoneum 12 and lungs 8 Only 18 of patients had an isolated initial local recurrence The estimated overall recurrence rate was 76 at 8 years After a recurrence-free period of 5 years 28 of patients developed a recurrence in the next 3 years Median RFS was 26 months Independent prognostic factors for RFS were resection margin lymph node status and tumor differentiation Only node-positive PHC precluded RFS beyond 7 years Perihilar cholangiocarcinoma will recur in most patients 76 after resection emphasizing the need for better adjuvant strategies The high recurrence rate of up to 8 years justifies prolonged surveillance Only patients with an isolated initial local recurrence 18 may have benefited from a more extensive resection or transplantation Node-positive PHC appears incurable,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 963, 3, 116, 2, 1177, 1, 146, 50, 1075, 1697, 170, 1, 9124, 2126, 9615, 7, 11, 159, 29, 18, 1143, 1955, 2348, 1593, 11, 2320, 20, 606, 98, 6, 146, 2, 146, 115, 25, 1272, 11, 661, 75, 3, 876, 882, 596, 418, 831, 1017, 2057, 10, 95, 6, 255, 306, 334, 177, 130, 59, 3372, 2, 1195, 9974, 935, 7, 543, 1680, 371, 52, 63, 25, 10, 327, 53, 8, 146, 10, 265, 4, 4699, 7, 717, 35, 388, 293, 146, 10, 204, 4, 432, 1, 7, 17244, 175, 23202, 66, 170, 959, 66, 15, 2107, 2920, 5644, 18, 35, 388, 626, 146, 10, 164, 4, 327, 1, 7, 2591, 263, 502, 213, 3022, 6565, 29, 3, 170, 959, 233, 6699, 133, 2, 4465, 66, 158, 203, 1, 7, 42, 35, 1355, 388, 293, 146, 3, 661, 63, 146, 116, 10, 846, 28, 66, 60, 50, 8, 146, 115, 727, 1, 33, 60, 339, 1, 7, 276, 8, 146, 4, 3, 1305, 27, 60, 52, 1272, 10, 432, 53, 306, 177, 130, 9, 1272, 11, 170, 959, 263, 289, 156, 2, 30, 910, 158, 289, 109, 9615, 8035, 1272, 1654, 67, 60, 9124, 2126, 303, 5609, 4, 96, 7, 846, 50, 170, 6826, 3, 594, 9, 380, 249, 422, 3, 64, 146, 116, 1, 126, 6, 66, 60, 13299, 1069, 617, 158, 7, 5, 35, 1355, 388, 293, 146, 203, 68, 47, 7067, 29, 8, 80, 1344, 170, 15, 497, 289, 109, 9615, 1233, 2641]",1650.0,26454735,1
A multi-institutional analysis of 429 patients undergoing major hepatectomy for colorectal cancer liver metastases: The impact of concomitant bile duct resection on survival.,Journal of surgical oncology,J Surg Oncol,2015-09-10,"Data are lacking on long-term outcomes of patients undergoing major hepatectomy requiring bile duct resection (BDR) for the treatment of colorectal cancer liver metastases. Patients who underwent major hepatectomy (3 segments) for metastatic colorectal cancer from 2000-2010 at three US academic institutions were included. The primary outcome was disease-specific survival (DSS). Of 429 patients, nine (2.1%) underwent BDR, which was associated with pre-operative portal vein embolization (25.0% vs. 4.3%; P=0.049). There were no significant differences in age, ASA class, margin status, number of lesions, tumor size, cirrhosis, perineural invasion, or lymphovascular invasion. BDR was independently associated with increased postoperative major complications (OR: 6.22; 95%CI:1.44-26.97; P=0.015). There were no differences in length of stay, reoperation, readmission, or 30-day mortality. Patients who underwent BDR had markedly decreased DSS (9.3 vs. 39.9mo; P=0.002). When accounting for differences between the two groups, the need for BDR was independently associated with reduced DSS (HR: 3.06; 95%CI:1.12-8.34; P=0.029). Major hepatectomy with concomitant bile duct resection is seldom performed in patients undergoing resection of colorectal cancer liver metastases and is associated with higher major morbidity and reduced disease-specific survival compared to major hepatectomy alone. Stringent selection criteria should be applied when patients may need bile duct resection during hepatectomy for colorectal cancer liver metastases.",Journal Article,1594.0,2.0,Data are lacking on long-term outcomes of patients undergoing major hepatectomy requiring duct resection BDR for the treatment of cancer metastases Patients who underwent major hepatectomy 3 segments for metastatic cancer from 2000-2010 at three US academic institutions were included The primary outcome was disease-specific survival DSS Of 429 patients nine 2.1 underwent BDR which was associated with pre-operative portal vein embolization 25.0 vs. 4.3 P 0.049 There were no significant differences in age ASA class margin status number of lesions tumor size cirrhosis perineural invasion or lymphovascular invasion BDR was independently associated with increased postoperative major complications OR 6.22 95 CI:1.44-26.97 P 0.015 There were no differences in length of stay reoperation readmission or 30-day mortality Patients who underwent BDR had markedly decreased DSS 9.3 vs. 39.9 mo P 0.002 When accounting for differences between the two groups the need for BDR was independently associated with reduced DSS HR 3.06 95 CI:1.12-8.34 P 0.029 Major hepatectomy with concomitant duct resection is seldom performed in patients undergoing resection of cancer metastases and is associated with higher major morbidity and reduced disease-specific survival compared to major hepatectomy alone Stringent selection criteria should be applied when patients may need duct resection during hepatectomy for cancer metastases,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[74, 32, 1941, 23, 319, 337, 123, 1, 7, 479, 458, 2711, 1888, 2920, 170, 19880, 9, 3, 24, 1, 12, 196, 7, 54, 208, 458, 2711, 2608, 5138, 9, 113, 12, 29, 1081, 1120, 28, 169, 843, 1916, 1764, 11, 159, 3, 86, 228, 10, 34, 112, 25, 1788, 1, 8406, 7, 762, 18, 14, 208, 19880, 92, 10, 41, 5, 671, 1208, 3307, 2762, 4232, 243, 13, 105, 39, 27, 19, 13, 5121, 125, 11, 77, 93, 362, 4, 89, 6453, 1040, 959, 156, 207, 1, 406, 30, 444, 3563, 4917, 578, 15, 2933, 578, 19880, 10, 1042, 41, 5, 101, 573, 458, 521, 15, 49, 350, 48, 58, 14, 584, 432, 1015, 19, 13, 3433, 125, 11, 77, 362, 4, 1318, 1, 2020, 5077, 3146, 15, 201, 218, 282, 7, 54, 208, 19880, 42, 2195, 340, 1788, 83, 27, 105, 587, 83, 2035, 19, 13, 1111, 198, 3116, 9, 362, 59, 3, 100, 271, 3, 594, 9, 19880, 10, 1042, 41, 5, 405, 1788, 168, 27, 1460, 48, 58, 14, 133, 66, 562, 19, 13, 4770, 458, 2711, 5, 1781, 2920, 170, 16, 10805, 173, 4, 7, 479, 170, 1, 12, 196, 2, 16, 41, 5, 142, 458, 787, 2, 405, 34, 112, 25, 72, 6, 458, 2711, 279, 6763, 881, 371, 257, 40, 1498, 198, 7, 68, 594, 2920, 170, 190, 2711, 9, 12, 196]",1420.0,26496211,75
Fluorescence in situ hybridization compared with conventional cytology for the diagnosis of malignant biliary tract strictures in Asian patients.,Gastrointestinal endoscopy,Gastrointest. Endosc.,2015-12-10,"Fluorescence in situ hybridization (FISH) has improved the diagnostic performance of cytology for the evaluation of malignant biliary strictures in the United States and Europe. The utility of FISH for the diagnosis of biliary strictures in Asia is currently unknown. We aimed to compare the sensitivity of FISH and conventional cytology for the diagnosis of malignant biliary strictures in Thai patients. A prospective study was performed at 2 university hospitals between 2010 and 2013. Patients being evaluated for malignant-appearing biliary strictures were included (N= 99). Bile duct brushings were collected and assessed by cytology and FISH. Sensitivities with 95% confidence intervals of cytology and FISH were the main outcome measures. The overall sensitivities of cytology and FISH were 38% and 55%, respectively (P= .001). For those with a diagnosis of cancer based on clinical evidence without biopsy confirmation (n= 44), the sensitivities of cytology and FISH were 43% and 57%, respectively (P= .06). For the 49 patients for whom a cancer diagnosis was confirmed by pathology, FISH had a significantly higher sensitivity than cytology, with a sensitivity of 53% versus 33%, respectively (P= .008). FISH improves the diagnostic performance of cytology and can be used as a complementary toolto bile duct brushing and biopsy for the evaluation of malignancy in biliary strictures in Asian populations.",Comparative Study,1503.0,13.0,Fluorescence in situ hybridization FISH has improved the diagnostic performance of cytology for the evaluation of malignant biliary strictures in the United States and Europe The utility of FISH for the diagnosis of biliary strictures in Asia is currently unknown We aimed to compare the sensitivity of FISH and conventional cytology for the diagnosis of malignant biliary strictures in Thai patients A prospective study was performed at 2 university hospitals between 2010 and 2013 Patients being evaluated for malignant-appearing biliary strictures were included N 99 duct brushings were collected and assessed by cytology and FISH Sensitivities with 95 confidence intervals of cytology and FISH were the main outcome measures The overall sensitivities of cytology and FISH were 38 and 55 respectively P .001 For those with a diagnosis of cancer based on clinical evidence without biopsy confirmation n 44 the sensitivities of cytology and FISH were 43 and 57 respectively P .06 For the 49 patients for whom a cancer diagnosis was confirmed by pathology FISH had a significantly higher sensitivity than cytology with a sensitivity of 53 versus 33 respectively P .008 FISH improves the diagnostic performance of cytology and can be used as a complementary tool to duct brushing and biopsy for the evaluation of malignancy in biliary strictures in Asian populations,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1591, 4, 957, 1554, 1277, 71, 231, 3, 752, 528, 1, 2045, 9, 3, 451, 1, 393, 2532, 7860, 4, 3, 1088, 907, 2, 3934, 3, 1207, 1, 1277, 9, 3, 147, 1, 2532, 7860, 4, 5958, 16, 694, 860, 21, 1295, 6, 932, 3, 485, 1, 1277, 2, 809, 2045, 9, 3, 147, 1, 393, 2532, 7860, 4, 49468, 7, 8, 482, 45, 10, 173, 28, 18, 1652, 1987, 59, 1120, 2, 1346, 7, 486, 194, 9, 393, 6536, 2532, 7860, 11, 159, 78, 1058, 2920, 14515, 11, 786, 2, 275, 20, 2045, 2, 1277, 6202, 5, 48, 307, 1582, 1, 2045, 2, 1277, 11, 3, 1895, 228, 1018, 3, 63, 6202, 1, 2045, 2, 1277, 11, 519, 2, 614, 106, 19, 144, 9, 135, 5, 8, 147, 1, 12, 90, 23, 38, 241, 187, 411, 3551, 78, 584, 3, 6202, 1, 2045, 2, 1277, 11, 601, 2, 696, 106, 19, 1460, 9, 3, 739, 7, 9, 953, 8, 12, 147, 10, 557, 20, 1117, 1277, 42, 8, 97, 142, 485, 76, 2045, 5, 8, 485, 1, 699, 185, 466, 106, 19, 2155, 1277, 1804, 3, 752, 528, 1, 2045, 2, 122, 40, 95, 22, 8, 3380, 1515, 6, 2920, 13607, 2, 411, 9, 3, 451, 1, 710, 4, 2532, 7860, 4, 2399, 1184]",1365.0,26684604,92
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation.,Cell reports,Cell Rep,2016-01-21,"The ampulla of Vater is a complex cellular environment from which adenocarcinomas arise to form a group of histopathologically heterogenous tumors. To evaluate the molecular features of these tumors, 98 ampullary adenocarcinomas were evaluated and compared to 44 distal bile duct and 18 duodenal adenocarcinomas. Genomic analyses revealed mutations in the WNT signaling pathway among half of the patients and in all three adenocarcinomas irrespective of their origin and histological morphology. These tumors were characterized by a high frequency of inactivating mutations of ELF3, a high rate of microsatellite instability, and common focal deletions and amplifications, suggesting common attributes in the molecular pathogenesis are at play in these tumors. The high frequency of WNT pathway activating mutation, coupled with small-molecule inhibitors of -catenin in clinical trials, suggests future treatment decisions for these patients may be guided by genomic analysis. ",Journal Article,1461.0,41.0,The ampulla of Vater is a complex cellular environment from which adenocarcinomas arise to form a group of histopathologically heterogenous tumors To evaluate the molecular features of these tumors 98 ampullary adenocarcinomas were evaluated and compared to 44 distal duct and 18 duodenal adenocarcinomas Genomic analyses revealed mutations in the WNT signaling pathway among half of the patients and in all three adenocarcinomas irrespective of their origin and histological morphology These tumors were characterized by a high frequency of inactivating mutations of ELF3 a high rate of microsatellite instability and common focal deletions and amplifications suggesting common attributes in the molecular pathogenesis are at play in these tumors The high frequency of WNT pathway activating mutation coupled with small-molecule inhibitors of -catenin in clinical trials suggests future treatment decisions for these patients may be guided by genomic analysis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 12837, 1, 14777, 16, 8, 840, 763, 3087, 29, 92, 1586, 3043, 6, 1297, 8, 87, 1, 8631, 8189, 57, 6, 376, 3, 219, 404, 1, 46, 57, 1096, 6762, 1586, 11, 194, 2, 72, 6, 584, 2107, 2920, 2, 203, 4748, 1586, 572, 318, 553, 138, 4, 3, 2112, 314, 308, 107, 1303, 1, 3, 7, 2, 4, 62, 169, 1586, 3500, 1, 136, 1938, 2, 1831, 2567, 46, 57, 11, 765, 20, 8, 64, 675, 1, 6096, 138, 1, 22041, 8, 64, 116, 1, 2226, 1753, 2, 186, 2137, 2439, 2, 4877, 802, 186, 7372, 4, 3, 219, 1384, 32, 28, 1343, 4, 46, 57, 3, 64, 675, 1, 2112, 308, 1616, 258, 3332, 5, 302, 1354, 222, 1, 1458, 1778, 4, 38, 143, 844, 508, 24, 1526, 9, 46, 7, 68, 40, 1808, 20, 572, 65]",961.0,26804919,25
"Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma.",Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,J. Gastrointest. Surg.,2016-03-08,"Differentiating intra-pancreatic distal bile duct carcinoma invading the pancreas from pancreatic ductal adenocarcinomas (PDAC) surrounding the distal common bile duct (CBD) can be challenging. Our aim is to identify clinical, morphological, and genetic features characteristic of intra-pancreatic distal bile duct carcinoma. Clinicopathologic data of 550 patients undergoing a pancreaticoduodenectomy between September 1990 and May 2008 were reviewed. KRAS status was assessed with mass-spectrometric genotyping. Ninety-seven patients with intra-pancreatic adenocarcinomas surrounding the CBD were identified; slides were available for 80. Two relationships with the CBD were recognized as follows: type I (n=42): cancer grew concentrically around the CBD and type II (n=38): cancer grew asymmetrically around the CBD. Type I adenocarcinomas were associated with high-grade biliary dysplasia (45 vs. 13%; p=0.003); type II were associated with high-grade pancreatic intra-epithelial neoplasia (PanIN-2 or -3) (39 vs. 9%; p=0.003). Type I tumors had a better median survival (46months) compared to type II (23months) or other PDAC (20months) (p<0.001). Mutated KRAS was identified in 3/26 (11%) type I and 20/21 (95%) type II cancers (p<0.001). There may be poorer survival in the presence of a KRAS mutation than wild-type KRAS (22.9 vs. 41.6months; p=0.3). Distal periductal adenocarcinomas fall into two distinct groups with biologic, morphologic and genetic differences. Those growing symmetrically around the CBD are more likely to be intra-pancreatic distal bile duct carcinomas and are associated with improved survival whereas cancers with asymmetric growth are more likely to have KRAS mutations and to be PDACs. These findings facilitate a more accurate histopathological diagnosis, which could improve patient selection for therapeutic trials.",Journal Article,1414.0,7.0,Differentiating intra-pancreatic distal duct carcinoma invading the from ductal adenocarcinomas PDAC surrounding the distal common duct CBD can be challenging Our aim is to identify clinical morphological and genetic features characteristic of intra-pancreatic distal duct carcinoma Clinicopathologic data of 550 patients undergoing a pancreaticoduodenectomy between September 1990 and May 2008 were reviewed KRAS status was assessed with mass-spectrometric genotyping Ninety-seven patients with intra-pancreatic adenocarcinomas surrounding the CBD were identified slides were available for 80 Two relationships with the CBD were recognized as follows type I n 42 cancer grew concentrically around the CBD and type II n 38 cancer grew asymmetrically around the CBD Type I adenocarcinomas were associated with high-grade biliary dysplasia 45 vs. 13 p 0.003 type II were associated with high-grade intra-epithelial neoplasia PanIN-2 or -3 39 vs. 9 p 0.003 Type I tumors had a better median survival 46 months compared to type II 23 months or other PDAC 20 months p 0.001 Mutated KRAS was identified in 3/26 11 type I and 20/21 95 type II cancers p 0.001 There may be poorer survival in the presence of a KRAS mutation than wild-type KRAS 22.9 vs. 41.6 months p 0.3 Distal periductal adenocarcinomas fall into two distinct groups with biologic morphologic and genetic differences Those growing symmetrically around the CBD are more likely to be intra-pancreatic distal duct carcinomas and are associated with improved survival whereas cancers with asymmetric growth are more likely to have KRAS mutations and to be PDACs These findings facilitate a more accurate histopathological diagnosis which could improve patient selection for therapeutic trials,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[5209, 2392, 14061, 2107, 2920, 134, 8653, 3, 29, 1258, 1586, 1356, 2976, 3, 2107, 186, 2920, 14624, 122, 40, 1950, 114, 1130, 16, 6, 255, 38, 4268, 2, 336, 404, 2037, 1, 2392, 14061, 2107, 2920, 134, 1399, 74, 1, 7935, 7, 479, 8, 4104, 59, 2636, 2289, 2, 68, 1375, 11, 446, 723, 156, 10, 275, 5, 782, 14506, 2686, 2493, 648, 7, 5, 2392, 14061, 1586, 2976, 3, 14624, 11, 108, 3830, 11, 390, 9, 493, 100, 2467, 5, 3, 14624, 11, 1904, 22, 2962, 267, 70, 78, 595, 12, 8033, 67747, 3337, 3, 14624, 2, 267, 215, 78, 519, 12, 8033, 46673, 3337, 3, 14624, 267, 70, 1586, 11, 41, 5, 64, 88, 2532, 2253, 512, 105, 233, 19, 13, 1421, 267, 215, 11, 41, 5, 64, 88, 2392, 701, 2298, 8071, 18, 15, 27, 587, 105, 83, 19, 13, 1421, 267, 70, 57, 42, 8, 380, 52, 25, 641, 53, 72, 6, 267, 215, 382, 53, 15, 127, 1356, 179, 53, 19, 13, 144, 1185, 723, 10, 108, 4, 27, 432, 175, 267, 70, 2, 179, 239, 48, 267, 215, 163, 19, 13, 144, 125, 68, 40, 1769, 25, 4, 3, 463, 1, 8, 723, 258, 76, 955, 267, 723, 350, 83, 105, 605, 49, 53, 19, 13, 27, 2107, 25557, 1586, 6712, 237, 100, 834, 271, 5, 1283, 2815, 2, 336, 362, 135, 1921, 44609, 3337, 3, 14624, 32, 80, 322, 6, 40, 2392, 14061, 2107, 2920, 826, 2, 32, 41, 5, 231, 25, 547, 163, 5, 14877, 129, 32, 80, 322, 6, 47, 723, 138, 2, 6, 40, 9142, 46, 272, 1876, 8, 80, 1481, 4370, 147, 92, 359, 401, 69, 881, 9, 189, 143]",1748.0,26956004,39
The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma.,PloS one,PLoS ONE,2016-03-14,"The aim of the present study is to determine if CEACAM6 can be detected in the bile of patients with biliary cancer and can serve as a diagnostic biomarker for cholangiocarcinoma. Distinguishing bile duct carcinoma from other diagnoses is often difficult using endoscopic or percutaneous techniques. The cell surface protein CEACAM6 is over-expressed in many gastrointestinal cancers and may be selectively elevated in biliary adenocarcinoma. Bile from patients with benign biliary disease and cholangiocarcinoma (hilar, intrahepatic and distal) was collected at the time of index operation. The concentration of CEACAM6 was quantified by sandwich enzyme-linked immunosorbent assay (ELISA) and correlated to pathologic diagnosis. Diagnostic capability of CEACAM6 was evaluated by Wilcoxon rank-sum, linear regression, multiple regression, and receiver operating characteristic (ROC) curve analysis. Bile from 83 patients was analyzed: 42 with benign disease and 41 with cholangiocarcinoma. Patients in the benign cohort were younger, predominantly female, and had lower median biliary CEACAM6 levels than patients in the malignant cohort (7.5 ng/ml vs. 40 ng/ml; p = <.001). ROC curve analysis determined CEACAM6 to be a positive predictor cholangiocarcinoma with a CEACAM6 level >14 ng/ml associated with 87.5% sensitivity, 69.1% specificity, and a likelihood ratio of 2.8 (AUC 0.74). Multiple regression analysis suggested elevated alkaline phosphatase and the presence of biliary endoprostheses may influence CEACAM6 levels. Biliary CEACAM6 can identify patients with extrahepatic cholangiocarcinoma with a high degree of sensitivity and should be investigated further as a potential screening tool.",Clinical Trial,1408.0,6.0,The aim of the present study is to determine if CEACAM6 can be detected in the of patients with biliary cancer and can serve as a diagnostic biomarker for cholangiocarcinoma Distinguishing duct carcinoma from other diagnoses is often difficult using endoscopic or percutaneous techniques The cell surface protein CEACAM6 is over-expressed in many cancers and may be selectively elevated in biliary adenocarcinoma from patients with benign biliary disease and cholangiocarcinoma hilar intrahepatic and distal was collected at the time of index operation The concentration of CEACAM6 was quantified by sandwich enzyme-linked immunosorbent assay ELISA and correlated to pathologic diagnosis Diagnostic capability of CEACAM6 was evaluated by Wilcoxon rank-sum linear regression multiple regression and receiver operating characteristic ROC curve analysis from 83 patients was analyzed 42 with benign disease and 41 with cholangiocarcinoma Patients in the benign cohort were younger predominantly female and had lower median biliary CEACAM6 levels than patients in the malignant cohort 7.5 ng/ml vs. 40 ng/ml p .001 ROC curve analysis determined CEACAM6 to be a positive predictor cholangiocarcinoma with a CEACAM6 level 14 ng/ml associated with 87.5 sensitivity 69.1 specificity and a likelihood ratio of 2.8 AUC 0.74 Multiple regression analysis suggested elevated alkaline phosphatase and the presence of biliary endoprostheses may influence CEACAM6 levels Biliary CEACAM6 can identify patients with extrahepatic cholangiocarcinoma with a high degree of sensitivity and should be investigated further as a potential screening tool,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1130, 1, 3, 364, 45, 16, 6, 223, 492, 24235, 122, 40, 530, 4, 3, 1, 7, 5, 2532, 12, 2, 122, 1833, 22, 8, 752, 901, 9, 2126, 4508, 2920, 134, 29, 127, 2403, 16, 629, 1740, 75, 2056, 15, 3720, 1092, 3, 31, 1255, 178, 24235, 16, 252, 570, 4, 445, 163, 2, 68, 40, 2382, 804, 4, 2532, 449, 29, 7, 5, 1002, 2532, 34, 2, 2126, 4793, 3022, 2, 2107, 10, 786, 28, 3, 98, 1, 558, 2589, 3, 1227, 1, 24235, 10, 2790, 20, 18189, 1644, 1199, 5339, 719, 3664, 2, 438, 6, 510, 147, 752, 6188, 1, 24235, 10, 194, 20, 3896, 1026, 3216, 1646, 320, 232, 320, 2, 3185, 2584, 2037, 3783, 1496, 65, 29, 852, 7, 10, 311, 595, 5, 1002, 34, 2, 605, 5, 2126, 7, 4, 3, 1002, 180, 11, 773, 2117, 1061, 2, 42, 280, 52, 2532, 24235, 148, 76, 7, 4, 3, 393, 180, 67, 33, 997, 542, 105, 327, 997, 542, 19, 144, 3783, 1496, 65, 509, 24235, 6, 40, 8, 109, 980, 2126, 5, 8, 24235, 301, 213, 997, 542, 41, 5, 912, 33, 485, 790, 14, 1121, 2, 8, 1420, 197, 1, 18, 66, 1376, 13, 794, 232, 320, 65, 1148, 804, 5355, 2577, 2, 3, 463, 1, 2532, 67790, 68, 1054, 24235, 148, 2532, 24235, 122, 255, 7, 5, 3710, 2126, 5, 8, 64, 1444, 1, 485, 2, 257, 40, 565, 195, 22, 8, 174, 453, 1515]",1628.0,26974538,48
Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer.,Journal of surgical oncology,J Surg Oncol,2016-05-20,"Although radical re-resection for gallbladder cancer (GBC) has been advocated, the optimal extent of re-resection remains unknown. The current study aimed to assess the impact of common bile duct (CBD) resection on survival among patients undergoing surgery for GBC. Patients undergoing curative-intent surgery for GBC were identified using a multi-institutional cohort of patients. Multivariable Cox-proportional hazards regression was performed to identify risk factors for a poor overall survival (OS). Among the 449 patients identified, 26.9% underwent a concomitant CBD resection. The median number of lymph nodes harvested did not differ based on CBD resection (CBD, 4 [IQR: 2-9] vs. no CBD, 3 [IQR: 1-7], P=0.108). While patients who underwent a CBD resection had a worse OS, after adjusting for potential confounders, CBD resection did not impact OS (HR=1.40, 95%CI 0.87-2.27, P=0.170). Rather, the presence of advanced disease (T3: HR=3.11, 95%CI 1.22-7.96, P=0.018; T4: HR=7.24, 95%CI 1.70-30.85, P=0.007) and the presence of disease at the surgical margin (HR=2.58, 95%CI 1.26-5.31, P=0.010) were predictive of a worse OS. CBD resection did not yield a higher lymph node count and was not associated with an improved survival. Routine CBD excision in the re-resection of GBC is unwarranted and should only be performed selectively. J. Surg. Oncol. 2016;114:176-180.  2016 Wiley Periodicals, Inc.",Comparative Study,1341.0,10.0,Although radical re-resection for cancer GBC has been advocated the optimal extent of re-resection remains unknown The current study aimed to assess the impact of common duct CBD resection on survival among patients undergoing surgery for GBC Patients undergoing curative-intent surgery for GBC were identified using a multi-institutional cohort of patients Multivariable Cox-proportional hazards regression was performed to identify risk factors for a poor overall survival OS Among the 449 patients identified 26.9 underwent a concomitant CBD resection The median number of lymph nodes harvested did not differ based on CBD resection CBD 4 IQR 2-9 vs. no CBD 3 IQR 1-7 P 0.108 While patients who underwent a CBD resection had a worse OS after adjusting for potential confounders CBD resection did not impact OS HR 1.40 95 CI 0.87-2.27 P 0.170 Rather the presence of advanced disease T3 HR 3.11 95 CI 1.22-7.96 P 0.018 T4 HR 7.24 95 CI 1.70-30.85 P 0.007 and the presence of disease at the surgical margin HR 2.58 95 CI 1.26-5.31 P 0.010 were predictive of a worse OS CBD resection did not yield a higher lymph node count and was not associated with an improved survival Routine CBD excision in the re-resection of GBC is unwarranted and should only be performed selectively J. Surg Oncol 2016 114:176-180  2016 Wiley Periodicals Inc,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 711, 1491, 170, 9, 12, 6344, 71, 85, 8866, 3, 665, 1039, 1, 1491, 170, 469, 860, 3, 291, 45, 1295, 6, 423, 3, 345, 1, 186, 2920, 14624, 170, 23, 25, 107, 7, 479, 152, 9, 6344, 7, 479, 1075, 1697, 152, 9, 6344, 11, 108, 75, 8, 1414, 1115, 180, 1, 7, 658, 418, 831, 1017, 320, 10, 173, 6, 255, 43, 130, 9, 8, 334, 63, 25, 118, 107, 3, 8865, 7, 108, 432, 83, 208, 8, 1781, 14624, 170, 3, 52, 207, 1, 263, 502, 6503, 205, 44, 1505, 90, 23, 14624, 170, 14624, 39, 2245, 18, 83, 105, 77, 14624, 27, 2245, 14, 67, 19, 13, 3590, 369, 7, 54, 208, 8, 14624, 170, 42, 8, 639, 118, 50, 1358, 9, 174, 4423, 14624, 170, 205, 44, 345, 118, 168, 14, 327, 48, 58, 13, 912, 18, 428, 19, 13, 5248, 1832, 3, 463, 1, 131, 34, 2065, 168, 27, 175, 48, 58, 14, 350, 67, 921, 19, 13, 4047, 2463, 168, 67, 259, 48, 58, 14, 431, 201, 772, 19, 13, 1999, 2, 3, 463, 1, 34, 28, 3, 221, 959, 168, 18, 717, 48, 58, 14, 432, 33, 456, 19, 13, 4873, 11, 464, 1, 8, 639, 118, 14624, 170, 205, 44, 2309, 8, 142, 263, 289, 1276, 2, 10, 44, 41, 5, 35, 231, 25, 1311, 14624, 1366, 4, 3, 1491, 170, 1, 6344, 16, 15644, 2, 257, 158, 40, 173, 2382, 3543, 8829, 8937, 1390, 3803, 5800, 3172, 2206, 1390, 4692, 5493, 3479]",1335.0,27198742,75
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.,Cancer discovery,Cancer Discov,2016-05-26,"Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver bile duct malignancy exhibiting frequent isocitrate dehydrogenase (IDH1/IDH2) mutations. Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tract cancers, we found that IDH mutant (IDHm) ICC cells demonstrate a striking response to the multikinase inhibitor dasatinib, with the highest sensitivity among 682 solid tumor cell lines. Using unbiased proteomics to capture the activated kinome and CRISPR/Cas9-based genome editing to introduce dasatinib-resistant ""gatekeeper"" mutant kinases, we identified SRC as a critical dasatinib target in IDHm ICC. Importantly, dasatinib-treated IDHm xenografts exhibited pronounced apoptosis and tumor regression. Our results show that IDHm ICC cells have a unique dependency on SRC and suggest that dasatinib may have therapeutic benefit against IDHm ICC. Moreover, these proteomic and genome-editing strategies provide a systematic and broadly applicable approach to define targets of kinase inhibitors underlying drug responsiveness. IDH mutations define a distinct subtype of ICC, a malignancy that is largely refractory to current therapies. Our work demonstrates that IDHm ICC cells are hypersensitive to dasatinib and critically dependent on SRC activity for survival and proliferation, pointing to new therapeutic strategies against these cancers. Cancer Discov; 6(7); 727-39. 2016 AACR.This article is highlighted in the In This Issue feature, p. 681.",Journal Article,1335.0,54.0,Intrahepatic cholangiocarcinoma ICC is an aggressive duct malignancy exhibiting frequent isocitrate dehydrogenase IDH1/IDH2 mutations Through a high-throughput drug screen of a large panel of cancer cell lines including 17 biliary tract cancers we found that IDH mutant IDHm ICC cells demonstrate a striking response to the multikinase inhibitor dasatinib with the highest sensitivity among 682 solid tumor cell lines Using unbiased proteomics to capture the activated kinome and CRISPR/Cas9-based genome editing to introduce dasatinib-resistant `` gatekeeper '' mutant kinases we identified SRC as a critical dasatinib target in IDHm ICC Importantly dasatinib-treated IDHm xenografts exhibited pronounced apoptosis and tumor regression Our results show that IDHm ICC cells have a unique dependency on SRC and suggest that dasatinib may have therapeutic benefit against IDHm ICC Moreover these proteomic and genome-editing strategies provide a systematic and broadly applicable approach to define targets of kinase inhibitors underlying drug responsiveness IDH mutations define a distinct subtype of ICC a malignancy that is largely refractory to current therapies Our work demonstrates that IDHm ICC cells are hypersensitive to dasatinib and critically dependent on SRC activity for survival and proliferation pointing to new therapeutic strategies against these cancers Cancer Discov 6 7 727-39 2016 AACR.This article is highlighted in the In This Issue feature p. 681,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3022, 2126, 2259, 16, 35, 571, 2920, 710, 4801, 908, 5795, 2374, 2662, 4520, 138, 298, 8, 64, 3643, 234, 2413, 1, 8, 375, 993, 1, 12, 31, 285, 141, 269, 2532, 1696, 163, 21, 204, 17, 3056, 620, 20913, 2259, 37, 608, 8, 5133, 51, 6, 3, 6524, 230, 1674, 5, 3, 1076, 485, 107, 11958, 537, 30, 31, 285, 75, 7271, 6478, 6, 2891, 3, 735, 14328, 2, 7736, 9071, 90, 898, 6120, 6, 7630, 1674, 436, 10899, 522, 620, 1549, 21, 108, 2023, 22, 8, 740, 1674, 283, 4, 20913, 2259, 1859, 1674, 73, 20913, 1348, 1416, 3517, 351, 2, 30, 320, 114, 99, 514, 17, 20913, 2259, 37, 47, 8, 991, 6359, 23, 2023, 2, 309, 17, 1674, 68, 47, 189, 247, 480, 20913, 2259, 1393, 46, 3784, 2, 898, 6120, 422, 377, 8, 1556, 2, 5482, 3801, 353, 6, 1107, 637, 1, 216, 222, 1181, 234, 3642, 3056, 138, 1107, 8, 834, 875, 1, 2259, 8, 710, 17, 16, 1733, 430, 6, 291, 235, 114, 1357, 1902, 17, 20913, 2259, 37, 32, 14077, 6, 1674, 2, 4331, 470, 23, 2023, 128, 9, 25, 2, 457, 11548, 6, 217, 189, 422, 480, 46, 163, 12, 7183, 49, 67, 14093, 587, 3456, 1630, 26, 946, 16, 3681, 4, 3, 4, 26, 2537, 2705, 19, 14442]",1471.0,27231123,29
Laparoscopic Spleen-Preserving Total Pancreatectomy for a Main-Duct Intraductal Papillary Mucinous Neoplasm.,Annals of surgical oncology,Ann. Surg. Oncol.,2016-09-02,"Main-duct intraductal papillary mucinous neoplasms of the pancreas (M-IPMN) are potentially malignant cystic neoplasms that can degenerate into invasive malignancy in 43% of cases.1 Although laparoscopic pancreaticoduodenectomy and distal pancreatectomy have been previously described for the management of pancreatic neoplasms, laparoscopic total pancreatectomy is rarely described. We present a video demonstrating a laparoscopic spleen-preserving total pancreatectomy in a patient with M-IPMN. A healthy 66-year-old male was diagnosed with recurrent pancreatitis. A computed tomography of the abdomen demonstrated a diffusely dilated pancreatic duct (10mm) and a 5mm mural nodule in the neck of the pancreas. Endoscopic retrograde cholangiopancreatography demonstrated a 'fish mouth' appearance at the major papilla, with a villous mass (15mm) in the pancreatic head. Biopsy was consistent with M-IPMN, and tumor markers were normal. A spleen-preserving laparoscopic total pancreatectomy was performed over a period of 270min, with 150cc of blood loss without complications. The patient was admitted to the intensive care unit for continuous insulin infusion. On postoperative day (POD) 1, his nasogastric tube was discontinued, transitioned to subcutaneous insulin injections, and transferred to the floor. He tolerated a diabetic diet on POD4. His surgical drain had minimal output with no evidence of a bile leak, and was discontinued on POD5. The patient's hospital course was uncomplicated and he was discharged home on POD7. Pathology demonstrated IPMN with moderate dysplasia. Laparoscopic total pancreatectomy can be safely performed in patients with M-IPMN. This video presentation describes the technique we used for this procedure.",Case Reports,1236.0,3.0,Main-duct intraductal papillary mucinous neoplasms of the M-IPMN are potentially malignant cystic neoplasms that can degenerate into invasive malignancy in 43 of cases.1 Although laparoscopic pancreaticoduodenectomy and distal pancreatectomy have been previously described for the management of neoplasms laparoscopic total pancreatectomy is rarely described We present a video demonstrating a laparoscopic spleen-preserving total pancreatectomy in a patient with M-IPMN A healthy 66-year-old male was diagnosed with recurrent pancreatitis A computed tomography of the abdomen demonstrated a diffusely dilated duct 10 mm and a 5 mm mural nodule in the of the Endoscopic retrograde cholangiopancreatography demonstrated a 'fish mouth appearance at the major papilla with a villous mass 15 mm in the head Biopsy was consistent with M-IPMN and tumor markers were normal A spleen-preserving laparoscopic total pancreatectomy was performed over a period of 270 min with 150 cc of blood loss without complications The patient was admitted to the intensive care unit for continuous insulin infusion On postoperative day POD 1 his nasogastric tube was discontinued transitioned to subcutaneous insulin injections and transferred to the floor He tolerated a diabetic diet on POD 4 His surgical drain had minimal output with no evidence of a leak and was discontinued on POD 5 The patient 's hospital course was uncomplicated and he was discharged home on POD 7 Pathology demonstrated IPMN with moderate dysplasia Laparoscopic total pancreatectomy can be safely performed in patients with M-IPMN This video presentation describes the technique we used for this procedure,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1895, 2920, 4851, 1796, 2391, 1179, 1, 3, 188, 4398, 32, 751, 393, 2965, 1179, 17, 122, 48881, 237, 416, 710, 4, 601, 1, 140, 14, 242, 1964, 4104, 2, 2107, 3762, 47, 85, 373, 1027, 9, 3, 284, 1, 1179, 1964, 181, 3762, 16, 2416, 1027, 21, 364, 8, 4139, 2219, 8, 1964, 4071, 4972, 181, 3762, 4, 8, 69, 5, 188, 4398, 8, 1331, 700, 111, 1095, 1045, 10, 265, 5, 387, 4535, 8, 1220, 872, 1, 3, 4036, 264, 8, 9333, 11536, 2920, 79, 321, 2, 8, 33, 321, 13977, 5072, 4, 3, 1, 3, 2056, 10583, 15476, 264, 8, 68929, 5831, 3592, 28, 3, 458, 26079, 5, 8, 10573, 782, 167, 321, 4, 3, 718, 411, 10, 925, 5, 188, 4398, 2, 30, 525, 11, 295, 8, 4071, 4972, 1964, 181, 3762, 10, 173, 252, 8, 727, 1, 6666, 1538, 5, 1577, 1951, 1, 315, 407, 187, 521, 3, 69, 10, 4319, 6, 3, 1686, 165, 2712, 9, 1314, 1601, 904, 23, 573, 218, 14653, 14, 3224, 26438, 2330, 10, 2402, 13987, 6, 2529, 1601, 4344, 2, 4747, 6, 3, 12557, 3174, 421, 8, 5943, 2453, 23, 14653, 39, 3224, 221, 9203, 42, 1048, 6911, 5, 77, 241, 1, 8, 4238, 2, 10, 2402, 23, 14653, 33, 3, 69, 292, 702, 906, 10, 13863, 2, 3174, 10, 6155, 3249, 23, 14653, 67, 1117, 264, 4398, 5, 1163, 2253, 1964, 181, 3762, 122, 40, 2268, 173, 4, 7, 5, 188, 4398, 26, 4139, 1031, 2677, 3, 1312, 21, 95, 9, 26, 1299]",1660.0,27590330,1
Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency.,Chinese clinical oncology,Chin Clin Oncol,2016-10-01,"The pathology of biliary carcinomas is diverse with different gross and histological features in tumors arising in the different segments of the biliary system. Various epidemiological risk factors, varied genetic makeup, and tissue microenvironment are contributory factors. As biliary tumors have been shown to be a part of the Lynch syndrome tumor spectrum, it is plausible to speculate that DNA mismatch repair (MMR) deficiency plays a role in biliary tumors. Literature data suggest that DNA MMR deficiency indeed occurs in these tumors, albeit infrequently with the reported frequencies (weighted for sample size) of high level microsatellite instability (MSI) being 5% each for gallbladder carcinoma and carcinoma of extra-hepatic bile ducts, and 10% each for intrahepatic cholangiocarcinoma and ampullary carcinoma. Importantly, the presence of MMR deficiency in these tumors has been shown to have different implications with regard to its association with Lynch syndrome, tumor histological features, and other clinical characteristics, when compared with non-biliary tumors or among the biliary tumors from the different segments of the biliary system. Ongoing and future efforts that utilize large scale sequencing techniques and aim at detecting actionable molecular targets should emphasize a multidisciplinary approach that integrates genomic discoveries with not only functional studies but also studies of tumor pathology and the tumor's clinical and biological behavior.",Journal Article,1207.0,31.0,The pathology of biliary carcinomas is diverse with different gross and histological features in tumors arising in the different segments of the biliary system Various epidemiological risk factors varied genetic makeup and tissue microenvironment are contributory factors As biliary tumors have been shown to be a part of the Lynch syndrome tumor spectrum it is plausible to speculate that DNA mismatch repair MMR deficiency plays a role in biliary tumors Literature data suggest that DNA MMR deficiency indeed occurs in these tumors albeit infrequently with the reported frequencies weighted for sample size of high level microsatellite instability MSI being 5 each for carcinoma and carcinoma of extra-hepatic ducts and 10 each for intrahepatic cholangiocarcinoma and ampullary carcinoma Importantly the presence of MMR deficiency in these tumors has been shown to have different implications with regard to its association with Lynch syndrome tumor histological features and other clinical characteristics when compared with non-biliary tumors or among the biliary tumors from the different segments of the biliary system Ongoing and future efforts that utilize large scale sequencing techniques and aim at detecting actionable molecular targets should emphasize a multidisciplinary approach that integrates genomic discoveries with not only functional studies but also studies of tumor pathology and the tumor 's clinical and biological behavior,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1117, 1, 2532, 826, 16, 1867, 5, 338, 1789, 2, 1831, 404, 4, 57, 2635, 4, 3, 338, 5138, 1, 3, 2532, 398, 747, 4614, 43, 130, 2051, 336, 14176, 2, 246, 995, 32, 19445, 130, 22, 2532, 57, 47, 85, 443, 6, 40, 8, 760, 1, 3, 3546, 681, 30, 1873, 192, 16, 7761, 6, 11778, 17, 261, 2617, 972, 2205, 2299, 1698, 8, 200, 4, 2532, 57, 789, 74, 309, 17, 261, 2205, 2299, 4462, 1780, 4, 46, 57, 5993, 6440, 5, 3, 210, 2722, 2337, 9, 1000, 444, 1, 64, 301, 2226, 1753, 1494, 486, 33, 296, 9, 134, 2, 134, 1, 3420, 939, 7310, 2, 79, 296, 9, 3022, 2126, 2, 6762, 134, 1859, 3, 463, 1, 2205, 2299, 4, 46, 57, 71, 85, 443, 6, 47, 338, 1268, 5, 2539, 6, 211, 248, 5, 3546, 681, 30, 1831, 404, 2, 127, 38, 374, 198, 72, 5, 220, 2532, 57, 15, 107, 3, 2532, 57, 29, 3, 338, 5138, 1, 3, 2532, 398, 942, 2, 508, 1413, 17, 6391, 375, 1124, 615, 1092, 2, 1130, 28, 2502, 2856, 219, 637, 257, 5560, 8, 1643, 353, 17, 9735, 572, 5012, 5, 44, 158, 583, 94, 84, 120, 94, 1, 30, 1117, 2, 3, 30, 292, 38, 2, 1037, 1710]",1449.0,27829276,11
Total Transthoracic Approach Facilitates Laparoscopic Hepatic Resection in Patients with Significant Prior Abdominal Surgery.,Annals of surgical oncology,Ann. Surg. Oncol.,2016-11-22,"While the oncologic safety of minimally invasive hepatectomy for colorectal liver metastases (CLM) has been demonstrated, lesions in the postero-superior segments may be challenging.1 <sup>-</sup> 3 For these lesions, a transthoracic approach may be particularly helpful, especially in patients with a hostile/reoperative abdomen or morbid obesity.4 <sup>,</sup> 5 PATIENT: A 43-year-old man with a body mass index of 36.0 who had undergone rectosigmoid resection for primary cancer 5years ago recurred with a solitary liver metastasis in SVIII. He had previously undergone the following resections for metachronous CLM: (i) partial resections of SV/VIII and SII/III; (ii) ablation for SVII; and (iii) left hepatectomy, common bile duct resection, and choledochojejunostomy. Following four cycles of FOLFIRI/panitumumab with good response, the patient was considered for his fourth abdominal cancer intervention via a thoracoscopic approach. In a modified French position with left-lung ventilation, access to the right thoracic cavity was gained. Following thoracic adhesiolysis, transdiaphragmatic intraoperative ultrasonography (IOUS) was performed. To ensure optimal margins, IOUS-guided transthoracic hepatic resection with partial resection of the diaphragm was conducted. The diaphragm was reconstructed and a chest tube placed. Operative time was 247min, with an estimated blood loss of 100mL. Postoperative recovery was uneventful; pathology demonstrated no viable tumor, with the closest margin 5mm from the necrotic area. Transthoracic hepatic resection of SVIII can optimize the port-target axis while minimizing morbidity. A systematic approach that includes precise port positioning, non-traumatic intrathoracic adhesiolysis, and meticulous transdiaphragmatic IOUS-guided parenchymal transection can optimize outcomes.",Case Reports,1155.0,4.0,While the oncologic safety of minimally invasive hepatectomy for metastases CLM has been demonstrated lesions in the postero-superior segments may be challenging.1 sup /sup 3 For these lesions a transthoracic approach may be particularly helpful especially in patients with a hostile/reoperative abdomen or morbid obesity.4 sup /sup 5 PATIENT A 43-year-old man with a body mass index of 36.0 who had undergone rectosigmoid resection for primary cancer 5 years ago recurred with a solitary metastasis in SVIII He had previously undergone the following resections for metachronous CLM i partial resections of SV/VIII and SII/III ii ablation for SVII and iii left hepatectomy common duct resection and choledochojejunostomy Following four cycles of FOLFIRI/panitumumab with good response the patient was considered for his fourth abdominal cancer intervention via a thoracoscopic approach In a modified French position with left-lung ventilation access to the right thoracic cavity was gained Following thoracic adhesiolysis transdiaphragmatic intraoperative ultrasonography IOUS was performed To ensure optimal margins IOUS-guided transthoracic hepatic resection with partial resection of the diaphragm was conducted The diaphragm was reconstructed and a chest tube placed Operative time was 247 min with an estimated blood loss of 100 mL Postoperative recovery was uneventful pathology demonstrated no viable tumor with the closest margin 5 mm from the necrotic area Transthoracic hepatic resection of SVIII can optimize the port-target axis while minimizing morbidity A systematic approach that includes precise port positioning non-traumatic intrathoracic adhesiolysis and meticulous transdiaphragmatic IOUS-guided parenchymal transection can optimize outcomes,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[369, 3, 1998, 367, 1, 2144, 416, 2711, 9, 196, 3994, 71, 85, 264, 406, 4, 3, 69383, 1123, 5138, 68, 40, 1950, 14, 172, 172, 27, 9, 46, 406, 8, 14806, 353, 68, 40, 823, 3951, 1093, 4, 7, 5, 8, 26412, 11250, 4036, 15, 8188, 1661, 39, 172, 172, 33, 69, 8, 601, 111, 1095, 3628, 5, 8, 642, 782, 558, 1, 511, 13, 54, 42, 1989, 14258, 170, 9, 86, 12, 33, 60, 5028, 3363, 5, 8, 3144, 278, 4, 50107, 3174, 42, 373, 1989, 3, 366, 2185, 9, 4796, 3994, 70, 450, 2185, 1, 6332, 9936, 2, 69384, 316, 215, 1650, 9, 69385, 2, 316, 1712, 2711, 186, 2920, 170, 2, 69386, 366, 294, 410, 1, 4957, 4309, 5, 1178, 51, 3, 69, 10, 515, 9, 3224, 3608, 1467, 12, 788, 847, 8, 5752, 353, 4, 8, 1230, 9254, 3559, 5, 1712, 5184, 7845, 1655, 6, 3, 1913, 2098, 2405, 10, 3711, 366, 2098, 50108, 18380, 1720, 4244, 10241, 10, 173, 6, 3478, 665, 1012, 10241, 1808, 14806, 939, 170, 5, 450, 170, 1, 3, 7482, 10, 426, 3, 7482, 10, 7267, 2, 8, 1662, 2330, 3295, 1208, 98, 10, 7708, 1538, 5, 35, 661, 315, 407, 1, 394, 542, 573, 1602, 10, 16742, 1117, 264, 77, 2663, 30, 5, 3, 12197, 959, 33, 321, 29, 3, 8724, 965, 14806, 939, 170, 1, 50107, 122, 2465, 3, 3083, 283, 2310, 369, 4501, 787, 8, 1556, 353, 17, 1920, 3260, 3083, 7172, 220, 11272, 7359, 50108, 2, 13764, 18380, 10241, 1808, 5338, 13575, 122, 2465, 123]",1761.0,27878479,53
Outcomes After Radio(chemo)therapy for Non-Metastatic Bile Duct Cancer.,"In vivo (Athens, Greece)",In Vivo,2017-01-01,"The role of radio(chemo) therapy for non-metastatic bile duct cancer is not well defined. This study provides additional data for this rare situation. Data of eight patients receiving radio(chemo)therapy for non-metastatic bile duct cancer were retrospectively analyzed regarding local control, metastases-free survival and overall survival. In addition to the entire cohort, five tumor- or treatment-related factors were investigated: tumor stage, histologic grading, point in time of radio(chemo)therapy, upfront surgery and concurrent chemotherapy. Median overall survival was 37 months. Overall survival rates at 3 and 5 years were 56% and 38%, respectively. Lower histologic grading was significantly associated with better overall survival (p=0.042). Metastases-free survival rates at 3 and 5 years were 38% and 19%, while local control rates were 43% and 21%, respectively. Concurrent radiochemotherapy (vs. radiotherapy alone) resulted in significantly improved local control (p=0.014). Radiochemotherapy can achieve promising results in selected patients with non-metastatic bile duct cancer.",Journal Article,1115.0,2.0,The role of radio chemo therapy for non-metastatic duct cancer is not well defined This study provides additional data for this rare situation Data of eight patients receiving radio chemo therapy for non-metastatic duct cancer were retrospectively analyzed regarding local control metastases-free survival and overall survival In addition to the entire cohort five tumor- or treatment-related factors were investigated tumor stage histologic grading point in time of radio chemo therapy upfront surgery and concurrent chemotherapy Median overall survival was 37 months Overall survival rates at 3 and 5 years were 56 and 38 respectively Lower histologic grading was significantly associated with better overall survival p=0.042 Metastases-free survival rates at 3 and 5 years were 38 and 19 while local control rates were 43 and 21 respectively Concurrent radiochemotherapy vs. radiotherapy alone resulted in significantly improved local control p=0.014 Radiochemotherapy can achieve promising results in selected patients with non-metastatic duct cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 200, 1, 6477, 3341, 36, 9, 220, 113, 2920, 12, 16, 44, 149, 395, 26, 45, 777, 402, 74, 9, 26, 622, 7747, 74, 1, 659, 7, 357, 6477, 3341, 36, 9, 220, 113, 2920, 12, 11, 894, 311, 666, 293, 182, 196, 115, 25, 2, 63, 25, 4, 352, 6, 3, 1797, 180, 365, 30, 15, 24, 139, 130, 11, 565, 30, 82, 884, 3452, 741, 4, 98, 1, 6477, 3341, 36, 2941, 152, 2, 750, 56, 52, 63, 25, 10, 567, 53, 63, 25, 151, 28, 27, 2, 33, 60, 11, 664, 2, 519, 106, 280, 884, 3452, 10, 97, 41, 5, 380, 63, 25, 19, 13, 5606, 196, 115, 25, 151, 28, 27, 2, 33, 60, 11, 519, 2, 326, 369, 293, 182, 151, 11, 601, 2, 239, 106, 750, 6836, 105, 310, 279, 627, 4, 97, 231, 293, 182, 19, 13, 3618, 6836, 122, 1359, 721, 99, 4, 715, 7, 5, 220, 113, 2920, 12]",1054.0,28064229,111
The American College of Radiology and the American Brachytherapy Society practice parameter for the performance of low-dose-rate brachytherapy.,Brachytherapy,Brachytherapy,,"Brachytherapy is the use of radionuclides to treat malignancies or benign conditions by means of a radiation source placed close to or into the tumor or treatment site. This practice parameter refers only to the use of radionuclide brachytherapy. Brachytherapy alone or combined with external beam therapy plays an important role in the management and treatment of patients with cancer. Low-dose-rate (LDR) brachytherapy has traditionally been used for treating prostate, head and neck, breast, cervical, and endometrial cancers as well as obstructive bile duct, esophageal, or bronchial lesions. It has been practiced for over a century with a variety of sources including radium-226, cesium-137, and, more recently, iridium- 192, iodine-125, and palladium-103. Low-dose-rate (LDR) brachytherapy can be given as interstitial, intracavitary, intraluminal, and/or plesiotherapy to a wide variety of treatment sites. This practice parameter addresses sealed sources as they are used for LDR brachytherapy. It is recognized that unsealed sources (e.g., yttrium-90) are also a form of LDR brachytherapy.",Journal Article,,4.0,Brachytherapy is the use of radionuclides to treat malignancies or benign conditions by means of a radiation source placed close to or into the tumor or treatment site This practice parameter refers only to the use of radionuclide brachytherapy Brachytherapy alone or combined with external beam therapy plays an important role in the management and treatment of patients with cancer Low-dose-rate LDR brachytherapy has traditionally been used for treating head and and cancers as well as obstructive duct or lesions It has been practiced for over a century with a variety of sources including radium-226 cesium-137 and more recently iridium- 192 iodine-125 and palladium-103 Low-dose-rate LDR brachytherapy can be given as interstitial intracavitary intraluminal and/or plesiotherapy to a wide variety of treatment sites This practice parameter addresses sealed sources as they are used for LDR brachytherapy It is recognized that unsealed sources e.g. yttrium-90 are also a form of LDR brachytherapy,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,"[1536, 16, 3, 119, 1, 14396, 6, 943, 441, 15, 1002, 1298, 20, 2263, 1, 8, 121, 2353, 3295, 2336, 6, 15, 237, 3, 30, 15, 24, 606, 26, 758, 4219, 11312, 158, 6, 3, 119, 1, 7967, 1536, 1536, 279, 15, 397, 5, 1455, 1345, 36, 1698, 35, 305, 200, 4, 3, 284, 2, 24, 1, 7, 5, 12, 154, 61, 116, 6962, 1536, 71, 4206, 85, 95, 9, 1367, 718, 2, 2, 163, 22, 149, 22, 6937, 2920, 15, 406, 192, 71, 85, 11121, 9, 252, 8, 7981, 5, 8, 1362, 1, 3375, 141, 6650, 7400, 31158, 4352, 2, 80, 761, 22134, 5016, 4287, 1731, 2, 22221, 3283, 154, 61, 116, 6962, 1536, 122, 40, 447, 22, 4543, 9122, 19960, 2, 15, 69700, 6, 8, 1019, 1362, 1, 24, 633, 26, 758, 4219, 5437, 31855, 3375, 22, 491, 32, 95, 9, 6962, 1536, 192, 16, 1904, 17, 46648, 3375, 563, 499, 7190, 424, 32, 120, 8, 1297, 1, 6962, 1536]",1001.0,28109633,11
The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.,"Hepatology (Baltimore, Md.)",Hepatology,2017-04-28,"Bile duct obstruction is a potent stimulus for cholangiocyte proliferation, especially for large cholangiocytes. Our previous studies reported that conjugated bile acids (CBAs) activate the protein kinase B (AKT) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling pathways through sphingosine 1-phosphate receptor (S1PR) 2 in hepatocytes and cholangiocarcinoma cells. It also has been reported that taurocholate (TCA) promotes large cholangiocyte proliferation and protects cholangiocytes from bile duct ligation (BDL)-induced apoptosis. However, the role of S1PR2 in bile-acid-mediated cholangiocyte proliferation and cholestatic liver injury has not been elucidated. Here, we report that S1PR2 is the predominant S1PR expressed in cholangiocytes. Both TCA- and sphingosine-1-phosphate (S1P)-induced activation of ERK1/2 and AKT were inhibited by JTE-013, a specific antagonist of S1PR2, in cholangiocytes. In addition, TCA- and S1P-induced cell proliferation and migration were inhibited by JTE-013 and a specific short hairpin RNA of S1PR2, as well as chemical inhibitors of ERK1/2 and AKT in mouse cholangiocytes. In BDL mice, expression of S1PR2 was up-regulated in whole liver and cholangiocytes. S1PR2 deficiency significantly reduced BDL-induced cholangiocyte proliferation and cholestatic injury, as indicated by significant reductions in inflammation and liver fibrosis in S1PR2 knockout mice. Treatment of BDL mice with JTE-013 significantly reduced total bile acid levels in serum and cholestatic liver injury. This study suggests that CBA-induced activation of S1PR2-mediated signaling pathways plays a critical role in obstructive cholestasis and may represent a novel therapeutic target for cholestatic liver diseases. (Hepatology 2017;65:2005-2018).",Journal Article,998.0,42.0,duct obstruction is a potent stimulus for cholangiocyte proliferation especially for large cholangiocytes Our previous studies reported that conjugated acids CBAs activate the protein kinase B AKT and extracellular signal-regulated kinase 1 and 2 ERK1/2 signaling pathways through sphingosine 1-phosphate receptor S1PR 2 in hepatocytes and cholangiocarcinoma cells It also has been reported that taurocholate TCA promotes large cholangiocyte proliferation and protects cholangiocytes from duct ligation BDL -induced apoptosis However the role of S1PR2 in bile-acid-mediated cholangiocyte proliferation and cholestatic injury has not been elucidated Here we report that S1PR2 is the predominant S1PR expressed in cholangiocytes Both TCA- and sphingosine-1-phosphate S1P -induced activation of ERK1/2 and AKT were inhibited by JTE-013 a specific antagonist of S1PR2 in cholangiocytes In addition TCA- and S1P-induced cell proliferation and migration were inhibited by JTE-013 and a specific short hairpin RNA of S1PR2 as well as chemical inhibitors of ERK1/2 and AKT in mouse cholangiocytes In BDL mice expression of S1PR2 was up-regulated in whole and cholangiocytes S1PR2 deficiency significantly reduced BDL-induced cholangiocyte proliferation and cholestatic injury as indicated by significant reductions in inflammation and fibrosis in S1PR2 knockout mice Treatment of BDL mice with JTE-013 significantly reduced total acid levels in serum and cholestatic injury This study suggests that CBA-induced activation of S1PR2-mediated signaling pathways plays a critical role in obstructive cholestasis and may represent a novel therapeutic target for cholestatic diseases Hepatology 2017 65:2005-2018,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2920, 3191, 16, 8, 1157, 15517, 9, 36366, 457, 1093, 9, 375, 24166, 114, 698, 94, 210, 17, 3868, 4562, 69715, 2977, 3, 178, 216, 132, 649, 2, 1976, 1235, 1065, 216, 14, 2, 18, 3533, 18, 314, 460, 298, 6451, 14, 4849, 153, 41654, 18, 4, 8291, 2, 2126, 37, 192, 120, 71, 85, 210, 17, 69716, 12674, 2148, 375, 36366, 457, 2, 8170, 24166, 29, 2920, 5307, 27357, 277, 351, 137, 3, 200, 1, 25800, 4, 26176, 971, 517, 36366, 457, 2, 24949, 2730, 71, 44, 85, 3901, 467, 21, 414, 17, 25800, 16, 3, 2750, 41654, 570, 4, 24166, 110, 12674, 2, 6451, 14, 4849, 4280, 277, 363, 1, 3533, 18, 2, 649, 11, 879, 20, 41655, 3612, 8, 112, 3137, 1, 25800, 4, 24166, 4, 352, 12674, 2, 4280, 277, 31, 457, 2, 1381, 11, 879, 20, 41655, 3612, 2, 8, 112, 978, 5957, 893, 1, 25800, 22, 149, 22, 3743, 222, 1, 3533, 18, 2, 649, 4, 830, 24166, 4, 27357, 399, 55, 1, 25800, 10, 126, 1065, 4, 902, 2, 24166, 25800, 2299, 97, 405, 27357, 277, 36366, 457, 2, 24949, 2730, 22, 1103, 20, 93, 2153, 4, 1815, 2, 3000, 4, 25800, 5687, 399, 24, 1, 27357, 399, 5, 41655, 3612, 97, 405, 181, 971, 148, 4, 524, 2, 24949, 2730, 26, 45, 844, 17, 21152, 277, 363, 1, 25800, 517, 314, 460, 1698, 8, 740, 200, 4, 6937, 19771, 2, 68, 1231, 8, 229, 189, 283, 9, 24949, 1342, 22809, 1759, 556, 1242, 2982]",1698.0,28120434,0
"Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium.",Diabetologia,Diabetologia,2017-03-07,"The aims of the study were to evaluate the association between type 2 diabetes and the risk of death from any cancer and specific cancers in East and South Asians. Pooled analyses were conducted of 19 prospective population-based cohorts included in the Asia Cohort Consortium, comprising data from 658,611 East Asians and 112,686 South Asians. HRs were used to compare individuals with diabetes at baseline with those without diabetes for the risk of death from any cancer and from site-specific cancers, including cancers of the oesophagus, stomach, colorectum, colon, rectum, liver, bile duct, pancreas, lung, breast, endometrium, cervix, ovary, prostate, bladder, kidney and thyroid, as well as lymphoma and leukaemia. During a mean follow-up of 12.7years, 37,343 cancer deaths (36,667 in East Asians and 676 in South Asians) were identified. Baseline diabetes status was statistically significantly associated with an increased risk of death from any cancer (HR 1.26; 95% CI 1.21, 1.31). Significant positive associations with diabetes were observed for cancers of the colorectum (HR 1.41; 95% CI 1.26, 1.57), liver (HR 2.05; 95% CI 1.77, 2.38), bile duct (HR 1.41; 95% CI 1.04, 1.92), gallbladder (HR 1.33; 95% CI 1.10, 1.61), pancreas (HR 1.53; 95% CI 1.32, 1.77), breast (HR 1.72; 95% CI 1.34, 2.19), endometrium (HR 2.73; 95% CI 1.53, 4.85), ovary (HR 1.60; 95% CI 1.06, 2.42), prostate (HR 1.41; 95% CI 1.09, 1.82), kidney (HR 1.84; 95% CI 1.28, 2.64) and thyroid (HR 1.99; 95% CI 1.03, 3.86), as well as lymphoma (HR 1.39; 95% CI 1.04, 1.86). Diabetes was not statistically significantly associated with the risk of death from leukaemia and cancers of the bladder, cervix, oesophagus, stomach and lung. Diabetes was associated with a 26% increased risk of death from any cancer in Asians. The pattern of associations with specific cancers suggests the need for better control (prevention, detection, management) of the growing epidemic of diabetes (as well as obesity), in order to reduce cancer mortality.",Journal Article,1050.0,35.0,"The aims of the study were to evaluate the association between type 2 diabetes and the risk of death from any cancer and specific cancers in East and South Asians Pooled analyses were conducted of 19 prospective population-based cohorts included in the Asia Cohort Consortium comprising data from 658,611 East Asians and 112,686 South Asians HRs were used to compare individuals with diabetes at baseline with those without diabetes for the risk of death from any cancer and from site-specific cancers including cancers of the oesophagus colorectum rectum duct cervix ovary and as well as and leukaemia During a mean follow-up of 12.7 years 37,343 cancer deaths 36,667 in East Asians and 676 in South Asians were identified Baseline diabetes status was statistically significantly associated with an increased risk of death from any cancer HR 1.26 95 CI 1.21 1.31 Significant positive associations with diabetes were observed for cancers of the colorectum HR 1.41 95 CI 1.26 1.57 HR 2.05 95 CI 1.77 2.38 duct HR 1.41 95 CI 1.04 1.92 HR 1.33 95 CI 1.10 1.61 HR 1.53 95 CI 1.32 1.77 HR 1.72 95 CI 1.34 2.19 HR 2.73 95 CI 1.53 4.85 ovary HR 1.60 95 CI 1.06 2.42 HR 1.41 95 CI 1.09 1.82 HR 1.84 95 CI 1.28 2.64 and HR 1.99 95 CI 1.03 3.86 as well as HR 1.39 95 CI 1.04 1.86 Diabetes was not statistically significantly associated with the risk of death from leukaemia and cancers of the cervix oesophagus and Diabetes was associated with a 26 increased risk of death from any cancer in Asians The pattern of associations with specific cancers suggests the need for better control prevention detection management of the growing epidemic of diabetes as well as obesity in order to reduce cancer mortality",1,1,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,"[3, 2970, 1, 3, 45, 11, 6, 376, 3, 248, 59, 267, 18, 1978, 2, 3, 43, 1, 273, 29, 500, 12, 2, 112, 163, 4, 6633, 2, 5452, 5108, 1830, 318, 11, 426, 1, 326, 482, 266, 90, 736, 159, 4, 3, 5958, 180, 2404, 3538, 74, 29, 13327, 10711, 6633, 5108, 2, 3726, 12324, 5452, 5108, 2733, 11, 95, 6, 932, 869, 5, 1978, 28, 330, 5, 135, 187, 1978, 9, 3, 43, 1, 273, 29, 500, 12, 2, 29, 606, 112, 163, 141, 163, 1, 3, 16966, 12355, 3660, 2920, 3629, 3631, 2, 22, 149, 22, 2, 2001, 190, 8, 313, 166, 126, 1, 133, 67, 60, 567, 8532, 12, 1043, 511, 10598, 4, 6633, 5108, 2, 11010, 4, 5452, 5108, 11, 108, 330, 1978, 156, 10, 712, 97, 41, 5, 35, 101, 43, 1, 273, 29, 500, 12, 168, 14, 432, 48, 58, 14, 239, 14, 456, 93, 109, 685, 5, 1978, 11, 164, 9, 163, 1, 3, 12355, 168, 14, 605, 48, 58, 14, 432, 14, 696, 168, 18, 474, 48, 58, 14, 849, 18, 519, 2920, 168, 14, 605, 48, 58, 14, 755, 14, 937, 168, 14, 466, 48, 58, 14, 79, 14, 713, 168, 14, 699, 48, 58, 14, 531, 14, 849, 168, 14, 720, 48, 58, 14, 562, 18, 326, 168, 18, 803, 48, 58, 14, 699, 39, 772, 3631, 168, 14, 335, 48, 58, 14, 1460, 18, 595, 168, 14, 605, 48, 58, 14, 1730, 14, 878, 168, 14, 874, 48, 58, 14, 339, 18, 660, 2, 168, 14, 1058, 48, 58, 14, 680, 27, 868, 22, 149, 22, 168, 14, 587, 48, 58, 14, 755, 14, 868, 1978, 10, 44, 712, 97, 41, 5, 3, 43, 1, 273, 29, 2001, 2, 163, 1, 3, 3629, 16966, 2, 1978, 10, 41, 5, 8, 432, 101, 43, 1, 273, 29, 500, 12, 4, 5108, 3, 1177, 1, 685, 5, 112, 163, 844, 3, 594, 9, 380, 182, 1070, 638, 284, 1, 3, 1921, 12515, 1, 1978, 22, 149, 22, 1661, 4, 1732, 6, 969, 12, 282]",1698.0,28265721,22
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.,Cell reports,Cell Rep,2017-03-01,"Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, with poor prognosis and limited treatment options. Here, we describe the integrated analysis of somatic mutations, RNA expression, copy number, and DNA methylation by The Cancer Genome Atlas of a set of predominantly intrahepatic CCA cases and propose a molecular classification scheme. We identified an IDH mutant-enriched subtype with distinct molecular features including low expression of chromatin modifiers, elevated expression of mitochondrial genes, and increased mitochondrial DNA copy number. Leveraging the multi-platform data, we observed that ARID1A exhibited DNA hypermethylation and decreased expression in the IDH mutant subtype. More broadly, we found that IDH mutations are associated with an expanded histological spectrum of liver tumors with molecular features that stratify with CCA. Our studies reveal insights into the molecular pathogenesis and heterogeneity of cholangiocarcinoma and provide classification information of potential therapeutic significance.",Journal Article,1056.0,93.0,Cholangiocarcinoma CCA is an aggressive malignancy of the ducts with poor prognosis and limited treatment options Here we describe the integrated analysis of somatic mutations RNA expression copy number and DNA methylation by The Cancer Genome Atlas of a set of predominantly intrahepatic CCA cases and propose a molecular classification scheme We identified an IDH mutant-enriched subtype with distinct molecular features including low expression of chromatin modifiers elevated expression of mitochondrial genes and increased mitochondrial DNA copy number Leveraging the multi-platform data we observed that ARID1A exhibited DNA hypermethylation and decreased expression in the IDH mutant subtype More broadly we found that IDH mutations are associated with an expanded histological spectrum of tumors with molecular features that stratify with CCA Our studies reveal insights into the molecular pathogenesis and heterogeneity of cholangiocarcinoma and provide classification information of potential therapeutic significance,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2126, 4317, 16, 35, 571, 710, 1, 3, 7310, 5, 334, 356, 2, 383, 24, 838, 467, 21, 897, 3, 2102, 65, 1, 1119, 138, 893, 55, 1337, 207, 2, 261, 569, 20, 3, 12, 898, 2643, 1, 8, 916, 1, 2117, 3022, 4317, 140, 2, 2548, 8, 219, 947, 4633, 21, 108, 35, 3056, 620, 2220, 875, 5, 834, 219, 404, 141, 154, 55, 1, 2287, 5663, 804, 55, 1, 2019, 214, 2, 101, 2019, 261, 1337, 207, 15023, 3, 1414, 2243, 74, 21, 164, 17, 5430, 1416, 261, 2575, 2, 340, 55, 4, 3, 3056, 620, 875, 80, 5482, 21, 204, 17, 3056, 138, 32, 41, 5, 35, 2064, 1831, 1873, 1, 57, 5, 219, 404, 17, 3570, 5, 4317, 114, 94, 2396, 1957, 237, 3, 219, 1384, 2, 1144, 1, 2126, 2, 377, 947, 487, 1, 174, 189, 724]",1027.0,28297679,36
Transarterial chemoembolization combined with computed tomography-guided 125iodine implantation enhances survival in hepatocellular carcinoma patients with portal vein tumor thrombus.,Oncotarget,Oncotarget,2017-04-01,"We conducted a retrospective study to evaluate the safety and efficacy of transarterial chemoembolization (TACE) combined with computed tomography-guided 125iodine implantation (TACE-125iodine) in hepatocellular carcinoma (HCC) patients with type B portal vein tumor thrombus (PVTT). From medical records, we determined that 50 patients who received 125iodine implantation 4-7 days after the first TACE session showed better survival than 50 patients who received only TACE (median survival, 13.1 vs. 6.0 months; P<0.01). Moreover, the PVTT control rate was higher in the TACE-125iodine than TACE alone group (78% vs. 18%; P<0.01). Multivariate analysis demonstrated that the TACE-125iodine procedure was an independent prognostic factor for overall survival. We also observed that bilirubin levels were increased at 4 weeks, indicating that 125iodine seeding in the PVTT beneficially impacted the small bile duct, which is proximal to the portal vein. No severe adverse events were observed in patients that received 125iodine seed implantation, and the mild adverse events were successfully treated. This study shows that TACE-125iodine therapy enhances patient survival with minimal adverse events. It is also more affordable than sorafenib, which is currently the recommended therapy for advanced HCC patients with PVTT.",Journal Article,1025.0,,We conducted a retrospective study to evaluate the safety and efficacy of transarterial chemoembolization TACE combined with computed tomography-guided 125iodine implantation TACE-125iodine in carcinoma HCC patients with type B portal vein tumor thrombus PVTT From medical records we determined that 50 patients who received 125iodine implantation 4-7 days after the first TACE session showed better survival than 50 patients who received only TACE median survival 13.1 vs. 6.0 months P 0.01 Moreover the PVTT control rate was higher in the TACE-125iodine than TACE alone group 78 vs. 18 P 0.01 Multivariate analysis demonstrated that the TACE-125iodine procedure was an independent prognostic factor for overall survival We also observed that bilirubin levels were increased at 4 weeks indicating that 125iodine seeding in the PVTT beneficially impacted the small duct which is proximal to the portal vein No severe adverse events were observed in patients that received 125iodine seed implantation and the mild adverse events were successfully treated This study shows that TACE-125iodine therapy enhances patient survival with minimal adverse events It is also more affordable than sorafenib which is currently the recommended therapy for advanced HCC patients with PVTT,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 426, 8, 459, 45, 6, 376, 3, 367, 2, 209, 1, 7671, 6056, 5202, 397, 5, 1220, 872, 1808, 25813, 4314, 5202, 25813, 4, 134, 663, 7, 5, 267, 132, 3307, 2762, 30, 5373, 19246, 29, 484, 1064, 21, 509, 17, 212, 7, 54, 103, 25813, 4314, 39, 67, 162, 50, 3, 157, 5202, 5510, 224, 380, 25, 76, 212, 7, 54, 103, 158, 5202, 52, 25, 233, 14, 105, 49, 13, 53, 19, 13, 355, 1393, 3, 19246, 182, 116, 10, 142, 4, 3, 5202, 25813, 76, 5202, 279, 87, 833, 105, 203, 19, 13, 355, 331, 65, 264, 17, 3, 5202, 25813, 1299, 10, 35, 306, 177, 161, 9, 63, 25, 21, 120, 164, 17, 5009, 148, 11, 101, 28, 39, 244, 1716, 17, 25813, 8051, 4, 3, 19246, 29182, 4619, 3, 302, 2920, 92, 16, 2805, 6, 3, 3307, 2762, 77, 905, 290, 281, 11, 164, 4, 7, 17, 103, 25813, 5467, 4314, 2, 3, 1980, 290, 281, 11, 1878, 73, 26, 45, 1949, 17, 5202, 25813, 36, 2519, 69, 25, 5, 1048, 290, 281, 192, 16, 120, 80, 8216, 76, 1034, 92, 16, 694, 3, 793, 36, 9, 131, 663, 7, 5, 19246]",1273.0,28418927,98
"NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2017-05-01,"The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.",Journal Article,995.0,94.0,The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the and ducts The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions examine relevant new data from publications and abstracts and reevaluate and update their recommendations These NCCN Guidelines Insights summarize the panel 's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with carcinoma,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1944, 677, 9, 4718, 163, 377, 24, 883, 9, 163, 1, 3, 2, 7310, 3, 1944, 4718, 163, 993, 13400, 28, 506, 4226, 6, 206, 13027, 29, 7171, 262, 136, 1764, 1004, 867, 217, 74, 29, 4463, 2, 5159, 2, 19087, 2, 2991, 136, 883, 46, 1944, 677, 1957, 2479, 3, 993, 292, 2488, 2, 96, 435, 883, 666, 1325, 36, 9, 24, 1, 7, 5, 134]",504.0,28476736,72
Identification of fucosylated Fetuin-A as a potential biomarker for cholangiocarcinoma.,Proteomics. Clinical applications,Proteomics Clin Appl,2017-07-10,"Cholangiocarcinoma (CCA) is a malignancy of the bile ducts. The purpose of this discovery study was to identify effective serum markers for surveillance of cholangiocarcinoma. Using a glycomic method, patients with CCA were determined to have increased levels of alpha-1,3 and alpha-1,6 linked fucosylated glycan. Proteomic analysis of the serum fucosylated proteome identified proteins such as alpha-2-macroglobulin, kininogen, hemopexin, fetuin-A, alpha-1 anti-trypsin, and ceruloplasmin as being hyperfucosylated in HCC. The levels of these glycoproteins in 109 patients with CCA, primary sclerosing cholangitis (PSC), and control patients were compared to the performance of CA-19-9, the current ""gold standard"" assay for cholangiocarcinoma. Fucosylated Fetuin-A (fc-Fetuin-A) had the best ability to differentiate CCA from PSC, with an AUROC of 0.812 or 0.8665 at differentiating CCA from those with PSC or other liver disease. CA-19-9 had poor ability to differentiate PSC from cholangiocarcinoma (AUROC of 0.625). Using glycomic and proteomic methods we identified a set of proteins that contain altered glycan in the sera of those with CCA. One of these proteins, fucosylated Fetuin-A may have value in the surveillance of people at risk for the development of cholangiocarcinoma.",Journal Article,925.0,3.0,"Cholangiocarcinoma CCA is a malignancy of the ducts The purpose of this discovery study was to identify effective serum markers for surveillance of cholangiocarcinoma Using a glycomic method patients with CCA were determined to have increased levels of alpha-1,3 and alpha-1,6 linked fucosylated glycan Proteomic analysis of the serum fucosylated proteome identified proteins such as alpha-2-macroglobulin kininogen hemopexin fetuin-A alpha-1 anti-trypsin and ceruloplasmin as being hyperfucosylated in HCC The levels of these glycoproteins in 109 patients with CCA primary sclerosing cholangitis PSC and control patients were compared to the performance of CA-19-9 the current `` gold standard '' assay for cholangiocarcinoma Fucosylated Fetuin-A fc-Fetuin-A had the best ability to differentiate CCA from PSC with an AUROC of 0.812 or 0.8665 at differentiating CCA from those with PSC or other disease CA-19-9 had poor ability to differentiate PSC from cholangiocarcinoma AUROC of 0.625 Using glycomic and proteomic methods we identified a set of proteins that contain altered glycan in the sera of those with CCA One of these proteins fucosylated Fetuin-A may have value in the surveillance of people at risk for the development of cholangiocarcinoma",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2126, 4317, 16, 8, 710, 1, 3, 7310, 3, 743, 1, 26, 1574, 45, 10, 6, 255, 323, 524, 525, 9, 617, 1, 2126, 75, 8, 25004, 596, 7, 5, 4317, 11, 509, 6, 47, 101, 148, 1, 950, 14, 27, 2, 950, 14, 49, 1199, 23305, 14626, 3784, 65, 1, 3, 524, 23305, 9895, 108, 652, 225, 22, 950, 18, 26378, 70488, 30921, 22880, 8, 950, 14, 312, 15990, 2, 26265, 22, 486, 70489, 4, 663, 3, 148, 1, 46, 18905, 4, 3486, 7, 5, 4317, 86, 6782, 8541, 5417, 2, 182, 7, 11, 72, 6, 3, 528, 1, 1568, 326, 83, 3, 291, 4159, 260, 522, 719, 9, 2126, 23305, 22880, 8, 4127, 22880, 8, 42, 3, 824, 801, 6, 3723, 4317, 29, 5417, 5, 35, 17024, 1, 13, 14162, 15, 13, 70490, 28, 5209, 4317, 29, 135, 5, 5417, 15, 127, 34, 1568, 326, 83, 42, 334, 801, 6, 3723, 5417, 29, 2126, 17024, 1, 13, 9629, 75, 25004, 2, 3784, 636, 21, 108, 8, 916, 1, 652, 17, 3725, 1495, 14626, 4, 3, 4210, 1, 135, 5, 4317, 104, 1, 46, 652, 23305, 22880, 8, 68, 47, 549, 4, 3, 617, 1, 3788, 28, 43, 9, 3, 193, 1, 2126]",1253.0,28561948,31
"Rare triad of periampullary carcinoid, duodenal gastrointestinal stromal tumor and plexiform neurofibroma at hepatic hilum in neurofibromatosis type 1: a case report.",BMC cancer,BMC Cancer,2017-08-29,"Neurofibromatosis type 1 is a relatively common inherited disorder. Patients with neurofibromatosis type 1 are at high risk of developing neurogenic, neuroendocrine and mesenchymal intra-abdominal tumors. Although coexistence of multiple tumors of different types is frequent in neurofibromatosis type 1, simultaneous occurrence of abdominal tumors of three types in very rare. A 66-year-old lady with neurofibromatosis type 1 presented with painless progressive jaundice for six months. Laboratory investigations revealed iron deficiency anemia and conjugated hyperbilirubinemia. Tumor markers were normal. Abdominal computed tomography showed a 32cm heterogenous mass in the periampullary region with mild dilation of the common bile duct and another 21.7cm mass in the fourth portion of the duodenum. Endoscopic biopsy confirmed the diagnosis of periampullary carcinoid. At surgery, multiple small nodules were detected at the hepatic hilum. Frozen section suggested them to be neurofibromas. Patient underwent pancreatoduodenectomy and had uneventful recovery with no recurrence at two months. Microscopic examination of the resected specimen confirmed presence of three tumors: periampullary well differentiated neuroendocrine tumor, gastrointestinal stromal tumor of the fourth part of duodenum and plexiform neurofibroma at the hepatic hilum. Patients of neurofibromatosis type 1 with abdominal symptoms should be treated with high index of clinical suspicion and thoroughly evaluated to rule out multiple tumors.",Case Reports,875.0,3.0,Neurofibromatosis type 1 is a relatively common inherited disorder Patients with neurofibromatosis type 1 are at high risk of developing neurogenic neuroendocrine and mesenchymal intra-abdominal tumors Although coexistence of multiple tumors of different types is frequent in neurofibromatosis type 1 simultaneous occurrence of abdominal tumors of three types in very rare A 66-year-old lady with neurofibromatosis type 1 presented with painless progressive jaundice for six months Laboratory investigations revealed iron deficiency anemia and conjugated hyperbilirubinemia Tumor markers were normal Abdominal computed tomography showed a 3 2 cm heterogenous mass in the periampullary region with mild dilation of the common duct and another 2 1.7 cm mass in the fourth portion of the duodenum Endoscopic biopsy confirmed the diagnosis of periampullary At surgery multiple small nodules were detected at the hepatic hilum Frozen section suggested them to be neurofibromas Patient underwent pancreatoduodenectomy and had uneventful recovery with no recurrence at two months Microscopic examination of the resected specimen confirmed presence of three tumors periampullary well differentiated neuroendocrine tumor stromal tumor of the fourth part of duodenum and plexiform neurofibroma at the hepatic hilum Patients of neurofibromatosis type 1 with abdominal symptoms should be treated with high index of clinical suspicion and thoroughly evaluated to rule out multiple tumors,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[7427, 267, 14, 16, 8, 1352, 186, 2986, 2645, 7, 5, 7427, 267, 14, 32, 28, 64, 43, 1, 931, 16731, 1542, 2, 1569, 2392, 1467, 57, 242, 15587, 1, 232, 57, 1, 338, 630, 16, 908, 4, 7427, 267, 14, 2824, 2291, 1, 1467, 57, 1, 169, 630, 4, 923, 622, 8, 700, 111, 1095, 38667, 5, 7427, 267, 14, 917, 5, 14963, 1014, 7655, 9, 437, 53, 1624, 2492, 553, 4231, 2299, 1545, 2, 3868, 7236, 30, 525, 11, 295, 1467, 1220, 872, 224, 8, 27, 18, 494, 8189, 782, 4, 3, 9180, 1053, 5, 1980, 8062, 1, 3, 186, 2920, 2, 1809, 18, 14, 67, 494, 782, 4, 3, 3608, 3206, 1, 3, 8401, 2056, 411, 557, 3, 147, 1, 9180, 28, 152, 232, 302, 2597, 11, 530, 28, 3, 939, 17244, 3015, 2917, 1148, 1370, 6, 40, 12351, 69, 208, 11710, 2, 42, 16742, 1602, 5, 77, 146, 28, 100, 53, 2984, 1385, 1, 3, 1133, 2360, 557, 463, 1, 169, 57, 9180, 149, 1442, 1542, 30, 1126, 30, 1, 3, 3608, 760, 1, 8401, 2, 16617, 20910, 28, 3, 939, 17244, 7, 1, 7427, 267, 14, 5, 1467, 507, 257, 40, 73, 5, 64, 558, 1, 38, 5782, 2, 11576, 194, 6, 5340, 1205, 232, 57]",1474.0,28851321,3
"Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.",Annals of surgical oncology,Ann. Surg. Oncol.,2017-09-05,"There is debate regarding the definition and clinical significance of margin clearance in pancreatic ductal adenocarcinoma (PDA). A comprehensive archival analysis of surgical resection margins was performed to determine the effect on locoregional recurrence and survival, and the impact of adjuvant therapy in PDA. We identified 105 patients with resected PDA. Pancreatic, anterior, bile duct, and posterior surgical resection margins (PM; posterior surface, uncinate and vascular groove) were identified. Three pathologists reviewed all archival surgical specimens and recategorized each margin as tumor at ink/transected, <0.5, 0.5-1, >1-2, or >2mm from the inked surface. The impact of these and other clinical variables was assessed on local control, disease-free survival (DFS), and overall survival (OS). Among all margins, PM clearance up to 2mm was prognostic of DFS (p=0.01) and OS (p=0.01). Dichotomizing the PM at 2mm revealed it to be an independent predictor of local recurrence-free survival [hazard ratio HR] 0.20, 95% confidence interval [CI] 0.048-0.881, p=0.033), DFS (HR 0.46, 95% CI 0.22-0.96, p=0.03), and OS (HR 0.31, 95% CI 0.14-0.74, p=0.008). A margin status of >2mm was also prognostic of OS in patients who received adjuvant chemotherapy (HR 0.31, 95% CI 0.11-0.89, p=0.03), however this difference was mitigated in patients receiving adjuvant chemoradiotherapy (HR 0.40, 95% CI 0.10-1.58, p=0.19). These data highlight the clinical significance of the PM and the lack of significance of other resection margins. Clearance in excess of 2mm should be considered to improve long-term clinical outcomes. The use of adjuvant radiotherapy should be strongly considered in patients with PMs <2mm.",Journal Article,868.0,7.0,There is debate regarding the definition and clinical significance of margin clearance in ductal adenocarcinoma PDA A comprehensive archival analysis of surgical resection margins was performed to determine the effect on locoregional recurrence and survival and the impact of adjuvant therapy in PDA We identified 105 patients with resected PDA anterior duct and posterior surgical resection margins PM posterior surface uncinate and vascular groove were identified Three pathologists reviewed all archival surgical specimens and recategorized each margin as tumor at ink/transected 0.5 0.5-1 1-2 or 2 mm from the inked surface The impact of these and other clinical variables was assessed on local control disease-free survival DFS and overall survival OS Among all margins PM clearance up to 2 mm was prognostic of DFS p 0.01 and OS p 0.01 Dichotomizing the PM at 2 mm revealed it to be an independent predictor of local recurrence-free survival hazard ratio HR 0.20 95 confidence interval CI 0.048-0.881 p 0.033 DFS HR 0.46 95 CI 0.22-0.96 p 0.03 and OS HR 0.31 95 CI 0.14-0.74 p 0.008 A margin status of 2 mm was also prognostic of OS in patients who received adjuvant chemotherapy HR 0.31 95 CI 0.11-0.89 p 0.03 however this difference was mitigated in patients receiving adjuvant chemoradiotherapy HR 0.40 95 CI 0.10-1.58 p 0.19 These data highlight the clinical significance of the PM and the lack of significance of other resection margins Clearance in excess of 2 mm should be considered to improve long-term clinical outcomes The use of adjuvant radiotherapy should be strongly considered in patients with PMs 2 mm,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[125, 16, 5220, 666, 3, 2470, 2, 38, 724, 1, 959, 1960, 4, 1258, 449, 3741, 8, 949, 3967, 65, 1, 221, 170, 1012, 10, 173, 6, 223, 3, 254, 23, 1325, 146, 2, 25, 2, 3, 345, 1, 249, 36, 4, 3741, 21, 108, 3263, 7, 5, 1133, 3741, 2882, 2920, 2, 3028, 221, 170, 1012, 3377, 3028, 1255, 14960, 2, 756, 17860, 11, 108, 169, 3354, 446, 62, 3967, 221, 623, 2, 48733, 296, 959, 22, 30, 28, 8054, 26996, 13, 33, 13, 33, 14, 14, 18, 15, 18, 321, 29, 3, 16707, 1255, 3, 345, 1, 46, 2, 127, 38, 682, 10, 275, 23, 293, 182, 34, 115, 25, 1010, 2, 63, 25, 118, 107, 62, 1012, 3377, 1960, 126, 6, 18, 321, 10, 177, 1, 1010, 19, 13, 355, 2, 118, 19, 13, 355, 31894, 3, 3377, 28, 18, 321, 553, 192, 6, 40, 35, 306, 980, 1, 293, 146, 115, 25, 360, 197, 168, 13, 179, 48, 307, 268, 58, 13, 4969, 13, 13057, 19, 13, 5254, 1010, 168, 13, 641, 48, 58, 13, 350, 13, 921, 19, 13, 680, 2, 118, 168, 13, 456, 48, 58, 13, 213, 13, 794, 19, 13, 2155, 8, 959, 156, 1, 18, 321, 10, 120, 177, 1, 118, 4, 7, 54, 103, 249, 56, 168, 13, 456, 48, 58, 13, 175, 13, 887, 19, 13, 680, 137, 26, 523, 10, 10042, 4, 7, 357, 249, 1464, 168, 13, 327, 48, 58, 13, 79, 14, 717, 19, 13, 326, 46, 74, 1817, 3, 38, 724, 1, 3, 3377, 2, 3, 926, 1, 724, 1, 127, 170, 1012, 1960, 4, 2612, 1, 18, 321, 257, 40, 515, 6, 401, 319, 337, 38, 123, 3, 119, 1, 249, 310, 257, 40, 1327, 515, 4, 7, 5, 31993, 18, 321]",1624.0,28871564,21
Evaluating the American College of Surgeons National Surgical Quality Improvement project risk calculator: results from the U.S. Extrahepatic Biliary Malignancy Consortium.,HPB : the official journal of the International Hepato Pancreato Biliary Association,HPB (Oxford),2017-09-07,"The objective of this study is to evaluate use of the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) online risk calculator for estimating common outcomes after operations for gallbladder cancer and extrahepatic cholangiocarcinoma. Subjects from the United States Extrahepatic Biliary Malignancy Consortium (USE-BMC) who underwent operation between January 1, 2000 and December 31, 2014at 10 academic medical centers were included in this study. Calculator estimates of risk were compared to actual outcomes. The majority of patients underwent partial or major hepatectomy, Whipple procedures or extrahepatic bile duct resection. For the entire cohort, c-statistics for surgical site infection (0.635), reoperation (0.680) and readmission (0.565) were less than 0.7. The c-statistic for death was 0.740. For all outcomes the actual proportion of patients experiencing an event was much higher than the median predicted risk of that event. Similarly, the group of patients who experienced an outcome did have higher median predicted risk than those who did not. The ACS NSQIP risk calculator is easy to use but requires further modifications to more accurately estimate outcomes for some patient populations and operations for which validation studies show suboptimal performance.",Evaluation Study,866.0,10.0,The objective of this study is to evaluate use of the American College of Surgeons ACS National Surgical Quality Improvement Program NSQIP online risk calculator for estimating common outcomes after operations for cancer and extrahepatic cholangiocarcinoma Subjects from the United States Extrahepatic Biliary Malignancy Consortium USE-BMC who underwent operation between January 1 2000 and December 31 2014 at 10 academic medical centers were included in this study Calculator estimates of risk were compared to actual outcomes The majority of patients underwent partial or major hepatectomy Whipple procedures or extrahepatic duct resection For the entire cohort c-statistics for surgical site infection 0.635 reoperation 0.680 and readmission 0.565 were less than 0.7 The c-statistic for death was 0.740 For all outcomes the actual proportion of patients experiencing an event was much higher than the median predicted risk of that event Similarly the group of patients who experienced an outcome did have higher median predicted risk than those who did not The ACS NSQIP risk calculator is easy to use but requires further modifications to more accurately estimate outcomes for some patient populations and operations for which validation studies show suboptimal performance,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 461, 1, 26, 45, 16, 6, 376, 119, 1, 3, 597, 2979, 1, 1613, 6004, 657, 221, 372, 767, 1243, 8280, 4123, 43, 11205, 9, 4563, 186, 123, 50, 3867, 9, 12, 2, 3710, 2126, 976, 29, 3, 1088, 907, 3710, 2532, 710, 2404, 119, 45661, 54, 208, 2589, 59, 1024, 14, 1081, 2, 1397, 456, 1409, 28, 79, 1916, 484, 1168, 11, 159, 4, 26, 45, 11205, 1423, 1, 43, 11, 72, 6, 3480, 123, 3, 686, 1, 7, 208, 450, 15, 458, 2711, 21089, 1369, 15, 3710, 2920, 170, 9, 3, 1797, 180, 256, 3065, 9, 221, 606, 930, 13, 12254, 5077, 13, 9297, 2, 3146, 13, 10852, 11, 299, 76, 13, 67, 3, 256, 4502, 9, 273, 10, 13, 10880, 9, 62, 123, 3, 3480, 920, 1, 7, 2985, 35, 774, 10, 1802, 142, 76, 3, 52, 783, 43, 1, 17, 774, 1813, 3, 87, 1, 7, 54, 592, 35, 228, 205, 47, 142, 52, 783, 43, 76, 135, 54, 205, 44, 3, 6004, 8280, 43, 11205, 16, 6261, 6, 119, 84, 1706, 195, 2916, 6, 80, 2141, 1191, 123, 9, 476, 69, 1184, 2, 3867, 9, 92, 929, 94, 514, 3291, 528]",1278.0,28890310,107
"In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of <sup>18</sup>F-(2S,4R)-4-Fluoroglutamine.",Radiology,Radiology,2018-01-31,"Purpose To assess the clinical safety, pharmacokinetics, and tumor imaging characteristics of fluorine 18-(2S,4R)-4-fluoroglutamine (FGln), a glutamine analog radiologic imaging agent. Materials and Methods This study was approved by the institutional review board and conducted under a U.S. Food and Drug Administration-approved Investigational New Drug application in accordance with the Helsinki Declaration and the Health Insurance Portability and Accountability Act. All patients provided written informed consent. Between January 2013 and October 2016, 25 adult patients with cancer received an intravenous bolus of FGln tracer (mean, 244 MBq  118, <100 g) followed by positron emission tomography (PET) and blood radioassays. Patient data were summarized with descriptive statistics. FGln biodistribution and plasma amino acid levels in nonfasting patients (n = 13) were compared with those from patients who fasted at least 8 hours before injection (n = 12) by using nonparametric one-way analysis of variance with Bonferroni correction. Tumor FGln avidity versus fluorodeoxyglucose (FDG) avidity in patients with paired PET scans (n = 15) was evaluated with the Fisher exact test. P < .05 was considered indicative of a statistically significant difference. Results FGln PET depicted tumors of different cancer types (breast, pancreas, renal, neuroendocrine, lung, colon, lymphoma, bile duct, or glioma) in 17 of the 25 patients, predominantly clinically aggressive tumors with genetic mutations implicated in abnormal glutamine metabolism. Acute fasting had no significant effect on FGln biodistribution and plasma amino acid levels. FGln-avid tumors were uniformly FDG-avid but not vice versa (P = .07). Patients experienced no adverse effects. Conclusion Preliminary human FGln PET trial results provide clinical validation of abnormal glutamine metabolism as a potential tumor biomarker for targeted radiotracer imaging in several different cancer types. <sup></sup> RSNA, 2018 Online supplemental material is available for this article. Clinical trial registration no. NCT01697930.","Clinical Trial, Phase I",720.0,14.0,"Purpose To assess the clinical safety pharmacokinetics and tumor imaging characteristics of fluorine 18- 2S,4R -4-fluoroglutamine FGln a glutamine analog radiologic imaging agent Materials and Methods This study was approved by the institutional review board and conducted under a U.S. Food and Drug Administration-approved Investigational New Drug application in accordance with the Helsinki Declaration and the Health Insurance Portability and Accountability Act All patients provided written informed consent Between January 2013 and October 2016 25 adult patients with cancer received an intravenous bolus of FGln tracer mean 244 MBq  118 100 g followed by positron emission tomography PET and blood radioassays Patient data were summarized with descriptive statistics FGln biodistribution and plasma amino acid levels in nonfasting patients n 13 were compared with those from patients who fasted at least 8 hours before injection n 12 by using nonparametric one-way analysis of variance with Bonferroni correction Tumor FGln avidity versus fluorodeoxyglucose FDG avidity in patients with paired PET scans n 15 was evaluated with the Fisher exact test P .05 was considered indicative of a statistically significant difference Results FGln PET depicted tumors of different cancer types neuroendocrine duct or glioma in 17 of the 25 patients predominantly clinically aggressive tumors with genetic mutations implicated in abnormal glutamine metabolism Acute fasting had no significant effect on FGln biodistribution and plasma amino acid levels FGln-avid tumors were uniformly FDG-avid but not vice versa P .07 Patients experienced no adverse effects Conclusion Preliminary human FGln PET trial results provide clinical validation of abnormal glutamine metabolism as a potential tumor biomarker for targeted radiotracer imaging in several different cancer types sup  /sup RSNA 2018 Online supplemental material is available for this article Clinical trial registration no NCT01697930",1,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[743, 6, 423, 3, 38, 367, 1159, 2, 30, 270, 374, 1, 10190, 203, 17482, 27837, 39, 48848, 20060, 8, 6425, 3497, 2812, 270, 420, 5102, 2, 636, 26, 45, 10, 850, 20, 3, 1115, 206, 2620, 2, 426, 669, 8, 1767, 695, 1773, 2, 234, 634, 850, 3093, 217, 234, 1581, 4, 8934, 5, 3, 24150, 27037, 2, 3, 341, 1935, 16400, 2, 13625, 2559, 62, 7, 1052, 6538, 2767, 3844, 59, 1024, 1346, 2, 2551, 1390, 243, 780, 7, 5, 12, 103, 35, 1262, 3604, 1, 20060, 6160, 313, 6567, 5372, 810, 4002, 394, 3802, 370, 20, 1900, 1799, 872, 495, 2, 315, 72056, 69, 74, 11, 3989, 5, 3778, 3065, 20060, 5250, 2, 554, 3078, 971, 148, 4, 31173, 7, 78, 233, 11, 72, 5, 135, 29, 7, 54, 15580, 28, 506, 66, 1459, 348, 1754, 78, 133, 20, 75, 8310, 104, 2255, 65, 1, 4446, 5, 10115, 5360, 30, 20060, 6071, 185, 4085, 1285, 6071, 4, 7, 5, 2355, 495, 1441, 78, 167, 10, 194, 5, 3, 3135, 2472, 412, 19, 474, 10, 515, 5572, 1, 8, 712, 93, 523, 99, 20060, 495, 14474, 57, 1, 338, 12, 630, 1542, 2920, 15, 945, 4, 269, 1, 3, 243, 7, 2117, 505, 571, 57, 5, 336, 138, 1771, 4, 1668, 6425, 1600, 286, 5706, 42, 77, 93, 254, 23, 20060, 5250, 2, 554, 3078, 971, 148, 20060, 5189, 57, 11, 4254, 1285, 5189, 84, 44, 10449, 10313, 19, 1615, 7, 592, 77, 290, 176, 1221, 1676, 171, 20060, 495, 160, 99, 377, 38, 929, 1, 1668, 6425, 1600, 22, 8, 174, 30, 901, 9, 238, 7610, 270, 4, 392, 338, 12, 630, 172, 2206, 172, 15426, 2982, 4123, 6303, 3692, 16, 390, 9, 26, 946, 38, 160, 3169, 77, 72057]",1988.0,29388903,28
The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma.,Annals of surgical oncology,Ann. Surg. Oncol.,2018-02-22,"The impact of re-resection of a positive intraoperative bile duct margin on clinical outcomes for resectable hilar cholangiocarcinoma (HCCA) remains controversial. We sought to define the impact of re-resection of an initially positive frozen-section bile duct margin on outcomes of patients undergoing surgery for HCCA. Patients who underwent curative-intent resection for HCCA between 2000 and 2014 were identified at 10 hepatobiliary centers. Short- and long-term outcomes were analyzed among patients stratified by margin status. Among 215 (83.7%) patients who underwent frozen-section evaluation of the bile duct, 80 (37.2%) patients had a positive (R1) ductal margin, 58 (72.5%) underwent re-resection, and 29 ultimately had a secondary negative margin (secondary R0). There was no difference in morbidity, 30-day mortality, and length of stay among patients who had primary R0, secondary R0, and R1 resection (all p>0.10). Median and 5-year survival were 22.3 months and 23.3%, respectively, among patients who had a primary R0 resection compared with 18.5months and 7.9%, respectively, for patients with an R1 resection (p=0.08). In contrast, among patients who had a secondary R0 margin with re-resection of the bile duct margin, median and 5-year survival were 30.6 months and 44.3%, respectively, which was comparable to patients with a primary R0 margin (p=0.804). On multivariable analysis, R1 margin resection was associated with decreased survival (R1: hazard ratio [HR] 1.3, 95% confidence interval [CI] 1.0-1.7; p=0.027), but secondary R0 resection was associated with comparable long-term outcomes as primary R0 resection (HR 0.9, 95% CI 0.4-2.3; p=0.829). Additional resection of a positive frozen-section ductal margin to achieve R0 resection was associated with improved long-term outcomes following curative-intent resection of HCCA.",Journal Article,698.0,9.0,The impact of re-resection of a positive intraoperative duct margin on clinical outcomes for resectable hilar cholangiocarcinoma HCCA remains controversial We sought to define the impact of re-resection of an initially positive frozen-section duct margin on outcomes of patients undergoing surgery for HCCA Patients who underwent curative-intent resection for HCCA between 2000 and 2014 were identified at 10 hepatobiliary centers Short- and long-term outcomes were analyzed among patients stratified by margin status Among 215 83.7 patients who underwent frozen-section evaluation of the duct 80 37.2 patients had a positive R1 ductal margin 58 72.5 underwent re-resection and 29 ultimately had a secondary negative margin secondary R0 There was no difference in morbidity 30-day mortality and length of stay among patients who had primary R0 secondary R0 and R1 resection all p 0.10 Median and 5-year survival were 22.3 months and 23.3 respectively among patients who had a primary R0 resection compared with 18.5 months and 7.9 respectively for patients with an R1 resection p 0.08 In contrast among patients who had a secondary R0 margin with re-resection of the duct margin median and 5-year survival were 30.6 months and 44.3 respectively which was comparable to patients with a primary R0 margin p 0.804 On multivariable analysis R1 margin resection was associated with decreased survival R1 hazard ratio HR 1.3 95 confidence interval CI 1.0-1.7 p 0.027 but secondary R0 resection was associated with comparable long-term outcomes as primary R0 resection HR 0.9 95 CI 0.4-2.3 p 0.829 Additional resection of a positive frozen-section ductal margin to achieve R0 resection was associated with improved long-term outcomes following curative-intent resection of HCCA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 345, 1, 1491, 170, 1, 8, 109, 1720, 2920, 959, 23, 38, 123, 9, 1899, 4793, 2126, 9280, 469, 2010, 21, 990, 6, 1107, 3, 345, 1, 1491, 170, 1, 35, 1625, 109, 3015, 2917, 2920, 959, 23, 123, 1, 7, 479, 152, 9, 9280, 7, 54, 208, 1075, 1697, 170, 9, 9280, 59, 1081, 2, 1409, 11, 108, 28, 79, 4718, 1168, 978, 2, 319, 337, 123, 11, 311, 107, 7, 1173, 20, 959, 156, 107, 6511, 852, 67, 7, 54, 208, 3015, 2917, 451, 1, 3, 2920, 493, 567, 18, 7, 42, 8, 109, 3239, 1258, 959, 717, 720, 33, 208, 1491, 170, 2, 462, 2050, 42, 8, 568, 199, 959, 568, 2328, 125, 10, 77, 523, 4, 787, 201, 218, 282, 2, 1318, 1, 2020, 107, 7, 54, 42, 86, 2328, 568, 2328, 2, 3239, 170, 62, 19, 13, 79, 52, 2, 33, 111, 25, 11, 350, 27, 53, 2, 382, 27, 106, 107, 7, 54, 42, 8, 86, 2328, 170, 72, 5, 203, 33, 53, 2, 67, 83, 106, 9, 7, 5, 35, 3239, 170, 19, 13, 1592, 4, 748, 107, 7, 54, 42, 8, 568, 2328, 959, 5, 1491, 170, 1, 3, 2920, 959, 52, 2, 33, 111, 25, 11, 201, 49, 53, 2, 584, 27, 106, 92, 10, 1279, 6, 7, 5, 8, 86, 2328, 959, 19, 13, 10853, 23, 658, 65, 3239, 959, 170, 10, 41, 5, 340, 25, 3239, 360, 197, 168, 14, 27, 48, 307, 268, 58, 14, 13, 14, 67, 19, 13, 4523, 84, 568, 2328, 170, 10, 41, 5, 1279, 319, 337, 123, 22, 86, 2328, 170, 168, 13, 83, 48, 58, 13, 39, 18, 27, 19, 13, 13904, 402, 170, 1, 8, 109, 3015, 2917, 1258, 959, 6, 1359, 2328, 170, 10, 41, 5, 231, 319, 337, 123, 366, 1075, 1697, 170, 1, 9280]",1770.0,29470820,30
Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging.,Journal of the American College of Surgeons,J. Am. Coll. Surg.,2018-04-06,"Many patients with resectable perihilar cholangiocarcinoma (PHC) on imaging are diagnosed intraoperatively with occult metastatic or locally advanced disease, precluding a curative-intent resection. This study aimed to develop and validate a preoperative risk score. Patients with resectable PHC on imaging who underwent operations in 2 high-volume centers (US and Europe) between 2000 and 2015 were included. Multivariable logistic regression analysis was used to develop the risk score. Cross-validation was used to validate the score, alternating the 2 centers as ""training"" and ""testing"" datasets. Of 566 patients who underwent operations, 309 (55%) patients had a resection, and in 257 (45%) patients, a curative-intent resection was precluded due to distant metastasis (n= 151 [27%]) or locally advanced disease (n= 106 [19%]). Preoperative predictors included bilirubin >2 mg/dL, bile duct involvement on imaging, portal vein involvement on imaging (180 degrees), hepatic artery involvement on imaging (180 degrees), and suspicious lymph nodes on imaging. The new risk score (c-index 0.75 after cross-validation) provided significantly more accurate predictions than the Bismuth classification (c-index 0.62), Blumgart T-staging (c-index 0.67), and cTNM staging (c-index 0.68). The new risk score identified 4 risk groups for occult metastatic or locally advanced disease: low (14.7%), intermediate (29.5%), high (47.3%), and very high risk (81.3%). The preoperative score groups also predicted survival after operation, irrespective of intraoperative findings (p<0.001). The validated risk score can predict occult distant metastatic or locally advanced PHC basedon 5 preoperatively available factors. The score can be useful in preoperative shared decision making and selection of patients in neoadjuvant clinical trials.",Journal Article,655.0,2.0,Many patients with resectable perihilar cholangiocarcinoma PHC on imaging are diagnosed intraoperatively with occult metastatic or locally advanced disease precluding a curative-intent resection This study aimed to develop and validate a preoperative risk score Patients with resectable PHC on imaging who underwent operations in 2 high-volume centers US and Europe between 2000 and 2015 were included Multivariable logistic regression analysis was used to develop the risk score Cross-validation was used to validate the score alternating the 2 centers as `` training '' and `` testing '' datasets Of 566 patients who underwent operations 309 55 patients had a resection and in 257 45 patients a curative-intent resection was precluded due to distant metastasis n 151 27 or locally advanced disease n 106 19 Preoperative predictors included bilirubin 2 mg/dL duct involvement on imaging portal vein involvement on imaging 180 degrees hepatic artery involvement on imaging 180 degrees and suspicious lymph nodes on imaging The new risk score c-index 0.75 after cross-validation provided significantly more accurate predictions than the Bismuth classification c-index 0.62 Blumgart T-staging c-index 0.67 and cTNM staging c-index 0.68 The new risk score identified 4 risk groups for occult metastatic or locally advanced disease low 14.7 intermediate 29.5 high 47.3 and very high risk 81.3 The preoperative score groups also predicted survival after operation irrespective of intraoperative findings p 0.001 The validated risk score can predict occult distant metastatic or locally advanced PHC based on 5 preoperatively available factors The score can be useful in preoperative shared decision making and selection of patients in neoadjuvant clinical trials,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[445, 7, 5, 1899, 9124, 2126, 9615, 23, 270, 32, 265, 6595, 5, 2879, 113, 15, 795, 131, 34, 13551, 8, 1075, 1697, 170, 26, 45, 1295, 6, 690, 2, 2183, 8, 498, 43, 368, 7, 5, 1899, 9615, 23, 270, 54, 208, 3867, 4, 18, 64, 433, 1168, 843, 2, 3934, 59, 1081, 2, 1483, 11, 159, 658, 812, 320, 65, 10, 95, 6, 690, 3, 43, 368, 1383, 929, 10, 95, 6, 2183, 3, 368, 5181, 3, 18, 1168, 22, 1741, 522, 2, 471, 522, 3455, 1, 14539, 7, 54, 208, 3867, 9440, 614, 7, 42, 8, 170, 2, 4, 7941, 512, 7, 8, 1075, 1697, 170, 10, 8035, 520, 6, 626, 278, 78, 5075, 428, 15, 795, 131, 34, 78, 3251, 326, 498, 674, 159, 5009, 18, 81, 1826, 2920, 799, 23, 270, 3307, 2762, 799, 23, 270, 31719, 4133, 939, 2872, 799, 23, 270, 31719, 4133, 2, 3230, 263, 502, 23, 270, 3, 217, 43, 368, 256, 558, 13, 481, 50, 1383, 929, 1052, 97, 80, 1481, 4340, 76, 3, 22291, 947, 256, 558, 13, 744, 26876, 102, 632, 256, 558, 13, 598, 2, 37895, 632, 256, 558, 13, 806, 3, 217, 43, 368, 108, 39, 43, 271, 9, 2879, 113, 15, 795, 131, 34, 154, 213, 67, 919, 462, 33, 64, 662, 27, 2, 923, 64, 43, 865, 27, 3, 498, 368, 271, 120, 783, 25, 50, 2589, 3500, 1, 1720, 272, 19, 13, 144, 3, 938, 43, 368, 122, 678, 2879, 626, 113, 15, 795, 131, 9615, 90, 23, 33, 3888, 390, 130, 3, 368, 122, 40, 999, 4, 498, 2664, 948, 1079, 2, 881, 1, 7, 4, 536, 38, 143]",1759.0,29627334,70
Technique for the administration of high-dose-rate brachytherapy to the bile duct using a nasobiliary catheter.,Brachytherapy,Brachytherapy,,"Cholangiocarcinoma patients who are potential candidates for liver transplantation may be treated with high-dose-rate (HDR) brachytherapy using a minimally invasive nasobiliary catheter in an effort to escalate the radiotherapy dose to the tumor and maximize local control rates. This work describes the equipment, procedures, and quality assurance (QA) that enables successful administration. This work describes the nasobiliary catheter placement, simulation, treatment planning, treatment delivery, and QA. In addition, a chart review was performed of all patients who received endoscopic retrograde cholangiopancreatography for HDR bile duct brachytherapy at our institution from 2007 to 2017. The review evaluated how many patients were treated and the number of patients who could not be treated because of anatomic and/or equipment limitations. From 2007 to 2017, 122 cholangiocarcinoma patients have been treated with HDR brachytherapy using a nasobiliary catheter. Three patients underwent catheter placement but did not receive brachytherapy treatment due to catheter migration between placement and treatment or because the HDR afterloader was unable to extend the source wire into the treatment site. Periodic QA is recommended for ensuring whether the HDR afterloader is capable of extending the source wire through an extensive and curved path. Intraluminal HDR brachytherapy with a nasobiliary catheter can be successfully administered. Procedures and QA are described for ensuring safety and overcoming technical challenges.",Journal Article,,1.0,Cholangiocarcinoma patients who are potential candidates for transplantation may be treated with high-dose-rate HDR brachytherapy using a minimally invasive nasobiliary catheter in an effort to escalate the radiotherapy dose to the tumor and maximize local control rates This work describes the equipment procedures and quality assurance QA that enables successful administration This work describes the nasobiliary catheter placement simulation treatment planning treatment delivery and QA In addition a chart review was performed of all patients who received endoscopic retrograde cholangiopancreatography for HDR duct brachytherapy at our institution from 2007 to 2017 The review evaluated how many patients were treated and the number of patients who could not be treated because of anatomic and/or equipment limitations From 2007 to 2017 122 cholangiocarcinoma patients have been treated with HDR brachytherapy using a nasobiliary catheter Three patients underwent catheter placement but did not receive brachytherapy treatment due to catheter migration between placement and treatment or because the HDR afterloader was unable to extend the source wire into the treatment site Periodic QA is recommended for ensuring whether the HDR afterloader is capable of extending the source wire through an extensive and curved path Intraluminal HDR brachytherapy with a nasobiliary catheter can be successfully administered Procedures and QA are described for ensuring safety and overcoming technical challenges,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2126, 7, 54, 32, 174, 1931, 9, 497, 68, 40, 73, 5, 64, 61, 116, 5309, 1536, 75, 8, 2144, 416, 28550, 3925, 4, 35, 2919, 6, 10400, 3, 310, 61, 6, 3, 30, 2, 4116, 293, 182, 151, 26, 1357, 2677, 3, 12583, 1369, 2, 372, 8050, 11714, 17, 4843, 1401, 634, 26, 1357, 2677, 3, 28550, 3925, 2613, 4026, 24, 1349, 24, 989, 2, 11714, 4, 352, 8, 2937, 206, 10, 173, 1, 62, 7, 54, 103, 2056, 10583, 15476, 9, 5309, 2920, 1536, 28, 114, 731, 29, 1307, 6, 1759, 3, 206, 194, 832, 445, 7, 11, 73, 2, 3, 207, 1, 7, 54, 359, 44, 40, 73, 408, 1, 2745, 2, 15, 12583, 1939, 29, 1307, 6, 1759, 3285, 2126, 7, 47, 85, 73, 5, 5309, 1536, 75, 8, 28550, 3925, 169, 7, 208, 3925, 2613, 84, 205, 44, 560, 1536, 24, 520, 6, 3925, 1381, 59, 2613, 2, 24, 15, 408, 3, 5309, 30740, 10, 4253, 6, 4087, 3, 2353, 9580, 237, 3, 24, 606, 9086, 11714, 16, 793, 9, 8397, 317, 3, 5309, 30740, 16, 2787, 1, 4782, 3, 2353, 9580, 298, 35, 1344, 2, 30529, 6361, 19960, 5309, 1536, 5, 8, 28550, 3925, 122, 40, 1878, 468, 1369, 2, 11714, 32, 1027, 9, 8397, 367, 2, 5344, 3359, 1427]",1507.0,29776892,22
"Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).",The oncologist,Oncologist,2018-05-31,"Ramucirumab plus pembrolizumab revealed no unexpected safety findings in patients with advanced or metastatic biliary tract cancer, which is consistent with reports of other tumor cohorts within this phase Ia/b trial.Ramucirumab plus pembrolizumab did not demonstrate an improvement in overall survival when compared with historical controls in biomarker unselected, heavily pretreated patients with advanced or metastatic biliary tract cancer.Patients with programmed death-ligand 1 (PD-L1)-positive tumors had improved overall survival compared with patients with PD-L1-negative disease. Few treatment options exist for patients with advanced biliary tract cancer (BTC) following progression on gemcitabine-cisplatin. Preclinical evidence suggests that simultaneous blockade of vascular endothelial growth factor receptor 2 (VEGFR-2) and programmed death 1 (PD-1) or programmed death-ligand 1 (PD-L1) enhances antitumor effects. We assessed the safety and efficacy of ramucirumab, an IgG1 VEGFR-2 antagonist, with pembrolizumab, an IgG4 PD-1 antagonist, in biomarker-unselected patients with previously treated advanced or metastatic BTC. Patients had previously treated advanced or metastatic adenocarcinoma of the gallbladder, intrahepatic and extrahepatic bile ducts, or ampulla of Vater. Ramucirumab 8 mg/kg was administered intravenously on days 1 and 8 with intravenous pembrolizumab 200 mg on day 1 every 3 weeks. The primary endpoint was safety and tolerability of the combination. Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Twenty-six patients were treated at 12 centers in five countries. Hypertension was the most common grade 3 treatment-related adverse event (TRAE), occurring in five patients. One patient experienced a grade 4 TRAE (neutropenia), and no treatment-related deaths occurred. Objective response rate was 4%. Median progression-free survival and overall survival were 1.6 months and 6.4 months, respectively. Ramucirumab<b>-</b>pembrolizumab showed limited clinical activity with infrequent grade 3-4 TRAEs in patients with biomarker-unselected progressive BTC.","Clinical Trial, Phase I",600.0,14.0,Ramucirumab plus pembrolizumab revealed no unexpected safety findings in patients with advanced or metastatic biliary tract cancer which is consistent with reports of other tumor cohorts within this phase Ia/b trial.Ramucirumab plus pembrolizumab did not demonstrate an improvement in overall survival when compared with historical controls in biomarker unselected heavily pretreated patients with advanced or metastatic biliary tract cancer.Patients with programmed death-ligand 1 PD-L1 -positive tumors had improved overall survival compared with patients with PD-L1-negative disease Few treatment options exist for patients with advanced biliary tract cancer BTC following progression on gemcitabine-cisplatin Preclinical evidence suggests that simultaneous blockade of vascular endothelial growth factor receptor 2 VEGFR-2 and programmed death 1 PD-1 or programmed death-ligand 1 PD-L1 enhances antitumor effects We assessed the safety and efficacy of ramucirumab an IgG1 VEGFR-2 antagonist with pembrolizumab an IgG4 PD-1 antagonist in biomarker-unselected patients with previously treated advanced or metastatic BTC Patients had previously treated advanced or metastatic adenocarcinoma of the intrahepatic and extrahepatic ducts or ampulla of Vater Ramucirumab 8 mg/kg was administered intravenously on days 1 and 8 with intravenous pembrolizumab 200 mg on day 1 every 3 weeks The primary endpoint was safety and tolerability of the combination Secondary endpoints included objective response rate ORR progression-free survival PFS and overall survival OS Twenty-six patients were treated at 12 centers in five countries Hypertension was the most common grade 3 treatment-related adverse event TRAE occurring in five patients One patient experienced a grade 4 TRAE neutropenia and no treatment-related deaths occurred Objective response rate was 4 Median progression-free survival and overall survival were 1.6 months and 6.4 months respectively Ramucirumab b /b pembrolizumab showed limited clinical activity with infrequent grade 3-4 TRAEs in patients with biomarker-unselected progressive BTC,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4521, 349, 2233, 553, 77, 3792, 367, 272, 4, 7, 5, 131, 15, 113, 2532, 1696, 12, 92, 16, 925, 5, 1198, 1, 127, 30, 736, 262, 26, 124, 3302, 132, 160, 4521, 349, 2233, 205, 44, 608, 35, 767, 4, 63, 25, 198, 72, 5, 2252, 535, 4, 901, 3594, 2447, 2193, 7, 5, 131, 15, 113, 2532, 1696, 12, 7, 5, 1846, 273, 1232, 14, 333, 729, 109, 57, 42, 231, 63, 25, 72, 5, 7, 5, 333, 729, 199, 34, 1021, 24, 838, 1923, 9, 7, 5, 131, 2532, 1696, 12, 8112, 366, 91, 23, 679, 540, 693, 241, 844, 17, 2824, 1189, 1, 756, 845, 129, 161, 153, 18, 2134, 18, 2, 1846, 273, 14, 333, 14, 15, 1846, 273, 1232, 14, 333, 729, 2519, 579, 176, 21, 275, 3, 367, 2, 209, 1, 4521, 35, 8019, 2134, 18, 3137, 5, 2233, 35, 11211, 333, 14, 3137, 4, 901, 3594, 7, 5, 373, 73, 131, 15, 113, 8112, 7, 42, 373, 73, 131, 15, 113, 449, 1, 3, 3022, 2, 3710, 7310, 15, 12837, 1, 14777, 4521, 66, 81, 503, 10, 468, 1672, 23, 162, 14, 2, 66, 5, 1262, 2233, 1250, 81, 23, 218, 14, 454, 27, 244, 3, 86, 1138, 10, 367, 2, 1543, 1, 3, 150, 568, 1387, 159, 461, 51, 116, 1735, 91, 115, 25, 300, 2, 63, 25, 118, 737, 437, 7, 11, 73, 28, 133, 1168, 4, 365, 2115, 1824, 10, 3, 96, 186, 88, 27, 24, 139, 290, 774, 29487, 1821, 4, 365, 7, 104, 69, 592, 8, 88, 39, 29487, 778, 2, 77, 24, 139, 1043, 489, 461, 51, 116, 10, 39, 52, 91, 115, 25, 2, 63, 25, 11, 14, 49, 53, 2, 49, 39, 53, 106, 4521, 132, 132, 2233, 224, 383, 38, 128, 5, 4475, 88, 27, 39, 12244, 4, 7, 5, 901, 3594, 1014, 8112]",2101.0,29853658,1
Challenges of surgical management of intrahepatic cholangiocarcinoma.,Expert review of gastroenterology & hepatology,Expert Rev Gastroenterol Hepatol,2018-06-27,"Intrahepatic cholangiocarcinoma (iCCA) is a rare malignancy arising from biliary tract epithelium within bile ducts proximal to the secondary biliary radicles. The majority of patients are diagnosed with locally advanced or metastatic disease at presentation. Surgical resection remains the only potentially curative option, but poses unique challenges due to the large size and aggressive behavior of these tumors. Areas covered: The goal of surgical management of iCCA is margin negative (R0) hepatic resection with preservation of adequate size liver remnant and function. Data regarding role of staging laparoscopy, margin status, portal lymphadenectomy, and vascular resection for iCCA are reviewed. Perioperative systemic therapy may have value, although prospective data have been lacking. Recurrence rates remain high even after R0 resection; among patients with recurrent disease limited to the liver, re-resection or locoregional therapies may play a role. Liver transplantation may be an option for select patients with very early-stage iCCA, although this should be done on a protocol-only basis. Expert commentary: Appropriate preoperative patient selection and surgical technique are paramount to ensure optimal oncologic outcomes for patients with resectable iCCA. Improving systemic and locoregional therapy options may help decrease recurrence rates and improve long-term survival for this aggressive malignancy.",Journal Article,573.0,8.0,Intrahepatic cholangiocarcinoma iCCA is a rare malignancy arising from biliary tract epithelium within ducts proximal to the secondary biliary radicles The majority of patients are diagnosed with locally advanced or metastatic disease at presentation Surgical resection remains the only potentially curative option but poses unique challenges due to the large size and aggressive behavior of these tumors Areas covered The goal of surgical management of iCCA is margin negative R0 hepatic resection with preservation of adequate size remnant and function Data regarding role of staging laparoscopy margin status portal lymphadenectomy and vascular resection for iCCA are reviewed Perioperative systemic therapy may have value although prospective data have been lacking Recurrence rates remain high even after R0 resection among patients with recurrent disease limited to the re-resection or locoregional therapies may play a role transplantation may be an option for select patients with very early-stage iCCA although this should be done on a protocol-only basis Expert commentary Appropriate preoperative patient selection and surgical technique are paramount to ensure optimal oncologic outcomes for patients with resectable iCCA Improving systemic and locoregional therapy options may help decrease recurrence rates and improve long-term survival for this aggressive malignancy,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3022, 2126, 14038, 16, 8, 622, 710, 2635, 29, 2532, 1696, 2781, 262, 7310, 2805, 6, 3, 568, 2532, 51123, 3, 686, 1, 7, 32, 265, 5, 795, 131, 15, 113, 34, 28, 1031, 221, 170, 469, 3, 158, 751, 1075, 1501, 84, 7056, 991, 1427, 520, 6, 3, 375, 444, 2, 571, 1710, 1, 46, 57, 1361, 4306, 3, 1326, 1, 221, 284, 1, 14038, 16, 959, 199, 2328, 939, 170, 5, 2224, 1, 1658, 444, 5644, 2, 343, 74, 666, 200, 1, 632, 3553, 959, 156, 3307, 2048, 2, 756, 170, 9, 14038, 32, 446, 1547, 403, 36, 68, 47, 549, 242, 482, 74, 47, 85, 1941, 146, 151, 918, 64, 871, 50, 2328, 170, 107, 7, 5, 387, 34, 383, 6, 3, 1491, 170, 15, 1325, 235, 68, 1343, 8, 200, 497, 68, 40, 35, 1501, 9, 1717, 7, 5, 923, 191, 82, 14038, 242, 26, 257, 40, 1822, 23, 8, 1182, 158, 877, 2005, 4662, 870, 498, 69, 881, 2, 221, 1312, 32, 7640, 6, 3478, 665, 1998, 123, 9, 7, 5, 1899, 14038, 1673, 403, 2, 1325, 36, 838, 68, 987, 775, 146, 151, 2, 401, 319, 337, 25, 9, 26, 571, 710]",1382.0,29911912,95
The Double Trouble: A Case of Duplicated Extrahepatic Bile Duct with Choledochal Cyst.,Indian journal of pediatrics,Indian J Pediatr,2018-09-12,"Biliary tract shows a large number of anatomic variations and duplication of the bile duct is an extremely rare anomaly. It has been reported to be associated with other congenital conditions like Abnormal Pancreato Biliary Junction (APBJ), biliary atresia and choledochal cyst and may lead to complications like cholangitis, choledocholithiasis and malignancy. The clinical presentation may be with one of the above complications and the condition usually reveals itself only on imaging investigations, as a surprise to the radiologist and the surgeon. Its detection is important prior to any biliary tract surgery to prevent inadvertent bile duct injury. The authors report a case of a rare subtype of extrahepatic bile duct duplication with coexisting choledochal cyst.",Case Reports,496.0,0.0,Biliary tract shows a large number of anatomic variations and duplication of the duct is an extremely rare anomaly It has been reported to be associated with other congenital conditions like Abnormal Pancreato Biliary Junction APBJ biliary atresia and choledochal cyst and may lead to complications like cholangitis choledocholithiasis and malignancy The clinical presentation may be with one of the above complications and the condition usually reveals itself only on imaging investigations as a surprise to the radiologist and the surgeon Its detection is important prior to any biliary tract surgery to prevent inadvertent duct injury The authors report a case of a rare subtype of extrahepatic duct duplication with coexisting choledochal cyst,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2532, 1696, 1949, 8, 375, 207, 1, 2745, 2293, 2, 4616, 1, 3, 2920, 16, 35, 2938, 622, 17085, 192, 71, 85, 210, 6, 40, 41, 5, 127, 6711, 1298, 733, 1668, 25456, 2532, 3322, 73562, 2532, 73563, 2, 14001, 3364, 2, 68, 1122, 6, 521, 733, 8541, 48179, 2, 710, 3, 38, 1031, 68, 40, 5, 104, 1, 3, 2090, 521, 2, 3, 2850, 2082, 4054, 4045, 158, 23, 270, 2492, 22, 8, 17853, 6, 3, 6247, 2, 3, 1897, 211, 638, 16, 305, 324, 6, 500, 2532, 1696, 152, 6, 1682, 18344, 2920, 2730, 3, 738, 414, 8, 473, 1, 8, 622, 875, 1, 3710, 2920, 4616, 5, 8859, 14001, 3364]",747.0,30209736,24
Actual 5-Year Survivors After Surgical Resection of Hilar Cholangiocarcinoma.,Annals of surgical oncology,Ann. Surg. Oncol.,2018-12-11,"The prevalence and characteristics of actual 5-year survivors after surgical treatment of hilar cholangiocarcinoma (HC) have not been described previously. Patients who underwent resection for HC from 2000 to 2015 were analyzed through a multi-institutional registry from 10 U.S. academic medical centers. The clinicopathologic characteristics and both the perioperative and long-term outcomes for actual 5-year survivors were compared with those for non-survivors (patients who died within 5years after surgery). Patients alive at last encounter who had a follow-up period shorter than 5years were excluded from the study. The study identified 257 patients with HC who underwent curative-intent resection with an actuarial 5-year survival of 19%. Of 194 patients with a follow-up period longer than 5years, 23 (12%) were 5-year survivors. Compared with non-survivors, the 5-year survivors had a lower median pretreatment CA 19-9 level (116 vs. 34 U/L; P=0.008) and a lower rate of lymph node involvement (42% vs. 15%; P=0.027) and R1 margins (39% vs. 17%; P=0.042). However, the sole presence of these factors did not preclude a 5-year survival after surgery. The frequencies of bile duct resection alone, major hepatectomy, caudate lobe resection, portal vein or hepatic artery resection, preoperative biliary sepsis, intraoperative blood transfusion, serious postoperative complications, and receipt of adjuvant chemotherapy were comparable between the two groups. One in eight patients with HC reaches the 5-year survival milestone after resection. A 5-year survival can be achieved even in the presence of traditionally unfavorable clinicopathologic factors (elevated CA 19-9, nodal metastasis, and R1 margins).",Journal Article,406.0,1.0,The prevalence and characteristics of actual 5-year survivors after surgical treatment of hilar cholangiocarcinoma HC have not been described previously Patients who underwent resection for HC from 2000 to 2015 were analyzed through a multi-institutional registry from 10 U.S. academic medical centers The clinicopathologic characteristics and both the perioperative and long-term outcomes for actual 5-year survivors were compared with those for non-survivors patients who died within 5 years after surgery Patients alive at last encounter who had a follow-up period shorter than 5 years were excluded from the study The study identified 257 patients with HC who underwent curative-intent resection with an actuarial 5-year survival of 19 Of 194 patients with a follow-up period longer than 5 years 23 12 were 5-year survivors Compared with non-survivors the 5-year survivors had a lower median pretreatment CA 19-9 level 116 vs. 34 U/L P 0.008 and a lower rate of lymph node involvement 42 vs. 15 P 0.027 and R1 margins 39 vs. 17 P 0.042 However the sole presence of these factors did not preclude a 5-year survival after surgery The frequencies of duct resection alone major hepatectomy caudate lobe resection portal vein or hepatic artery resection preoperative biliary sepsis intraoperative blood transfusion serious postoperative complications and receipt of adjuvant chemotherapy were comparable between the two groups One in eight patients with HC reaches the 5-year survival milestone after resection A 5-year survival can be achieved even in the presence of traditionally unfavorable clinicopathologic factors elevated CA 19-9 nodal metastasis and R1 margins,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1078, 2, 374, 1, 3480, 33, 111, 332, 50, 221, 24, 1, 4793, 2126, 7487, 47, 44, 85, 1027, 373, 7, 54, 208, 170, 9, 7487, 29, 1081, 6, 1483, 11, 311, 298, 8, 1414, 1115, 1608, 29, 79, 1767, 695, 1916, 484, 1168, 3, 1399, 374, 2, 110, 3, 1547, 2, 319, 337, 123, 9, 3480, 33, 111, 332, 11, 72, 5, 135, 9, 220, 332, 7, 54, 1016, 262, 33, 60, 50, 152, 7, 1701, 28, 1060, 8650, 54, 42, 8, 166, 126, 727, 985, 76, 33, 60, 11, 1800, 29, 3, 45, 3, 45, 108, 7941, 7, 5, 7487, 54, 208, 1075, 1697, 170, 5, 35, 2361, 33, 111, 25, 1, 326, 1, 5434, 7, 5, 8, 166, 126, 727, 589, 76, 33, 60, 382, 133, 11, 33, 111, 332, 72, 5, 220, 332, 3, 33, 111, 332, 42, 8, 280, 52, 1194, 1568, 326, 83, 301, 3790, 105, 562, 1767, 805, 19, 13, 2155, 2, 8, 280, 116, 1, 263, 289, 799, 595, 105, 167, 19, 13, 4523, 2, 3239, 1012, 587, 105, 269, 19, 13, 5606, 137, 3, 4991, 463, 1, 46, 130, 205, 44, 6064, 8, 33, 111, 25, 50, 152, 3, 2722, 1, 2920, 170, 279, 458, 2711, 10199, 4940, 170, 3307, 2762, 15, 939, 2872, 170, 498, 2532, 4227, 1720, 315, 2785, 1762, 573, 521, 2, 1699, 1, 249, 56, 11, 1279, 59, 3, 100, 271, 104, 4, 659, 7, 5, 7487, 24486, 3, 33, 111, 25, 12821, 50, 170, 8, 33, 111, 25, 122, 40, 513, 871, 4, 3, 463, 1, 4206, 2483, 1399, 130, 804, 1568, 326, 83, 779, 278, 2, 3239, 1012]",1668.0,30539494,1
Intraoperative Air Leak Test to Prevent Bile Leak After Right Posterior Sectionectomy with En Bloc Diaphragm Resection for Metastatic Teratoma.,Annals of surgical oncology,Ann. Surg. Oncol.,2019-05-07,"The intraoperative air cholangiogram, or ""air leak test"" (ALT), at the time of hepatectomy can significantly reduce the rates of bile leak and symptomatic fluid collection after high-risk procedures.1<sup>,</sup>2 Because a bile leak in the setting of an en bloc diaphragm resection and mesh reconstruction would be a particularly dreaded complication, this video shows the technique for resection, reconstruction, and ALT. The video presents the case of a 29-year-old woman who had metastatic teratoma with an 87-cm liver metastasis in segment 7 and diaphragm invasion to the level of the right hepatic vein. The authors performed a formal right posterior sectionectomy with en bloc diaphragm resection. The 128-cm diaphragmatic defect was reconstructed using biologic mesh (Surgimend, Integra LifeSciences, Plainsboro, NJ). An intraoperative ALT (air injection into the cystic duct with finger compression of the distal bile duct) identified several areas of bubbles from biliary radicles on the cut surface of the liver, which were ligated with 4-0 polypropylene. The ALT was repeated until no bubbles remained. Because no evidence of bubbles was observed, no surgical drain was needed. The patient did well postoperatively with no complications. In cases of combined liver and diaphragmatic resection, prevention of bile leak, with subsequent contamination of the diaphragm repair and even the thoracic cavity, is particularly vital. An easily replicated intraoperative air leak test can mitigate the risk of bile leak and organ-space infection, as well as associated sequelae on quality of life, return to intended oncologic therapy, and oncologic outcomes.",Case Reports,259.0,0.0,The intraoperative air cholangiogram or `` air leak test '' ALT at the time of hepatectomy can significantly reduce the rates of leak and symptomatic fluid collection after high-risk procedures.1 sup /sup 2 Because a leak in the setting of an en bloc diaphragm resection and mesh reconstruction would be a particularly dreaded complication this video shows the technique for resection reconstruction and ALT The video presents the case of a 29-year-old woman who had metastatic teratoma with an 8 7-cm metastasis in segment 7 and diaphragm invasion to the level of the right hepatic vein The authors performed a formal right posterior sectionectomy with en bloc diaphragm resection The 12 8-cm diaphragmatic defect was reconstructed using biologic mesh Surgimend Integra LifeSciences Plainsboro NJ An intraoperative ALT air injection into the cystic duct with finger compression of the distal duct identified several areas of bubbles from biliary radicles on the cut surface of the which were ligated with 4-0 polypropylene The ALT was repeated until no bubbles remained Because no evidence of bubbles was observed no surgical drain was needed The patient did well postoperatively with no complications In cases of combined and diaphragmatic resection prevention of leak with subsequent contamination of the diaphragm repair and even the thoracic cavity is particularly vital An easily replicated intraoperative air leak test can mitigate the risk of leak and organ-space infection as well as associated sequelae on quality of life return to intended oncologic therapy and oncologic outcomes,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1720, 6909, 28026, 15, 6909, 4238, 412, 522, 4548, 28, 3, 98, 1, 2711, 122, 97, 969, 3, 151, 1, 4238, 2, 1704, 2357, 2442, 50, 64, 43, 1369, 14, 172, 172, 18, 408, 8, 4238, 4, 3, 546, 1, 35, 4375, 5590, 7482, 170, 2, 11332, 1470, 688, 40, 8, 823, 23386, 1447, 26, 4139, 1949, 3, 1312, 9, 170, 1470, 2, 4548, 3, 4139, 2740, 3, 473, 1, 8, 462, 111, 1095, 2854, 54, 42, 113, 4845, 5, 35, 66, 67, 494, 278, 4, 4610, 67, 2, 7482, 578, 6, 3, 301, 1, 3, 1913, 939, 2762, 3, 738, 173, 8, 5057, 1913, 3028, 40823, 5, 4375, 5590, 7482, 170, 3, 133, 66, 494, 15311, 5398, 10, 7267, 75, 1283, 11332, 74769, 74770, 74771, 74772, 12754, 35, 1720, 4548, 6909, 1754, 237, 3, 2965, 2920, 5, 8079, 3481, 1, 3, 2107, 2920, 108, 392, 1361, 1, 27157, 29, 2532, 51123, 23, 3, 3554, 1255, 1, 3, 92, 11, 18971, 5, 39, 13, 38084, 3, 4548, 10, 2113, 1100, 77, 27157, 958, 408, 77, 241, 1, 27157, 10, 164, 77, 221, 9203, 10, 575, 3, 69, 205, 149, 3541, 5, 77, 521, 4, 140, 1, 397, 2, 15311, 170, 1070, 1, 4238, 5, 706, 9866, 1, 3, 7482, 972, 2, 871, 3, 2098, 2405, 16, 823, 3511, 35, 4697, 6714, 1720, 6909, 4238, 412, 122, 5626, 3, 43, 1, 4238, 2, 1259, 3865, 930, 22, 149, 22, 41, 4156, 23, 372, 1, 358, 4656, 6, 4081, 1998, 36, 2, 1998, 123]",1591.0,31065963,17
